



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: 6:

G01N 33/68, 33/53, C07K 16/00, C12N  
15/11, 15/12, 15/00, 15/63, A61K 38/17,  
38/16, C12P 21/02

A1

(11) International Publication Number:

WO 99/24836

(43) International Publication Date:

20 May 1999 (20.05.99)

(21) International Application Number: PCT/US98/23435

(22) International Filing Date: 4 November 1998 (04.11.98)

(72) Inventors; and  
(75) Inventors/Applicants (for US only): FENG, Ping (CN/US);  
4 Reda Court, Gaithersburg, MD 20878 (US); CARTER,  
Kenneth, C. (US/US); 11601 Brandy Hall Lane, North Po-  
loma, MD 20878 (US); ENDRESS, Gregory, A. (US/US);  
9729 Clagett Farm Drive, Potomac, MD 20854 (US);  
ROSEN, Craig, A. (US/US); 22400 Rolling Hill Road, Lay-  
tonville, MD 20882 (US); RUBEN, Steven, M. (US/US);  
18528 Heritage Hills Drive, Olney, MD 20832 (US);  
JANAT, Fouad (US/US); 140 High Street #202, West-  
bury, RI 02891 (US); NI, Jian (CN/US); 5502 Man-  
field Road, Rockville, MD 20853 (US); WEI, Ying-Fei  
(CN/US); 1714-C Marina Court, San Mateo, CA 94403  
(US); MOORE, Paul, A. (GB/US); 19005 Leatherbark  
Drive, Germantown, MD 20874 (US); SOPPET, Daniel,  
R. (US/US); 15050 Stillfield Place, Centerville, VA 22020  
(US); KYAW, Hia (MM/US); 520 Sugarbush Circle, Fred-  
erick, MD 21703 (US); LAFFLEUR, David, W. (CN/US);  
3142 Quenda Street, N.W., Washington, DC 20015 (US);  
OLSEN, Henrik, S. (DK/US); 182 Kendrick Place #24,  
Gaithersburg, MD 20878 (US); SHI, Yanggu (CN/US); 437  
West Side Drive #102, Gaithersburg, MD 20878 (US);  
EBNER, Reinhard (DE/US); 9906 Shelburne Terrace #316,  
Gaithersburg, MD 20878 (US).(30) Priority Data:  
60/064,911 7 November 1997 (07.11.97) US  
60/064,912 7 November 1997 (07.11.97) US  
60/064,983 7 November 1997 (07.11.97) US  
60/064,900 7 November 1997 (07.11.97) US  
60/064,988 7 November 1997 (07.11.97) US  
60/064,987 7 November 1997 (07.11.97) US  
60/064,908 7 November 1997 (07.11.97) US  
60/064,984 7 November 1997 (07.11.97) US  
60/064,985 7 November 1997 (07.11.97) US  
60/066,094 17 November 1997 (17.11.97) US  
60/066,100 17 November 1997 (17.11.97) US  
60/066,089 17 November 1997 (17.11.97) US  
60/066,095 17 November 1997 (17.11.97) US  
60/066,090 17 November 1997 (17.11.97) US(71) Applicant (for all designated States except US): HUMAN  
GENOME SCIENCES, INC. (US/US); 9410 Key West  
Avenue, Rockville, MD 20850 (US).(74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences,  
Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,  
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD,  
GE, GH, GM, GR, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,  
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW,  
ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF,  
BI, CF, CG, CI, CM, GA, GN, GY, ML, MR, NE, SN,  
TD, TO).Published  
With international search report.  
With an indication in relation to deposited biological  
material furnished under Rule 13bis separately from the  
description.

(54) Title: 125 HUMAN SECRETED PROTEINS

(57) Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	ML	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	MR	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MT	Malta	UA	Ukraine
BJ	Benin	IE	Ireland	MN	Mongolia	UG	Uganda
BR	Brazil	IL	Israel	MR	Mauritania	US	United States of America
BY	Belarus	IS	Iceland	MU	Mauritius	UZ	Uzbekistan
CA	Canada	IT	Italy	NE	Niger	VN	Viet Nam
CF	Central African Republic	JP	Japan	NL	Netherlands	YU	Yugoslavia
CG	Congo	KE	Kenya	NO	Norway	ZW	Zimbabwe
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand		
CI	Cote d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	St. Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## 125 Human Secreted Proteins

### *Field of the Invention*

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

### *Background of the Invention*

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using secreted proteins or the genes that encode them.

### *Summary of the Invention*

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

### *Detailed Description*

#### Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig

analysis). A representative clone containing all or most of the sequence for SEQ ID NO.X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO.X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42°C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl, 0.2M NaH<sub>2</sub>PO<sub>4</sub>, 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA, followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a

complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods.

Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine,

formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table I.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

## 25 Polynucleotides and Polypeptides of the Invention

### FEATURES OF PROTEIN ENCODED BY GENE NO: 1

The translation product of this gene shares sequence homology with transcytosis-associated protein (TAP), which is thought to be important in the docking of transport vesicles with their target membrane. The gene encoding the disclosed cDNA is thought to reside on chromosome 4. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 4.

This gene is expressed primarily in developing brain, other embryonic tissue and placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental and neurodegenerative diseases of the brain as well as other developmental anomalies or fetal deficiencies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. embryonic, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:136 as residues: Pro-51 to Arg-56, Lys-89 to Gln-94, Glu-144 to Gln-151, Gln-178 to Gln-183, Leu-224 to Gln-229, Tyr-284 to Pro-298, Lys-324 to Lys-334.

The tissue distribution in developing brain and placental tissues and the homology to transcytosis-associated protein (TAP) indicates that polynucleotides and polypeptides corresponding to this gene are useful for a host of conditions which arise as a result of a failure of, or deficiency in, the secretory or endocytic pathway. In addition, the expression in brain would suggest a role in the detection and treatment of brain tumors, developmental and behavioral disorders such as mania, depression, paranoia, addictive behavior and sleep disorders. Furthermore, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 996 of SEQ ID NO:11, b is an integer of 15 to

1010, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 11, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 2

This gene is expressed primarily in human adrenal gland tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine disorders, particularly adrenal gland tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the adrenal gland, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. endocrine, adrenal gland, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis or treatment of adrenal gland tumors. Furthermore, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g. hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

a-b, where a is any integer between 1 to 1545 of SEQ ID NO: 12, b is an integer of 15 to 1559, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 12, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 3

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells, including their progenitors, through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in small intestine.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, a variety of gastrointestinal disorders including duodenal ulcers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the gastrointestinal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. gastrointestinal, smooth muscle, endothelial, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 138 as residues: Gln-77 to Pro-86.

The tissue distribution in small intestine indicates that the translation product of this gene is useful for the diagnosis and/or treatment of a number of disorders having to do with the gastrointestinal system, and specifically the small intestine, such as obstructions of the ileum, meckel's diverticulum, Crohn's disease, celiac sprue, tropical

spine, and lymphoma. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1575 of SEQ ID NO:13, b is an integer of 15 to 1589, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 4

The translation product of this gene shares sequence homology with the mouse astrocytin protein, which is thought to be important in supporting neuronal migration along glial fibers. Additionally, astrocytin is thought to act as a ligand for neuron-glial binding during neuronal migration. The gene encoding the disclosed cDNA is thought to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in brain tissue from a patient with Alzheimer's disease.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural or CNS disorders, particularly neurodegenerative disorders such as Alzheimer's disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. brain, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the

expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:139 as residues: Gln-43 to Trp-53, Arg-69 to Ser-76.

The tissue distribution in brain combined with the homology to mouse astrocytin indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of CNS diseases, such as Alzheimer's disease. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep

patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1241 of SEQ ID NO:14, b is an integer of 15 to 1255, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1241 of SEQ ID NO:14, b is an integer of 15 to 1255, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1241 of SEQ ID NO:14, b is an integer of 15 to 1255, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 5

The translation product of this gene shares sequence homology with transporter protein, which is thought to be important in metabolic and respiratory functions.

This gene is expressed primarily in T-cell lymphoma and dendritic cells, and to a lesser extent in placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, haemopoietic disorders, particularly cancer including T-cell lymphoma and disorders associated with embryogenesis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.140 as residues: Thr-87 to Trp-94.

The tissue distribution in T-cell lymphoma and dendritic cells and the homology to transporter protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of haemopoietic disorders such as cancer, particularly T-cell lymphoma and disorders associated with embryogenesis. Furthermore, this gene product may play a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. Expression of this gene product in T cells and primary dendritic cells also strongly indicates a role for this protein in immune function and immune surveillance.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO.15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

a-b, where a is any integer between 1 to 1177 of SEQ ID NO.15, b is an integer of 15 to 1191, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.15, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 6

This gene is expressed primarily in the liver, and to a lesser extent, in testis.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hepatic, reproductive, or endocrine disorders, particularly hepatoma or male infertility. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. hepatic, reproductive, endocrine, testical, immune, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, seminal fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.141 as residues: Ser-21 to Trp-34, Cys-68 to Gly-89, Cys-122 to Phe-133.

The tissue distribution in liver tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of liver disorders, particularly those affecting the immune and hematopoietic systems such as hepatomas. Furthermore, the protein product of this gene would also be useful for the detection and treatment of hepatoblastoma, jaundice, hepatitis, or liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells. Furthermore, the expression within testis indicates that the protein may show utility in the treatment and/or detection of a variety of reproductive disorders such as male infertility, impotence, and may even be useful as a contraceptive. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more

- 5 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1172 of SEQ ID NO:16, b is an integer of 15 to 1186, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

#### 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 7

The translation product of this gene shares sequence homology with urokinase receptor which is thought to be important in cell matrix remodeling and cell movement.

- 15 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

FYIADHSFTARPTLRMFRISAVVATDKMTFTSGGTLFGDGCASSVA GEVMNC  
QTVLCILWTFVFCPSIAVIIPCFTSKALEAIWKWCRVERPHIEVDVLGKCP  
AF (SEQ ID NO:261), RPTLRMFRISAVVATDKMTFTSGGT (SEQ ID NO:262),  
20 PSTAVIIPCFTSKALEAIWKWCRVER (SEQ ID NO:263), TSVSFHHR YKSS  
DRPAHKVS (SEQ ID NO:264). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in fetal lung, breast, and Hodgkin's Lymphoma II.

- 25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pulmonary, reproductive, immune, or hematopoietic disorders, particularly cell growth and differentiation conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal lung, breast, and tissues involved in Hodgkin's Lymphoma II expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Pulmonary, immune, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, pulmonary surfactant or sputum, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual
- 30
- 35

having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID

- 5 NO:142 as residues: Asn-32 to Asp-38, Thr-40 to Phe-46, Asn-53 to Gln-74, Ser-84 to Ile-91, Cys-95 to Glu-100, Ser-109 to Cys-121.

The tissue distribution in proliferating and differentiating tissues, combined with the homology to a urokinase receptor indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cell growth and differentiation disorders, particularly of the lung, renal, breast, immune and endothelial tissues. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more

- 25 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1168 of SEQ ID NO:17, b is an integer of 15 to 1182, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

#### 30 FEATURES OF PROTEIN ENCODED BY GENE NO: 8

The translation product of this gene shares sequence homology with cell adhesion molecules, which are implicated in cell migration, axonal guidance and fasciculation, and growth and tumorigenesis. When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid

15

cells, including their progenitors, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

10 RHNDFNKLSYTECNMNMKMAKPEKKKGSVKSLGIFLGPNCNLISLFLFS  
VSLYPFATQFPHYVLFIIQAFGLCLPLTERQEAQSGLGGLCPDYTWPC  
PCLLVSQLSLRL (SEQ ID NO:265), CEVFSWHFPWSKLSPHLFLVSFLCIPL  
SLCHTVSFLCSNINYPGLRTMLAPHRETGGQVWAGWALSRLHYALPMSLG  
VLSLPAPTYYVRMEGGDWKVCCEQLGQCTYSHRMTK (SEQ ID NO:266),  
KRMAKPEKKKGSVKSLGIFLGP (SEQ ID NO:267), and/or YNPGLRTMLA  
15 PHRETCGQVWAGWALSRLHYA (SEQ ID NO:268). Polynucleotides encoding  
these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the meninges, melanocytes, and to a lesser extent, in breast.

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disease states and behavioral disorders, in addition to integumentary or reproductive disorders, particularly of the breast. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. neural, integumentary, breast, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:143 as residues: Asn-71 to Asp-79.

The tissue distribution in meninges combined with the homology to cell adhesion molecules and the detected GAS biological activity indicates that

16

polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.

5 Moreover, the expression within melanocytes and breast tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell

10 carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, linea, athlete's foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chondromalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Aciosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Furthermore, This protein may show utility in modulating the immune systems response to various degenerative neural conditions based upon the detected GAS biological activity. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

35 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1157 of SEQ ID NO:18, b is an integer of 15

to 1171, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 9

This gene is expressed primarily in fetal liver and spleen, and infant brain. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, neural, and developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and developmental systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Immune, hematopoietic, neural, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:144 as residues: Thr-187 to Lys-192, Asn-255 to Leu-262.

The tissue distribution of this gene in fetal liver spleen indicates a key role in the development of the immune system. Thus this gene could be used in the treatment and/or detection of immune disorders including arthritis, asthma, immunodeficiency diseases and leukemia. Expression in infant brain also indicates a role in the treatment and/or detection of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Moreover, expression within fetal tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1323 of SEQ ID NO:19, b is an integer of 15 to 1337, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 10

This gene is expressed primarily in breast, and to a lesser extent in liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, breast cancer, hepatoblastoma, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the breast and liver, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. breast, liver, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:145 as residues: Gln-29 to Gly-38, Lys-57 to Asp-62.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases), and conditions that are attributable to the differentiation of hepatocyte progenitor cells. In

addition, the expression in breast would suggest a possible role in the detection and treatment of breast cancer.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1148 of SEQ ID NO:20, b is an integer of 15 to 1162, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 11

This gene is expressed primarily in brain, and to a lesser extent in retina.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, degenerative and behavioral diseases of the brain such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, specific brain tumors, aphasia, mania, depression, dementia, paranoia, addictive behavior and sleep disorders as well as conditions that affect vision and function of the eye such as retinoblastoma and cataracts. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and eye, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., brain, retina, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:146 as residues: Pro-46 to Gln-60, Pro-68 to Gly-75, Leu-78 to Ala-86, Gln-93 to Asp-98.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of developmental, degenerative and behavioral diseases, and conditions of the brain such as aphasia, depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, specific brain tumors, mania, depression, dementia, paranoia, addictive behavior and sleep disorders. In addition, the expression in retina would also suggest a role for this gene product in the diagnosis and treatment of conditions that affect vision and function of the eye such as retinoblastoma, myopia, hyperopia and cataracts.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1823 of SEQ ID NO:21, b is an integer of 15 to 1837, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 12

The gene encoding the disclosed cDNA is thought to reside on chromosome 8. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 8. One embodiment of this gene comprises polypeptides of the following amino acid sequence:

35 MSPYASQGFPELPPYPQEANRSTLSVADTVSSSTTSHHTAKAPAPSPGVLN  
LPLPTVDASIPTSQNGFGYKMPDVPDAFPELSELVSQQLTDMNEQEEVLLLEQF  
LTLPOLKQUTDKDDL VKSIEELARKNLLLEPSLEAKRQTVLDKYELLTQMKSTF  
30 EKKMQRQHELSSECSASALQARLKVAHAHEABEESDNIADFL EGKMEIDDFLSS  
FMEKRTICHCRAKKEKLQQAIAHMSQFAPL (SEQ ID NO:269). LPPYPQE  
ANRSTLSVADTVS (SEQ ID NO:270). TAKPAPSPGVLNPLPPTVDASIP  
(SEQ ID NO:271). PDVPDAFPELSELVSQQLTDMNEQ (SEQ ID NO:272). QFLTL  
POLKQUTDKDDL VKSIEELARKN (SEQ ID NO:273). RQTVLDKYELLTQ MKS  
TFEKKMQRQ (SEQ ID NO:274). ASALQARLKVAHAHEABEESDNIADFL E (SEQ  
ID NO:275), and/or MEKRTICHCRAKKEKLQQAIAHMSQF (SEQ ID NO: 276).  
An additional embodiment is the polynucleotides encoding these polypeptides.

This gene is expressed primarily in breast and placenta, and to a lesser extent in a variety of other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, breast and endometrial cancers as well as prenatal disorders and deficiencies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the breast and reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. breast, placental, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of breast cancer, ovarian and other endometrial cancers, infertility and pre-natal disorders. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating female infertility. The protein product is likely involved in preparation of the endometrium of implantation and could be administered either topically or orally. Alternatively, this gene could be transfected in gene-replacement treatments into the cells of the endometrium and the protein products could be produced. Similarly, these treatments could be performed during artificial insemination for the purpose of increasing the likelihood of implantation and development of a healthy embryo. In both cases this gene or its gene product could be administered at later stages of pregnancy to promote healthy development of the endometrium.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1040 of SEQ ID NO:22, b is an integer of 15

to 1054, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 13

This gene is expressed primarily in anergic T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly autoimmune disorders such as lupus. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:148 as residues: Lys-49 to Gln-57, Arg-63 to Ala-69.

The tissue distribution in T-cells indicates that the polypeptides or polynucleotides are useful for treatment, prophylaxis, and diagnosis of immune and autoimmune diseases, such as lupus, transplant rejection, allergic reactions, arthritis, asthma, immunodeficiency diseases, leukemia, and AIDS. The expression observed predominantly in hematopoietic cells also indicates that the polynucleotides or polypeptides are important in treating and/or detecting hematopoietic disorders, such as graft versus host reaction, graft versus host disease, transplant rejection, myelogenous leukemia, bone marrow fibrosis, and myeloproliferative disease. The polypeptides or polynucleotides are also useful to enhance or protect proliferation, differentiation, and functional activation of hematopoietic progenitor cells (e.g., bone marrow cells), useful in treating cancer patients undergoing chemotherapy or patients undergoing bone marrow transplantation. The polypeptides or polynucleotides are also useful to increase the proliferation of peripheral blood leukocytes, which can be used in the combat of a range of hematopoietic disorders, including immunodeficiency diseases, leukemia,

and septicemia. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1052 of SEQ ID NO:23, b is an integer of 15 to 1066, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 14

The translation product of this gene shares sequence homology with a drought-induced protease inhibitor from soybean. As a result, the protein product of this gene may show utility in the treatment and/or prevention of a variety of proliferative disorders (e.g. for inhibition of key proteolytic events during cellular metabolism of the tumor which may lead to cessation of mitosis) or for the treatment of degenerative conditions where the inhibition of aberrant proteolysis may lead to cessation of degeneration and ultimately in immune protection.

This gene is expressed primarily in the kidney.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the kidney. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the urogenital system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. kidney, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:149 as residues: Glu-48 to Arg-56, Ser-61 to Gly-66.

The tissue distribution in kidney tissue combined with the homology to a protease inhibitor indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the kidney. Furthermore, this gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 914 of SEQ ID NO:24, b is an integer of 15 to 928, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

## 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 15

When tested against U937 cell lines, supernatants removed from cells

containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells, including their progenitors, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

TRPVLSMTPLKGIKSVILPQVFLCAYMAAFNSINGNRSYTKPLERSLLMAGA  
 VASSTFLGVIPQFVQ (SEQ ID NO:277), PLKGIKSVILPQVFLCAYMAA (SEQ ID  
 NO:278), and/or AFNSINGNRSYTKPLERSLL (SEQ ID NO:279). Polynucleotides  
 encoding these polypeptides are also encompassed by the invention. The gene encoding  
 the disclosed cDNA is believed to reside on chromosome 10. Accordingly,  
 polynucleotides related to this invention are useful as a marker in linkage analysis for  
 chromosome 10.

This gene is expressed primarily in B cell and T cell lymphomas.

Therefore, polynucleotides and polypeptides of the invention are useful as  
 reagents for differential identification of the tissue(s) or cell type(s) present in a  
 biological sample and for diagnosis of diseases and conditions which include, but are  
 not limited to, immune or hematopoietic disorders, particularly B cell and T cell  
 lymphomas, infections, multiple myeloma, immunodeficiencies, and inflammatory  
 conditions. Similarly, polypeptides and antibodies directed to these polypeptides are  
 useful in providing immunological probes for differential identification of the tissue(s)  
 or cell type(s). For a number of disorders of the above tissues or cells, particularly  
 immune or hematopoietic disorders, such as B- and T-cell lymphomas, expression of  
 this gene at significantly higher or lower levels may be routinely detected in certain  
 tissues and cell types (e.g. Immune, hematopoietic, and cancerous and wounded  
 tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal  
 fluid) or another tissue or cell sample taken from an individual having such a disorder,  
 relative to the standard gene expression level, i.e., the expression level in healthy tissue  
 or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID

25 NO:150 as residues: Phe-85 to Gly-96, Glu-133 to Thr-143.

The tissue distribution in B- and T-cell lymphomas, combined with the detected  
 GAS biological activity indicates that polynucleotides and polypeptides corresponding  
 to this gene are useful for the diagnosis and treatment of a variety of immune disorders,  
 particularly proliferative conditions such as cancer and leukemias. In addition,  
 polynucleotides and polypeptides corresponding to this gene are useful for the treatment  
 and diagnosis of hematopoietic related disorders such as anemia, pancytopenia,  
 leukopenia, thrombocytopenia or leukemia since stromal cells are important in the  
 production of cells of hematopoietic lineages. The uses include bone marrow cell ex  
 vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or  
 chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis,  
 therefore, it can be used in immune disorders such as infection, inflammation, allergy,  
 immunodeficiency etc. In addition, this gene product may have commercial utility in the

expansion of stem cells and committed progenitors of various blood lineages, and in the  
 differentiation and/or proliferation of various cell types. Protein, as well as, antibodies  
 directed against the protein may show utility as a tumor marker and/or immunotherapy  
 targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available  
 and accessible through sequence databases. Some of these sequences are related to SEQ  
 ID NO:25 and may have been publicly available prior to conception of the present  
 invention. Preferably, such related polynucleotides are specifically excluded from the  
 scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more  
 polynucleotides comprising a nucleotide sequence described by the general formula of  
 a-b, where a is any integer between 1 to 952 of SEQ ID NO:25, b is an integer of 15 to  
 966, where both a and b correspond to the positions of nucleotide residues shown in  
 SEQ ID NO:25, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 16

The protein product of this gene was found to have homology to the Poly(A)  
 polymerase of *Bos taurus*, which is known to be important in the creation of the 3'  
 poly(A) tail of mRNA's. The gene encoding the disclosed cDNA is believed to reside  
 on chromosome 14. Accordingly, polynucleotides related to this invention are useful as  
 a marker in linkage analysis for chromosome 14.

This gene is expressed primarily in brain, and to a lesser extent, in prostate.

Therefore, polynucleotides and polypeptides of the invention are useful as  
 reagents for differential identification of the tissue(s) or cell type(s) present in a  
 biological sample and for diagnosis of diseases and conditions which include, but are  
 not limited to, neural disorders, such as neurodegenerative disease states and behavioral  
 conditions, in addition to reproductive disorders, particularly of the prostate. Similarly,  
 polypeptides and antibodies directed to these polypeptides are useful in providing  
 immunological probes for differential identification of the tissue(s) or cell type(s). For a  
 number of disorders of the above tissues or cells, particularly of the nervous system,  
 expression of this gene at significantly higher or lower levels may be routinely detected  
 in certain tissues and cell types (e.g. neural, reproductive, and cancerous and wounded  
 tissues) or bodily fluids (e.g. lymph, serum, seminal fluid, plasma, urine, synovial fluid  
 and spinal fluid) or another tissue or cell sample taken from an individual having such a

disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:151 as residues: Glu-47 to Ser-52.

5 The tissue distribution in brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinsons Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Moreover, expression of the gene in prostate indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection or treatment of prostate disorders including benign prostate hyperplasia, prostate cancer, and metabolic disorders. The homology to the PAP polyA polymerase indicates that the protein product of this gene, antibodies directed to this protein, or the gene encoding this protein via a gene therapy approach, may show utility as a

15 preventative therapy for proliferative conditions. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1132 of SEQ ID NO:26, b is an integer of 15 to 1146, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

### 30 FEATURES OF PROTEIN ENCODED BY GENE NO: 17

This gene is expressed primarily in epididymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the reproductive organs. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes

for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:152 as residues: Met-1 to Pro-6, Glu-58 to Cys-63, Glu-65 to Gly-72, Thr-74 to Val-87.

The tissue distribution in epididymus indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders of the epididymus and reproductive organs. Furthermore, the tissue distribution indicates that the protein product of this gene is useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 786 of SEQ ID NO:27, b is an integer of 15 to 802, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 18

5 This gene is expressed primarily in synovium and rhabdomyosarcoma. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscular skeletal system and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the muscular skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. musculo-skeletal, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:153 as residues: Trp-30 to Val-35, Lys-44 to Arg-49.

20 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the muscular skeletal system and cancer. Furthermore, the expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Ateleostegenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the

scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1155 of SEQ ID NO:28, b is an integer of 15 to 1169, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 19

10 The gene encoding the disclosed cDNA is thought to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

15 This gene is expressed primarily in fetal liver/spleen, and to a lesser extent, in tonsils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, or hepatic disorders, particularly multiple myeloma, immunodeficiencies, and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, bile, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:154 as residues: Asp-27 to Ser-36.

25 Expression of this gene at either the RNA or protein level could be used as a diagnostic indicator of hepatic cancer. Furthermore, the tissue distribution in fetal liver and tonsil tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Moreover, the protein product of this gene may play a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all

31

hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1452 of SEQ ID NO:29, b is an integer of 15 to 1466, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 20

This gene is expressed primarily in human brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders or diseases of the central nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. brain, cancerous and wounded tissues) or bodily fluids (e.g.

32

lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and the treatment of CNS disorders. Furthermore, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1212 of SEQ ID NO:30, b is an integer of 15 to 1226, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 21

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

MSDEKVDISVHQIHVGPLLMTTESWGPSCAPALLSGHTAASFTHTLGG  
VLGPPYHKFYSS AHTSDRKETNKVEGRWVDVTRSLGNFNFRKFFC  
VSELLIGIFLDSSWKI QNSNDCKVL (SEQ ID NO:280), VGPLLMTTESW  
GPSCAPSALLSGHTAAS (SEQ ID NO:281), and/or ETNKVEEGRWVDVTRS

LGNFNRRKFF (SEQ ID NO:282). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in fetal spleen or liver, adult spleen, and to a lesser extent, in activated T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly abnormal proliferation or activation of hematopoietic cells, particularly of T-cells and their progenitors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:156 as residues: Arg-19 to Phe-24, Ala-44 to Asp-51, Glu-60 to Ile-66.

The tissue distribution in spleen tissues and T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for modulating or detecting the abnormal proliferation or activation of T-cells and immune cell precursor cells. Moreover, expression within fetal spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Similarly, This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by

boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1080 of SEQ ID NO:31, b is an integer of 15 to 1094, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 22

This gene is expressed primarily in the amygdala.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, degenerative and behavioral diseases of the brain such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, specific brain tumors, aphasia, mania, depression, dementia, paranoia, addictive behavior and sleep disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential

35

identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. brain, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:157 as residues: Pro-94 to Ala-107.

15 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of developmental, degenerative and behavioral diseases and conditions of the brain such as aphasia, depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, specific brain tumors, mania, depression, dementia, paranoia, addictive behavior and sleep disorders.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1023 of SEQ ID NO:32, b is an integer of 15 to 1037, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

### 30 FEATURES OF PROTEIN ENCODED BY GENE NO: 23

35 The translation product of this gene shares sequence homology with octaprenyltransferase, which is thought to be important in cellular respiration and metabolism. When tested against fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates fibroblast cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. The

36

gene encoding the disclosed cDNA is thought to reside on chromosome 4. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 4.

5 This gene is expressed primarily in synovium, liver cells, dendritic cells and stromal cells.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic and respiratory disorders, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic processes and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, liver, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:158 as residues: Asp-54 to Asn-69, His-176 to Asp-181, Phe-194 to Trp-201, Ser-220 to Pro-225, Arg-248 to Trp-253, Trp-276 to Ile-288.

25 The tissue distribution and homology to octaprenyltransferase indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of metabolic and respiratory disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1362 of SEQ ID NO:33, b is an integer of 15 to 1376, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 24

5 This gene is expressed primarily in activated T cells and in the spleen from a patient suffering from lymphocytic leukemia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly immunodeficiencies, multiple myeloma, and leukemias. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in T-cells and spleen tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis or treatment of leukemia. Furthermore, the tissue distribution indicates that the polypeptides or polynucleotides are useful for treatment, prophylaxis, and diagnosis of immune and autoimmune diseases, such as lupus, transplant rejection, allergic reactions, arthritis, asthma, immunodeficiency diseases, leukemia, and AIDS. The expression observed predominantly in hematopoietic cells also indicates that the polynucleotides or polypeptides are important in treating and/or detecting hematopoietic disorders, such as graft versus host reaction, graft versus host disease, transplant rejection, myelogenous leukemia, bone marrow fibrosis, and myeloproliferative disease. The polypeptides or polynucleotides are also useful to enhance or protect proliferation, differentiation, and functional activation of hematopoietic progenitor cells (e.g., bone marrow cells), useful in treating cancer patients undergoing chemotherapy or patients undergoing bone marrow transplantation. The polypeptides or polynucleotides are also useful to increase the proliferation of peripheral blood leukocytes, which can be used in the combat of a range of hematopoietic disorders, including immunodeficiency diseases, leukemia,

and septicemia. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1206 of SEQ ID NO:34, b is an integer of 15 to 1220, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

# 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 25

This gene is expressed primarily in bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly disorders affecting stem cell or myeloid progenitors, and in particular multiple myeloma, immunodeficiencies, or SCID. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in bone marrow indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the immune and hematopoietic systems. In addition, The protein product of this gene is useful for the diagnosis and/or treatment of hematopoietic disorders. Furthermore, this gene product is primarily expressed in hematopoietic cells

and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. This is particularly supported by the expression of this gene product in bone marrow, which is a primary sites of definitive hematopoiesis. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1332 of SEQ ID NO:35, b is an integer of 15 to 1346, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

## 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 26

This gene is expressed primarily in the cells of the immune system.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the immune systems, such as AIDS. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or

another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:161 as residues: His-17 to Ser-24, Glu-53 to Asn-58, Glu-66 to Lys-72.

The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Further, the expression of this gene product indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1012 of SEQ ID NO:36, b is an integer of 15 to 1026, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

## 35 FEATURES OF PROTEIN ENCODED BY GENE NO: 27

The translation product of this gene shares sequence homology with glucan synthetase which is thought to be important in modifying carbohydrate moieties on extracellular molecules.

5 This gene is expressed primarily in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly autoimmune diseases and inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:162 as residues: Gly-33 to Leu-39, Thr-69 to Ser-77, Arg-102 to Thr-109.

The tissue distribution in T-cells combined with the homology to glucan synthetase indicates that polynucleotides and polypeptides corresponding to this gene are useful for modifying the response and production of active cytokines by T cells, in modulating cell-cell interactions, or cell-tissue interactions, and in inflammatory conditions. Alternatively, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS,

leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease,

scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 818 of SEQ ID NO:37, b is an integer of 15 to 832, where both a and b correspond to the positions of nucleotide residues shown in  
15 SEQ ID NO:37, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 28

20 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

GRGDKPRQDRPASRLKGPSPQAPASHSTLSSHCPCSLFAACGSVWPGSLGS  
GIFARLSQLLPSPASWG WDFLTRQAQQMLGPSLCPGHSTSAHQHYGAYVLP  
RDLCSELLTSTVQGTAPLKNRSRVTCIGSQQVPLC (SEQ ID NO:283), AEVTSPA  
25 KTDLQVFYSRDLPHARPLPLTAAPFLIVPVPELPVDLFGQGPWGQEYLQDSAS  
SFPAQPLGA GTFSPCGRHNRCDVPVSAQVTAQVHISTMGPMSCPETSAPSC  
SHPQFARRSPRTSPESVSSAPSKCLFV YDVPLL (SEQ ID NO:284), SLRLKGP  
PSCQAPASHSTLSSHCPCSLFA (SEQ ID NO:285), QQMLGPSLCPGHS TSAH  
QHYGAYVLPRLDLC (SEQ ID NO:286), DLQVFSRDLPHARPLPLTAAPFLIV  
30 PVPPF (SEQ ID NO:287), AQVHISTMGPMSCPETSAPSCSHPQFARRP SRTPE  
SPV (SEQ ID NO:288), and/or QAPPRQTCKSSSQGTSL (SEQ ID NO:289).

Polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in endometrial tumors, fetal spleen, and to a lesser extent, in activated monocytes and T-cells.

35 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, reproductive, immune, hematopoietic disorders, particularly pregnancy defects. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. reproductive, endometrial, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:163 as residues: Ser-66 to Thr-75.

The tissue distribution in endometrial tissue indicates that the protein product of this gene could be used in the treatment and/or detection of pregnancy associated disorders including miscarriage, and endometriosis. Alternatively, expression in hematopoietic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of immune system related diseases including arthritis, asthma, immunodeficiency diseases and leukemia. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 692 of SEQ ID NO:38, b is an integer of 15 to 706, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 29

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

AALRPSGLAGPEWPQHWCGRHXVYKPOQVDLHSARLWAAPAAVGPA  
HAGSGMPPGGTAPHARRHSLPSPTAQSHLWHVHGLRQRGPKAVPLDLAQ  
LVTTTPPLFXLALSALLGRHHPLQLAAMGPLCLGACSLAGEFRTPPT  
GCGFLAATCLRGLKSVQSSALLQEEERLDAVTLVATSLPSFCLLAGAALVLEA  
GVAPPPTAGDSRLWACILSCLLSVLNINLASFILLATSLATVHVLGNLTIV  
GNILSRLFGSRLSALSYVGLALTLGMLYHNCFFVASWAARGLW  
RRDQPSKGL (SEQ ID NO:290), GQPSGPPAAWPGPSGHGSTGVAAAGSTXSSL  
NKWFTVHGFGRPLLSALHMLVAALACHRGARRP (SEQ ID NO:291), WPGPS  
GHGSTGVAAAGSTXSS (SEQ ID NO:292), EWPWQHWCGRHXVYKPOQVD  
LHSA (SEQ ID NO:293), QQSALLQEEERLDAVTLVATSLPSFCLL (SEQ ID  
NO:294), ACILSCLLSVLNINLASFILLATSL (SEQ ID NO:295), and/or  
SLNKWFTVHGFGRPLLSAL (SEQ ID NO:296). Polynucleotides encoding these  
polypeptides are also encompassed by the invention.

This gene is expressed primarily in brain tissue from a patient suffering from Alzheimer's disease (spongy change), and to a lesser extent, in human umbilical vein and human pancreas tumor tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, immune, metabolic, digestive or neural disorders, such as Alzheimer's disease, in addition to cancers and tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and secretory systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. developmental, immune, metabolic, digestive, cancerous and wounded tissues) or bodily fluids (e.g. lymph, bile, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of Alzheimer's disease, and immune and secretory system disorders such as cancers. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Parkinsons Disease, Huntingtons Disease, Tourette

Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1333 of SEQ ID NO:39, b is an integer of 15 to 1347, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 30

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, infection and inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell

types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 165 as residues: Asn-43 to Ala-49.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of infection and inflammation related immune diseases. Furthermore, the gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency, etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune surveillance.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1453 of SEQ ID NO:40, b is an integer of 15 to 1467, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 31

The translation product of this gene shares sequence homology with Ly6C antigen, which is thought to be important in T-cell activation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

KSTLSAAVVAITLRTLA (SEQ ID NO:297), GDHSEQLIKEMGARERFFCKAR  
GYRDTG REAQAKAGRRGSQWNEQSQRPRPAKEVRKTRPRAGVGRGP  
ALLQLSLQQVVLVYRPSRLVWLKA S (SEQ ID NO:298), MERGEYGGWG  
TYGSLDLSQLCTVRSSGPCSLHWGQH RSPISGDPNPFSSR GQQSIGSK

VGSPSRQWRSWKEVGRDPEKGE (SEQ ID NO:299), QAKAGGRGSGQWNESSQ  
CSSQRRP (SEQ ID NO:300), VGRGPALLQL SILQQVLYVRPSRL (SEQ ID  
NO:301), YGSLDGSQLCTVRSSGPCGSL (SEQ ID NO:302), and/or KYGSPSR  
SQWRSWKEVGRDP (SEQ ID NO:303). Polynucleotides encoding these polypeptides  
are also encompassed by the invention.

This gene is expressed primarily in bone cancer, fetal brain, lung, and adipose  
tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, skeletal, developmental, pulmonary, or metabolic disorders, particular  
disorders in the immune responses to the above conditions, such as in autoimmune  
disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in  
providing immunological probes for differential identification of the tissue(s) or cell  
type(s). For a number of disorders of the above tissues or cells, particularly of the  
immune system, expression of this gene at significantly higher or lower levels may be  
routinely detected in certain tissues or cell types (e.g. skeletal, developmental,  
pulmonary, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g.  
lymph, amniotic fluid, pulmonary surfactant or sputum, serum, plasma, urine, synovial  
fluid and spinal fluid) or another tissue or cell sample taken from an individual having  
such a disorder, relative to the standard gene expression level, i.e., the expression level  
in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID  
NO:166 as residues: Gln-37 to Gln-45, Phe-76 to Leu-83, Thr-89 to Thr-105.

The tissue distribution combined with the homology to the Ly6C T-cell  
activation antigen indicates that polynucleotides and polypeptides corresponding to this  
gene are useful for the diagnosis and intervention of immune related disorders. The  
tissue distribution in tissues particularly active in immune reaction, for example bone  
cancer, indicate that this gene may also be involved in T-cell activation. Thus the gene  
product can be used either for the development of immune suppressants, or modulators,  
for immune responses. Moreover, the expression within brain tissue indicates that the  
protein is useful for the treatment and/or prevention of neurodegenerative disorders,  
particularly, but not limited to, Alzheimer's or Parkinson's disease. Alternatively, the  
expression within fetal tissue and other cellular sources marked by proliferating cells  
indicates that this protein may play a role in the regulation of cellular division, and may  
show utility in the diagnosis and treatment of cancer and other proliferative disorders.  
Similarly, developmental tissues rely on decisions involving cell differentiation and/or

apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or  
tissue differentiation and could again be useful in cancer therapy. Protein, as well as,  
antibodies directed against the protein may show utility as a tumor marker and/or  
immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available  
and accessible through sequence databases. Some of these sequences are related to SEQ  
ID NO:41 and may have been publicly available prior to conception of the present  
invention. Preferably, such related polynucleotides are specifically excluded from the  
scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more  
polynucleotides comprising a nucleotide sequence described by the general formula of  
a-b, where a is any integer between 1 to 900 of SEQ ID NO:41, b is an integer of 15 to  
914, where both a and b correspond to the positions of nucleotide residues shown in  
SEQ ID NO:41, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 32

The gene encoding the disclosed cDNA is thought to reside on chromosome 12.  
Accordingly, polynucleotides related to this invention are useful as a marker in linkage  
analysis for chromosome 12.

This gene is expressed primarily in brain, keratinocytes and fibroblasts.  
Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, disorders of the brain and epidermal system. Similarly, polypeptides and  
antibodies directed to these polypeptides are useful in providing immunological probes  
for differential identification of the tissue(s) or cell type(s). For a number of disorders  
of the above tissues or cells, particularly of the epidermal and neural systems,  
expression of this gene at significantly higher or lower levels may be routinely detected  
in certain tissues or cell types (e.g. skin, brain, cancerous and wounded tissues) or  
bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or  
another tissue or cell sample taken from an individual having such a disorder, relative to  
the standard gene expression level, i.e., the expression level in healthy tissue or bodily  
fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides  
corresponding to this gene are useful for the treatment and diagnosis of diseases of the

neural and epidermal systems. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Additionally, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. Moreover, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm).

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1117 of SEQ ID NO:42, b is an integer of 15 to 1131, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

### 35 FEATURES OF PROTEIN ENCODED BY GENE NO: 33

The translation product of this gene shares sequence homology with a sodium dependent sulfate transporter which is thought to be important in sulfate uptake by cells. The gene encoding the disclosed cDNA is thought to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7. One embodiment of this gene comprises polypeptides of the following amino acid sequence:

MPQSLSSLASSSSFQKXKPCFGKKNKGNGENQEHSLGTEPIITWKDFQKTMPPWE  
 IVILVGGGYALASGSKSSGLSTWIGNQMLSLSSLPWAVTLACILVSIIVTEFVS  
 NPATITFLPILCSLSETLHINPLYTLIPVTMCISFVMLPVGNPPNAIVFSYGHCCQ  
 IKDMVKAGLVNIGLVVMVAINTWGVSLFHLDTYPAWARVSNITDQA (SEQ  
 ID NO:304), NDGENQEHSLGTEPIITWKDFQK (SEQ ID NO:305), IGNOQMLSLSS  
 LPPWAVTLACILV (SEQ ID NO:306), ATTITFLPILCSLSETLHINPLYTLIP (SEQ  
 ID NO:307), LPVGNPPNAIVFSYGHCCQIKDMVKAG (SEQ ID NO:308), and/or  
 LVVMVAINTWGVSLFHLDTYPAWARVSN (SEQ ID NO:309). An additional  
 embodiment is the polynucleotides encoding these polypeptides.

This gene is expressed primarily in placenta, and to a lesser extent, in infant brain and spinal cord.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic, reproductive, or central nervous system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. CNS, reproductive, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in placental and neural tissues, combined with the homology to a sodium dependent sulfate transporter indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of metabolic disorders involving sodium and sulfate metabolism and CNS disorders involving neuronal signalling abnormalities. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative

disease states, behavioural disorders, or inflammatory conditions such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and precognition. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1319 of SEQ ID NO:43, b is an integer of 15 to 1333, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 34

Contact of cells with supernatant expressing the product of this gene increases the permeability of bovine chondrocyte cells to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product of this gene binds a receptor on the surface of the chondrocyte cell. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating chondrocyte cells.

This gene is expressed primarily in CD34 positive cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or reproductive disorders, particularly diseases related to lymphocytes. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. bone, immune, hematopoietic, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:169 as residues: Leu-26 to Arg-32, Asn-40 to Ser-46.

The tissue distribution in CD34 positive cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis or treatment of the diseases of the immune system particularly those related to T lymphocytes.

Furthermore, the tissue distribution, as well as the detected calcium flux biological activity data, suggest that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of bone and hematopoietic disorders. The ability of the translation product of this gene to induce a calcium flux in chondrocytes indicates that it may play a role in the survival, proliferation, and/or growth of bone.

Therefore, it may be useful in influencing bone mass in such conditions as osteoporosis. More generally, as evidenced by expression in CD34 positive cells, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells, and may be of use in the augmentation of the numbers of stem cells and committed progenitors. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 990 of SEQ ID NO:44, b is an integer of 15 to 1004, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 35

The gene encoding the disclosed cDNA is thought to reside on chromosome 9. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 9.

This gene is expressed primarily in the brain, and to a lesser extent, in liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting the brain, central nervous system, or liver, including cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, hematopoietic, or central nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. brain, liver, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, bile, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25

The tissue distribution in brain and liver tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the immune, hematopoietic, or central nervous systems.

Furthermore, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo. Alternatively, the

35

expression within hepatic tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1480 of SEQ ID NO:45, b is an integer of 15 to 1494, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

15

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 36

When tested against U937 and Jurkat cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid and T-cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

20

25

30

35

ETCPNIGIELRQAPTSLYILLHHIQPTTPHPMLGRSYVLPFASXNHEHGLPNQI  
PKGDRNGNIRHSRIT FPCSSSTLPQESHLGFIRSKLHGLVRPGKDLRGRRSL  
QLSKHSLSTCYMLRWETYSYKQVSYTAV (SEQ ID NO:310), QRHQENDKRNVH  
RFLHTCVHMPMCTHTHTQAVLSLTWEGQFSNVASFSLKRIPLSII YIHSSHSP  
RRFVKVCQLRQEKALEL TEVYVSASLKLQLYHLHCHFTAV (SEQ ID NO:311),  
RQAPTSLYILLHHIQPTTPHPMLG (SEQ ID NO:312), SHLGFIRSKLHGLVRPG  
KDLRGRRS (SEQ ID NO:313), RNVHRLHTCVHMPMCTHTHTQ (SEQ ID

55

NO:314), and/or QLROEKALTEVYVSASLKLQLYH (SEQ ID NO:315).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in neutrophils.

- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the immune system, particularly neutropenia, cancer, inflammatory diseases and allergies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- The tissue distribution in neutrophils, combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of diseases of the immune system since expression is primarily in neutrophils, and may be useful as a growth factor for the differentiation or proliferation of neutrophils for the treatment of neutropenia following chemotherapy or may be useful in the treatment of immune dysfunction or anti-inflammatory by inhibiting infiltration of neutrophils to the site of injury or distress.

- Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

- Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

- Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1152 of SEQ ID NO:46, b is an integer of 15 to 1166, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

56

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 37

- In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PRVGRKEPGCLGPRAGGDSQKEIGSWQDM (SEQ ID NO:316), LSKGNRMAADDNDGDTSLFDVFSASPLKNNDEGLDIA GLDSAVSDSA SKSCVPSRNCIDL YEELTEEGTAKATYNDLQVEYGGCQ LQMKELMKKFEIQTNFSLINENQSLKKN ISALIKTAR VEINRKDEEI SNLHQKIVLSFHFEIILKQGHILQKQKILNLDLHWMLVQRLTRAKS DYSKD VHHSTSLPNLEKEGKPHSDKRSTSHLPTSVKEKCTNGVWSRSHYQVGE GSSN EDSRRGRKDIRHS QFNRGTERVRKDLSTGCGDGEPRILEASQRLQGT S (SEQ ID NO:317), NRMAADDNDGDTSLFDVFSASPLKN (SEQ ID NO:318), CLDLY EELTEEGTAKATYNDL (SEQ ID NO:319), DEISNLHQKIVLSFHFEIILKQG (SEQ ID NO:320), EKEGKPHSDKRSTSHLPTSVKE (SEQ ID NO:321), and/or TERVRKDLSTGCGDGEPRILEASQRL (SEQ ID NO:322). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in activated T cells.

- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and inflammatory disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- The tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune and inflammatory disorders. Furthermore, expression of this gene product in tonsils indicates a role in regulating the proliferation, survival, differentiation, and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other

processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmune disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1522 of SEQ ID NO:47, b is an integer of 15 to 1536, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 38

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of chondrocytes to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both chondrocytes, in addition to other cell lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating chondrocytes. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH

and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

5 KSYRRTMGGTRGIIKLVNVCLKHPKNTLSQQLVFAKINKILISKTTK  
STNLKGLKCLPPLSVSIHPTFIYKHNHTTLRIVFGTYFDFFPYRKNKDKQAFEGE  
DWESSLNVSDAW (SEQ ID NO:323), TKRGIKLVNVCLKHPKNTLS (SEQ ID  
NO:324), and/or SIHPTFIYKHNHTTLRIVFGTYFDFF (SEQ ID NO:325).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

10 The gene encoding the disclosed cDNA is believed to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

This gene is expressed primarily in resting T-cells, and to a lesser extent in retina and placenta.

15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, reproductive, or eye disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Immune, hematopoietic, eye, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:173 as residues: Met-1 to Pro-12.

The tissue distribution of this gene predominantly in T-cells and placenta, combined with the detected calcium flux activity indicates that the gene could be important for the treatment or detection of immune or hematopoietic disorders including arthritis, asthma, immunodeficiency diseases and leukemia. Expression of the gene at high levels in the retina indicates a role in the treatment and/or detection of eye disorders including color blindness, blindness, vision defects, and light sensitivity. Protein, as

well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1024 of SEQ ID NO:48, b is an integer of 15 to 1038, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 39

This gene is expressed primarily in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, degenerative and behavioral diseases of the brain such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, specific brain tumors, aphasia, mania, depression, dementia, paranoia, addictive behavior and sleep disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., brain, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:174 as residues: Pro-35 to Met-42.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of developmental,

degenerative and behavioral diseases and conditions of the brain such as aphasia, depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, specific brain tumors, mania, depression, dementia, paranoia, addictive behavior and sleep disorders.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1162 of SEQ ID NO:49, b is an integer of 15 to 1176, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 40

The gene encoding the disclosed cDNA is thought to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.

This gene is expressed primarily in synovium.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the muscular-skeletal system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the muscular skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., synovium, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:175 as residues: Pro-15 to Cys-29, Gly-40 to Tyr-54, Pro-72 to His-79.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the muscular skeletal system. Furthermore, the expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis, as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Ateleostegenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 717 of SEQ ID NO:50, b is an integer of 15 to 731, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 41

The translation product of this gene shares sequence homology with Enoyl-CoA hydratase, which is an RNA binding protein with intrinsic enzymatic activity thought to be important in metabolic disorders. The gene encoding the disclosed cDNA is thought to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in fetal liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic disorders, liver disorders and cancer. Similarly, polypeptides

and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic and metabolic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. liver, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:176 as residues: Pro-10 to Arg-15, Leu-96 to Ser-103, Gly-172 to Pro-178, Gly-213 to Asp-218, Asn-268 to Leu-275, Arg-282 to Phe-289.

The tissue distribution and homology to Enoyl-CoA hydratase indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of metabolic and liver diseases and cancer. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1423 of SEQ ID NO:51, b is an integer of 15 to 1437, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 42

This gene is expressed primarily in rhabdomyosarcoma tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the muscular skeletal system and cancer. Similarly,

polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the muscular skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. musculo-skeletal, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides

corresponding to this gene are useful for treatment and diagnosis of disorders of the muscular skeletal system and cancer. Furthermore, the tissue distribution indicates a role in the detection and treatment of disorders and conditions affecting the musculo-skeletal system, in particular rhabdomyosarcomas as well as related cancers. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1355 of SEQ ID NO:52, b is an integer of 15 to 1369, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 43

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of aberrant immune responses to foreign antigens. Furthermore, expression of this gene product in neutrophils indicates a role in the regulation of the proliferation, survival, differentiation, and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1023 of SEQ ID NO:53, b is an integer of 15

to 1037, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

#### 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 44

This gene is expressed primarily in neutrophils induced with IL-1 and LPS. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly in aberrant neutrophil responses to infection. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:179 as residues: Lys-36 to Cys-42.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a lack of immune response to infection. Furthermore, expression of this gene product in neutrophils indicates a role in the regulation of the proliferation, survival, differentiation, and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion

of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1359 of SEQ ID NO:54, b is an integer of 15 to 1373, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

#### 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 45

This gene is expressed primarily in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, CNS disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system (CNS), expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. brain, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the central nervous system. Furthermore, elevated expression of this gene product within the frontal cortex of the brain indicates that it may be involved in neuronal survival, synapse formation, conductance, neural differentiation, etc. Such involvement may

impact many processes, such as learning and cognition. It may also be useful in the treatment of such neurodegenerative disorders as schizophrenia, ALS, or Alzheimer's. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1333 of SEQ ID NO:55, b is an integer of 15 to 1347, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 46

This gene is expressed primarily in spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly those affecting the spleen, such as in T- and B-cell maturation and their resulting efficacy in the immune response. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, spleen, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:181 as residues: Ser-20 to Ser-34, Thr-40 to Ser-46.

The tissue distribution in spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the spleen and immune system. Furthermore, this gene may play a role in the

survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in the augmentation of the numbers of stem cells and committed progenitors. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmune disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 808 of SEQ ID NO:56, b is an integer of 15 to 822, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

## 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 47

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

QRPRQPWXPMTLMGTGIPVFAHKMLPDPCHLSTHINPKPXXPDGDEQK  
SQGTIEWCDREGKKRSI (SEQ ID NO:326), PMTLMGTGIPVFAHKMLPDP

(SEQ ID NO:327), PPCHLSCTHINPKPXPQGDE (SEQ ID NO:328), EQKSQGT  
 EEWCDEGKKRRSI (SEQ ID NO:329), DEWGAGRRMEWEDNLPLEFSCPVT  
 KLLSVPSWTPLDAQMLLLFFPSLSHHSSVPWLFCSPPCGXXGLGFI (SEQ ID  
 NO:330), EWEDNLPLEFSCPVTKLLSVP (SEQ ID NO:331), PSWTPLDAQM  
 5 LLLFFPSLSHH (SEQ ID NO:332), and/or HSSVPWLFCSPPCGXXGLGFI (SEQ  
 ID NO:333). Polynucleotides encoding these polypeptides are also encompassed by the  
 invention.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as  
 10 reagents for differential identification of the tissue(s) or cell type(s) present in a  
 biological sample and for diagnosis of diseases and conditions which include, but are  
 not limited to, diseases of the immune system, including neutropenia, cancer,  
 inflammatory diseases and allergies. Similarly, polypeptides and antibodies directed to  
 these polypeptides are useful in providing immunological probes for differential  
 15 identification of the tissue(s) or cell type(s). For a number of disorders of the above  
 tissues or cells, particularly of the immune system, expression of this gene at  
 significantly higher or lower levels may be routinely detected in certain tissues and cell  
 types (e.g. Immune, hematopoietic, and cancerous and wounded tissues) or bodily  
 fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another  
 20 tissue or cell sample taken from an individual having such a disorder, relative to the  
 standard gene expression level, i.e., the expression level in healthy tissue or bodily  
 fluid from an individual not having the disorder.

The tissue distribution in neutrophils indicates that polynucleotides and  
 polypeptides corresponding to this gene are useful for treatment/diagnosis of diseases  
 25 of the immune system since expression is primarily in neutrophils, and may be useful  
 as a growth factor for the differentiation or proliferation of neutrophils for the treatment  
 of neutropenia following chemotherapy or may be useful in the treatment of immune  
 dysfunction or anti-inflammatory by inhibiting infiltration of neutrophils to the site of  
 injury or distress. Protein, as well as, antibodies directed against the protein may show  
 30 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available  
 and accessible through sequence databases. Some of these sequences are related to SEQ  
 ID NO:57 and may have been publicly available prior to conception of the present  
 invention. Preferably, such related polynucleotides are specifically excluded from the  
 35 scope of the present invention. To list every related sequence is cumbersome.  
 Accordingly, preferably excluded from the present invention are one or more  
 polynucleotides comprising a nucleotide sequence described by the general formula of

a-b, where a is any integer between 1 to 522 of SEQ ID NO:57, b is an integer of 15 to  
 536, where both a and b correspond to the positions of nucleotide residues shown in  
 SEQ ID NO:57, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 48

This gene is expressed primarily in prostate, brain and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as  
 10 reagents for differential identification of the tissue(s) or cell type(s) present in a  
 biological sample and for diagnosis of diseases and conditions which include, but are  
 not limited to, disorders of the reproductive, CNS and immune system. Similarly,  
 polypeptides and antibodies directed to these polypeptides are useful in providing  
 immunological probes for differential identification of the tissue(s) or cell type(s). For a  
 15 number of disorders of the above tissues or cells, particularly of the reproductive, CNS  
 and immune system, expression of this gene at significantly higher or lower levels may  
 be routinely detected in certain tissues or cell types (e.g. immune, brain, prostate,  
 cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine,  
 synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual  
 20 having such a disorder, relative to the standard gene expression level, i.e., the  
 expression level in healthy tissue or bodily fluid from an individual not having the  
 disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID  
 NO:183 as residues: Asp-26 to Gly-32, Ile-37 to Trp-44.

The tissue distribution indicates that polynucleotides and polypeptides  
 25 corresponding to this gene are useful for the treatment and diagnosis of disorders of the  
 reproductive, CNS and immune systems. Furthermore, the tissue distribution indicates  
 that polynucleotides and polypeptides corresponding to this gene are useful for the  
 detection/treatment of neurodegenerative disease states and behavioural disorders such  
 as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome,  
 mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning  
 disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in  
 30 feeding, sleep patterns, balance, and perception. Additionally, the tissue distribution  
 indicates that polynucleotides and polypeptides corresponding to this gene are useful for  
 the diagnosis and/or treatment of hematopoietic disorders. This gene product is  
 primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in  
 the survival, proliferation, and/or differentiation of hematopoietic lineages. Expression

71

of this gene product in T cells strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

10 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1248 of SEQ ID NO:58, b is an integer of 15 to 1262, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.

15

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 49

This gene is expressed primarily in frontal cortex of schizophrenics.

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, CNS diseases and Schizophrenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. brain, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample

25 taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the CNS and schizophrenia. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the brain and nervous system. Elevated

35

72

expression of this gene product within the frontal cortex of the brain indicates that it may be involved in neuronal survival; synapse formation; conductance; neural differentiation, etc. Such involvement may impact many processes, such as learning and cognition. It may also be useful in the treatment of such neurodegenerative disorders as schizophrenia, ALS, or Alzheimer's.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

10 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1255 of SEQ ID NO:59, b is an integer of 15 to 1269, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.

15

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 50

20 This gene is expressed primarily in the testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive or endocrine disorders, particularly for male infertility and testicular cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, testicular, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30

35 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:185 as residues: His-62 to Ser-74, Leu-99 to Gln-104.

The tissue distribution in testes indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating male infertility. The protein product is likely involved in sperm development and could be administered by injection or related techniques. Alternatively, this gene could be transfected in gene-replacement treatments into the cells of the testes and the protein products could be produced. The presence of expression of this gene at either the RNA or protein level could be used as a diagnostic in testicular cancer. Furthermore, the tissue distribution indicates that the protein product of this gene is useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:60 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1815 of SEQ ID NO:60, b is an integer of 15 to 1829, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 51

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: QGLSHIFWMNEQTLK (SEQ ID NO:334). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in activated T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, particularly acute inflammatory conditions or autoimmune disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in activated T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for modulating the response of activated T-cells to treat inflammation or autoimmune diseases. The expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmune disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

75

ID NO:61 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1098 of SEQ ID NO:61, b is an integer of 15 to 1112, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:61, and where b is greater than or equal to a + 14.

10

## FEATURES OF PROTEIN ENCODED BY GENE NO: 52

When tested against U937 cell lines, supernatants removed from cells

containing this gene activated the GAS (gamma activating sequence) promoter element.

15

Thus, it is likely that this gene activates myeloid cells, including their progenitors,

through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT

pathway is a large, signal transduction pathway involved in the differentiation and

20

proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the

binding of the GAS element, can be used to indicate proteins involved in the

proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

25

TLVCLGVSSSEGCPRDVTGPGCCFSLTLTGF (SEQ ID NO:335), ADLIVLWH  
HHPLWPQHLLPSSGASHDH VELTVYPKTVASWILLELSRPPIFCLFTXPALT  
XHGLDRVAALVECTWXXXGMWYRRRYSCCQFRDRSI RDVFPEAVMLQQH  
LRHLAVATYRCRRSPCKAFTVEAEGGKPRAPVSGTGFKHGOEPGOSTSP  
HWFWG HLQLLVLSVNNRQLFVQGRAGYLTENTGLPCPKLLTLRLGLT

30

PGVGHGLCA YRRGCLAWRLDXAS (SEQ ID NO:336), ILWRQAPEPHCSQDSV  
SSSPRLQEDLAHYTVTRHPHFRSLPSAWCSHSSLLPVSLPRHALATKSPNMX  
XSSPILHLIQFTQISS PLGGXVQPPQOTASPICTQPMSHPRRQASQQCEQ  
QLWTGQTSHLQIPCPALNKL PVVDTOQKELQMSPE PMWGCPSRLPLM  
LLESCA (SEQ ID NO:337), MLQQLRHLAVATYRCRRSPCKAFTVEAEGGK  
(SEQ ID NO:338), VTQYTRHPHFRSLPSAWCSHSSLLPVSLP (SEQ ID NO:339),  
and/or GQTASPICTQPMSHPRRQASQQCEQLW (SEQ ID NO:340).

35

Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in activated T-cells.

76

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, particularly autoimmune diseases and inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15

Preferred epitopes include those comprising a sequence shown in SEQ ID

NO.187 as residues: Ser-25 to Lys-33.

The tissue distribution in neutrophils, combined with the detected GAS

biological activity indicates that polynucleotides and polypeptides corresponding to this

gene are useful for modulating the response of activated T-cells and other cells of the

20

immune system involved in inflammation and autoimmune diseases. Similarly, this

gene product may be involved in the regulation of cytokine production, antigen

presentation, or other processes that may also suggest a usefulness in the treatment of

cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of

lymphoid origin, the natural gene product may be involved in immune functions.

25

Therefore it may be also used as an agent for immunological disorders including

arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid

arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne,

neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated

cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-

30

graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune

infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug

induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and

tissues. In addition, this gene product may have commercial utility in the expansion of

stem cells and committed progenitors of various blood lineages, and in the

35

differentiation and/or proliferation of various cell types. Protein, as well as, antibodies

directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:62 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1660 of SEQ ID NO:62, b is an integer of 15 to 1674, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:62, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 53

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

FTLRLGPKNMAGVLWRHSLQTPHYISWCPLNLYRETGNCLLHVSG FLNSR  
LLANCSGEASGKVIQTLLWPGEISAVA (SEQ ID NO:341), KIRTLFSGHRLFT  
QQQSLTVKAHTAF MLIVKNLRYFIAFKFLMGISDSSEIGLVMQPLQKPHTV  
ILRGIEFLSPGGVLP (SEQ ID NO:342), MAGVLWRHSLQTPHYISWCPLNLYR  
(SEQ ID NO:343), and/or YFIAFKFLMGISDSSEIGLVMQPLQKPHT (SEQ ID  
NO:344). Polynucleotides encoding these polypeptides are also encompassed by the  
invention. The gene encoding the disclosed cDNA is believed to reside on chromosome  
12. Accordingly, polynucleotides related to this invention are useful as a marker in  
linkage analysis for chromosome 12.

This gene is expressed primarily in spleen, and to a lesser extent, in bone marrow and B-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic disorders, particularly multiple myeloma, immunodeficiencies, and infections. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic disorders, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Immune, hematopoietic, and cancerous and wounded

tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene predominantly in hematopoietic cell types and immune tissues indicates that the gene could be important for the treatment or detection of immune or hematopoietic disorders including arthritis, asthma, immunodeficiency diseases and leukemia. Moreover, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:63 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1031 of SEQ ID NO:63, b is an integer of 15 to 1045, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:63, and where b is greater than or equal to a + 14.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:63 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1031 of SEQ ID NO:63, b is an integer of 15 to 1045, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:63, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 54

The translation product of this gene shares very weak sequence homology with follicle-stimulating hormone beta subunit, which is thought to be important in hormonal regulation. When tested against K562 leukemia cell lines, supernatants removed from cells containing this gene activated the ISRE assay. Thus, it is likely that this gene activates leukemia cells through the Jak-STAT signal transduction pathway. The interferon-sensitive response element is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. The gene encoding the disclosed cDNA is thought to reside on chromosome 4. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 4.

This gene is expressed primarily in adult brain and adipocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., brain, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain and homology to follicle stimulating hormone indicates that polynucleotides and polypeptides corresponding to this gene are useful as a hormone for the diagnosis and treatment of endocrine disorders. The brain is a major site for secreting various hormones that regulate a wide range of body physiology. The secretory molecule encoded by this gene has very weak homology with FSH, and further indicates that it may serve as an endocrine. Endocrines can often be used in hormonal treatment of pathological disorders or change of physiology under certain circumstances such as in the treatment of reproductive disorders.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:64 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1037 of SEQ ID NO:64, b is an integer of 15 to 1051, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:64, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 55

The translation product of this gene shares homology with a number of a C. elegans proteases, which are thought to be important in programmed cell death.

This gene is expressed primarily in activated T-cells and to a lesser extent in human stomach.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders or stomach diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:190 as residues: Lys-41 to Arg-47, Asp-125 to Lys-139, Ser-177 to Glu-185.

The tissue distribution in activated T-cells and stomach indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders, transplantation or stomach disease.

Particularly, the expression of the gene by activated T-cells can be used for the development of therapeutic agents as immune suppressants or immune modulators.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

5 ID NO:65 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more

10 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1168 of SEQ ID NO:65, b is an integer of 15 to 1182, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:65, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 56

The translation product of this gene shares sequence homology with CD53 tetraspan transmembrane molecule which is thought to be important in leukocyte activation. The gene encoding the disclosed cDNA is thought to reside on chromosome

20 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

This gene is expressed primarily in KMH2 and activated T-cells, and to a lesser extent in tonsils.

Therefore, polynucleotides and polypeptides of the invention are useful as

25 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, infection, inflammation and other immune disorders. Similarly,

polypeptides and antibodies directed to these polypeptides are useful in providing

30 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system,

expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily

fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another

tissue or cell sample taken from an individual having such a disorder, relative to the

35 standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:191 as residues: Lys-99 to Arg-107.

The tissue distribution and homology to CD53 indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and development

5 of therapeutic agents for immune disorders including infection, allergy, inflammation, transplantation and immune deficiencies. Furthermore, expression of this gene product in tonsils indicates a role in the regulation of the proliferation; survival; differentiation;

and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production,

10 antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against

the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological

15 disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion

of stem cells and committed progenitors of various blood lineages, and in the

differentiation and/or proliferation of various cell types. Expression of this gene product

20 in T cells strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

25 ID NO:66 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the

scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more

30 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 661 of SEQ ID NO:66, b is an integer of 15 to

675, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:66, and where b is greater than or equal to a + 14.

## 35 FEATURES OF PROTEIN ENCODED BY GENE NO: 57

The gene encoding the disclosed cDNA is thought to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.

This gene is expressed primarily in fetal liver and to a lesser extent in neutrophils and keratinocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammation, autoimmune and skin defects. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., liver, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:192 as residues: Pro-41 to Glu-50.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of inflammatory, general immune, and skin disorders. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. This is particularly supported by the expression of this gene product in fetal liver, which is a primary site of definitive hematopoiesis. Expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune surveillance.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:67 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1091 of SEQ ID NO:67, b is an integer of 15 to 1105, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:67, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 58

This gene is expressed primarily in induced neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and haematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the haematopoietic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the haematopoietic and immune systems. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g., by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune surveillance.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:68 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1265 of SEQ ID NO:68, b is an integer of 15 to 1279, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:68, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 59

10 This gene is expressed primarily in the endometrium.  
Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of female infertility or reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, endometrium, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 The tissue distribution in endometrium indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating female infertility. The protein product may show utility in the preparation of the endometrium of implantation and could be administered either topically or orally. Alternatively, this gene could be transfected in gene-replacement treatments into the cells of the endometrium and the protein products could be produced. Similarly, these treatments could be performed during artificial insemination for the purpose of increasing the likelihood of implantation and development of a healthy embryo. In both cases this gene or its gene product could be administered at later stages of pregnancy to promote healthy development of the endometrium. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

35 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:69 and may have been publicly available prior to conception of the present

invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1624 of SEQ ID NO:69, b is an integer of 15 to 1638, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:69, and where b is greater than or equal to a + 14.

#### 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 60

This gene is expressed primarily in the cells of the immune system, such as eosinophils, T-cells, dendritic cells, and tonsils.

15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, such as AIDS, inflammatory conditions, multiple myeloma, or SCID. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types or cell type (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 The tissue distribution in various immune cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune system disorders, such as AIDS. Furthermore, expression of this gene product in tonsils and other immune cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility

as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:70 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 873 of SEQ ID NO:70, b is an integer of 15 to 887, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:70, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 61

The translation product of this gene shares homology with human stannin, which is thought to play a role in the toxic effects of organotins. Moreover, the protein product of this gene may also show utility in the treatment, and/or prevention of a variety of defects in calcium regulation and metabolism.

This gene is expressed primarily in GM-CSF treated macrophages.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, particularly in the treatment or amelioration of aberrant immune response to tumor or foreign antigens, and in phagocytosis.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, and cancerous and

wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:196 as residues: Gly-43 to Gly-55.

The tissue distribution in macrophages indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of immune disorders. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. Expression of this gene product in macrophage also strongly indicates a role for this protein in immune function and immune surveillance. The protein product may even serve to stimulate the immune response, or may be used to inhibit such a response which may be useful during host versus graft disease or autoimmune disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:71 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 850 of SEQ ID NO:71, b is an integer of 15 to 864, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:71, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 62

This gene is expressed primarily in activated monocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, immune or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in monocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and/or treating immune or hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. Expression of this gene product in monocytes also strongly indicates a role for this protein in immune function and immune surveillance. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:72 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1203 of SEQ ID NO:72, b is an integer of 15

to 1217, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:72, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 63

This gene is expressed primarily in activated monocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:198 as residues: Met-1 to Gly-6.

The tissue distribution in monocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and/or treating immune or hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. Expression of this gene product in monocytes also strongly indicates a role for this protein in immune function and immune surveillance. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors

of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:73 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1703 of SEQ ID NO:73, b is an integer of 15 to 1717, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:73, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 64

When tested against K562 leukemia cell lines, supernatants removed from cells containing this gene activated the ISRE assay. Thus, it is likely that this gene activates leukemia cells through the Jak-STAT signal transduction pathway. The interferon-sensitive response element is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.

Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. The gene encoding the disclosed cDNA is thought to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

This gene is expressed primarily in spleen from a chronic lymphocytic leukemia patient.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly leukemias. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system,

expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. spleen, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in leukemia cells combined with the detected ISRE biological activity in K562 cell lines indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of chronic lymphocytic leukemia. Furthermore, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:74 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

a-b, where a is any integer between 1 to 1262 of SEQ ID NO:74, b is an integer of 15 to 1276, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:74, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 65

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neutrophils inactivation and other immune system disorders. Furthermore,

polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. Expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune surveillance. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmune disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease,

35

scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:75 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

10

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1130 of SEQ ID NO:75, b is an integer of 15 to 1144, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:75, and where b is greater than or equal to a + 14.

15

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 66

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25

30

The tissue distribution in neutrophils indicates that polynucleotides and

polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system disorders. Furthermore, expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune

35

surveillance. The protein may also be useful in the inhibition of neutrophil activation which may show utility in host-versus-graft disease and autoimmune disorders.

Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmune disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:76 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 904 of SEQ ID NO:76, b is an integer of 15 to 918, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:76, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 67

When tested against U937 myeloid cell lines, supernatants removed from cells containing this gene activated the GAS promoter element. Thus, it is likely that this gene activates myeloid cells, and their progenitors, through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by

the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, such as neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:202 as residues: Asp-23 to Trp-29.

The tissue distribution in neutrophilism, combined with the detected GAS biological activity in myeloid cell lines indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune system disorders. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. Expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune surveillance. The protein product of this gene may show utility in the inhibition of neutrophil activation which may show utility in host-versus-graft disease and in autoimmune disorders. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmune disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease,

scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:77 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1051 of SEQ ID NO:77, b is an integer of 15 to 1065, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:77, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 68

This gene is expressed primarily in neutrophils induced with IL-1 and LPS. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, such as neutropenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of inactive immune response to foreign antigens. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for

the diagnosis and/or treatment of hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. Expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune surveillance. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The protein product of this gene may also show utility in the inactivation of neutrophils which may show utility in host-versus-graft disease or in autoimmune disorders, for example. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:78 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1112 of SEQ ID NO:78, b is an integer of 15 to 1126, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:78, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 69

The translation product of this nucleotide sequence shares homology with a number of cysteine proteinases. Contact of cells with supernatant expressing the product of this gene increases the permeability of TF-1 Myeloid cells to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that

is initiated when the product of this gene binds a receptor on the surface of the myeloid cell. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating myeloid cells.

This gene is expressed primarily in tissue from an ovarian tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders, particularly ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, immune, hematopoietic, ovarian, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The homology to proteins of the cysteine proteinase family, tissue distribution in ovarian tissues, combined with the detected calcium flux activity in myeloid cells indicates that the protein product of this gene may show utility in the treatment, and/or prevention of a variety of reproductive disorders, such as in ovarian cancer, or even in the modulation of the immune response to. Thus, it is useful for diagnosis and treatment of ovarian cancer. Furthermore, the biological activity data, when compared to the tissue distribution, suggest that the translation product of this gene could be useful in activating the immune system to respond to cancerous growths, particularly those involving ovarian cancer. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:79 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 970 of SEQ ID NO:79, b is an integer of 15 to

984, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:79, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 70

This gene is expressed primarily in anergic T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, such as autoimmune disorders including lupus. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:205 as residues: Ser-26 to Lys-34.

The tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in T-cells indicates a role in the regulation of the proliferation, survival, differentiation, and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Expression of this gene product in T cells also strongly indicates a role for this protein in immune function and immune surveillance. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-

host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:80 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1233 of SEQ ID NO:80, b is an integer of 15 to 1247, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:80, and where b is greater than or equal to a + 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 71

This gene shares homology with the human adult heart neutral calponin, which is implicated in the regulation and modulation of smooth muscle contraction. It is capable of binding to actin, calmodulin, troponin C, and tropomyosin. The interaction of calponin with actin inhibits the actomyosin Mg-ATPase activity. Therefore, the protein product of this gene may be beneficial as a vasoconstrictor or vasodilator, a muscle relaxor, treatment for tetanus stimuli, or for the treatment of various cardiovascular disorders. The gene encoding the disclosed cDNA is thought to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 19.

This gene is expressed primarily in adrenal gland tumor and human 12 week embryo. Furthermore, the gene is expressed in cardiomyopathy tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and disorders: endocrine, developmental, cardiovascular disorders, particularly diseases involving abnormal cellular proliferation such as cancers particularly of the adrenal gland, and disorders

involving heart muscle, such as cardiomyopathy. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the adrenal gland, heart, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. heart, muscle, endocrine, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of abnormal cellular proliferation, such as tumors. Alternatively, given the tissue distribution and the homology to human adult heart neutral calponin, it indicates that the translation product of this gene is useful for detecting, identifying, and/or treating disorders involving the degeneration of the regulation and modulation of smooth muscle contraction, such as is seen with cardiomyopathies. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:81 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 932 of SEQ ID NO:81, b is an integer of 15 to 946, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:81, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 72

This gene is expressed primarily in human bone and 9 week embryo. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, skeletal, immune, hemopoietic, or developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, bone, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:207 as residues: Ala-22 to Lys-36.

The tissue distribution in bone and embryonic tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis or the treatment of hemopoietic diseases. Furthermore, it may be useful in influencing bone mass in such conditions as osteoporosis. More generally, this gene may play a role in the survival, proliferation, and/or differentiation of hematopoietic cells in general, and may be of use in augmentation of the numbers of stem cells and committed progenitors.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:82 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1378 of SEQ ID NO:82, b is an integer of 15 to 1392, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:82, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 73

This gene is expressed primarily in T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, disorder of the immune or hematopoietic systems, particularly immunodeficiencies or inflammatory conditions, such as AIDS, SCID, leukemias, or multiple myeloma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:208 as residues: Asp-26 to Leu-36, Leu-42 to Phe-50.

The tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of disorders of the immune system such as AIDS. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in T cells also strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:83 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

a-b, where a is any integer between 1 to 1141 of SEQ ID NO:83, b is an integer of 15 to 1155, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:83, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 74

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells, including progenitors, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

DVLLPLLYLLVRKHINRAGINTFQGGANCI (SEQ ID NO:345), MCCCLCCT  
 SWSGSTSTERVSGTRFREVPTASCSSAPAPSELGSSLSVAAAALLSLPPRARLA  
 20 LPRLPRLPSQENLRNPKPGQNFQAPGAFVLSVA (SEQ ID NO:346), CAAA  
 SAVPPGPEAHQQSGYREHVSGRCQLHHVRPLHPRRPNASALLLLLSFSASH  
 QEPGWHSQGSRAFQARRISGIPRDRGTSKHLELLSFLVWHRCCLPGG RXF  
 CESLXQGRSACLLHQKPLMLSLAPLGEQLP TQLLLPPRSSGSKFXRYQRPGP  
 RVGVHLHKGSSEIREAGGPQLWPQCPLPVDLDVLRITQHCLQSEGPTS VH  
 25 LSSV (SEQ ID NO:347), EVEEAELAAALPMEPRASIAGASGAADMHFCPAXGTH.  
 RXA YPQEGSTYATELERTKAPGAWKFPWGPLGFLRFWSLGRGSLGSAS  
 RALGGRLLRAAAATEREEPSSDGA GAEDHDAVGTSCLKRVPDTRS VDVLDP  
 QEVQRQQHI (SEQ ID NO:348), RRISGIPRDRGTSKHLELLSFLVWHRCCL  
 (SEQ ID NO:349), and/or RTKAPGAWKFPWGPLGFLRFWSLGRGSL (SEQ ID  
 30 NO:350). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of smooth muscle tissue, particularly vascular disorders, such as vasculitis, microvascular disease, atherosclerosis, stroke, aneurysm, and

embolism. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of smooth muscle tissue, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. smooth muscle, vascular, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:209 as residues: Ser-23 to Glu-54.

The tissue distribution in smooth muscle, combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of vascular or cardiopulmonary disorders. In addition, the protein may show utility in the modulation of the immune system in response to various vascular disorders, particularly in the early stages of atherosclerosis, embolism, thrombosis, and stroke. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:84 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1359 of SEQ ID NO:84, b is an integer of 15 to 1373, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:84, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 75

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PRLAQLRLLSL (SEQ ID NO:351), QSDFREMNQNTNSTNAAKAREAQQGRGRD REAIFSSSALEHLVCYLQAYKHT

LLFIRSLNEHGLQQLLFQWRDGLFGNWFYRIPLLFTFGHCYHLSC PHLPC  
AQRSSRGTVPYVYLCPHPHHLHHYSWFPFLPYLHTLPKLQPKFGRPEQL  
NLLQVKPTSGTI ASAEQVWVK (SEQ ID NO:352). VCYLQAYKHTLLFIRSLNEH  
GLQQLLFQW (SEQ ID NO:353), and/or VPYVYLCPHPHHLHHYSWFPFLPYLH  
TLPKL (SEQ ID NO:354). Polynucleotides encoding these polypeptides are also  
encompassed by the invention. The gene encoding the disclosed cDNA is believed to  
reside on chromosome 1. Accordingly, polynucleotides related to this invention are  
useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in brain, ulcerative colitis, pancreas tumor,  
placenta, and to a lesser extent, in thyroid, bone marrow stromal cells, B-cell  
lymphoma, and hemangiopericytoma.

Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, tumors and degenerative conditions involving infiltration by the immune  
system, particularly in soft-tissues, in addition to, neural, gastrointestinal, metabolic,  
reproductive, endocrine, and hematopoietic, or immune disorders. Similarly,  
polypeptides and antibodies directed to these polypeptides are useful in providing  
immunological probes for differential identification of the tissue(s) or cell type(s). For a  
number of disorders of the above tissues or cells, particularly of the immune system,  
expression of this gene at significantly higher or lower levels may be routinely detected  
in certain tissues and cell types (e.g. neural, gastrointestinal, metabolic, reproductive,  
endocrine, hematopoietic, immune disorders, and cancerous and wounded tissues) or  
bodily fluids (e.g. lymph, serum, bile, amniotic fluid, plasma, urine, synovial fluid and  
spinal fluid) or another tissue or cell sample taken from an individual having such a  
disorder, relative to the standard gene expression level, i.e., the expression level in  
healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID  
NO:210 as residues: Lys-33 to Arg-51, Gly-64 to Gly-74.

The tissue distribution in brain tissues indicates that polynucleotides and  
polypeptides corresponding to this gene are useful for treating the secondary effects of  
immune system involvement in diseases such as pancreatic tumors, ulcerative colitis,  
and Alzheimer's disease. Protein, as well as, antibodies directed against the protein may  
show utility as a tumor marker and/or immunotherapy targets for the above listed  
tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available  
and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:85 and may have been publicly available prior to conception of the present  
invention. Preferably, such related polynucleotides are specifically excluded from the  
scope of the present invention. To list every related sequence is cumbersome.  
Accordingly, preferably excluded from the present invention are one or more  
polynucleotides comprising a nucleotide sequence described by the general formula of  
a-b, where a is any integer between 1 to 1244 of SEQ ID NO:85, b is an integer of 15  
to 1258, where both a and b correspond to the positions of nucleotide residues shown  
in SEQ ID NO:85, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 76

When tested against PC12 cell lines, supernatants removed from cells  
containing this gene activated the EGR1 (early growth response gene 1) promoter  
element. Thus, it is likely that this gene activates sensory neuron cells through the  
EGR1 signal transduction pathway. EGR1 is a separate signal transduction pathway  
from Jak-STAT, genes containing the EGR1 promoter are induced in various tissues  
and cell types upon activation, leading the cells to undergo differentiation and  
proliferation. In specific embodiments, polypeptides of the invention comprise the  
following amino acid sequence: ESERAVVYLITGALFIVSSCVLCPLPSSRRE (SEQ  
ID NO:355). Polynucleotides encoding these polypeptides are also encompassed by the  
invention. The gene encoding the disclosed cDNA is believed to reside on chromosome  
12. Accordingly, polynucleotides related to this invention are useful as a marker in  
linkage analysis for chromosome 12.

This gene is expressed primarily in activated T cells, tonsils, and activated  
monocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, immune and inflammatory disorders. Similarly, polypeptides and  
antibodies directed to these polypeptides are useful in providing immunological probes  
for differential identification of the tissue(s) or cell type(s). For a number of disorders  
of the above tissues or cells, particularly of the activated T cells, tonsils and activated  
monocytes, expression of this gene at significantly higher or lower levels may be  
routinely detected in certain tissues and cell types (e.g. Immune, hematopoietic, neural,  
and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma,  
urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an

individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in T-cells and immune tissues or cell types, combined with the detected EGR biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune and inflammatory disorders. Moreover, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO-86 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1304 of SEQ ID NO-86, b is an integer of 15 to 1318, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO-86, and where b is greater than or equal to a + 14.

35 FEATURES OF PROTEIN ENCODED BY GENE NO: 77

When tested against fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates fibroblast cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. The gene encoding the disclosed cDNA is thought to reside on chromosome 16.

Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 16.

10 This gene is expressed primarily in eosinophils and activated T-cells and to a lesser extent in lung and thymus stromal cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 Preferred epitopes include those comprising a sequence shown in SEQ ID NO-212 as residues: Met-1 to Trp-10.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders, including infection, allergy, inflammation, graft rejection and immunodeficiency. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. Expression of this gene product in T cells and eosinophils also strongly indicates a role for this protein in

immune function and immune surveillance.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:87 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 964 of SEQ ID NO:87, b is an integer of 15 to 978, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:87, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 78

One embodiment of this gene comprises polypeptides of the following amino acid sequence:

15 MWVXGEEVLGSHAAPAFELHRCFSEESCVSIPEVEGYVVLQPDAPQLLSGTA  
HFAFPAVDDEGTNGVLPPLDQITCSISHQVEAKKDESWQGTITDTRMSDEIVH  
NLDGCEISLVGDDLDPERESLLDITSLQQRGLLETNTSAYLTIAGVESITVYEEI  
20 LRQARYRLRHGAALYTRKFRLLSCSEMNGRYSSNEFIVEVNLHSMNRVAHP  
HVLXQQFELHRGHQPPPEMAGHSLASSHRNST (SEQ ID NO:356). LGSHAA  
SPAFLHRCFSEESCVSI (SEQ ID NO:357), GYVVVLPDPAPQLLSGTAHFAF  
AVDFE (SEQ ID NO:358), ITCSISHQVEAKKDESWQGTITDTRM (SEQ ID  
25 NO:359), NLDGCEISLVGDDLDPERESLLDITSLQ (SEQ ID NO:360), SAYLTI  
AGVESITVYEEILRQAR (SEQ ID NO:361), RLSCSEMNGRYSSNEFIVEVNLH  
SM (SEQ ID NO:362), and/or QQFELHRGHQPPPEMAGHSLASSHRN (SEQ ID  
NO:363). An additional embodiment is the polynucleotides encoding these  
polypeptides.

This gene is expressed primarily in brain and spleen.

30 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, brain afflictions such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, specific brain tumors, aphasia, mania, depression, dementia, paranoia, addictive behavior and sleep disorders, as well as  
35 immune disorders such as leukemias, lymphomas, AIDS, arthritis and inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in

providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., brain, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:213 as residues: Gly-36 to Leu-44.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of developmental, degenerative and behavioral diseases and conditions of the brain such as aphasia, depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, specific brain tumors, mania, depression, dementia, paranoia, addictive behavior and sleep disorders. In addition, the expression in spleen would suggest a possible role in the detection and treatment of immune disorders including: leukemias, lymphomas, auto-immunities, immunodeficiencies (e.g., AIDS), immuno-suppressive conditions (transplantation) and hematopoietic disorders as well as conditions of general microbial infection, inflammation or cancer.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:88 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1849 of SEQ ID NO:88, b is an integer of 15 to 1863, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:88, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 79

35 When tested against K562 leukemia cell lines, supernatants removed from cells containing this gene activated the ISRE assay. Thus, it is likely that this gene activates

leukemia cells through the Jak-STAT signal transduction pathway. The interferon-sensitive response element is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.

5 Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. One embodiment of this gene comprises polypeptides of the following amino acid sequence: MADSETFISLE

ECRGHKRARKRTSMETALALEKLPKQCQVLGIVTPGIVVXXPMGSGSNRPQEI  
10 EIGESGFALLFPQIEGI KIQPFHFQKPKNLTLERHQLTEVGLLDNPELRVVLV  
FGYNCKVGASNYLQQVVSTFSDMNILAGGQV DNLSLTSEKNPLDID AS  
GVVGLSFGHRIQSATVLLNEDVSDEKTAEAAMQRLKAANIPEHNTIGMFMA  
CVGRGFQYRAKGNVEADAFRKFPSPVPLGFFGNGEIGCDRIVTGNFILRKC  
NEVKDDDLFHSYTTIMA LIHLGSSK (SEQ ID NO:364), HKRARKRTSMETAL

15 ALEKLP (SEQ ID NO:365), MGSGSNRPQIEIGESGFALLFPQ (SEQ ID  
NO:366), FHFQKDPKNLTLERHQLTEVGL (SEQ ID NO:367), FGYNCKVGASN  
YLQVVSTFSD (SEQ ID NO:368), TSEKNPLDIDAGVVGLSFS (SEQ ID  
NO:369), NEDVSDEKTAEAAMQRLKAANIPEHN (SEQ ID NO:370), YYRAKGNV  
EADAFRKFPSPVPLGFG (SEQ ID NO:371), and/or IGCDDRVGTGNFILRKCNE  
20 VKDDDLFH (SEQ ID NO:372). An additional embodiment is the polynucleotides encoding these polypeptides.

This gene is expressed primarily in endothelial cells and to a lesser extent in reproductive and various endocrine organs.

25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer, cardiovascular and immune defects. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, cardiovascular, and reproductive systems, expression of this gene at significantly higher or lower levels

30 may be routinely detected in certain tissues or cell types (e.g. endothelial, reproductive, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:214 as residues: Ser-44 to Ala-50.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer, cardiovascular and reproductive disorders.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:89 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2072 of SEQ ID NO:89, b is an integer of 15 to 2086, where both a and b correspond to the positions of nucleotide residues shown  
10 in SEQ ID NO:89, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 80

20 This gene is expressed primarily in human tongue and TNF-induced epithelium. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, mucosal, oral, and inflammatory conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of mucosal and epidermal tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. tongue, epithelial, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:215 as residues: Ser-39 to Leu-48, Ala-65 to Pro-75, Pro-81 to Cys-87.

30

35

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of disorders of the oral and intestinal mucosa, inflammation and other epithelial disorders.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:90 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of  $a-b$ , where  $a$  is any integer between 1 to 877 of SEQ ID NO:90,  $b$  is an integer of 15 to 891, where both  $a$  and  $b$  correspond to the positions of nucleotide residues shown in SEQ ID NO:90, and where  $b$  is greater than or equal to  $a + 14$ .

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 81

This gene is expressed primarily in activated neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, autoimmune, and inflammatory conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and treatment of immune, autoimmune, and inflammatory disorders. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin,

the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Expression of this gene product in neutrophils strongly indicates a role for this protein in immune function and immune surveillance.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:91 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of  $a-b$ , where  $a$  is any integer between 1 to 1960 of SEQ ID NO:91,  $b$  is an integer of 15 to 1974, where both  $a$  and  $b$  correspond to the positions of nucleotide residues shown in SEQ ID NO:91, and where  $b$  is greater than or equal to  $a + 14$ .

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 82

This gene is expressed primarily in primary dendritic cells, and to a lesser extent in neutrophils, monocytes, and osteoblasts.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:217 as residues: Gly-47 to Arg-53.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of immune,

inflammatory and hematopoietic disorders. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Expression of this gene product in neutrophils and primary dendritic cells also strongly indicates a role for this protein in immune function and immune surveillance.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:92 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1409 of SEQ ID NO:92, b is an integer of 15 to 1423, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:92, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 83

One embodiment of this gene comprises polypeptides of the following amino acid sequence:

MPKRKVTFGVGDEDEDEIIVPKKLVDPVAGSGPGSRFGKHKSLDSDEEE  
 DDDGGSSKYDILASEDVEGQEAATLPSEGGVRIITPFIHQEEMEEGHFDADGN  
 YFLNRDAQRDSWLDNIDWVKIRERPPGQASDSEEDSLGQTSMSAQALLEG  
 LLELLPRETVAGALRRLGARGGGKGRKGPSPQRLDRLSGLADQMVAR  
 GNLGVVQETRELRAMRLKGLGCQTLPNPTPPSLDMFAEELAEELTPTPT  
 QRGEAESRGDGLVDMWVEYKWKENTGDAELYGPFTSAQMQTWVSEGYFPDGV  
 YCRKLDPPGGQFYNSKRIDFDLYT (SEQ ID NO:373), TFQGVGDEDEDEIIVP  
 KKKLVDP (SEQ ID NO:374), PGRFRFGKHKSLDSDEEDDDGGSSKY (SEQ ID  
 NO:375), EAATLPSEGGVRIITPFIHQEEMEEG (SEQ ID NO:376), FLNRDAQRDS  
 WLDNIDWVKIRERPPGQ (SEQ ID NO:377), SLGQTSMSAQALLEGLELL  
 PRETV (SEQ ID NO:378), RGGGKGRKGPSPQRLDRLSGLADQ (SEQ ID  
 NO:379), QETRELRAMRLKGLGCQTLPNPT (SEQ ID NO:380), DMFAEELAEEL  
 LETPTPTQRGEAESRGD (SEQ ID NO:381), and/or ELYGPFTSAQMOTW

VSEGYFPDGVYCRKLD (SEQ ID NO:382). An additional embodiment is the polynucleotides encoding these polypeptides.

This gene is expressed primarily in fetal lung, stromal cells and lymphoma cells. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, haemopoietic and respiratory disorders and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the haemopoietic and respiratory systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. lung, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:218 as residues: Met-1 to Trp-15, Thr-52 to Met-58.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of diseases of the haemopoietic and respiratory systems. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:93 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1351 of SEQ ID NO:93, b is an integer of 15 to 1365, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:93, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 84

In specific embodiments, polypeptides of the invention comprise the following

amino acid sequence: PHSSRVSFLQSLSF (SEQ ID NO:383), RGQPRPCVSGVCLSPHSRFECCSFYLQGLPALRCSTRTPGCHFRVFRSPCFSSRSRSCFT HICPVARIQSRALWVSTCLVLATPGKWLPLEDRALSLMLASLQCCPPFGAWWMIQVLTHKGRQAGLG PGVSSRPL (SEQ ID NO:384, S NIKSLPTNLSLLRAQTGDCAVSPGLAGPCHQGLEDTGPRAPCLPCVSTCIHQAPKGGQHWREASSIRDALSSGRSHFPGVMAKTKHVDTHNARENWIRKTGQMWVKHEGEBEBEGHEGKTLKK (SEQ ID NO:385), VCLSPHSRFECCSFYLQGLPALRC (SEQ ID NO:386), QFSRALWVSTCLVLATPGKWLPLEDR (SEQ ID NO:387), SLSLRAQTGDCAVSPGLAGPCHQRG (SEQ ID NO:388), and/or SGRSHFPGVMAKTKHVDTHNARENWIRT (SEQ ID NO:389). Polynucleotides encoding these polypeptides are also encompassed by the invention. When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells, including their progenitors, through the Jak-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in T-cells and lungs.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, respiratory and immune diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and respiratory systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. pulmonary, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, pulmonary surfactant or sputum, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:219 as residues: His-38 to Ala-43.

The tissue distribution in T-cells and lung tissue, combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the respiratory and immune systems. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The protein may show utility in modulating the immune response to various pulmonary disorders or conditions, particularly in emphysema, or ARDS.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:94 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 742 of SEQ ID NO:94, b is an integer of 15 to 756, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:94, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 85

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ARVEVQCQPGAKVDAGEGQ (SEQ ID NO:390), WVVL

5 SQLQA QGVAGMMCSYPEGQKKKEATRSRHWVPRSLPGMGSLAAPH  
 NPWLAPLLEIPXPVLCWEWKRKLJAL EEVSECRPGVGGGGFLSXCR  
 GHLSFLSGAPYPLFISPLX (SEQ ID NO:391), ELRHGGPRQVKDSFLDYM  
 GYPDEDRAGPSPRWFPFRFLSPPTV VPLCVELRLGFESGMGWGVPSSHS  
 EGGPEARWPLJAPMYTQTQWFQRPNSGRGPQPPQXRGEIGKRGY GAPER  
 10 KLRWPLLXWERXPPPTPRHSETSSAISFLFHSQRTGTWGISSANGASQGL  
 LWGAARXLPIP GRDLGTHLWDLVASFPFCPSG (SEQ ID NO:392), PEGQKK  
 GKEATRSRHWVPRSLPGM (SEQ ID NO:393), LRLGFESGMGWGVPSSHSEG  
 GPEAR (SEQ ID NO:394), and/or HSQRTCGWGISSANGASQGLLWGA (SEQ ID  
 NO:395). Polynucleotides encoding these polypeptides are also encompassed by the  
 15 invention.

This gene is expressed primarily in eosinophils, dendritic cells, Jurkat cells and tonsils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, or hematopoietic disorders, particularly inflammatory, autoimmune, allergy, and hypersensitivity conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in a variety of immune and hematopoietic-specific cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for modifying the response of the immune system in autoimmune diseases and inflammatory conditions. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or

leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines;

10 immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility);

15 chemotactic and chemokinetic activities (e.g. for treating infections, tumors), hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:95 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 924 of SEQ ID NO:95, b is an integer of 15 to 938, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:95, and where b is greater than or equal to a + 14.

123

This gene is expressed primarily in cells from fibrosarcoma tumors. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscle, or endothelial disorders, particularly fibrosarcomas and fibroids. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal-muscular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. skeletal-muscular, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fibrosarcoma tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various muscle disorders, in particular fibrosarcomas. In addition, the expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation). The gene or protein product of its gene may also show utility in modulating the immune response to proliferative tissues. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:96 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 914 of SEQ ID NO:96, b is an integer of 15 to 928, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:96, and where b is greater than or equal to a + 14.

124

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 87

This gene is expressed primarily in helper T-Cells, cerebellum, and to a lesser extent, in mesangial cells, fetal lung, fetal liver, cortex, and adipose tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, or neural disorders, particularly, for modulation of immune responses to viral or bacterial infections, or neurodeficiencies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. renal, developmental, pulmonary, hepatic, neural, metabolic, immune, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, bile, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in helper T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for modifying the immune response to foreign agents such as bacteria or virus. In addition, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed

progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Moreover, based upon the expression within the cerebellum and cortex, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:97 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1701 of SEQ ID NO:97, b is an integer of 15 to 1715, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:97, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 88

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates promyelocytic cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many

genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

FIMKLLYQLLMLTSSSYSLTHLCYSIFLCSFYHFPCNVSLFVLISEEPIYD  
(SEQ ID NO:396), LMLTTSSSYSLTHLCYSIFL (SEQ ID NO:397), LCSFYHF  
FPCNVSLFVLISEE (SEQ ID NO:398), MRKNIFAIDKMLTCLINELFRNQYKET  
NITREVKIKGTEENGIAQMSYKAI (SEQ ID NO:399), DKMLTCLINELFRNQ  
YKETN (SEQ ID NO:400), and/or NITREVKIKGTEENGIAQMSY (SEQ ID  
NO:401). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in fetal lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pulmonary and developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developmental and pulmonary systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Pulmonary, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, pulmonary surfactant or sputum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene only in fetal lung, combined with the detected GAS biological activity indicates that it plays a key role in development of the pulmonary system. This would suggest that misregulation of the expression of this protein product in the adult could lead to lymphoma or sarcoma formation, particularly in the lung. It may also be involved in the predisposition to certain pulmonary defects such as pulmonary edema and embolism, bronchitis and cystic fibrosis. Moreover, the protein product of this gene may be beneficial in the treatment of underdeveloped lung tissue, as exists in premature infants, both through the use of antibodies directed against the protein, through a gene therapy-based regime, or through the action of the protein

itself, either directly or indirectly. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:98 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 664 of SEQ ID NO:98, b is an integer of 15 to 678, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:98, and where b is greater than or equal to a + 14.

#### 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 89

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells, including their progenitors, through the Jak-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GISERKP (SEQ ID NO:402). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural or immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues

or cell types (e.g. neural, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:224 as residues: Ile-40 to Trp-50.

The tissue distribution in brain combined with the detected GAS biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of central nervous system disorders. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Furthermore, the protein may show utility in modulating the immune response to various neurodegenerative conditions. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:99 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1527 of SEQ ID NO:99, b is an integer of 15

to [54], where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:99, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 90

In specific embodiments, polypeptides of the invention comprise the following

amino acid sequence: QSPA VSYTVTSQVPWGLGLLAGEKR (SEQ ID NO:403),  
 LP SHPLRPLTFS SAMCMHLPPLCRRAALSAPFATQHRPWSVAAACLPRIHQN  
 10 PLDAEYPSGCCRMISFLPAACSNISQECH YTLMSHSEASTLQXAQLL (SEQ ID  
 NO:404), MLLQAAGRKLMRQPDGYSASRGFWWMRGRQAAATLHGRCWVA  
 KGADSAAL RQGGGRCMHIADEKVRGLSGCDGS (SEQ ID NO:405), LCRRA  
 ALSAPFATQHRPWSVAAACL (SEQ ID NO:406), RGFWMRGRQAAATLHGR  
 CWVAKG (SEQ ID NO:407), and/or QRGGRCMHIADEKVRGLSGCDG (SEQ ID  
 15 NO:408). Polynucleotides encoding these polypeptides are also encompassed by the  
 invention.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as  
 reagents for differential identification of the tissue(s) or cell type(s) present in a  
 20 biological sample and for diagnosis of diseases and conditions which include, but are  
 not limited to, inflammatory and immune conditions. Similarly, polypeptides and  
 antibodies directed to these polypeptides are useful in providing immunological probes  
 for differential identification of the tissue(s) or cell type(s). For a number of disorders  
 of the above tissues or cells, particularly of the immune system, expression of this gene  
 25 at significantly higher or lower levels may be routinely detected in certain tissues or cell  
 types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily  
 fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another  
 tissue or cell sample taken from an individual having such a disorder, relative to the  
 standard gene expression level, i.e., the expression level in healthy tissue or bodily  
 30 fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID  
 NO:225 as residues: Pro-34 to His-39, Pro-44 to His-54.

The tissue distribution in neutrophils indicates that polynucleotides and  
 polypeptides corresponding to this gene are useful for the study, diagnosis, and  
 35 treatment of inflammatory, general immune, and infectious diseases. Moreover, the  
 expression of this gene indicates a role in regulating the proliferation; survival;  
 differentiation; and/or activation of hematopoietic cell lineages, including blood stem

cells. This gene product may be involved in the regulation of cytokine production,  
 antigen presentation, or other processes that may also suggest a usefulness in the  
 treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed  
 in cells of lymphoid origin, the natural gene product may be involved in immune  
 5 functions. Therefore it may be also used as an agent for immunological disorders  
 including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia,  
 rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne,  
 neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated  
 cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-  
 10 graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune  
 infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug  
 induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and  
 tissues. In addition, this gene product may have commercial utility in the expansion of  
 stem cells and committed progenitors of various blood lineages, and in the  
 15 differentiation and/or proliferation of various cell types. Protein, as well as, antibodies  
 directed against the protein may show utility as a tumor marker and/or immunotherapy  
 targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available  
 and accessible through sequence databases. Some of these sequences are related to SEQ  
 20 ID NO:100 and may have been publicly available prior to conception of the present  
 invention. Preferably, such related polynucleotides are specifically excluded from the  
 scope of the present invention. To list every related sequence is cumbersome.  
 Accordingly, preferably excluded from the present invention are one or more  
 polynucleotides comprising a nucleotide sequence described by the general formula of  
 25 a-b, where a is any integer between 1 to 867 of SEQ ID NO:100, b is an integer of 15  
 to 881, where both a and b correspond to the positions of nucleotide residues shown in  
 SEQ ID NO:100, and where b is greater than or equal to a + 14.

## 30 FEATURES OF PROTEIN ENCODED BY GENE NO: 91

When tested against Jurkat cell lines, supernatants removed from cells  
 containing this gene activated the GAS (gamma activating sequence) promoter element.  
 Thus, it is likely that this gene activates myeloid cells through the JAK-STAT signal  
 transduction pathway. GAS is a promoter element found upstream of many genes  
 35 which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal  
 transduction pathway involved in the differentiation and proliferation of cells.

131

Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In addition, contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of stromal cells to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both stromal, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating stromal cells. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

15 THPSHPISVIQSTVSLCLTASSRRKKSDCLSCQVSCSQRPQSHKTNVAVWGFLM  
SRVHFSVRWVSGGRGI TGAICKESSLPCKEIQGKACYFCHHPAQQSTPFSHI  
(SEQ ID NO:409, VIQSTVSLCLTASSRRKKSDCLSCQV (SEQ ID NO:410),  
and/or ICKESSLPCKEIQGKACYFCHHPAQQ (SEQ ID NO:411)). Polynucleotides  
encoding these polypeptides are also encompassed by the invention.

20 This gene is expressed primarily in neutrophils, and to a lesser extent, in cord blood.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or developmental disorders, particularly inflammatory conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hemopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:226 as residues: Glu-32 to Arg-37.

132

The tissue distribution in neutrophils, combined with the detected GAS and calcium flux biological activities, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of inflammatory, infectious, and hemopoietic disorders. Similarly, expression within cord blood indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders, particularly of the developing hematopoietic system. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:101 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 933 of SEQ ID NO:101, b is an integer of 15 to 947, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:101, and where b is greater than or equal to a + 14.

## 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 92

The gene encoding the disclosed cDNA is thought to reside on chromosome 15. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 15.

30 This gene is expressed primarily in macrophages, T cells, dendritic cells, testes and pancreas tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders including testis and pancreas tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a

number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID

NO:227 as residues: Gln-85 to Lys-91, Pro-106 to Ser-117, Pro-124 to Ala-130, Trp-154 to Trp-160.

The tissue distribution indicates that polynucleotides and polypeptides

corresponding to this gene are useful for the diagnosis and treatment of immune disorders such as testes and pancreas tumors. Furthermore, polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. Expression of this gene product in T cells and primary dendritic cells also strongly indicates a role for this protein in immune function and immune surveillance. Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma,

immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity, immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:102 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1355 of SEQ ID NO:102, b is an integer of 15 to 1369, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:102, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 93

This gene is expressed primarily in brain tissue from a patient suffering from manic depression.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural disorders, particularly manic depression. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. brain, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of manic depression and other disorders of the CNS. Furthermore, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of

135

developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:103 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1217 of SEQ ID NO:103, b is an integer of 15 to 1231, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:103, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 94

This gene is expressed primarily in anergic T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly autoimmune disorders such as lupus. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Moreover, the protein product of this gene may play a role in the regulation of the proliferation; survival; differentiation; and/or activation of

136

potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Expression of this gene product in T cells also strongly indicates a role for this protein in immune function and immune surveillance. Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmune disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:104 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1228 of SEQ ID NO:104, b is an integer of 15 to 1242, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:104, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 95

This gene is expressed primarily in the spinal cord.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, neural disorders, particularly CNS, PNS, and a variety of congenital malformations of the spinal column and injuries of the spinal cord. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s) present in a biological sample. For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. CNS, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID

NO:230 as residues: Ser-44 to His-52.

The tissue distribution in spinal cord tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the brain and nervous system. Such involvement may impact many processes, such as learning and cognition. It may also be useful in the treatment of such neurodegenerative disorders as schizophrenia; ALS; or Alzheimer's. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:105 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1137 of SEQ ID NO:105, b is an integer of 15 to 1151, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:105, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 96

This gene is expressed primarily in smooth muscle.

35

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscular, vascular, or cardiopulmonary disorders, particularly a variety of diseases that include wasting and muscle mass loss including amyotrophic lateral sclerosis, embolism, atherosclerosis, stroke, and aneurysm. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neuromuscular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. muscle, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:231 as residues: Leu-37 to Trp-44.

The tissue distribution in smooth muscle indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various muscle disorders, such as muscular dystrophy, cardiomyopathy, fibroids, myomas, vascular disorders, and rhabdomyosarcomas. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:106 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1614 of SEQ ID NO:106, b is an integer of 15 to 1628, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:106, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 97

35

139

This gene is expressed primarily in the brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting the brain and central nervous system, such as Alzheimer's disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. brain, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:107 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1451 of SEQ ID NO:107, b is an integer of 15 to 1465, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:107, and where b is greater than or equal to a + 14.

140

# FEATURES OF PROTEIN ENCODED BY GENE NO: 98

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: SLQVLRITLGSKCGDPLRSRCKDVLPKLAGSLVT QAPISARAGPVYSHTLAFKQLAVLQGLGCLCERLDLGEGLDNKVADACILYLS VKQPVKIQEAARSVELHLMKVDPDSTWFLINELYCPVQFTPPHPSLHPVQLX GASGQNPXHDQAPAAQGAAVTLLPHHRGHRSLPYCQPEAGLTPRP (SEQ. ID NO:412). GADGNVSDFDNEEBEQSVPPKVDENDTRPDVEPPLPLQIQIAM DVMERCHLLSDKNLQIRLKVLVDVLDL CVVVLQSHKNQLPLAHQAWPSL VHRLTRDAPLAVLRAFKFYVPWEASVITFFAAGSAKMSCQSWLAP (SEQ ID NO:413), TLGSKCGDPLRSRCKDVLPLKLAGSL (SEQ ID NO:414), PVYSHTL AFKQLAVLQGLGCLCERLDLG (SEQ ID NO:415), SVPPKVDENDTRPDV EPPPLPLQIQIAM (SEQ ID NO:416), and/or WPSL VHRLTRDAPLAVLRAFK FYVPW (SEQ ID NO:417). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in kidney cortex, hemangiopericytoma, fetal spleen, infant brain, and to a lesser extent, in pancreas, lymph node, fetal liver, ovarian tumor, T-cells and other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, renal, immune, neural, or developmental disorders, particularly tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. renal, immune, neural, developmental, reproductive, ovarian, hepatic, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, bile, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:233 as residues: Pro-24 to Pro-37.

The tissue distribution in proliferating tissues and cells, combined with its distribution in developing tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating tumors. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:108 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1251 of SEQ ID NO:108, b is an integer of 15 to 1265, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:108, and where b is greater than or equal to a + 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 99

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: SLGISTFGIMVFSVYFGGIMISIPYSGISFGNKKELNID SCYNMVLKNIMFERSQT (SEQ ID NO:418), HASGNNDPLWELTYL (SEQ ID NO:419), MVFSVYFGGIMISIPYSGISF (SEQ ID NO:420), and/or FGNKKELNID SCYNMVLKN (SEQ ID NO:421). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in T-cells, spleen, and pancreas.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or endocrine disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Immune, hematopoietic, endocrine, pancreatic, cancerous and wounded

tissues) or bodily fluids (e.g. lymph, serum, bile, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:234 as residues: Thr-24 to Arg-29.

The tissue distribution of this gene predominantly in cell types or tissues associated with the immune system indicates that the gene could be important for the treatment or detection of immune or hematopoietic disorders including, but not limited to, arthritis, asthma, immunodeficiency diseases and leukemia. Moreover, the expression within pancreatic tissues indicates that the protein product of this gene may be useful in the treatment or prevention of a variety of metabolic disorders, such as diabetes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:109 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 992 of SEQ ID NO:109, b is an integer of 15 to 1006, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:109, and where b is greater than or equal to a + 14.

## 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 100

The gene encoding the disclosed cDNA is believed to reside on the X chromosome. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for the X chromosome.

This gene is expressed primarily in urinary bladder carcinoma HSC172 cells, and to a lesser extent, in human adult heart, lung, osteoclastoma, and liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, urogenital, or renal disorders, particularly urinary bladder carcinoma and

143

other cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the bladder, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. renal, cardiopulmonary, hepatic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, bile, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:235 as residues: Gly-18 to Lys-23, Pro-31 to Gly-38.

The tissue distribution in urinary bladder carcinoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and therapeutic targeting of urinary bladder carcinoma, osteoclastoma, and other cancers. Additionally, the tissue distribution in heart, lung and osteocarcinoma indicates an indication for the use of this gene and gene product in diagnosis and treatment of disorders in the heart and lung. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:110 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1244 of SEQ ID NO:110, b is an integer of 15 to 1258, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:110, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 101

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

MNSFSVIASIVLLPPGLSVSACLPSHSHQCKTFILLPSSEKTLXXXXP

144

SHSSTLGGQGQIMRSGDRHXHG (SEQ ID NO:422), VVFEXXFEMESH  
SVAQAGVQWRNLGSLQAL PQFMFPSCLSLPGSWDYRRPPSPANLXCIF  
SRDGGHHVSQXGLDLLTS (SEQ ID NO:423), IVVLLPFGLSVSACLPS  
HSHQCKTFIL (SEQ ID NO:424), and/or PGFMFPSCLSLPGSWDYRRPPSPAN  
(SEQ ID NO:425). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in adipose tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, obesity and other metabolic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. adipose, metabolic, neural, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:236 as residues: Arg-28 to Asn-33.

The tissue distribution in adipose tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of obesity and other metabolic and endocrine conditions or disorders. Furthermore, the protein product of this gene may show utility in ameliorating conditions which occur secondary to aberrant fatty-acid metabolism (e.g. aberrant myelin sheath development), either directly or indirectly. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:111 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1439 of SEQ ID NO:111, b is an integer of 15

to 1453, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:111, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 102

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: YRFKNPKCRLFSVPCR (SEQ ID NO:426), TQNRELLAWK PKGTDDICTSHNTHIQKMPGE ANSCCPRGAKSYHDCWPPALFPRCVAYLFL NKPATLRKKYYCKPYHTQLHPAWHREKSAFWIFETVSQS KQSLTSLVYS VNELLVLSNLAQWALG (SEQ ID NO:427), AWKPKGTDDICTSHNTHIQKMP (SEQ ID NO:428), CPRGAKSYHDCWPPALFPRCVAYL (SEQ ID NO:429), SYHI DCWPPALFPRCVAYLFLNKPAT (SEQ ID NO:430), and/or RKKYYCKPY HTQLHPAWHREKSAFWIFET (SEQ ID NO:431). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in dendritic cells and activated monocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly inflammation, immune defects, multiple myeloma, or immunodeficiencies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:237 as residues: Thr-27 to Arg-33.

The tissue distribution in dendritic cells and monocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of inflammatory and immune disorders such as cancers, particularly of dendritic cells and monocytes, but also of hematopoietic progenitors. Similarly, polynucleotides and polypeptides corresponding to this gene are useful for

the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency, etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:112 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1538 of SEQ ID NO:112, b is an integer of 15 to 1552, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:112, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 103

When tested against K562 leukemia cell lines, supernatants removed from cells containing this gene activated the ISRE assay. Thus, it is likely that this gene activates leukemia cells through the Jak-STAT signal transduction pathway. The interferon-sensitive response element is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.

Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. The gene encoding the disclosed cDNA is thought to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

This gene is expressed primarily in placenta, adipose tissue and fibroblasts. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the skin, developing organs and metabolic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the epidermal system metabolic system and embryogenesis, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. epidermal, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of the epidermal system, metabolic system and embryogenesis. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:113 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1475 of SEQ ID NO:113, b is an integer of 15 to 1489, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:113, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 104

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ICLDSCSQVSVTSLWSFLRVHSLVQTLW (SEQ ID NO:432). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the immune system, including neutropenia, cancer, inflammatory diseases and allergies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:239 as residues: Ala-35 to Asp-44.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of diseases of the immune system since expression is primarily in neutrophils, and may be useful as a growth factor for the differentiation or proliferation of neutrophils for the treatment of neutropenia following chemotherapy or may be useful in the treatment of immune dysfunction or anti-inflammatory by inhibiting infiltration of neutrophils to the site of injury or distress. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:114 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 593 of SEQ ID NO:114, b is an integer of 15 to 607, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:114, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 105

This gene is expressed primarily in stromal cells. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in stromal cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of immune disorders. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease,

sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmune disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:115 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1484 of SEQ ID NO:115, b is an integer of 15 to 1498, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:115, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 106

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: HYCC DFGTSLGFGYVPFHYVHMVNILTTIDFYHYKFC CSQNANKHCFKHQJMTTPYLNINKENLRFKNIF K (SEQ ID NO:433), TSL LGFYVPFHYVHMVNIL TTIDFY (SEQ ID NO:434), and/or FQIMTTVPYLN INKENLRFKNI (SEQ ID NO:435). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

This gene is expressed primarily in spleen, breast, placenta, ovarian cancer, and to a lesser extent, in B-cell lymphoma, pancreas tumor, osteoclastoma, thyroid, bone marrow, fetal liver, and stromal cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

151

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases characterized by immune cell activation and proliferation, particularly of the reproductive system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Immune, reproductive, metabolic, skeletal, endocrine, hepatic, placental, ovarian, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, bile, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.241 as residues: Ser-21 to Ser-27.

The tissue distribution in spleen and reproductive tissues indicates that the product of this gene is useful for modifying or detecting the proliferation or activation of cells in the hematopoietic system. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

152

ID NO.116 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1783 of SEQ ID NO.116, b is an integer of 15 to 1797, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO.116, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 107

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

```

15 ISESMSL VRSLOFYRGKNAERTVISSSHSCHLIDLEFQPRSDGEVISISLEKGY
   ELRWGMGLEDLGLGLGVSTRSTYRKKEPTKAGMHTACSEEMEPENREN
   (SEQ ID NO:436), DGSRSVAQARVQWHHRSGLPLPRFKQFPLRHLRVGGITG
   ACRHTQIFVVLVQMGFHHVGQAQLELLTSGDPPALASQAGITGVSHSTRPKL
   LSWLPSDNLGMALYSIQWALLANSLYFQVPSPLSMLCAFLPLWVPSA (SEQ
20 ID NO:437), RGKNRAERTVISSSHSCHLIDLEFQ (SEQ ID NO:438), LGLGVST
   RSTVRRKEPTKAGMHTACSEMEP (SEQ ID NO:439), GDPALASQSAGI
   TGVSHSTRPKL (SEQ ID NO:440), and/or ALYSIQWALLANSLYFQVPSPLSML
   (SEQ ID NO:441). Polynucleotides encoding these polypeptides are also encompassed
   by the invention.
```

This gene is expressed primarily in bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly bone marrow related diseases such as multiple myeloma, immunodeficiencies, and hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the bone marrow, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a

disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:242 as residues: Gln-46 to Asn-56.

5 The tissue distribution in bone marrow indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of central nervous system disorders and hemopoietic system developmental disorders.

Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia,

10 pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:117 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

25 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 938 of SEQ ID NO:117, b is an integer of 15 to 952, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:117, and where b is greater than or equal to a + 14.

30

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 108

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: DRILLFYSRDGGTTTSKGPNPACCLFLKKFYWNTA (SEQ ID NO:442), and/or DGQTTSKGPNPACCLFLKKF (SEQ ID NO:443). Polynucleotides encoding these polypeptides are also encompassed by the invention.

35

This gene is expressed primarily in early stage human brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural disorders, particularly developmental disorders of the brain. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the early stage human brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. neural, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:243 as residues: Asn-16 to Gln-21.

The tissue distribution in early stage brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of brain developing disorders. In addition, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Moreover, the expression within embryonic tissue indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly,

35

155

developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:118 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1171 of SEQ ID NO:118, b is an integer of 15 to 1185, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:118, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 109

20 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: DPRVRRRLDLGITL YLFL YIFL SL (SEQ ID NO:444), PALGECCLD A FL L L G K Q L K K S G E K P L L G S L M E Y A L S A I A A M N E P K T C S T A L K K Y V L E N H P G T S N S Y Q M H L L K K T L Q K C E K N G W M E Q I S G K G F S G T F Q L C F Y Y P S P G V L F P K K E P D S R D E D E D E D E S S E D S E D E P P K R R L Q K K T P A K S P G K A S V K Q R G S K P A P K V S A A Q R G K A R P L P K K A P P K A K T P A K K T R P S S T V I K K P S G G S S K K P A T S A R K E V K L P G K G S T M K K S F R Y K K (SEQ ID NO:445), D F E F H H D I L F S Y K I Y F T L K D F F M V D L P L P G N F T S F L A L V A G F F E E P P L G F L M T V D E G L V F L A G V L A L G G A F L G K L A P P R W A A E T L G A G L D P L C F T D A A F P G D L A G V F F C N L L L G G G S S S E S S D D S S S S S L E S S G F H C N R T P G L G (SEQ ID NO:446), C L D A F L F L G K Q L K K S G E K P L L G S L M E (SEQ ID NO:447), Y Q M H L L K K T L Q K C E K N G W M E Q I S G K G F S G T (SEQ ID NO:448), K T P A K S P G K A A S V K Q R G S K P A P K V S A A Q (SEQ ID NO:449), S S K R P A T S A R K E V K L P G K G S T M K K S F R (SEQ ID NO:450), V D E G L V F L A G V L A L G G A F L G K G L (SEQ ID NO:451), and/or G L D P L C F T D A A F P G D L A G V F F C N L L (SEQ ID NO:452). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in bone marrow stromal cells, and to a lesser extent, in human osteoblasts and T cells (helper 1).

156

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, connective tissues, haemopoietic, or immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. hematopoietic, immune, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:244 as residues: Glu-18 to Cys-38.

The tissue distribution in bone marrow stromal cells and T-cells suggest that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of defects of stromal development, and immune system disorders. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Moreover, the expression of this gene product in osteoblasts would suggest a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis, bone cancer, as well as, disorders affecting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Aicosteo genesis type II, metaphyseal

chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:119 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1084 of SEQ ID NO:119, b is an integer of 15 to 1098, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:119, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 110

This gene is expressed primarily in rhabdomyosarcoma, CD34 positive cells, breast lymph nodes, neutrophils and endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, developmental, proliferative, and vascular disorders, particularly fibroids or atherosclerosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune or hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, developmental, vascular, endothelial, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils and lymph nodes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of disorders in immune or hematopoietic systems. Similarly,

the secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. The protein may also show utility in the treatment or prevention of a variety of vascular disorders, particularly embolism, thrombosis, aneurysms, stroke, or atherosclerosis. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:120 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 791 of SEQ ID NO:120, b is an integer of 15 to 805, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:120, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 111

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: TMLFYLSQPDWQLDFFRVSFNG PVFFIIFNDRAGFRM QALVSAACRRSRYKLSVVY (SEQ ID NO:453), and/or DRAGFRMQALVLS

159

QAACRSRKYKL (SEQ ID NO:454). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

5 This gene is expressed primarily in human cerebellum, and to a lesser extent, in colon carcinoma cells, activated T-cells, fetal spleen, and placenta.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, or neural disorders, particularly neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune or central nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. neural, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 The tissue distribution in human cerebellum indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of diseases in the central nervous system and immune disorders. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo.

160

sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:121 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1584 of SEQ ID NO:121, b is an integer of 15 to 1598, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:121, and where b is greater than or equal to a + 14.

#### 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 112

The gene encoding the disclosed cDNA is thought to reside on chromosome 8. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 8.

20 This gene is expressed primarily in testes, fetal brain, and fetal liver. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, brain and liver diseases, reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver and brain expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, reproductive, hepatic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35 The tissue distribution in brain and liver tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of neural, hepatic, or metabolic diseases. Furthermore, the tissue distribution indicates that

polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the brain and nervous system. Such involvement may impact many processes, such as learning and cognition. It may also be useful in the treatment of such neurodegenerative disorders as schizophrenia; ALS; or Alzheimer's. The tissue distribution further indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Additionally, the tissue distribution indicates that the protein product of this gene is useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:122 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1006 of SEQ ID NO:122, b is an integer of 15 to 1020, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:122, and where b is greater than or equal to a + 14.

35 FEATURES OF PROTEIN ENCODED BY GENE NO: 113

This gene is expressed primarily in apoptotic T-cells, and to a lesser extent, in the frontal cortex of the brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or neural disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. Immune, hematopoietic, neural, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:248 as residues: Arg-19 to Gly-36, Val-44 to Leu-59.

The tissue distribution in apoptotic T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of immune disorders. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Expression of this gene product in T cells also strongly indicates a role for this protein in immune function and immune surveillance. Alternatively, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation,

neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:123 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1364 of SEQ ID NO:123, b is an integer of 15 to 1378, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:123, and where b is greater than or equal to a + 14.

#### 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 114

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly inflammatory conditions or immunodeficiencies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a malfunctioning immune system response to foreign antigens. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by

boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune surveillance. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:124 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1132 of SEQ ID NO:124, b is an integer of 15 to 1146, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:124, and where b is greater than or equal to a + 14.

#### 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 115

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: LAAGLNSLPALYHSVEISQ (SEQ ID NO:45), XYRMNT KLEESYKMTSLSRHQNVSLCKDMKTPAGDTYKAFLE (SEQ ID NO:456), SYKMTSLSRHQNVSLCKDM (SEQ ID NO:457), ICIESLMHYALVFEMAF MFPLVYHEMGSDSIRFHLQYVDCLPSMMRFFSFPL (SEQ ID NO:458), YI ALVFEMAFMFPLVYHEMG (SEQ ID NO:459), and/or SDSIRFHLQYVDCL PSMMPRF (SEQ ID NO:460). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in melanocytes, Merkel cells, synovial cells, ulcerative colitis, and to a lesser extent, in fetal spleen, bone marrow, jurkat cells, adrenal gland tumor rejected kidney from a failed transplantation.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, integumentary, skeletal, or gastrointestinal disorders, particularly tumors, including melanoma, lymphoma, and adrenal gland tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a

number of disorders of the above tissues or cells, particularly of the integumentary system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Integumentary; skeletal, gastrointestinal, immune, hematopoietic, renal, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in melanocytes indicates that polynucleotides and

polypeptides corresponding to this gene are useful for detecting and treating tumors particularly those involving melanocytes, lymphocytes and the adrenal gland. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines;

immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:125 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1661 of SEQ ID NO:125, b is an integer of 15

to 1675, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:125, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 116

When tested against fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 (early growth response gene 1) promoter element. Thus, it is likely that this gene activates fibroblast cells through the EGR1 signal transduction pathway. EGR1 is a separate signal transduction pathway from Jak-STAT, genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

15 GGVSVDGSLREETDVGEGRPRGGQSEGARVTRRPPDSNASAFDLDLDFS  
PFCWCYRLETPAEVVF SPAPLRLSGPLAPVVFVSTLPSLQSSFCGWD  
LPARPRGLSGFR (SEQ ID NO:461), FTNKCSKMSSTHLYKGSVDVLCYARS  
SESMSLSCGDVANAGR LTPRLHLARSASQGPPTLPRVPPRGRSPPPTA GESPA  
PRTXSLNHHKNIDHLSSNSHGKFRIYGQNDIKI (SEQ ID NO:462), QDVYTFVQ  
20 RFRPMLCTLRKYEPPVVRGRRRWQA HPSSAFGKKRLPRPPHPAQGAQRE  
QASHSWREPQNTFPRKP (SEQ ID NO:463), REETDVGEGRPRGGQSEGA  
RV (SEQ ID NO:464), GPGLAPVVFVSTLPSLQSSFCGWDLP (SEQ ID NO:465),  
MSSTHLYKGSVDVLCYARSESMSL (SEQ ID NO:466), SQGPPTLPRVPPRG  
SRPPTAGESPAPT (SEQ ID NO:467), RFRPMLCTLRKYEPPVVRGRRRW  
25 (SEQ ID NO:468), and/or RLPRPPHPAQGAQREQASHSWRE (SEQ ID NO:469).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in hematopoietic cells, endothelial cells, and in spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as

30 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic, integumentary, and immune disorders, particularly multiple myeloma, immunodeficiencies, leukemias, and vascular conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic, immune, and vascular systems, expression of this gene at significantly higher or lower

levels may be routinely detected in certain tissues and cell types (e.g. Immune, hematopoietic, integumentary, endothelial, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in spleen and hematopoietic cells, combined with the detected EGR1 biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of vascular, immune and/or hematopoietic disorders including arthritis, ischemia, auto-immune diseases, host-graft rejection, AIDS, leukemia and microbial infection. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphoproliferosis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, a utility for treating or preventing vascular or integumentary disorders may be anticipated for this gene based upon its expression within endothelial tissues in addition to its EGR1 activity. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:126 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1050 of SEQ ID NO:126, b is an integer of 15 to 1064, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:126, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 117

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

RGMGRGWL VSSGAAPFPLNGFCESREFFPDGSGVLLHWRPNXVLEIKVFGS  
RSQSLISSK NLKTSLLTFYGVVEVLNN (SEQ ID NO:470), LKLSADSSQA  
INMFSADCMRLHIALQTEMIPNRAPOGGAANLWHEAQYRRLPFSR AP  
TDAHQASARQGAQLPREQ (SEQ ID NO:471), PPLNGFCESREFFPDGSG  
VLLHWRPNX (SEQ ID NO:472), and/or NIFSADCMRLHIALQTEMIP NRA  
POGGA (SEQ ID NO:473). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the immune system, including neutropenia, cancer, inflammatory diseases and allergies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of diseases of the immune system since expression is primarily in neutrophils, and may be useful as a growth factor for the differentiation or proliferation of neutrophils for the treatment of neutropenia following chemotherapy or may be useful in the treatment of immune dysfunction or anti-inflammatory by inhibiting infiltration of neutrophils to the site of injury or distress. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:127 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1593 of SEQ ID NO:127, b is an integer of 15 to 1607, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:127, and where b is greater than or equal to a + 14.

10

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 118

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of renal mesangial cells to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both mesangial cells and other cell types, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating mesangial cells; Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell. In addition, when tested against fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 (early growth response gene 1) promoter element. Thus, it is likely that this gene activates fibroblast cells through the EGR1 signal transduction pathway. EGR1 is a separate signal transduction pathway from Jak-STAT, genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

TFRLVSAHLKTRKLINPEAAERRWRDWDSDRQGWLSVK (SEQ ID NO:474), and/or KTRKLINPEAAERRWRDWDSDR (SEQ ID NO:475). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in bone marrow cell lines, and to a lesser extent, in human endometrial stromal cells, human adult small intestine and human pancreas tumor.

35

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, haemopoietic and gastrointestinal tract disorders and stomatosis, in addition to endothelial, mucosal, or epithelial cell disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and digestive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g.hemaopoietic, immune, reproductive, gastrointestinal, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g.lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:253 as residues: Gly-25 to Arg-31, Ile-47 to Glu-57, Glu-120 to Arg-138.

The tissue distribution in bone marrow cells, combined with the detected calcium flux and EGR1 biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for immune and gastrointestinal tract disorders, and stomatosis, particularly tumors and proliferative disorders. More specifically, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:128 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the

35

171

scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1023 of SEQ ID NO:128, b is an integer of 15 to 1037, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:128, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 119

10 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: WNYTVNNLYLFSFSIVSMKFMHVL SINIF FGRARWLT  
 15 PVIPALLEAGGSLGQEFKTSLGKDGTPSLKIQKL AGHGGRLL (SEQ ID NO:476, DQPGKHGETLSLLKMOKL TWCGGMPFVIP SYSRSPRPENRLNL  
 GDRGCTELLHSLGNRVRLSKKKEVYMMELYSK (SEQ ID NO:477), VIPALLE  
 20 AEGGSLGQEFKTSLGKDGET (SEQ ID NO:478), and/or NRLNLGDRGCT  
 ELLHSLGNRVRLSKKKE (SEQ ID NO:479). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human fetal brain.

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological, developmental, and immunological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. neural, developmental, immune, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

35 The tissue distribution in fetal brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders relating to CNS and immune system. In addition, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of

172

neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, A.L.S., psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Furthermore, expression within fetal tissue indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:129 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

25 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1132 of SEQ ID NO:129, b is an integer of 15 to 1146, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:129, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 120

35 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: HASEHLAALPVNVKIGK (SEQ ID NO:480). Polynucleotides

encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

5 This gene is expressed primarily in T cells/helper 1.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, or haemopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Immune, haemopoietic disorders, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID

20 NO:255 as residues: Ile-31 to Glu-36, Leu-59 to Glu-73, Ser-109 to Ser-121, Ser-175 to Gln-182, Lys-258 to Lys-264.

The tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune disorders. Moreover, expression of this gene product indicates a role in regulating the proliferation, survival, differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease,

30 in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS,

leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease,

scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:130 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1158 of SEQ ID NO:130, b is an integer of 15 to 1172, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:130, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 121

20 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

LVCIILVHWIPLGAWGLSLMLFLIEQRGKGKWRNALLSVSFSVPQLQMOK  
VS LDSTPLNVNHDKMDIWKLTPLK (SEQ ID NO:481), IMIKWIFGNLL SCD  
LGCISTGLPQYQGLRLNFEYSLGFMRLSLWRSIAIQCFSS (SEQ ID NO:482),  
25 LLLSCDLGCISTGLPQYQGL (SEQ ID NO:483), and/or LRLNFEYSLGFM  
LRSLSWRS (SEQ ID NO:484). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 11. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 11.

30 This gene is expressed primarily in human gall bladder.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic, or gastrointestinal disorders, particularly those relating to the gall bladder. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of

the gastrointestinal tract system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. Metabolic, gastrointestinal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, bile, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:256 as residues: Ser-18 to Gly-26.

The tissue distribution in gall bladder tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of gall bladder disorders, or related metabolic conditions, such as gall stones. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 131 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 649 of SEQ ID NO:131, b is an integer of 15 to 663, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:131, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 122

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ASPHL FLEKWGRAFLKLL VPVISKIINIMAHQVKPPI FCAMIMCNLFCSGYEHLFTLMRFSEQJFDEV VFH (SEQ ID NO:485), and/or KLLVPVISKRINIMAH QVK PPIF (SEQ ID NO:486). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 4. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 4.

This gene is expressed primarily in glioblastoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural disorders, particularly glioblastoma multiform. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system (CNS), expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. neural, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:257 as residues: Ser-40 to Gly-45, Leu-73 to Arg-80.

The tissue distribution in glioblastoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of neural cell disorders. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:132 and may have been publicly available prior to conception of the present

invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 762 of SEQ ID NO:132, b is an integer of 15 to 776, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:132, and where b is greater than or equal to a + 14.

## 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 123

When tested against U937 and Jurkat cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells, including their progenitors, through the Jak-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway.

The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence:

FAVIRFESIHEFDWPNFYRSTHHLASHGFYFLNWFDERAWYPLGRIVGGTVY  
PGLMITAGLIHWILNT LNTVHIRDVCVFLAPTFSGLTSTISITLLTRELWNQGA  
GLLAACFIAIVPGYISRSVAGSFDNEGIAIFA LQFTYYLWVKS VKTGSVVF  
25 TMCCCLSYFYMVSAWGGYVFIINLPLHVFVILLMQRYSKRVYIAYSTFYI VGL  
ILSMQIPVGFQPIRTSEHMAAGVAFALLQAYAFQLYLRDLRTKQEFQTLFELGV  
SLAAGA VFLSVI YLTGTGYPWSGRFYSLWDTGYAKHIPIIASVSEHQ PTT  
WVSFFDLHL VCTFPAGLWFCIKNINDE RYFGKXGF (SEQ ID NO:487), EFD  
PWPNYRSTHHLASHGFYFLNWF (SEQ ID NO:488), TRELWNQAGALL  
AACFIAIVPGY (SEQ ID NO:489), TYLYLWVKS VKTGSVFWTMCCCL (SEQ ID  
30 NO:490), GVFAALLQA YAFQLYLRDLRTKQEFQ (SEQ ID NO:491), and/or YSLWD  
TGAYAKHIPIIASVSEHQPTTW (SEQ ID NO:492). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human colon carcinoma (HCC) cell line, and to a lesser extent, in human eosinophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, gastrointestinal or immune disorders, particularly colon carcinoma and leukemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the excretory and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. gastrointestinal, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:258 as residues: Glu-49 to Ser-54.

The tissue distribution in human colon carcinoma cell lines, combined with the detected GAS biological activity, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of colon cancer and immune disorders. In addition, expression within cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy, particularly in modulating the immune response to cancer-specific antigens.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:133 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1529 of SEQ ID NO:133, b is an integer of 15 to 1543, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:133, and where b is greater than or equal to a + 14.

# FEATURES OF PROTEIN ENCODED BY GENE NO: 124

5 This gene shares homology with elongation factor 1-Alpha (*giardia intestinalis*), which promotes the GTP-dependent binding of aminoacyl tRNA to the A-site of ribosomes during protein biosynthesis. One embodiment of this gene comprises polypeptides of the following amino acid sequence:

MGHML YLLGNINKRIMHKYXQESKKAGKASFAY AWVLDETGEERER  
10 GVTMDVGMTKEETTKVYT LMDAPGHKDFPNMITGAAQADVAVLVVDASR  
GHEBAGFETGGQTRHEGLL VRS LGVTQLAVAVN KMDQVNWQDERF QEIT  
GKLGHFLKQAGFKESDV GFPTSGLSGENLTRSSSELTKWYKGLCLEQ  
IDSFKPPQRSIDKPFRLCVSDVFKDQSGFCITG KIEAGYIQTGDRLL AMP  
NETCTVKGITLHDEPV DWAAAGDHVSLTL VGMDIKINVGCIFCGPKYP  
15 IKACTRFRARLLJFNIPTTKGFPVLLHYQTVSE PAVIKRLISVLNKSTG  
EVTKKKPKFLTKGQNAL VELQTRPPLALEL YKDFKELGRFMLRYGGSSTIAA  
GVVTEIKE (SEQ ID NO:493), L YLLGNINKRTMHKXQESKK (SEQ ID  
NO:494), LDETGEEREGVTMDVGMTKEET (SEQ ID NO:495), GHKDFPNMIT  
GAAQADVAVLV (SEQ ID NO:496), GFETGGQTRHEGLL VRS LGVTQL (SEQ ID  
20 NO:497), WQDERFQETGKLGHFLKQAGFK (SEQ ID NO:498), TSGLSGENL  
TRSSSELTKWY (SEQ ID NO:499), PQRSIDKPFRLCVSDVFKDQSGG (SEQ ID  
NO:500), LISVLNKSTGEVTKKKPKFLTK (SEQ ID NO:501), and/or QRPPLALELY  
KDFKELGRFMLRYGGS (SEQ ID NO:502). An additional embodiment is the  
polynucleotides encoding these polypeptides. The gene encoding the disclosed cDNA is  
25 thought to reside on chromosome 6. Accordingly, polynucleotides related to this  
invention are useful as a marker in linkage analysis for chromosome 6.

This gene is expressed primarily in colon tissue from a patient having ulcerative colitis, brain tissue, lung tissue, testes and endometrial tumor.

30 Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, ulcerative colitis, and testes and endometrial tumors. Similarly,  
polypeptides and antibodies directed to these polypeptides are useful in providing  
immunological probes for differential identification of the tissue(s) or cell type(s). For a  
35 number of disorders of the above tissues or cells, particularly of the immune system  
and reproductive system, expression of this gene at significantly higher or lower levels  
may be routinely detected in certain tissues or cell types (e.g. reproductive, immune,

cancerous and wounded tissues) or bodily fluids (e.g., serum, seminal fluid, pulmonary surfactant or sputum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 The tissue distribution in ulcerative colitis, testes and endometrial tumors indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing or treatment of a variety of reproductive or gastrointestinal disorders. Furthermore, the tissue distribution indicates that the protein product of this gene is useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g., endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:134 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2143 of SEQ ID NO:134, b is an integer of 15 to 2157, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:134, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 125

35 This gene is expressed primarily in skin.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, integumentary diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the integumentary system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g. integumentary, melanocyte, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in skin indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of diseases relating to integumentary conditions. Specifically, polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, vitiligo, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chondromalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:135 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 406 of SEQ ID NO:135, b is an integer of 15 to 420, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:135, and where b is greater than or equal to a + 14.

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HUSIG64	209423 10/30/97	pSport1	11	1010	1	1010	9	9	136	1	21	22	334
2	HATCI78	209368 10/16/97	Uni-ZAP XR	12	1559	1	1559	283	283	137	1	20	21	42
3	HSIDR70	209368 10/16/97	Uni-ZAP XR	13	1589	1	1589	110	110	138	1	17	18	86
4	HFADD53	209368 10/16/97	Uni-ZAP XR	14	1255	1	1255	183	183	139	1	22	23	121
5	HPMGT51	209423 10/30/97	Uni-ZAP XR	15	1191	1	1191	152	152	140	1	29	30	275
6	HFVAB79	209368 10/16/97	Uni-ZAP XR	16	1186	1	1186	139	139	141	1	15	16	194
7	HDTBP51	209407 10/23/97	pCMVSPORT 2.0	17	1182	1	1182	93	93	142	1	25	26	182

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
8	HLHFR19	209407 10/23/97	Uni-ZAP XR	18	1171	1	1171	24	24	143	1	30	31	121
9	HMEET96	209407 10/23/97	Lambda ZAP II	19	1337	73	1200	121	121	144	1	30	31	266
10	HTXCV12	209423 10/30/97	Uni-ZAP XR	20	1162	1	1162	183	183	145	1	27	28	91
11	HCEFB70	209423 10/30/97	Uni-ZAP XR	21	1837	1	1837	223	223	146	1	24	25	108
12	HDTAV25	209423 10/30/97	pCMVSPORT 2.0	22	1054	1	1054	100	100	147	1	38	39	87
13	HSATA21	209368 10/16/97	Uni-ZAP XR	23	1066	1	1060	49	49	148	1	25	26	73
14	HKIX103	209368 10/16/97	pBluescript	24	928	1	928	61	61	149	1	24	25	71
15	HDTDC56	209407 10/23/97	pCMVSPORT 2.0	25	966	1	966	210	210	150	1	24	25	151



Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
32	HRKPA09	209423 10/30/97	pBluescript	42	1131	1	1131	101	101	167	1	33	34	86
33	HAGAQ26	209368 10/16/97	Uni-ZAP XR	43	1333	157	1333	251	251	168	1	20	21	62
34	HCWFL55	209368 10/16/97	ZAP Express	44	1004	1	1004	40	40	169	1	19	20	47
35	HKAAE44	209368 10/16/97	pCMVSPORT 2.0	45	1494	1	1494	113	113	170	1	39	40	136
36	HNGEU90	209407 10/23/97	Uni-ZAP XR	46	1166	1	1166	17	17	171	1	20	21	88
37	HCFCC07	209407 10/23/97	pSport1	47	1536	1	1536	94	94	172	1	47	48	57
38	HLWBI63	209407 10/23/97	pCMVSPORT 3.0	48	1038	1	1038	149	149	173	1	30	31	63
39	HDUAC77	209423 10/30/97	pSport1	49	1176	1	1176	193	193	174	1	19	20	60

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
40	HFOYV27	209423 10/30/97	pSport1	50	731	1	731	171	171	175	1	18	19	103
41	HGBHI35	209423 10/30/97	Uni-ZAP XR	51	1437	71	1276	87	87	176	1	16	17	292
42	HRDEU27	209423 10/30/97	Uni-ZAP XR	52	1369	1	1369	285	285	177	1	18	19	45
43	HNGJE50	209368 10/16/97	Uni-ZAP XR	53	1037	1	1037	77	77	178	1	36	37	46
44	HNH DU48	209368 10/16/97	Uni-ZAP XR	54	1373	1	1373	99	99	179	1	20	21	54
45	HFXJU68	209423 10/30/97	Lambda ZAP II	55	1347	1	1347	148	148	180	1	25	26	66
46	HMMAH60	209368 10/16/97	pSport1	56	822	1	822	142	142	181	1	15	16	50
47	HNGFR31	209407 10/23/97	Uni-ZAP XR	57	536	1	536	108	108	182	1	23	24	90

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO:	Total NT Seq.	5' NT 3' NT Clone Seq.	Start of Codon	5' NT First Signal AA of Y	AA First SEQ AA First	Seq. of AA First	Sig. of AA First	Secreted of AA First	Last AA Portion ORF
56	HTXAJ12	209423	Uni-ZAP XR	66	675	I	675	91	91	191	I	18	111
57	HKAEL80	209423	PCMVSPORT 2.0	67	1105	I	1105	398	398	192	I	17	79
58	HNNHFL04	209423	Uni-ZAP XR	68	1279	I	1279	162	162	193	I	16	87
59	HPCAM01	209368	Uni-ZAP XR	69	1638	I	1638	311	311	194	I	24	41
60	HJACA79	209368	pBluescript-SK-	70	887	I	887	84	84	195	I	28	68
61	HMADCK33	209368	Uni-ZAP XR	71	864	I	864	161	161	196	I	24	152
62	HMSFI26	209368	Uni-ZAP XR	72	1217	I	1217	120	120	197	I	34	62
63	HMSJR08	209368	Uni-ZAP XR	73	1717	I	1717	165	165	198	I	28	63

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
64	HMWIO93	209368 10/16/97	Uni-Zap XR	74	1276	1	1276	72	72	199	1	18	19	42
65	HNGAK47	209368 10/16/97	Uni-ZAP XR	75	1144	1	1144	89	89	200	1	23	24	40
66	HNGAL31	209368 10/16/97	Uni-ZAP XR	76	918	1	918	34	34	201	1	20	21	43
67	HNGIZ06	209368 10/16/97	Uni-ZAP XR	77	1065	1	1065	108	108	202	1	16	17	41
68	HNHBI75	209368 10/16/97	Uni-ZAP XR	78	1126	1	1126	12	12	203	1	15	16	41
69	HOFNT24	209368 10/16/97	pCMVSPORT 2.0	79	984	1	984	63	63	204	1	22	23	112
70	HSAXI95	209368 10/16/97	Uni-ZAP XR	80	1247	1	1247	147	147	205	1	19	20	44
71	HCMTB45	209368 10/16/97	Uni-ZAP XR	81	946	1	946	209	209	206	1	27	28	70

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
72	HE9CP41	209368 10/16/97	Uni-ZAP XR	82	1392	1	1392	132	132	207	1	21	22	41
73	HHENV10	209368 10/16/97	pCMVSPORT 3.0	83	1155	1	1155	143	143	208	1	27	28	50
74	HSKDD72	209407 10/23/97	Uni-ZAP XR	84	1373	1	1373	94	94	209	1	23	24	64
75	HAGDO20	209407 10/23/97	Uni-ZAP XR	85	1258	184	1258	218	218	210	1	20	21	76
76	HCFBH15	209407 10/23/97	pSport1	86	1318	1	1318	156	156	211	1	22	23	44
77	HSYBX48	209423 10/30/97	pCMVSPORT 3.0	87	978	38	961	246	246	212	1	34	35	65
78	HATDQ62	209423 10/30/97	Uni-ZAP XR	88	1863	323	1863	412	412	213	1	25	26	61
79	HMEJE13	209423 10/30/97	Lambda ZAP II	89	2086	1	1131	147	147	214	1	26	27	55

Gene No.	cDNA Clone ID	ATCC Deposit No and Date	Vector	NT SEQ ID NO:	Total NT Seq.	5' NT 3' NT of Clone	Seq.	Start of 5' NT	Signal	First AA of 5' NT	AA of First	SEQ ID NO.	First AA	Sig of AA	Sig Pep	First AA	Secreted of AA	Last of AA Portion	ORF
88	HLHFP18	209407	Uni-ZAP XR	98	678	I		678	25	25	25	223	I	24			25	46	
89	HFXBWW09	209423	Lambda ZAP II	99	1541	I		1541	159	159	224	I	29			30	51		
90	HNGEM62	209423	Uni-ZAP XR	100	881	I		881	78	78	225	I	21			22	65		
91	HNGJF92	209423	Uni-ZAP XR	101	947	I		947	40	40	226	I	31			32	46		
92	HMEED18	209368	Lambda ZAP II	102	1369	28		1369	34	34	227	I	34			35	221		
93	HMTAM45	209368	Uni-ZAP XR	103	1231	I		1231	68	68	228	I	37			38	48		
94	HSAVK10	209368	Uni-ZAP XR	104	1242	I		1242	131	131	229	I	32			33	40		
95	HSDHC81	209368	Uni-ZAP XR	105	1151	I		1151	184	184	230	I	22			23	52		

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO:	X Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT Start	Signal AA of First	Seq NO.	ID of AA	Sig of AA	First AA	Last AA	Secreted of AA	ORF
80	HNAAF65	209423	pSport1	90	891	I		891	140	140	215	I	Pep	AA First	Portion	212
81	HNHFHY30	209423	Uni-ZAP XR	91	1974	I		1974	134	134	216	I	30	AA First	31	
82	HNFR81	209423	pBluescript	92	1423	I		1423	19	19	217	I	20	AA First	21	59
83	HNTRB157	209423	pCMVSPORT 3.0	93	1365	134		1365	210	210	218	I	26	AA First	27	58
84	HSAVYR13	209423	Uni-ZAP XR	94	756	I		756	171	171	219	I	19	AA First	20	45
85	HTOHV49	209407	Uni-ZAP XR	95	938	I		729	62	62	220	I	19	AA First	20	61
86	HSFAG37	209368	Uni-ZAP XR	96	928	I		928	264	264	221	I	18	AA First	19	51
87	HTXBU52	209407	Uni-ZAP XR	97	1715			1715	574	574	222	I	34	AA First	35	50

195

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
96	HSLCT04	209368 10/16/97	Uni-ZAP XR	106	1628	1	1628	159	159	231	1	36	37	49
97	HMDAB56	209368 10/16/97	Uni-ZAP XR	107	1465	1	1465	273	273	232	1	33	34	44
98	HUDBZ89	209407 10/23/97	ZAP Express	108	1265	1	1265	197	197	233	1	17	18	54
99	HLYCT47	209407 10/23/97	pSport1	109	1006	1	1006	47	47	234	1	22	23	68
100	HOSDJ25	209423 10/30/97	Uni-ZAP XR	110	1258	1	1258	146	146	235	1	18	19	40
101	HADAO89	209423 10/30/97	pSport1	111	1453	1	1453	244	244	236	1	22	23	44
102	HMSG14	209423 10/30/97	Uni-ZAP XR	112	1552	1	1552	138	138	237	1	18	19	77
103	HPMGD01	209423 10/30/97	Uni-ZAP XR	113	1489	140	1489	157	157	238	1	36	37	52

196

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
104	HNHFU32	209407 10/23/97	Uni-ZAP XR	114	607	1	607	175	175	239	1	30	31	52
105	HMLAL40	209368 10/16/97	Uni-ZAP XR	115	1498	1	1498	235	235	240	1	19	20	42
106	HAMFY69	209407 10/23/97	pCMVSport 3.0	116	1797	314	1797	359	359	241	1	17	18	48
107	HBMCT17	209407 10/23/97	pBluescript	117	952	1	952	160	160	242	1	25	26	74
108	HEBF191	209407 10/23/97	Uni-ZAP XR	118	1185	1	1185	132	132	243	1	20	21	43
109	HHEAH86	209407 10/23/97	pCMVSport 3.0	119	1098	1	1098	75	75	244	1	16	17	64
110	HRDFD27	209423 10/30/97	Uni-ZAP XR	120	805	1	805	82	82	245	1	36	37	83
111	HTPCS72	209423 10/30/97	Uni-ZAP XR	121	1598	306	1598	530	530	246	1	29	30	71



Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No.Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below).

It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

- 5 The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, *Gene* 67:31-40 (1988).
- 10 Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

### Signal Sequences

- 15 Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, *supra*.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

- 25 In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., *Protein Engineering* 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

- 30 As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO: Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely

uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

- 5 Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

### Polynucleotide and Polypeptide Variants

- 10 "Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

- 15 By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

- 25 As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (*Comp. App. Biosci.* (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are:
- 30 Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization

Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query

amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brailag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity.

For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level.

Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after

deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., *J. Biotechnology* 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem.* 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1 $\alpha$ . They used random mutagenesis to generate over 3,500 individual IL-1 $\alpha$  mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., *Science* 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln; replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp; and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

### Polynucleotide and Polypeptide Fragments

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-

60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred.

5 Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

10 Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

20

### Epitopes & Antibodies

In the present invention, "epitopes" refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983).)

30 Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et al., J. Gen. Virol. 66:2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')<sub>2</sub> fragments) which are capable of specifically binding to protein. Fab and F(ab')<sub>2</sub> fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

20

### Fusion Proteins

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

30 Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the

35

polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4 polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Trautnecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Elton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).) Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

### Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and pUC99a, pKK223-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

### 30 Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

35 The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat

polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinherence between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library).) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinherence is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.

First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying

personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

### Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99mTc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, 131I, 112In, 99mTc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then

preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

### Biological Activities

The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

### Immune Activity

A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the

proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotide or polypeptide of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. A polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, DiGeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat blood coagulation disorders (e.g., fibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

A polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1).

#### **Hyperproliferative Disorders**

A polypeptide or polynucleotide can be used to treat or detect hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect

interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

10 Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

15 Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

### Infectious Disease

25 A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

30 Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes

Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhadoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picomaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, encephalitis eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases:

10 Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Aspergillus, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, 20 Coccidioidomycosis, Cryptococcosis, Dermatocycosis, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Pasteurellaceae Infections (e.g., Actinobacillus, Haemophilus, Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme 30 Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycosis), toxemia, urinary tract infections, wound infections.

35 A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

### Regeneration

A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g., osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vascular (including vascular endothelium), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue

regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

### Chemotaxis

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body.

For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

### Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit

(antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

#### Other Activities

10 A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

15 A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

20 A polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

25 A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

#### Other Preferred Embodiments

30 Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

35 Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of

positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type

Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1, and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO: Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO: Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1, which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO: Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO: Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO: Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO: Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO: Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO: Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO: Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO: Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

### Examples

#### Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

Vector Used to Construct Library	Corresponding Deposited Plasmid
Lambda Zap	pBluescript (pBS)
Uni-Zap XR	pBluescript (pBS)
Zap Express	pBK
lalfmid BA	plafmid BA
pSport1	pSport1
pCMVSPORT 2.0	pCMVSPORT 2.0
pCMVSPORT 3.0	pCMVSPORT 3.0
pCR <sup>2.1</sup>	pCR <sup>2.1</sup>

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128,256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS-. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain

5 DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Benito Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into *E. coli* strain XL-1 Blue. Vector pCR<sup>2.1</sup>, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., BioTechnology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

10 The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

20 Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported.

25 The oligonucleotide is labeled, for instance, with <sup>32</sup>P-γ-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).)

30 The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μl of reaction mixture with 5 0.5 ug of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl<sub>2</sub>, 0.01% (w/v) gelatin, 20 μM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

10 Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

20 Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

30 This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

35 This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is

used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

5

#### **Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

10

#### **Example 3: Tissue Distribution of Polypeptide**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P<sup>32</sup> using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

20

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

25

#### **Example 4: Chromosomal Mapping of the Polynucleotides**

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions: 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated

30

32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on

35

either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

#### **Example 5: Bacterial Expression of a Polypeptide**

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp<sup>r</sup>), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

15

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>r</sup>). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

20

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.<sub>600</sub>) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalactopyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

25

gene expression.

30

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high

35

affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lacose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

### 35 Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Separech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filttron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem

columns of strong anion (Poros HQ-50, Perceptive Biosystems) and weak anion (Poros CM-20, Perceptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Comassie blue stained 16% SDS-PAGE gel when 5  $\mu$ g of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

#### 15 Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring

signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five  $\mu$ g of a plasmid containing the polynucleotide is co-transfected with 1.0  $\mu$ g of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417 (1987). One  $\mu$ g of BaculoGold™ virus DNA and 5  $\mu$ g of the plasmid are mixed in a sterile well of a microtiter plate containing 50  $\mu$ l of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10  $\mu$ l Lipofectin plus 90  $\mu$ l Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture

and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200  $\mu$ l of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5  $\mu$ Ci of  $^{35}$ S-methionine and 5  $\mu$ Ci  $^{35}$ S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

#### 20 **Example 8: Expression of a Polypeptide in Mammalian Cells**

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter). Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QCl-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992).) Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphatase by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli*/HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five  $\mu$ g of the expression plasmid pC6 is cotransfected with 0.5  $\mu$ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1  $\mu$ M, 2  $\mu$ M, 5  $\mu$ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100-200  $\mu$ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

#### Example 9: Protein Fusions

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Trautnecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

#### Human IgG Fc region:

GGGATCGGAGGCCAAATCTTCTGACAAAACTCACACATGCCACCGTGCC  
CAGCACTGAATTGAGGGTGACCGTCAGTCTTCTCTTCCCCCAAACC  
CAAGGACACCTCATGATCTCCCGGACTCTCTGAGGTCAATGCTGTTGACG  
GGACGTAAGCCACGAAGACCTGAGGTCAAGTTCAACTGTTGACGTGGACG  
CCGTGGAGGTGCATAATGCCAAGACAAAGCCGGGAGGAGCAGTACAAC  
AGCAGTACCGTGTGTGTCAGCGTCTCACCGTCTTGACACGAGACTGGCTG  
AATGGCAAGGAGTACAAAGTGCAAGGTCTCCAAAGCCGAGCCCGAGAACACAGGT  
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCGAGAACACAGGT  
GTACACCTGCCCCATCCCGGATGAGCTGACCAAGAACACAGGTCAACCT  
GACCTGCTGTCAAAGGCTTCTATCCAAGGACATCGCGCTGGAGTGGGA  
GAGCAATGGCAGCCGGAGAACAACTACAAGACCACGCTCCCGTGGCTGG  
ACTCCGACGGTCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCA  
GGTGGCAGCAGGGGAAGCTTCTTCTCATGTCCGTGATGTCATGAGGCTCTGC  
ACAAACCACTACACGCAGAAAGACCTCTCCCTGTCTCCGGTAAATGAGTGC  
GACGGCCGGACTCTAGAGGAT (SEQ ID NO:1)

#### Example 10: Production of an Antibody from a Polypeptide

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera

containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., *Nature* 256:495 (1975); Köhler et al., *Eur. J. Immunol.* 6:511 (1976); Köhler et al., *Eur. J. Immunol.* 6:292 (1976); Hammetting et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as pepsin (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For *in vivo* use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Tamiguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., *Nature* 312:643 (1984); Neuberger et al., *Nature* 314:268 (1985).)

#### **Example 11: Production Of Secreted Protein For High-Throughput Screening Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhitaker) for a working solution of 50ug/ml. Add 200 µl of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhitaker))/10% heat inactivated FBS(14-503F Biowhitaker))/1x Penstrep(17-602E Biowhitaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 µl Lipofectamine (18324-012 Gibco/BRL) and 5ml Opimem 1 (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in

Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with 5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl<sub>2</sub> (anhyd); 0.00130 mg/L CuSO<sub>4</sub>·5H<sub>2</sub>O; 0.050 mg/L of Fe(NO<sub>3</sub>)<sub>3</sub>·9H<sub>2</sub>O; 0.417 mg/L of FeSO<sub>4</sub>·7H<sub>2</sub>O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl<sub>2</sub>; 48.84 mg/L of MgSO<sub>4</sub>; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO<sub>3</sub>; 62.50 mg/L of NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O; 71.02 mg/L of Na<sub>2</sub>HPO<sub>4</sub>; 4320 mg/L of ZnSO<sub>4</sub>·7H<sub>2</sub>O; .002 mg/L of Arachidonic Acid; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L-Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H<sub>2</sub>O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H<sub>2</sub>O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H<sub>2</sub>O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H<sub>2</sub>O; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of D-Inositol; 3.02 mg/L of Nicotinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine;

0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

#### Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class 1, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

251

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schindler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN- $\alpha$ , IFN- $\gamma$ , and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

Ligand	Tyk2	JAKs Jak1	JAKs Jak2	JAKs Jak3	STATs	GAS(elements) or ISRE
IFN family						
IFN- $\alpha$ / $\beta$	+	+	+	-	1,2,3	ISRE
IFN- $\gamma$	+	+	+	-	1	GAS (IRF1>Lys6>IFP)
IL-10	+	?	?	-	1,3	
gp130 family						
IL-6 (Pleiotropic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
IL-11 (Pleiotropic)	?	+	?	?	1,3	
Onm (Pleiotropic)	?	+	+	?	1,3	
LIF (Pleiotropic)	?	+	+	?	1,3	
CNTF (Pleiotropic)	-/+	+	+	?	1,3	
G-CSF (Pleiotropic)	?	+	?	?	1,3	
IL-12 (Pleiotropic)	+	-	+	+	1,3	
gC family						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >> Lys6>Lys6)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	-	+	5	GAS
IL-13 (lymphocyte)	-	+	?	?	6	GAS
IL-15	?	+	?	+	5	GAS
gp140 family						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Lys6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
Growth hormone family						
GH	?	-	+	-	5	
PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	GAS(B-
CAS>IRF1=IFP>>Lys6						
Receptor Tyrosine Kinases						
EGF	?	+	+	-	1,3	GAS (IRF1)
PDGF	?	+	+	-	1,3	
CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994)), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5'-GCGCCTCGAGATTTCGCCGAAATCTAGATTTCGCCGAAATGATTTCGCCG  
 10 AAATGATTTCGCCGAAATATGCCCATCTCAATTAG-3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5'-GCGGCAAGCTTTTGTGCAAGCCTAGGC-3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal-promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5'-CTCGAGATTTCGCCGAAATCTAGATTTCGCCGAAATGATTTCGCCGAAATG  
 20 ATTTCGCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCC  
 CTAATCCGCCCATCCGCCCTAACTCGCCAGTTCGCCCATCTCCGC  
 CCCATGGCTGACTAATTTTATTATGTCAGAGCGAGCGCCGCTCGGC  
 CTCTGAGCTATTCCAGAAAGTAGTGAGGAGGCTTTTGTGAGGCTAGGCTTT  
 TGCAAAAAGCTT-3' (SEQ ID NO:5)

25 With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

30 The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS-SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

### Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATs signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

25 Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/Neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies)

with 10 µg of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 µl of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Genticin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 µl of cells into each well (therefore adding 100,000 cells per well).

After all the plates have been seeded, 50 µl of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 µl samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophane covers) and stored at 20°C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 40°C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

#### Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jak-STAT3 signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or K562 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^6$  U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 µg GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 µM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 1 mM  $\text{MgCl}_2$ , and 675 µM  $\text{CaCl}_2$ . Incubate at 37°C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 µg/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 µg/ml G418 for couple of passages.

These cells are tested by harvesting  $1 \times 10^6$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200 µl cells per well in the 96-well plate (or  $1 \times 10^5$  cells/well).

Add 50 µl of the supernatant prepared by the protocol described in Example 11. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

#### Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGFR (early growth response gene 1), is induced in various tissues and cell types upon

activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat pheochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCGGATCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes Xho/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type 1 (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS

(Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to  $1 \times 10^5$  cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

#### Example 16: High-Throughput Screening Assay for T-cell Activity

NF- $\kappa$ B (Nuclear Factor  $\kappa$ B) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF- $\kappa$ B regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- $\kappa$ B appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- $\kappa$ B is retained in the cytoplasm with I- $\kappa$ B (Inhibitor  $\kappa$ B). However, upon stimulation, I- $\kappa$ B is phosphorylated and degraded, causing NF- $\kappa$ B to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- $\kappa$ B include IL-2, IL-6, GM-CSF, ICAM-1 and class I MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF- $\kappa$ B promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF- $\kappa$ B would be useful in treating diseases. For example, inhibitors of NF- $\kappa$ B could be used to treat those diseases related to the acute or chronic activation of NF- $\kappa$ B, such as rheumatoid arthritis.

259

To construct a vector containing the NF- $\kappa$ B promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF- $\kappa$ B binding site (GGGGACTTCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site.

5'-GCCGGCCICGAGGGGACTTTCGCCGGGACTTTCCGGGGACTTTCGGGAC  
TTTCCATCCTGGCAITCTCAATTAG-3' (SEQ ID NO.9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5'-GCCGCAAGCTTTTGCAAAGCCTAGGC-3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal-promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into B1SK2<sup>-</sup> (Stratagene)

Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

15  
5'-CTCGAGGGGACTTCCCGGGGACTTCCGGGACTTCCGGGACTTCC  
ATCTGCCATCTCAATTAGTCAGACAAACCATAGTCCGCGCCCTAACTCCGCCCA  
TCCCGCCCTAACTCCGCCAGTTCGCCCATCTCCGCCCATGGCTGACT  
AATTTTATTTATTTATGACAGAGCCGAGGCCGCTCGGCTCTGAGCTATTC  
20 CAGAAGTAGTCAGGAGGCTTTTGGAGGCCCTAGGCTTTTGCAAAAGCTT-  
3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2

promoter plasmid (Clontech) with this NF- $\kappa$ B/SV40 fragment using XhoI and HindIII.

25 However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF- $\kappa$ B/SV40/SEAP

30 NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF- $\kappa$ B/V40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described

260

in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

### Example 17: Assay for SEAP Activity

5 As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15  $\mu$ l of 2.5x dilution buffer into Opiplates containing 35  $\mu$ l of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Opiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 µl Assay Buffer and incubate at room

15 temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50  $\mu$ l Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set HI2 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

### **Reaction Buffer Formulation:**

# of plates	Run buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25

28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

**Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-3, used here.

For adherent cells, seed the cells at 10,000-20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-3 is made in 10% pluronic acid DMSO. To load the cells with fluo-3, 50 ul of 12 ug/ml fluo-3 is added to each well. The plate is

incubated at 37°C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10<sup>6</sup> cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-3 solution in 10% pluronic acid DMSO is added to each ml of cell suspension.

The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10<sup>6</sup> cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-3. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mV; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca<sup>++</sup> concentration.

**Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating

tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately

- 5 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or
- 10 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture
- 15 plates can also be used in some proliferation experiments.

- To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20
- 20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na3VO4, 2 mM Na4P2O7 and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for
- 25 5 minutes at 40°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and
- 30 centrifuged for 15 minutes at 40°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and

PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

- The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sup>2+</sup> (5mM
- 5 ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGT A, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.
- 10 The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

- Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide.
- 15 Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as above.

- Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.
- 20

## 25 **Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

- As a potential alternative and/or complement to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine
- 30 phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.
- 35

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1 ml of protein G (1 µg/ml) for 2 hr at room temp. (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100 ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6 ng/well) or 50 µl of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10 ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1 µg/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

#### Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR

products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenin deoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

#### Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 µg/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10.

The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide.

Next, 50  $\mu$ l of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbound conjugate.

Add 75  $\mu$ l of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale).

Interpolate the concentration of the polypeptide in the sample using the standard curve.

#### Example 23: Formulating a Polypeptide

The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1  $\mu$ g/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1  $\mu$ g/kg/hour to about 50  $\mu$ g/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracutaneously, intravaginally,

intrapertoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules.

Sustained-release matrices include poly(lactides) (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Siddman, U. et al., Biopolymers 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

#### Example 24: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

#### Example 25: Method of Treating Increased Levels of the Polypeptide

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

#### Example 26: Method of Treatment Using Gene Therapy

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

PMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic PA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other

disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

*What Is Claimed Is:*

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
  - (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
  - (f) a polynucleotide which is a variant of SEQ ID NO:X;
  - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
  - (h) a polynucleotide, which encodes a species homologue of the SEQ ID NO:Y;
  - (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. A recombinant host cell produced by the method of claim 8.
10. The recombinant host cell of claim 9 comprising vector sequences.
11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
  - (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
  - (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

- (g) a variant of SEQ ID NO: Y;
  - (h) an allelic variant of SEQ ID NO: Y; or
  - (i) a species homologue of the SEQ ID NO: Y.
12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim

11.

15. A method of making an isolated polypeptide comprising:

- (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and
- (b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

- (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

- (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

- (a) contacting the polypeptide of claim 11 with a binding partner; and
- (b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO: Y.

22. A method of identifying an activity in a biological assay, wherein the method comprises:

- (a) expressing SEQ ID NO: X in a cell;
- (b) isolating the supernatant;
- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Rosen et al.  
Human Genome Sciences, Inc.

<120> 125 Human Secreted Proteins

<130> P2020.PCT

<140> Unassigned

<141> 1998-11-04

<150> 60/064,911

<151> 1997-11-07

<150> 60/064,912

<151> 1997-11-07

<150> 60/064,983

<151> 1997-11-07

<150> 60/064,900

<151> 1997-11-07

<150> 60/064,988

<151> 1997-11-07

<150> 60/064,987

<151> 1997-11-07

<150> 60/064,908

<151> 1997-11-07

<150> 60/064,984

<151> 1997-11-07

<150> 60/064,985

<151> 1997-11-07

<150> 60/066,094

<151> 1997-11-17

<150> 60/066,100

<151> 1997-11-17

<150> 60/066,089

<151> 1997-11-17

<150> 60/066,095

<151> 1997-11-17

<150> 60/066,090

<151> 1997-11-17

<160> 502

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggattccgga gcccaaatct tctgacaaaa ctcaacacatg cccaccgtgc ccagccacctg 60  
aattcgaggg tgcacgtca gttctctct tcccccaaa acccaaggac acctctatga 120  
tctcccgag tcttgaggtc acatgctggtg tggtagacgt aagccacgaa gacctgagg 180  
tcaagttaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagcccggg 240  
aggagcagta caacagcaeg taccgtgtgg tcagctctct caccgtctctg caccaggaat 300  
ggctgaatgg caaggatgac aagtcaagg tctccaaca agcctccca accctcatcg 360  
agaaaacct ctccaaagcc aaaggcagc ccgagaacc acaggtgtac acctgccc 420  
catcccgga tgaagtacc aagaaccagg tcagctgac ctgctgtgtc aaaggtttct 480  
atccaaagca catgcccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga 540  
caagcctcc cgtgtggac tcgacgggt cctctctct ctacagcaag ctaccgtgg 600  
acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggtctgc 660  
acaaccacta caccagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc 720  
gactctagag gat 733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser

1 5

<210> 3

<211> 86

<212> DNA

<213> Homo sapiens

<400> 3

gagcctcgag atttcccga aatctagatt tccccgaat gatttcccgc aaatgatttc 60  
ccgaaatat ctgccatctc aattag 86

<210> 4

<211> 27

<212> DNA

<213> Homo sapiens

<400> 4

gcggcaagct tttgcaag ctaggc

<210> 5

<211> 271

<212> DNA

<213> Homo sapiens

27

<400> 5  
 cccggagatt ccccggaatc tagattccc cgaatgatt tcccgaat gattcccc  
 aatatccgc catctcaatt agtcagcaac catagtcgc ccccaattc ccccatccc  
 gcccttaact ccgcccaggt ccggccaatc tccgcccac ggcctgaataa tttttttat  
 ttatgcagaag gccgagccgc cctcgccctc tgagctatc cagaagcagt gaggaagctt  
 ttctggagagc ctgagctttt gcaaaaagc t 271

J

<210> 6  
 <211> 32  
 <212> DNA  
 <213> Homo sapiens

<400> 6  
 gccctcgaag gatgcagcg atagaacccg gg 32

<210> 7  
 <211> 31  
 <212> DNA  
 <213> Homo sapiens

<400> 7  
 gcgaagcttc gcgactccc ggaatccgct c 31

<210> 8  
 <211> 12  
 <212> DNA  
 <213> Homo sapiens

<400> 8  
 ggggacttcc cc 12

<210> 9  
 <211> 73  
 <212> DNA  
 <213> Homo sapiens

<400> 9  
 ggggacttcca ggggacttcc ccgggactt tccggggact ttccgggact ttcatctctg  
 ccactcaat tag 73

<210> 10  
 <211> 256  
 <212> DNA  
 <213> Homo sapiens

<400> 10  
 ctcgagggga ctctccggg gacttccgg ggaacttccg ggaacttcca tctgscatct  
 caattagica gcaaccatag tccgcgcctt aactccgccc atccgccc taactccgc  
 cagtcgcgc catctccgc cccatgctg actaatltt ttatctatg cagagggcga  
 ggcgcgcgc ggcctcgaag tatccagaa gtagtagga gactttttg gaggcctag  
 ctcttgcaaa aagctt 256

<210> 11  
 <211> 1010  
 <212> DNA  
 <213> Homo sapiens

H

<400> 11  
 gccctcgat gtccagtggt ggggtatgct agcagcttg tactatcta atggtactag  
 gggctctcgc tgatctctg actgagacca taatatctgt atcgaagct atcgaggt  
 gccaggtaaa ccaagactac ttgcatctg taatgcacc ttcaaccca ccaagaccg  
 caattgtagt actctcatg tccatggtta atgaagcca gccatttgt ttgctgtg  
 ctgtctcta ttgttccag tgttctctgt ataaaaa aaaaagcaaa ggaagaaatg  
 tgcacacact ttacctctt accattgagt caacagtaa ttcagttca gctggcag  
 tattatggtg aggttgttt tctactgatt caatttcaa ctgtgtgtc gctgtggcc  
 ttgcccattg gtgcagaaa aatgcacacc agaaaagaaa gtgtccaggt gtccaactg  
 ctcaagttat tgcacaccc ccagtttct tacttcaaa gtgcaccaat atcttccac  
 aggaagtcga aatacaaca agagtgtgat tatatgtt gcttggacc tggctaagca  
 atgtcccat tgcagtacg catlttctc acaattcag caatgtcca ttccctaacg  
 gacaattgc agaaactt ggagagagag agcagttgt ccaaggctta tggccctt  
 tgttggagct ttgatttat ttcaatgta actcacttga gactatag aagagaaac  
 taataaact gatlgagag aggatttgc aagagatct catagagaa ctgagattta  
 ttgacaaca tgaattgat tccagagcat ctcaagaac ccagccaac ttccagctc  
 cagaatacat gatattgat catgagttta cgaagcttgt aaaaagactt gaaggtgtta  
 taactaagc tatttatag tccagtgag agatataaaa aaaaaaaaa 1010

<210> 12  
 <211> 1559  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1547)  
 <223> n equals a, t, g, or c

<220>  
 <221> SITE  
 <222> (1549)  
 <223> n equals a, t, g, or c

<400> 12  
 ccggctacca ggaactagtg gattccccgg gctgcagagt ttattatct tatataaaa  
 atgtcccaca gataccaaaa gatcaataaa aaatcccacc cctctactg cgttccaa  
 ttggcgtgat actatctga ggaatgttcc acagcccttg ttcatgca gtaattctg  
 gttatgggg ctggaatcaa aggagccgt attccctctg cccaacaca cgaacttag  
 aatcagtgct cccatagca ccaatgcga ggaattgtg gcatgactgt ggcattcac  
 agacatattc tggtagagat ctggttacg atagccttag ccaatggcac ccgagccctc  
 actcaaatg taagtgtcat tcaatccaga agcaatggg caatctctg aagttgtct  
 ggcctctcgc ttctctttt tagtaggtct gatttataa tatgacaat acaggttaac  
 ttgtgaagtc ctatatcaa caatcttct cctctagaca acttgcata tgcacttag  
 aaatgatga aatcatgga ggtgtagaaa attacaat attagttt taaccatag  
 caagggagat atgggctag agtgaataac acagagcat taatatcat aggaattta  
 ggggttaaat ttgatgta atttccaaa atcaattca ctattctg tcatataag  
 atgtgcaca catttgat ggcacccac agtagccaca ggcgaatag aaaaaatct  
 gcttccaaa acaaaagagc atatagaaa atgagtcaaa gtaaaaaaa tggcagttac  
 catccatctc ccagtgaaa atgaatagtg agtgtattta atgaatatt tccaattata  
 tatcgcata ataaagaaa ggaatatgaa acaaatcaa atgtgtttg ttgaataag 960

cgatgagct tgaaggatcm agtactgatg gctccagggt ttttccatgt tagatttccct 1020  
 tgaagagac tgaagcacc agcactgac agctgtacc caatgatga aattttgagc 1080  
 tgaataact ttcattggar rgcatcacat tctaaagga gacaaatgac cactaaaaac 1140  
 taaccattac tatagattac ttatggagg ttttacttg actactaat aaggagatga 1200  
 tttctctct aaactttata tcaattggc agtgatttg ccagatttatt aatgtctttt 1260  
 tgaataact 999999999 gttataacta cataacacag tttttcat tttttaaag 1320  
 ggtttggacc aagacataag ttctattgac aatcttaagt ttctactgt agacaatag 1380  
 tgaataaac tgcgtgaggt cacacagcat ataacttctt aatggttaat tcgaataacg 1440  
 ttttccaagt aagcaatgat acacatttag ttaaaaaaa aaaaaaa aaaaaaaca 1500  
 aaaaaaaa aaaaactcg aggggggggt ccgtacccaa tctctnana tgcattgta 1559

&lt;210&gt; 13

&lt;211&gt; 1589

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

ggcagagctt ttgtcttgag aaaaatgcta ccggttagtt ccagtggtt tgccttgctt 60  
 tttatttga attttagaat ttattatttt aaaaatttat cttattttaa tgtatttcat 120  
 ttttctcta ctaatttga gtaacacagc ttgtactcc ttgacttga tctctccagg 180  
 agctggggag ccaagctcgg tctccgcttc ggtgggttca ggtccgggtt ttgtctggc 240  
 ggctctgctt ctaattgcta ctggcgggtt tgcagcaacg cttttgccag tagcgccac 300  
 tgaaggttt ttactgtgct gcaacgttct tagcgcaca cggaaacgtt ccctgacgcg 360  
 gagtccataa gttgtctgt tgcacttt ctgggttctg gcamcgtctag tatctctag 420  
 gtaacttcta aamcgtttt acggtgcaga acgtaattg caccgagct ctgtgccaac 480  
 tagtacttc gtaatacgt tagcggcttc tttctctg ccaacacatt aaaaagctgt 540  
 aaaaacatt aaacggatta aacacattar acggtattaa acacattaaa acgttcaaac 600  
 acattttaa agagtggct cattcycca gacagtatg ttccggatgg aagcaccct 660  
 cttaagaact cgcagtttct tttagcagc accgtatgg cgcytaaacg gatatttgt 720  
 tggcaatac agcgtatcc gctaggctgc ggcgttgcct gagtctcagc gcgcagat 780  
 ttgtctagc gagtctcaga gactagcag gactagcgg acagtttcc ggtggcagca 840  
 algctcatt cccggacaca gatgttttt ggsccttgaa gaactctta atccctggt 900  
 ttgtagcgc tctgtctctg taactgttc tttatccg ttctatttc actcttttc 960  
 tgcgtgttt ttgtcggaa ttaagatttg tttgtttct atgtgtctc tagaatttta 1020  
 ccggttttca tttgtcact aatttctg ccttgctac tatgagttt cataatct 1080  
 ggtgtgcmcc tgccacckag ctcggagag cataaatacc caggctgat gtagtctaa 1140  
 aggttctgt tcatctctc aatcagcga aacgcttatg tctctctgct ctgagctta 1200  
 attaaagcat ggagcaacat tttcttggt atgtgaagc tgcctgagat tccgagag 1260  
 tggctccta gctccagctt cggcctattt tgaattcaga agactgtgat attactgt 1320  
 gagccaccac ttgtggagggc cagatccttg aggtcaggag ttggagacca 1380  
 gctgtcccca agtgggtgaaa cccatctct actaaaaata caaaaatag ccggtgatga 1440  
 tgcactgctg caatccagc tactcggag gctgaggag gagaattct tagctcga 1500  
 ggcagaggtt gcagtggct cagatctgac caccgtctc cagctgggc agactgagc 1560  
 tccataaaaa aaaaaaaa aaaaactga

&lt;210&gt; 14

&lt;211&gt; 1255

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

gctgaaatgt ctcatttagc taaatgaaa cattcaccag acacttttag ctgactctcc 60  
 cacataact ttgagccaac aggcacttcc atgtttggga ctgaattgct tggaaatccg 120  
 tataccaaa atctgagccc tcaattttac ctttggttga tgccttcca tagccttag 180  
 caatgctct cactctctgg atcctggctac atctctgca gattttgg cgtctttag 240  
 ccagttcggc aaccatttaca tccaggaaag tatctacgc tttagagagt cgtttctat 300

ctgttaccac aacaagcagg tccagcgagg actctggctg gagtatga acatcagtaa 360  
 aggcaactcc ccatcagatg agtctgagga gcgggaaaga gaccccaagt gctgacattc 420  
 ccagaataca tcaccagctt gtcagactcc ggcaccaagc gcatggcgcc tggagtccgc 480  
 atgagtgcc agagcaaggg acgattgccc tgcctctgccc ccatgtgcta tgtgacattc 540  
 agccctgaca cccctgctga gcgggtctg ctggagtgga ccaaagcagc cccatctat 600  
 gaactagta ccaacaacca gaccagagg ccttggcagg aggtactcat gactctctc 660  
 ttgtgtccag ggaactggga tgcactgag gactgggtgc gatgtgactc cactgctttt 720  
 ggagctcag actctcccac ctgtgcctt ccccacagc ctgtgtatgg ttctctttc 780  
 cctttcagc attactctgg aaacagataa tgaagtcta ctatttcaa agaataggc 840  
 tgggtactgg gaacaaaga aaaaatagc aaaaactctg cttttagaga gctttcaatc 900  
 taccagaagg ggcagcacag atggttttag tagagaaagg gttgtacaag tgttaacag 960  
 aggcatttaa agaaagtgtg aaggggaat ggtcaagctt gaactgacg catggtgacg 1020  
 gctctgtgga ggggtggcg cttgaacttc tccatgaagg tgagaaagt aggcagcat 1080  
 aactagaaga caatgggag aaaaigcca ttgtaatgga agaagttaga gatctacat 1140  
 gagagcttaa ctgacccaaa acataacca ctcatgaa acttactgg tgcacagca 1200  
 ttgtatggag cagttagata ctgtctattt aatagacaaa aaaaaaaaaaaaaa 1255

&lt;210&gt; 15

&lt;211&gt; 1191

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

gaattcggca cgagcgaggg ccgaagagtt ggtccgttgg ctaagcaacg aacttcacg 60  
 acagcgatcc ccaggtgttt catttggtt atcagtggtt aatttgatga atgcatcat 120  
 gggaagtggc atcttggct tagcttatgt tatggcta at accggtgtct tggatttag 180  
 cttcttctg ctgacagttg ctctctggc tcttactca gtccacttcc tgcctagat 240  
 ggtatcag acagtgtaa catctatga agatcttggga ctcttggcat ttggattacc 300  
 tggaaagtgt ggtgtggcag gcaccataat aaltcagaat attggagcta tgcattctta 360  
 tcttttaatt attaaacag agctctgc tgcatttga gaatttttga cggagactta 420  
 tagtatgat tggatcttg atgacaac actactaata atcatatgtg ttggatctgt 480  
 gtccctctt gcaacttct ccaaatagg ctctctggc tacacagta gttatcat 540  
 ttgttatg aatttcttg ctcttgggt aataattaa aagatgcca tccctgtgc 600  
 tctgacatta attatgtag agaaagctt ccagatttca aaygtttacag atgatttga 660  
 gccaaagct tttacttct ccaagagag tgcctatgcc ttaccaacca tggcttttcc 720  
 atttctgc catactcaa tattgccat atactgtgaa ctccaagtc ctccaagaa 780  
 aagaatcag aatgttaca atacagcaat tgccttaagt ttctcatatt attttatc 840  
 tgcactttt gggtactca cttttatgg gctctattct gtgcacag ttggcgttga 900  
 gggtgtgat ctgactcat tgaacctct gctctccgga ctcaagcaat cctccacct 960  
 cagctccag agtagctgag actacagaaa aggaagagat accatggaga tgtgaccca 1020  
 gaggaaggc accaaagga cacagcaga aggaactgt ttacaagcca agggaagg 1080  
 ctacaggga accaaagtg tccacactt gatcttgac ttcccaact ccagaactgt 1140  
 ggcacataa atgatgtgt ttaataaaa aaaaaaaaaa caagggggggc 9 1191

&lt;210&gt; 16

&lt;211&gt; 1186

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

gaattcggca cgagattgaa tgttccagat aatcccttcc ccagtctcgc ctgacatcgc 60  
 gttcaggtt ttgtccctgg aattctgga cactggctgg gggttgagga gagaaagccag 120  
 taccactgt gtcgaggtt gaagctggcc aggtctctct tggtttctg gtcagcttct 180  
 ggggtggcc ttggtcagag gcacagcagc cctgacacgg aggagtctta ttacagctg 240  
 ggcctcggc accctccggg aagcttggaa tccgtcaata gctacttga ttctttcgc 300  
 gactgctcgg gagggaagaa tggagtctgt cagtacaggt gccgatatgg aaagaccca 360

atgccacagac ctgggtacacaa gccccacagag cccaatggtc ggggtctccta ttctctgggt  
ctcaaggtgac cagaagatgat ggaacttgggc attccagacaa tgaacaagtgt cgcgaacag  
ctgagatgctc gtaataacac ttgggtgtgc aaaaatatac gctgtgtatgc aaatctcga  
tgggtctccc amcagatctc ctctgacctt aagcgagatc tgggtcttctgt ccccacatgc  
gaagctgtgt attccctgtgt tgaactctgt ttcaaacagc tgtgacctgt gggctggcgc  
cccttattaga attgcctgtgt ggcacatctgc atctgtgcag agtagggagaa ggaagagtta  
tgaaggaagaa gtgattccctc cctgttctgt agtgaacaca cagctgtgcag ccttaagaat  
gtcaagctctc ggaatcagc tgaactcattc gttctcccaa cagtttggag acccaacagc  
aggaagaagag gaacattctt ctacagctgcg aaagtgaagc ctatcctctg aggaattctg  
aaaaaagaca tggagtgtgt tgaagaagctc tcttcatlta agactgtctc ccccacaaa  
gaacattctg cgcgaagatc cagttctctag cttaagaact aaaaatgcag caaacctgcg  
aatctctgga cctgatagtt atatcatgaa gtgaatltgt ggggagttcca gcatlctgg  
aagcaatgac ttctctgtgc cccatgttctc agttgcaggt aagcttctta catttaataa  
agttactctt ttgaacactt tggaaaaaaa aaaaaaaaat actcga

<210> 17  
<211> 1182  
<212> DNA  
<213> Homo sapiens

<400> 17  
ccacagcgtc cgttaaata taaagaact gaaccaggtgt gttctttcac catagatata  
aagatctgga ccggccagca caaagtgta gcatgtgtct cctctgtcac gttctcgtta  
tagctgtgtgt ccagatgtgt attctctcag aaagctgggc attgtgcag aacatcaact  
tctataatgt gaggcctcct ctcgaacctc caacattccc aatagatctc aagttcttca  
ctgtgtaaa ccgaagaggt aatttaact gcaatcgatg ggcagaagac aatgtgtctc  
cacaataact acagatagct ttgacagatc atcaactcac cagcacaagga agaaacacat  
ccatcaccaa aaggtgtgct tccagaagtgt aatgtactt tgtcgtgtgc caacacagc  
ggatctctga acatagcgag tgaatgtctt gctgtgaagc aatgtctgc aatgtatgaa  
taccacacca tcaactaat gcaagtgtct ccgttaagca cgtccagaga aactctgtga  
gaatgctccc cactacttac cttaacatgt ctgtccttgg tcttctgtct tccattgtctg  
tgaatgcac atctctaga gggcagaga ccaagctcta aagcacaagc caaaactgt  
gtgaacgtgtg aactcttggg tgaagatcaa tcttgacctt ggtgaagagt gcaacttga  
cctcaagagc aaagcaggtg gttgtcttgg ataaatgtt cccgcatgag gccaagagc  
tgaagatggg aatttgcag ggcctggaaa gatgtatcga ctccagagct tccctgtcaa  
agaagagctac gtttggcag ttctgcagag agaatcctgt caactagctc cactgtacta  
ggcctttagc tgaagagat tcttgacctc ctgtactgc tcaagagctg ccaagtcaaa  
ccctcttgtt tatgtatla gctcagagca tctctatgaa atctaacct tcccctcag  
agaagaagcatt ttcccacc aacagatag tcaatgaaa aggaacatgt acgaagaaa  
cttccaggtg aactaatatg aactctattt gcaattatg gggggaaata aagctttaa  
athtatacat gtaaaaaaa aaaaaaaa aa

<210> 18  
<211> 1171  
<212> DNA  
<213> Homo sapiens

<400> 18  
gttccagac ttgtgatac accatgtgc gttggacgat gaagcgtgtg agagaatga  
ggcttgaggt cagactgtgt tgcctctcct tagcacagc aggtcgtctt gctgatatga  
acgaagctcc tcaagttcac gttccagcgt cgtccacagt ccaagaagcc gtaggacatg  
tgatcttggc ctgggtgtgt gaaccctcaa gtagaattgt aactggcgc ctgaatgaaa  
aagaagctgaa tggctcggat gatgtctgtg gttctccat caaccaaggg accctgtgta  
tcaatgctct taacaacac acgtgtggac gttacaggt tgggtccgg attcctgcg  
ggagctgtgc caggtgcag ccaactgtac actagccagt gagtgtgtc ctctgtc  
ctgcagatgt ggggtccctc ctcatcttc ccaactgaa gccccacaa ttcatgtgc

ctctgttacc tcttagcata aaatggacct taactgcga<sup>g</sup> aatgtcaat cagaacagta  
gtctccaggt aatggccagt gatggggag cctgtgtccc ttggaaacc tcaactcaag  
taagaggtgt actgtgagt agtgcctaca gagaaggaaa ttggtcaggt catgcaaga  
cttgaacagc cgaagatgt cctgtggccc cagaacaggg cctgcgtgtc ctctcaact  
gtatcctgt tggctgttag tgcactgtgc caactgtca caacattccc agtccctcc  
ctccatcttc aaccaagta cagtctgagc aggtgagagc aggaacccaa gagaatggg  
cagaagcagc tgaatctcgg acgaagccca cccagccagc acttggcttc ctgtctct  
gttaggggca agcatagctc gaagcctcgt attataata tgaacata atgaagaa  
aactgtgtg caaaggatga aaggatata gagaagaa acaaggaa gatgaatga  
cagttgtgac caaggaaat gccaaagaaa gaattcacac taactcttct ttctctgt  
ttgcacat tttaatac gttgttacc tcaatlagat atagtattt aaatcatla  
tgtctgtaga aaaaaaaa aaaaaaaa a

<210> 19  
<211> 1337  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (22)  
<223> n equals a, t, g, or c

<220>  
<221> SITE  
<222> (1318)  
<223> n equals a, t, g, or c

<400> 19  
cggggtctgc ggcacagcc angcgtagt cgtctgtga agaatltaca aaagtgtcag  
gtatagagag gttctgaagac taacatttgg tgaagtgtga aaacagaaa cctgttgaa  
atgtgtgtgt ttcaagaaag cctcaatttc ctctctcag ccttgttaat ttgacatctc  
gtcgtcttca taatttcaata taactactga gtaaacctc accatataga cccgtctta  
ccttatatca gtgaacgtgg taacagtagt ccagaataat gctatagtg ggcacgtca  
aatatggcg cagttttatg catgtctacc attcatgtc gttatagca agttcagct  
ctgggtctcg aagagaagat taccatcaaa ttaacaagc ctggcctgt acttgatga  
ctgaggttgt taggacttc tatgttgaa aacttccaga aaacacccct ttgtctgca  
cagtgaagt gaggctgtct taactttgtt atgggtctat tatatgtct tgttcaagc  
atccttctct accaaatga gcccaaatc catggcaac aagttctctg gatcagctg  
ttgtgtgta tctgtgtgtg agtaagtga cttagcatgc tgaattgttc atcagtttg  
ggttgtgtgc ttacatgtat cactactga gcagaatgt ctatgtcatl ttctcttct  
ggtttttct tgaattacat tctgtgattct cagaataat cttaaggtt ggaagccaat  
ttacatgat taacctctca tgaactgca cctgtcccta ttaacaatga acgaacagc  
ctacattcca gagaatttg atgaagat aaatatctc tgaatgatt atgatctca  
gggatttggg aaagtctcac agaagtgtct tatctctc tgaatttcc aacctttaa  
tcaagctga cagtaaacat gatgaatgt gataactag aacatgaaa gaacccatc  
gataatcat tctaaagat atcatcaaga agactatata aaacacactt gcttactct  
tttatctca gaataaagaa tctaaagact atgawmaw agtttttat acctatata  
agaagaanaa cctgcagctgc accawtcagt ctgcacatcc caaccttca catttttaa  
attatgtag atcaatttct gtttagagcc ctthtatga gaggaatatt tccatgntc  
taagtaacc agccttct

<210> 20  
<211> 1162  
<212> DNA

&lt;213&gt; Homo sapiens

9

&lt;400&gt; 20

ggcagcaggc gccccggact ctctcagtt gagagtcggt tctctgggca ggtttccaca 60  
 ccagttctctt tccggtctct tccgctcttg ctctggctgc ctggcgaggg tggggtagca 120  
 ttgtcattt gcacactgct gcttttatct ttgggctgc acccgaggc acaaatgca 180  
 ggtatgcttg tccaccacat ctccaccac atctgggttg ctttttgctt actttgactt 240  
 tctctctaaa tctctctgt gctgagcaaa catctccag ccagcagagc aatggagagt 300  
 tcatggccac tctctccagt atcagcaagc aatttgggtt gatcgttttg aagcctcaga 360  
 gaaaagatgt caccaggtt cctgtggctt tgtctctcag catggggctc ggtctgtctt 420  
 cactcgctt aggaagatt ctggctcttg ggtcttgata tggcgagggc tggaggtttt 480  
 ggtatcttga gctgcctct agctgggtat gtcgctcgg ttggcgggcc ttgagttttt 540  
 ttgtaatgac tcaactgtgc tctttctgg atctgtctcc ctccacatg acccctggg 600  
 gtctctgaat gactgtttaa gtagtaccat gtgggttccc tgaatccag caggggatgt 660  
 ttaataagga gcttagctct tcttgacgt gcaataact cgtataggct aatcagcagg 720  
 gaaggagcag gttacttctt gctctggcc ccttggggat tcatctctct cctctgtaac 840  
 ctataagtt aaaaaggcta ccgctggcc ctttggggat tcaatccctt cctctgtaac 840  
 ttgagatgt ttgttctctg tgcagactca gaggtttcgg atgaagatgt gtgggactga 900  
 ttgagaaagc ttaactcttc gctgggttgg aggtttctaa ttgacctgtt ctttgggga 960  
 tctttaaagc cagctctccag gtggggcgag cgataggacc aagtctctct agtactctt 1020  
 gggaaagcac ttgaggggag ctgcccgtca tgcctatgca cccatgtgtc ttctgcagc 1080  
 aggcctctga ggtcgtgca tgttctatgt cctctgggtt tcttgggga gaaggaggt 1140  
 gttagaaaaa aaaaaaaaaa aa 1162

&lt;210&gt; 21

&lt;211&gt; 1837

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

aggaagaaat gaataatgt agcattaggg cggcagtcgg gattactcag tgttgagaga 60  
 aacacacgg aagaccagga gcagagagg gagaagccc cattctaca gctttaatct 120  
 atcgcacct gagggcgaga gctctaaac gacacctgg ataaagctcc gctggctct 180  
 ggaagctccc tggtagacc cagatctct ctttgggtgc tgaaggccat tctgctggcc 240  
 tgttccagc cgtcttggc ctatctgc ctccagttct ggtgtctgc ttgccatgag 300  
 ccgcatggt ctacagggc tggccacatg gagagacca atgggttgggt gagtggcca 360  
 gagaggccc cggactcttg tccaggggag gaagactgc agggctccc cctgtggaa 420  
 atgccacga agaactccag agatggagct gaactgac cgaagccaa ccaggatgcc 480  
 cctgatcgg gtgccttaca gaggggggggt ggtgacccac ccgtatact gctctatgt 540  
 ggggaatgag agtggggagg agagccccc catcatgag cttaagctt tccacacagt 600  
 aggtcgtttg tacaatgtg tctatagact accctattct ctccactcaa acgtcactgc 660  
 tatgtaggt cacttgggtt ggtatgaatgc cccatgaca agctctctaa gctggaaaaat 720  
 gtatccccc ggtatgcca aggcacaaac tagctctc tagcagcgr tccactcga 780  
 ggaacagtt agaatgtgaa agcatgtgtt taactataa acaaacatgg atatgttaa 840  
 aagtgaag caaaaatttg catgacttaa ataaacaca gcaactgaag gaacacttg 900  
 agtwacagt aggtctctcag argtacaact ttggggcaag tagatgtccc agttctctt 960  
 gcccttgagg ggaatcttg gaataattt gggatattt ggaaataatt tggagaacc 1020  
 ctgtctcgg ttacttttcc aacttttag caatcacata ccaccgytyr ctatttttt 1080  
 aaacatgga ttacttccat tattattaat aatacttcc tttaaatgga ytcattttt 1140  
 aagcgtaaac ttaatttcaa agacagctt atattactc ataatgtgaa aaccagcac 1200  
 ctctgtgtgc aaacagaagg gagagaaac agaatatac atcatgaaa cagataata 1260  
 ttaataatc tgaacttagt tctatgctt gccagtgtt ctagctttaa tgcctgcttg 1320  
 ctgtctctt ataaaaagg agatccagtg ttggagaggt ataaagaca tattagacc 1380  
 aatattgtc ttctctctg atatagcata agattgaaa gagaatcgaa aagggaagtg 1440  
 ctgtttttac ttgtgagtc agtgttagt aatggccatg tctgtgaacc acctcaatg 1500  
 gctgcagca gcttcccttg atttgaaa attgtctga ccagactagg caggtcttct 1560  
 ttgggaagac gcttgactc tccaagcac atccaagacc tcccagtagc cctcttata 1620

16

ctatagagca caaatccca gaatcacagg acgacactgc agtgaatcaa ctaagaatca 1680  
 gcagagctg agaagccaag acgagaagcc ccaatccctt attccctgc ctactctag 1740  
 catctccgc tccgaccca gactttgccc ccatctctg ctacttgtga acaataaag 1800  
 attcatatac tcaaaaaa aaaaaaaaaa aactcga 1837

&lt;210&gt; 22

&lt;211&gt; 1054

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

ccagcgtccg cggcagctg ggaagaatc ctccagttt agctctact tcaacagct 60  
 tctctatct atacagttaac caagtggga tgcctctta tgcctctcag ggttttccat 120  
 tctctctcc atactctca caagaagcaa acaggagtat cactcttcta tctgttgtg 180  
 acaactgttc tcttcaaca caagtcata ccacagcaa gctgcgctt ccttcatctg 240  
 gtgtctcttc aaatcgcca ttaccctatc ccacagtga tgcctcaata ccgacaagcc 300  
 aaaaatggtt tgggtacaag atgcagatg tccctgatgc atttccagaa ctttcagaa 360  
 taagtgtctt caactcaaa caaatatta ccgacaaa tgaacttagt aagaacttg 420  
 tgaactgttc tcaactaaa caaatatta ccgacaaa tgaacttagt aagaacttg 480  
 aggaactagc aaaaaaaa cctcttttgg agccagctt ggaagccaaa agacaactg 540  
 tttagataa gtatgaata ctacacaga tgaagtccac ttccgaaa agatgcaaa 600  
 ggcagcatga acttagtgag agctgtatg caagtccct tccagcaaga ttgaaagtg 660  
 ctgcacatga agctgaggaa gaatctgata atattcaga agactctttt ggggaaaga 720  
 ttgaaataga tgatttctc agtagcttca tggaaaaag acaatttgc cactgtagaa 780  
 gagccaaaga aggaactt cagcaggcga tagcaatgca cagccaattt catgtctcc 840  
 tataggtaaa ttgtattca agtttgatg tcaagtgat tgcacagtg tcttttaaa 900  
 agacatgttg ttaacggcgc ctgttcata gctttagca taactctgc attatagta 960  
 ctgtgtatg taacatagaa tgcctgtgat tataataa gcataataa acatataac 1020  
 tagtagaaa aaaaaaaaaa aaaaaaaa aaaa 1054

&lt;210&gt; 23

&lt;211&gt; 1066

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

gaattcggca cgaaaaaag caaagtaaa ataatatta aggaagaat gtaagagta 60  
 gctctctct tcttttctat tctcttttc tttttctct ttgtctctc ctatctctt 120  
 tctctttct ttgtacata tgaaaaacta gtgcaagtga aagaatgtt gattctatt 180  
 ctcaaaaaa taaaattaa ggaatacaag actagacaat gttatctttt aataagttg 240  
 ggaacaatg gggccaagt gcaagtga acacagttg aagcagttg aagcagcagc 300  
 cgtagaagaa gtcaagcaac ttgttccaa gcaggtttt aagctcacat taggcagtg 360  
 gggctcagc agagctccc agaggtcag atgcatlgt agatactta ctgtctact 420  
 gtctctgt ccagaaaaa cctatgcta taacattcat aaaaatttaa tctactga 480  
 aaactagat ctgactgta gtgtagttt gattcttat tttycaatt catatttgt 540  
 aattgaaaat atgaagagt gtgtatag aagaagaag agagaagaa ggaaggaag 600  
 agagaagaa agaaaggga gaaagaaaa gaggaaaaat tgaattcaa gttcagta 660  
 ttgagttgg cgtctctcc caaggaattt tacattggct ttgttcaac tctgactta 720  
 aattgcaact gctctaaaa tgaattttat aaattggggc aggggggtat aaattgtat 780  
 tttagttgt agaatcttag ttgattggag tttagttaca gatcgaaga actatagtg 840  
 ggaataactg agaatggaa ttaagccatg caaataaaa atctaaggc cagctctatg 900  
 aaaaatgt ctactgaaa gtttaggag cagcagctg gtgagcaaa cctctgtatg 960  
 gaagaattt ctaattctaa gctacttca aatttgatg ggtgaaaaa tatctctctg 1020  
 aatcaaatg agacataaa aaaaaaaaaa aaaaaagg ccctctc 1066

<210> 24  
 <211> 928  
 <212> DNA  
 <213> Homo sapiens

<400> 24  
 ggcacatccat cttaagatagt aactcagaaa gtcgacttat ctctctgtga atttcccttc  
 atgtcaagct ctctaaaaaa ccacctggac cactgcttct tgcattcgtc gcttaagag  
 ctctgttccc ccaccataag tagcttcttg cctcaactaa ggcacctccca gcttaacttc  
 aacctctctc cactgtatgc agaaagtaca aaggagaacc ctggcccgac tgcacagttc  
 agtaaaacac ccagagagagc aactatgitt attlaggtcg ttcaagagct tgcctcctg  
 cctgaactat tgaagaagc ctgaactatc tagagcttct cctaaaaa tccacacttg  
 gctgagacac agtcaatgaa aacaacagca cccaagaac agagaatcgt agcttctgct  
 ctgtgtctgt ttgttctta ttgttcttc atttcttgc atgaacatg aaactctcgg  
 tcttggataa gatttggac ctgactcag cagtgaataa ttgtttgacc ttgggttggat  
 taactaactt ctctgggct aaattcttc atctaagaag tggattagat acagcaaat  
 attatagttc gaagctctg gctggagctt gtcgtcagc actgtatcc cagcatlttg  
 ggaagctgag gtggagagat ctcttgaac cagaagttca agactagcct gggcaaatg  
 gcaaaacct gtcctacta aacatacaaa aattagtcag gcatggatga gcatgcctg  
 aatcccaagc atcagaagag ctggagtgag aggatcgatt gagcccgaga gtttagagt  
 gcagtgaacc atgattgac cactatattc caacttggc aacagagcaa gacctgtct  
 caaaaaaaaa aaaaaaaaaa aaaaaaaaaa 928

<210> 25  
 <211> 966  
 <212> DNA  
 <213> Homo sapiens

<400> 25  
 ccaagctgc ggtatttttg tcaatgagc cactgaagag gattcaagtc gtgattttac  
 ccaagttct cctctgtgc tacatggcag cgttcaacag catcaatgaa aacagaagtt  
 acacttgtaa gccaatgaa agatcttacc taatggcggg agcctgtct tcttaactt  
 tcttaagagt aatccctag ttgttccaca tgaagtatg cctgactggc ccttgatata  
 aaagactct accgtgatac ttccctggtc aagccatgg aatgaatttc taactgtccc  
 gaagttctta atccattag gggattggcg tcatggacaa ggaagagcaat gtcttggatc  
 atcccaagat tgcgtggaca aagctgttga gagaagcgt agcatccaga atgtgtctgt  
 ttggagacct agctctgatt cctgaagctt tcaactact tcttaaaag accagatct  
 tctggaaaaa cccaggttca ttgttagatt tgaactgtc ttgtactgtc ctggcaatgg  
 tcaagtaggt ggcatttctc tttagatatt ttcaacagat tggacagata cagtactgta  
 gttcttgaaga gaaattcag tctccaacag aagaacaga aactcttatt cacagaaggg  
 gtttagcggt agttttagat gaaattatgt ggttccgtct tgaanaactt ccccttcca  
 gtttcggttt agagaacttt gccacagttc ttctgggttt ttlaagggtg gctggagaag  
 acagtggagag gtgcaccccg tctgacaccc ctgggtgtgc tgaaggagag gttaggttgg  
 ggtacggcct gcgaagagat actgtgaat cactaatata ctaataaacc tgtcttaagt  
 tgaagatttg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa  
 aaaaaa 966

<210> 26  
 <211> 1146  
 <212> DNA  
 <213> Homo sapiens

<400> 26  
 gctaacctca taatccgccc gctctggcct cccatagtcg tggattaca ggcgttagca  
 ccgcgtccgg ctgtcgagat ttcttttaat gccatacata tataagcaaa taagtcttt  
 aagaagctaa ccttgaatgt aagaatggca ggtgtctcc agtttttacc tcttccatat  
 60  
 120  
 180

ggagccaag tagctagtt atggaacaca tatgaatg tggttatcc accaagtttt 240  
 actactcac ttgtcttacc acttttaagt catgaatttc aatattatc atacccttt 300  
 gccgtgacg agaagttaact tttaaatata tcaactgact ttgattgaa ctgatataa 360  
 ggcagaatlt ttgtcttca gtgagaatlt atctgttca aggttgaagt ggaacatca 420  
 ttaactggg atggtacttc ttattttaa tagctttaa aagttcttg atggaagag 480  
 aacttlttg gtttcaatc gagaagctca ccaatgtgt taagtcaat tcaatagtag 540  
 gaataaanaa ttttgaatag tcaatgtcgg tcaagaaga tttaaatg gtatgtacca 600  
 aagaagcaga atgamaagag atcaagttca caaatctgt atgttaca aatatagttt 660  
 agatggtaat atccaatagt ctatccaagt gttcaaatc tttaaacag ggaatggcca 720  
 aatcccgctc tatgaanaa gcttgaaga tgaacttca atttgcctgt atgggacca 780  
 aggtttatga tatatttt tcccctacca atccacactg tgaataaca agtaaaatc 840  
 atctgacata atcccaaggag gactccagc ctlttacta tgaatgttca tgcctgatt 900  
 aactcttctt tttaagatc tcaattacaa ttgttccca ctatattga tgtgaagaac 960  
 ataatatgt accctgtaaa ccaatttcaa ttgtatagag ttlttaaac agatttact 1020  
 acaattttaa ttatttcat atagaaactac ctgtgaagtc aaagtgtgt gggcatltt 1080  
 gctttaaana aatatnaaag atactcaaaa aaaaaaaaaa aaaaactcga gactagttc 1140  
 ctctctc 1146

<210> 27  
 <211> 802  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (337)  
 <223> n equals a, t, g, or c

<220>  
 <221> SITE  
 <222> (359)  
 <223> n equals a, t, g, or c

<400> 27  
 ggtgtggtgac cagagatccc tctctatcct aggaagaga caatcagccc aaatccagc 60  
 ccaatctgc acaatataga gcaatttctg aaatctgc tgcgtatctt gctttcttc 120  
 ggtattggcag aagcctgtac tctctgtgaa gtcaacttc tgaaggagat catagtctc 180  
 atgagagagac tgtcacggga tgaatctcta ggttgttga gcttccagat atgtgttng 240  
 gaaaacaagt gtgcagaaga ggaattttaa cctcttctag gacacaccc atccagaana 300  
 ccaatcccca agagagaaga aacagtggaa yttccnnga atgcsctac actgtatgaa 360  
 acctactctc tctatctca caaaaagg gactgttca ctlttcttc ccaagtgtta 420  
 ctgcacatc tgaacttgg aactggaatc caggatagat cccctgttgt ctltctagtg 480  
 agcctctcct atctcaact agccttaca aggcctcat ctcccaagg ttctaaccctc 540  
 tgaagaagc tctctgtcc ctggaatgc tgtgtgagag gtaatgaact ggttctctta 600  
 agaatggga cctggtgtgc cagaagtcagt gccagaagt gttctgtggg gcaatgcctc 660  
 agggggatgc acccagggcg gctgaagag caactgaag agtttccctt aaatctctc 720  
 ctccagatcg ttctggaact ttcccacta ctccaatat aaatgtata ctgttgaaa 780  
 aaaaaaaaa aaaaactcg ag 802

<210> 28  
 <211> 1169  
 <212> DNA  
 <213> Homo sapiens

<400> 28  
 ggaattgag tgaanaattg aatttccatg tacacatgac ccggtgtgca catatctgtc 60

120 tgaatgtgct agtggtttcta tgaatgtga ctgagtgtaa atgtgttggg gcattacaa  
 180 cctgggacac agagaaagtg aatatattta tggcacactg gagtaaaactg aagagggtta  
 240 ggggtactag agtgtagtga aaagaaattt ctacatttt cctcatatta tacaattatg  
 300 ggagaaaat taataatgcag aattttaggg gatttaltaa atattgaatt tgtgtacaac  
 360 ttcaaatga aatcttttca gttttttatg acacacttga gctcaattct agaaacactgt  
 420 cttagctgt ttgtgtctg tctaacagaa tacttgagac tgggttaatt ttacaacaga  
 480 gagattttt tcttacagt ctgagggtca ggaagtccaa ggttgagggg catgcattca  
 540 gcaaggcctg ccttctgctg tcatccata gtgaaggga gaaaggaag agaacacgct  
 600 ttgtcatgag agagagaag agagagaaga gaagggaagg gaagagaag agagagaag  
 660 aagagagag agagagaaga agagggaaga aactcatcta ttatcagga acccttctta  
 720 tgatagaac ccaactccat gaaacagga ttaacttgt tatgagga gagtccatc  
 780 tactcatca sttcttaag gtctcatctc tgaactcgc tgaactggg attaggtttc  
 840 caacatga actctggag acacattcaa ggcgtagcat tctyccttga ctccmaaat  
 900 ccatgctt ctatgtctga aatagatta atyccatccc atwgcccca agtcttgac  
 960 tctgtccagc accaactcaa aattccaag tccagagtc catttgaatc agacagaga  
 1020 gactccaggt gcaattcct ctgaggcaaa ttctctcca gatgttagc tatgaataa  
 1080 gcaattact tcttccaaa atacaatggt gggacagga taggatagac attccatc  
 1140 caaaggag aataagcaa gaagaagg gtaactggc ccaagtaagt ccaaatcca  
 1166 acagaaaaa aaaaaaaag ggcggcgcg

&lt;210&gt; 29

&lt;211&gt; 1466

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 29

60 ggcacagatg cctcaagac tatctttgg gaggatctag tgcaaatgtt agtaatgtgg  
 120 atattgtga gtgtccagg atattaatgt tttagcttc ttgctttta tctgtattg  
 180 ttgcccacaa agatgatgt cactatctt tcatccagt taaggatate tggaaagaca  
 240 acagaagta tagtgtttt catttcaaa gtgacagct gcttgagcta gcaagcagg  
 300 ctgtcactag ctccagagg cagtcacga gtttcacagc aggcgcggtt cctctgagc  
 360 accagagct gccctgcggt agtcagcagt tgtctgttgg ctgacctgac aggtctgggtg  
 420 gcatgtgat cggagccagc agatgtggt caggaaagtc ctcttggcc tctcttaaat  
 480 ctcttcaaga stctgtggc cttgtattgc actgtgggtt gttcagact ccagttatag  
 540 gagactgaac ccttgggtt ttittttgtg tgtgtgtgct gactgggtt gagacatgt  
 600 taacaggtg ggtgcytc cctgggtttg cctcgggttg taactgtgtt gtcgggttgg  
 660 tctgagtgt tctggccca ctgctggagt atctgccay agcttcttg agatggcagg  
 720 gctcactct ggtctggtg ctcatcttct tcttttagc tgggttaga accaatgac  
 780 attcccaagt taagtattt tctgtagct taattattac agcttcttg taccataagc  
 840 ctcttact tctgttctg agggagaag agataatgt tgtttctcg cccccccgg  
 900 agtggccca ggaacttga tggcatttg acattttga gctgtattg ttgtgcttta  
 960 cttaggtgaa agcttgcac cccacagac ccacaaaggc acctctgct accctcggg  
 1020 gagtcttga ctggcccttg gacatcact gctccagat cctatggc tcatccagg  
 1080 agagtgtg gagggaagg gaaaaaggc ttacatttgc ttgattgaa tcatgtatag  
 1140 ctgagttcgt catgatttc taagtgcag agcccttgc ctttgcgtt ttgtgaaty  
 1200 ttagtctgt ttaapcttt tcaagctgt gctctagct gctcagag gtcacagct  
 1260 cctgctctc ctcagggga gtcgcccct ctctctgtc ggtagctgtc aggtcccct  
 1320 ttctcttga gtagactgic ctgggttctt gctggcctt ccccttacc gtagcctgc  
 1380 agcttcatc aagcccctg tgaagaaga taggcaacta aagcagctga ctggcagcc  
 1440 tagaaacatg agggtttca ttatagttt cagtcctttt ccttcttct agcttaatt  
 1466 taacaaaaa aaaaaaaa ctctga

&lt;210&gt; 30

&lt;211&gt; 1226

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 30

60 ggcagtgcgc gactggact aaataagtat tagattctgc cttcaagctt gctaccagat  
 120 ggcagtgtaa aatggaagta cctcatctca ctgtgccacta taaagcctgc taccagatgc  
 180 agcttaatta tcaacttcca cctcactact gatagggttt tgatatgagt ctgcaagcaa  
 240 ttgatttat ggggtccctg tgcactcaaa cctctctgtt aacattaalc tgratttgca  
 300 gcaactccca agccctatca tcatcacctc agctcacctc cagatcatca agcatttagt  
 360 tctcatagg acatgcaacc tagatcccta acatgtgcag ttacaatag ggtttgact  
 420 cctcatgaa tctaatgttg ccaactatct gacaggaggt ggagctcagg cagtaatgcg  
 480 agtcatggag aatggtctga agacagatg agctgtgtt tectcactg ctactcact  
 540 cctgctctgc tgcctgttct ctaacaggtt gtcgagaacc ctgggattat attgtatagg  
 600 atgtccact tatgttcca ttatgtacca gtattatgta tccactgtat agactgata  
 660 ttattttta ccaactcaga acatgttttc gtttttagta galatggta catagatagg  
 720 gcaatttgt gagatactag gaaatgtgt ttgagactt attcttttc agtgggtgaa  
 780 tgaattctt tggactgta ctccctcga gaaaaattag gaattttatt tgcctaaagc  
 840 atgagagaac tatcaaac atgagaatt tcaagagatt tagggaggtt acaatgcaa  
 900 ggcatacaac acaggcawtt tgtgtaatt taacctttag acagttagaa atctgtgaaa  
 960 cctcctgaga cactgagcag tctttttgc agccattaca gaggaaacaa attagatc  
 1020 cagatgtgc aaggaagagg agccttgga taactttag acccttgaat catcataatc ttttataga  
 1080 attctaaac ctactctga taactagccc acccttgaat acccttgaat ttttataga  
 1140 ttatgtgaa atgcccataa tgtagttaga tggcaacata aagataaat acttatga  
 1200 gtgagataac atcatatgga gcttaaatg attcttcta tatacatat acaatattg  
 1226 gcaacaaact aaaaaaaa ctctgag

&lt;210&gt; 31

&lt;211&gt; 1094

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 31

60 ggcagagccc cagggtgaga agtttgggag acatgttcca ttttggcttg tgggatctgc  
 120 attcttctt tatagttag gctcatagag atgactgtc ttccaagggt ggttctgtgc  
 180 tattagagcg ttccaatgt ccccaactt ctctctcag tgcctagctaa agcgaacttg  
 240 cagatagtt ggaatgtctt tggagatag aaagaacaca gactaggatc agaaaaatct  
 300 gctcccaac cctcatcgc catcttctg ctgtgtgact ttaccgctct aactctttaa  
 360 aatagccca cactcactcg ccaggattgt ctacagaatt acataaaata acacatacca  
 420 aagctcttag aatagagcat gtacataat agactcaaca aaggtcagca tctctttt  
 480 ctcttggga tgaactaagt agcctaata aataagtatt ccgcaatgca tgacttgata  
 540 acataaact ttgttaact ctattactc caagcataaa acaattatg agacaaaga  
 600 aatacaat ttcttaagt cgaagacaaa aaaaaactt accaataaag aaggagctg  
 660 tctgtacc aaacacaa gccacagtt ttctctctt aaatgcaga ctttgaagag  
 720 gttgacatt ctgttccca gcataacac gctctctct cgggcccct tcttaactag gaccacag  
 780 tcttgggac ctgtctgctg tccagccca gtctctct cgggcccac tgcgctctc  
 840 ttcacgata cactgggttg tgcctgggc tgcctctctt accacaagt ttatcttca  
 900 gcaacact cagatcacag aagagaca aataagtg gggaagag atgggttga  
 960 gaaactagt cacttggtaa ttcaattc agactgaat ttctctgtg ttcagattta  
 1020 ttgatctg gaatttct tgattctct tggaaatc aaataaattc aaatgattgt  
 1080 aaagtctct gaaagctct acagtcttct taagagaata aaaaaacctg aaaaataaaa  
 1094 aaaaaaaa aaaa

&lt;210&gt; 32

&lt;211&gt; 1037

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

<221> SITE  
<222> (6)  
<223> n equals a,t,g, or c

15

<400> 32  
ggcggnccca tgaagaagct cgaatcacgc cagatcacga cccacagctc ctcccccatt  
gagtcggccc acagaagaag gaatactcgc gcccggaagga aatggagagt gtccccgga  
agaaaacagt tctctcgtaa cgggaagatc atgattggcc ggcagagagg cgctctcac  
ctgacgcttc tctctacct ggtacatcgc ggaattctct tccgcttcga ctgtccgtac  
atggggagacc tgcctccgac cagcttcagc gaaccggag tccctccagc agccacact  
gataaagcgc ccgacttggc aagcaaatga gtaaacatc aaatctggcc catgctctc  
gtacatctcc cgtctggccc cagctacagt ggggaagcga ggcgcgagcg tktgcagag  
gagctgaagc tgaagaagag gtgtgatata aggtctgaag gacagatc ctgaagcag  
gactgcagcg ccacttgcgc aaagcatcgt tgragctgt gctctgagt ttctcttga  
accgaagtgt ttgattccac tctactaagc agctccacc ccgagagat acagttgtag  
gttgcggccc ttactccct ttgcacatct tgcacatga tgragctgt tttcttga  
ctagaagaat tacactttag gcaacttct tgttatcca ggcagagat ggaatttcc  
ttactatagg tataataaac atgtatctgt gatatttct tatataaac catttgaag atataaac  
agatccatc cctctacaca ataaacttct acagtttct ttttataaaa aaaaaaaaaa  
aaaaaaaaaa atccgag

60  
120  
180  
240  
300  
360  
420  
480  
540  
600  
660  
720  
780  
840  
900  
960  
1020  
1037

<210> 33  
<211> 1376  
<212> DNA  
<213> Homo sapiens

<400> 33  
ggcgaacctt cccccacca gagactgggc agatgtgctt ggtgacttct ggcgcgcgc  
cccttcagcc glacttggcg ctcatgcggt tggacaagcc catlgnacc tggcttctgt  
alttaccatg tacttggagc altgttttgg cagctgaacc aggttcttcc ccagattgtt  
acatgccttc cctcttggc acttggagcta ttctgattcg tggagcagcg tgtacttata  
abgacatltg ggaacagagc tatgtataaa aggttacaag aacagccact cgtccaatg  
ccgctggaga catlccact ttccagctc ttgttttct tggggagcag ctaacctgg  
-cactgggtgt tcttctgtt ctaactact acagttatgc tctggagcga ggaatccttac  
ttctgtcat cacttaccga ctaatgaana gaattcata ctggcttcaa ctagcttgg  
gcttgacatc taattgggga ggttactct gatgtctgc tatcaagggt tcttctgac  
cactgttct cctgctctt tatcttctg gatttatgtt gacatata tatgacata  
ttatgacca tcaaggacaa agagatltgt ttctgattcg tcttaagta acggtctgc  
ggttcggaga aaataaccag ccgttgcctca ggcgtttag tgttgcagt cggggggcag  
tgaagctagt ggggtgtgac agtggacaga ctgtctctga ctacgtcgc cgggttgcgt  
tggagacca tctgactcac cagatttaca ctctagaat ccaagacct gaggatltgt  
ggaataaact tatctccaac cgaacacgag gactaatgt ttitttggg attgtcttg  
ggaatttgg gaaagaaag aagacagaca aaacaagaa gggatlagg aataaataag  
aaatltatg aatgaattt atctagagat tttaaaaa ttitttcaa aataaatta  
gatttgaata caaatctga tacaatltgt taaagaatta agaacttga gatgaagat  
tagagcatat ttaccgtgat ttacttatt tgcctagcaa atccacctt gtaacagaa  
ccaggacac ttcaagattt ggaatggcct tgaatttct agttgacaa ttcttctgc  
cattataat ctacactgaa gtatgggga ttgcacgggt ttggacct tgaagaagc  
cgaatctgg tcttacaata atgaattgtt gataaagaa atgagcttct ttttttggg  
aaaaataaaa gcaactatg gaaaaaaaa aaaaaaaaa aaaaaggcg ggcgcg

60  
120  
180  
240  
300  
360  
420  
480  
540  
600  
660  
720  
780  
840  
900  
960  
1020  
1080  
1140  
1200  
1260  
1320  
1376

<210> 34  
<211> 1220

<212> DNA  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (803)  
<223> n equals a,t,g, or c

16

<400> 34  
ggaagaagtc ctacatcccc atgtgtgcta agttggcaga tcttgagctc tccagatgc  
ctcatcttgg cctcaagcga caaccagggc cagaatcagc aaacatcagt cactgtctta  
gggaaggagc tccgaagacc ctcttcttgg actcaactc ccaggcttct gtcccttgg  
cagaatggcc aggcacagca gaaggagccc cctttttagc agtttccag tccagcggt  
ttatggggcc ttcttctct ggtttctgt ttcccatct gaaggtgtgtt ggaataatac  
ggagagctac ccagagcttg agcgtgttat tagaagagc agccttgagt gttccggg  
agccacctgc ccttttccc ttggaagtg gactatggc cacttgcaca aacacttct  
aataccagcg tgcctgttgc tacatttgt ggtttcttgg ttagtgtata ttatagttc  
agatctatc actctgcaca gtgaataaa catttgtt taacttgaat ataatttca  
ttattgtat tattttctt ttaattgtc taaagtgc cagcttggc aagtgagtc  
agaacctta aatagcttca atgcacagtc agtgcgctc gtgagtcagc gtaacatgc  
aagacaagct ctcatlctat actgttctga ttatataat ggaatttag taacatagc  
ccctctgag gccagcttag atgttatga tgcataatg gtaaatctg tgaagatgt  
caacatctgc ctgtattgt acnccctaaa actgaatat acatattgta catgatatga  
tgggtcagtg attttatga cataatcat tcccttact aagttcttg gaaatagc  
tgaacagta cagaagatga aaacaaacac tggcatctta caaaccttg ctltgtat  
ttagctcat taggttaaat ttaactatt ccatttacc aaatltgaaa caattctat  
ctgttctcgc gtatgcact ttacagtg ttgagcaga tgrtltaat atgcacagc  
tgggtctgt ttctcagctc tgggttggaa ataaaagga atggagaca tatlttaga  
gtcttctgg gacttgtat ttctggcct atagctatga aatttgaag agggaga  
aaaaaaaaaa aaactctga

60  
120  
180  
240  
300  
360  
420  
480  
540  
600  
660  
720  
780  
840  
900  
960  
1020  
1080  
1140  
1200  
1220

<210> 35  
<211> 1346  
<212> DNA  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (537)  
<223> n equals a,t,g, or c  
<220>  
<221> SITE  
<222> (880)  
<223> n equals a,t,g, or c  
<220>  
<221> SITE  
<222> (1115)  
<223> n equals a,t,g, or c

<400> 35  
ggcagaagct tgrgaaggt aagttttaa cccctctgt tagccctgc ctccagctc  
tgcagaagat aatgtctc catagtactc tgaatcact gtaattgg ctcccttct  
tttttctt cctctctc tcttctct tcccttctc ttccttctc tccatctc  
cctctctc tctctcca tcttctcct cctctctat cctcatctc tccctctc  
cctctctc acatcttca ggaactagca tcaactctc taggcagct tctctgagt

60  
120  
180  
240  
300

17

accacaytt atgcacaaa cactaagca ytaacttatg tggcctcatt tatcaactgct 360  
 taaatatttt ttawacaagt gctgtgatgt ggcacatgca ggtgtcaattc ttgkagatcc 420  
 acgtgttatt gctttagagg gatgacaact gcccgtagg gtwacctggt gtgactgcac 480  
 ctanaacagc aatacacaag ggcacatgct cagttctgtc actgaccagc tggggcctct 540  
 ggtcatatc cttacacact ttggaactta atttggatc tgcacaatga gatgtggaa 600  
 ctctgagaaac tctaaggccc ctactgtgca ggtcttatta atgattacaa cagcagcagc 660  
 agccgtggt tactagagac ttacaagca ccaagcact ttgcctatct aatccttaca 720  
 tcaactctac gaagttagta tggttactat cctatlttta cagatgagga gactaaggct 780  
 aagagaggt tactgactgt accacataag cacaatgaag aatcagatctt gaatccagc 840  
 attctgactt tctgttctt agccacataa tgggcacasn ttgacacac rgttttgtgt 900  
 acgtttggt ggtcactcac agactccatc coagactctg catgaacctt cctgttcta 960  
 cattttaag gctcaactgt gactcgggt gaaacctggg gacagaagac tgcatagtc 1020  
 acaattatta gagggaatgt ggtgagac agtggcagc tctgttcatg aactttgac 1080  
 aattctaca gagagtcttg ctttgagac agacnaactta cgttgtgtt ttcagttacc 1140  
 ctcttttaga ggggagagta ggcctgagtc atgtttcaga cacagattaa aatcagattt 1200  
 ggtaccaggt gcagtgggtc acgctgttaa tccagcact ttgggaggt gagttagag 1260  
 tataacttga ggcacagaagt ttgagagcag cctgggcagc atagttagac atctctctc 1320  
 ttcaaaaaa aaaaaaaa actcga 1346

&lt;210&gt; 36

&lt;211&gt; 1026

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 36

ggcacagcc tctgtcacca aacagtagta agtatctaaa caatgttita aaacaattta 60  
 ttgtagcct tcaactgttg ctgtctccat ggcaggtgag ctgagacctt ttgtcagcag 120  
 ctactgtag atgggtgctg atgctgcag gtaaatga ctgtcaattt tcttactca 180  
 ttatcttgc tgtctcatgt ttaactaga agaagtgtt catctcaagt gctctcaatg 240  
 tcaatctatc atgtttgctt aatttgcct ttgtacatca catctcacag tcaccagaac 300  
 atgtagact gctccaggt gctctgctt ctgttactt gccactgaa gggagagcag 360  
 ttaagcaat ttgcagagga ccaactgtt ccagagtca gagacagaa tcaccactc 420  
 attttgtta aagaatcaca tcagaaaaga aaataaagga caggagagga aagaagagga 480  
 aactaataa acacgccgtt ctaaaagtgt gatccaga ttatgacag aatcaggcaa 540  
 aactaatta aaataatct tgcgaactt gatccactt caaactgaa atgattccag 600  
 gagcaaaaag acaaatcat tgcacaaa caatactttt caaactgaa atgattccag 660  
 agtcaacttc atggacactaa atagatcat taacatctca caatactat ttgtaatttt 720  
 atccttgagc agtatagtgagg agaggtgact tctaagcaaa ttatagtagt gaagttaggt 780  
 taagtgggca tattccatt ttacatctt tcttctccat ttatttactt cctatatgtt 840  
 taggggtctt caccacctt atcctctgaa ataacatag agcttttgcc attctctca 900  
 ccaaaagctt ctcatagatt ggaccagcaa ggcgatcaag ttgttgtttt gtttgtttat 960  
 ttgttgtttt gtttgttga gactgggtct cactgtcacc cagggttagg tcagagtggc 1020  
 tgcga 1026

&lt;210&gt; 37

&lt;211&gt; 832

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

gctataacca accatgctag caaacttcat actgttcaatt ctgactctaa tatcttttct 60  
 gctgttagtc ttttctcgt ttaacatct caagatgatg cagctcccat gcaaaagatc 120  
 tcaagacttc accacagag tccataaaa accittgcaa actgttatct cctctttat 180  
 gttatttgc atttacttct tgtgtataat cacatcaact tggaaactta ggaacagca 240  
 gacacactt gttatctctg tttaacaaa tcttgcaatc atgttatctt cattcacctc 300  
 atctactctg attatgaaa gtggagagct aaacagagcc tctcttttag ttltgtgta 360

18

ggtgacgtgc tgggtgaatt aacagaaacc ctoaaactca tagattcaac aggggagcat 420  
 ggtgtgtctt ttacagaaa agaaactgat ggtgtctaga acgttttata ttctgtcag 480  
 ttgtgtgag tgcattgatt tgaataatt caaaacagat tccacagata gtcttttata 540  
 tataataat atataaaaa tcatatata tataaaaatc taaagagat atagtgtgc 600  
 atgtgtgga atataaacat tgcacataaa ttatgaagcc tagtatattt catatataa 660  
 agtatgtga ttatgtaga gctaaattga tgalatttca ttgaagaat ttactctct 720  
 tttgaattaa gaattacag cattatcag aaaaatcttg ctgttttcca ttgtaattg 780  
 taccacatac atgtacttaa ctatcaaaa aaaaaaaa aaagggcgg cc 832

&lt;210&gt; 38

&lt;211&gt; 706

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 38

ggcagaggtg acaagcccg ccaagacaga cctgcaagtc ttcttctcaa gggactctcc 60  
 tcatgccagg cccctgctc tcaagcagc acccttctt ctcattgtcc ctgttccctt 120  
 ttgtctgtg gatctgttg gccagggtcc ctgggttcag gaatatitgc aagactcagc 180  
 cagctctctt ccagccacgc ctcttggggc tgggacttct tcaacctgag gcaggacaba 240  
 cagatgtcgg gaccagctct ctgcccaggt cacagacaa gtgcacatca gcactatggg 300  
 gctatgtcc tggccagaga cctctgtccc ttctgtctca catcacagt teaggagcag 360  
 ggccccctca agaatccag agtcaactgt ctcactggt cccagcaagt gctctttgt 420  
 ctatgatgc cccctctctt gaggcctgga cccaccatc ttgttccctg ggcctgtgc 480  
 cagcactg aggcctctc tggccagggg agaagagct gccgtgctgc ttcccctgc 540  
 cccgtctccc tgettggttc tcccctctt tccctgccc gctgccatgg ccaggagcta 600  
 agtgcctttt tgtgtcaac caattacct ttcttgaaa aacctgtctt caggaaggat 660  
 ctgataaact catttactct yaaaaaaa aaaaaaaa aaaaaa 706

&lt;210&gt; 39

&lt;211&gt; 1347

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (83)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (334)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 39

ggcagcctt caggcctcc ggcagcctgg ccgggcccca gtggccatgg cagcactggt 60  
 gtgtgtctg gcggagcac atngtcaag ctcacaagt ggaattctac agtgcagggc 120  
 ttgtggcggc cctgtgctg gtcggcctg cacatgttg tggcagcctt ggcagctcac 180  
 cggggggcca ggcgcccat gccaggcggc actcgtgctc agtctactat gctcagcttc 240  
 accitttgca cgtccatggc ctgggcaac gtgggcttaa ggcgtgtgcc ctggaactgg 300  
 cacaactgt tactaccac acaactctgt tcaactggc cctgtcggcg ctgctgttg 360  
 gcgcgcga caccactt cagttggccg ccaatggctc gctctgctg ggggcggcct 420  
 gcagctgagc tggagagttc cggacacccc ctaccggctg tggattctctg ctgcagcca 480  
 cctctctcg cggactcaag tgggttcagc aaagtgcct gctcagagc gagagcttg 540  
 acgagtgac cctgtttac gccactgc tgcacagct ctgcctgtg gcggtgagc 600  
 cctgtgtgt gaggctggc gttgccac cgcactgc tgggactct cgcctctggg 660  
 cctgcactc gtcagctgc ctctgtctg ttctctataa cctggccagc ttctctctgc 720

19

tgccctcaac cctctgcctc accgtccagc tccctggaca cctcaacgtg gtggagcaac	780
tcactctgtc ccggtctgtg ttggagcaac gccctatgac cctcagctac gtggagcaac	840
ccctccctc ttcaggatgt ttcccttacc acaactgcga ttctgtggcc tccctggcctg	900
cccgctgggg gctgtggcgg agggagccagc ccaggaaagg tctttgaagc ctggggggtac	960
tcaggagcca ccttggatgg cctctggctg aatccagctt ccgctgttgg catagaaagg	1020
aggagaaaca gggcttggcca tggtagctca ggcctaat cccagcactt ccagagcttcg	1080
agggtgggtt atccactgg gcccagaggt cgagccagc ctggcttagca tggcaaaacc	1140
tcactcttc taanaaraga aaatattagt gggcatgttg ggcgttgctc atagctccag	1200
ctccatggga ggtctgggtg ggaagatcac ttgagccctg gaaatccagg ctggagtagg	1260
ccaagatcgc atgctatgct actccagctt gggagacaga gcgagagctt gtctcaatta	1320
aaaaaaaaa aaaaaaccgg caccgtg	1347

<210> 40  
<211> 1467  
<212> DNA  
<213> Homo sapiens

<400> 40

gaattcggga cggagcagac aagactccca ctcaaaaa ataaaaaga agaaagaac	60
atcccggga cccctgcctc calcatgctt gttgtttac cgtctgacct ccccttctcg	120
atgtctagca aggttagcac cagcttttgc agatggcagc tcaactatt tgttccact	180
ttttaaag atgctctgtt tcaactgttc aatgacaga atcagaaagc agaatltgaa	240
ggaactnaaa agtctctgtt acagtgcaca tccctcatg ccttggata tcaacagag	300
agctttcgag tgaatggaa agtccctcag atcagaagc gggctctggg ccaacaaga	360
ctttgagac cctgcaatgc cgggtccacc aggaatgga gccagagatc cagcccccgc	420
agggccctc gtccagaca caggcaaaag ccacagccac acagctgggg gctctctcac	480
ltcaagccaa ttgtatctt ctgccttgc aatcatctt ctgaaagctc ttacgtctct	540
cttcattctc tcaaccagca ccagcagctg gctctctct tgaagcaatt cccagaaagc	600
aataagctga gttcatctt ttcaaggttg ctgaaagctg cccatggggg gaggcggagc	660
aatagagca gctgggttac ccagcaaaac aactccctc caagccacag cctgttgga	720
gggtgacttc aaagtattc cccctgagaa agcaaaatc atgtgtctga ccttggca	780
ctcccccgg ggtccacacac tgaacattac actctggga tagatccac cccgttggga	840
ctgtcttagc accctgcaga atcccaagag ggccttggc agagctagga cccgcgaagc	900
ccattagacc tctctagacc ttccactgtc cctgttctt ttgattttg ttgtttttt	960
tgatttttag agataagat cacttggctg cccaggtctg atgtcagttg tacaatcatg	1020
gtacactgca accccaact cctgggtcga agtgcctc caccctgggc tcccaaatg	1080
ctgagattac aggcaccatg cctgggtcat attttttt ttltggatg atgttcatc	1140
cctgttgcac aggtctggagt acaatgggc gatctgggt cactgcaac tctgtctcc	1200
gggttcaagc gattcgcctg cctcagctc ccaagtatg ggaattacag gacccacca	1260
ccatgctctg ttatttttg taatttttag agagacatag ttccacatg ttggctgggc	1320
tggtcttga cctctgacct caggtgatct acccaacct taagcccca agtcttggga	1380
ttaaagttgt gaaacctgt gccacggcaa tttaaaaaa ttttttaag agatagggtc	1440
tcactatgtt gccaggtctg gtctcga	1467

<210> 41  
<211> 914  
<212> DNA  
<213> Homo sapiens

<400> 41

ggcagagtg aaaaactact ctatcagctg ctgtgtgtgc caccatcttc aggaacctg	60
ccaatgaagc ccttatgctg ctcaacctgt cgtctctgt cctgtgggc tcaagtgcga	120
ttcgtgtca ctctcttacc aaggtccctg tgttggctg ttgtgaacag cagttctgc	180
ggcctggacc aggaacagca ttgcctgaca caaatgata ccttggtaag atgtgggtt	240
tctcaatct ggcgttggc acacaagaa agccttgta ggaagcttc aaccaacaa	300
accgtaagct ggtcttgaca tatacacca cctgtgcga caaggaacac tgcacagcg	360

20

caggacccc ggcacttcca gccctgggc ttgtcttct tactctctg gcttgccttg	420
gctctgggtt gttcagatga gactatccc atgtgtctgc cctctccca cctggcttg	480
cctgaagctc tctcccttg tcttgatc ccttggtctt acagaaatcgt cctctccctg	540
ctccacttc tttaatnaa caatgttccg agtgcctcc tcatcatcc tcccaacctc	600
aaccccttca cctccctt ttgggtccc ttccacttc ctccaagac ctccacttgc	660
ttccagaagg gctccactt ttgtcttca taccctggc tccctctct gaggagggatc	720
ttggatcttg gcttgaatg ggtctctgt gtgttccca gtgaagctc ccaagaagac	780
cttatgacct caatgtacag agtgtatcc ccaatccag gtcccatat gtaaccatc	840
cccactacc acccttccc atttggatg ataattgct gactctgaa aaaaaaaaaa	900
aaaaaaaaa aaaa	914

<210> 42  
<211> 1131  
<212> DNA  
<213> Homo sapiens

<400> 42

ggcagagga tctctctt atatactat tacaagctg acacatca agtatgat	60
gaattcatc ttgcacagctg tcaatggag cgtccgttga atgtcttgg tagcttgtg	120
gtggccattt gaaactctc cgaatcgat gctctgtgt ggaactagc ttgggtctct	180
catctgtcca gtgacttct ttactccat gggaaacca aagaatttct atgatatg	240
tgatctctg gtcaacttct ctggatagc tatctcatl ccaatgattc tcaatggctg	300
cctaaagata ctgaaatcac ttacttggg tagtcatlg gctctatc gttgtttta	360
agccattgc agttactgt ccaagactt ttcttcatl actttgagc taactaagg	420
agggcccaac aagratctc caaagactl tcaaaatgt gctcttcaa actaaagat	480
tcattatct ggcgttatlg ggcacgtctg ctgtaaatg aatttcaga caagtgcga	540
ggaagagag acgacgttct tccctcccc acccaatca gttatggag caagagagag	600
agggccggat gacaaactc ctggaacctc gctaccatc tcttccatg agagagagag	660
tcataggccg attaacccag attaaaggc tcttccaga ggaagagacca gctggagaga	720
gaaagctct gttcttgag atggccagg gcttgatcag ttgtcttag ctlttgat	780
catgctctga gttcttcaac agtctctgt gcaagtctaa taagagatca ggcatala	840
ttgtcttct gcaataatc atgtgtgctt tatgtata ttgtatgggt gtactaggg	900
attagataga ttgtaagga atgaaaga tgaacaaag gttgttga ggaagctt	960
ttcttatct caaahactg agaaatacc ctltgttta caaatcatg atcaacttat	1020
tcactaat agatcatla aaaaattaa aaactgact ctctgcag aaaaaaaaaa	1080
agaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa a	1131

<210> 43  
<211> 1331  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (411)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1264)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1319)  
<223> n equals a,t,g, or c

&lt;400&gt; 43

cctggaaacac ttcaacaacc agtaccagc cgcagagggt gtgaactttg gcacctgggt  
 cctcttcagc ttcccacat cctccatcat gctgggtgtc agctgggttct ggaagcactg  
 gctgttcttg ggtgcgaatt taaagagac ctgctctctg agcaagaga agaagaccac  
 agggaaacag ttgtcagaga agagsmtcca aagaataat gaaaacttg gagacattag  
 ctaccagaa atgggtgact gwttttctt catctgatg accgtactgt ggtttamccg  
 ggaagctggc ttgtcccttg cctgggatic ttctttgaa asgaaggct accgtactga  
 tgcacagtc cctgtctctc ttggctctct cctctctc attccagcga nagaagccct  
 tcaatggaa ggaacttcag agaccatgc actkaggacc gagcccatca  
 gctatctct ggtcttgtt agcaagatc ctggcctctc tacatggatt ggaagaccga  
 ttgttctct gageagcctc ccacgtggg ttgtcaacct gctggcatgc acctcgtgt  
 ccaattgcac tgaattttg agcaacccag caacatcac catctctctg cctactctgt  
 gcaagctgtc tgaacgctg cacattaacc cctctacac cctgatccca gtcaacctgt  
 gcatctctt tgcagtgtg ctgctgtgtg gcaatcccc taatgccatc gttctcagct  
 atgggcaact ccagatcaaa gataagtgta aagttggctt gggagtcacac gttatggac  
 tgggtgatgt aatgtgtgccc atcaacacct gggaggttag cctctccac ctggacactt  
 accagcatg ggcgggggtc agcaacatca ctgatcaagc cttaagcccaa gtgtacaac  
 tggcccaacc acagagactg ccagatcca gcatctctg gaccacaggc aagaacac  
 actaggacca ccagagagac acaacccag accacggcg gagggcaccc ctccacaga  
 agatctggc acctcaagt aactgcagga atctccaac aaccacaa acatgctctg  
 ctgttagtgt ctctctctg cctccagcac cacagtcaa gaaaactcaa agtttcaata  
 caancatag gctcacaac aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa  
 aaaaaaaaaa aaa

&lt;210&gt; 44

&lt;211&gt; 1004

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 44

gcttcaactgg agttctaagt ttctccctt ctgttttgaa tgaatcagct ctgcttctca  
 ctactgttt ctccacatg ccacggagg gttgcagcc tcttgacctc agaccttagc  
 tctagttcc atgtttctc catctgact aatgtgaatc actctaagta ttctagtctc  
 tgaattgttt tgaagcaga agcagtcaga gggcactgt caccaggtcg ggtcggcag  
 gcagatcaca cggaaacct gctctgtcac agttgttaac actgcaggga gatggtggg  
 agacactatg ggaagactga ggaatcatg ttcaaatgt acttcaaac cactgtgagt  
 ttctttgtc ttgtcttgg aataatac ttatgtctg ggggataatg agttatctt  
 ttaaaaaa gatgcatlct taagtcctc tgtttgtct tgaactccag ctcccaaca  
 tactcaact ccaactlta ttctotatt taactttact gctcttcta ctittttta  
 gtttaactt tatttttat tttttgagc cagartcttg ctctgcaac caggctggag  
 tgcataagc ccaatttggc tcaatgcaag ctccgctcc caggttcatg tcaattctc  
 gctccagct ccaagttggc tggagactaca ggtgcccgcc accagccct gctaattttt  
 tgaattttta gccagtcag gttgatcacc tgaatcagc agtttgaac cagctctggc  
 aactggcga aaccatct ctactaaaaa tacaataa gcagggcggt ggtgtgacct  
 cctgtaatc ttgagctgag gagggtgag acagagaat cacttgaac caggagccag  
 aagtcagagt gacgtgtat catgccattg caccctggc tgggcacaaa gagcgaaact  
 ccatctcaa aataaaaac aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

&lt;210&gt; 45

&lt;211&gt; 1494

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 45

&gt;

gtgaccac ggttcggcg gcggcaggcg cgggcgaggg ccacggggag aggaagacga  
 gcccgggg tggcacctc ggcggggcc cggccggcg tcaacggcg caatgctctt  
 ctgctcccg gactgtgtc agtggctagg cctgcacc ctcgagatct tctgacact  
 gctggccttg ttgtgttct ctgtcgtgt ggcactcgt gtcgagtcga tggctccggg  
 cctctcttg tgaagcgtgt tctgctctt cctgcggct gacgggctca gcacctatt  
 caccacac gtgtccgtg cctcttcca ggaatggag agcggcctg cgtgctctg  
 cytttcttg gtacttacgg tcttgagct caagtctc ttcgagatgc tgtttgtcca  
 gaagctggg gacgactc gggagcttg gtcggctc attacgtccc cgtcttcat  
 tctctcgag ctgctcatg tccggcctg tccggctcaac tagctcac gagggtccgg  
 agaggagcg ctggacaact agaatttga cctcagcg agccctact tgcagcga  
 cggagagag gctcttagt ctgaaggac cgcggcctg cgcgagctg agtgcgggt  
 tctctatc caatctgt ttgaattgtt tcttcagcag gcttaaaag agcagcctc  
 attctgaata tgaattctt ttgtttaa gttttgata gataatctt aattgagtc  
 atgagaggc cccacggc agacgtctt gaaacctt gacacttga aactgaat  
 aagtaaatg tccagggtga ctctgagat tctcttga tctctggaaa gtaactgt  
 acaaggctg caaagtga ctcaggatg tctctgccc acgagagaga ttgctttt attcagctt  
 tctctgccc gttatccag accagactt ggtatagct ttgttagat ctatcacatg  
 taacagact tgaattctt tctctgccc acgagagaga ttgctttt attcagctt  
 aggcagagac agagaatgt tgaataagag cagcatlaga tctctgctg gtaactgt  
 gcccaaaa gaaacttgc tgcacaggca ctgcttggc tactatcca gaaaagactg  
 cagtttttg gactttgac cactctggc tggcactct agcacctc agcacactg  
 agctctctt aagagactga agagagaaac aggtgtcaga tactcatagg cactggactc  
 tacaatagg aagcttga gtggccatc ttgttggcc taagaaatctt ggtttgctg  
 cagtcagggt ccacatgaga acctttgctg agatgcaat aagtaagag aatgttttc  
 tgaaaaaa aaaaaaaa aaaaaaaa aaaaaaaa aaaaaaaa aaaaaaaa gggc

&lt;210&gt; 46

&lt;211&gt; 1166

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 46

gagactgcc catgaatgg aattgagctt cgtcaggcg ctacttctct ttacattctt  
 cttctccaca ttacgccac cccacccac cccatgcttg gaagttctta tgcctgctt  
 gctcttcca ttaaayaaaga acacggggg ctccaaac aaatccctaa gggagatgg  
 acgggaata tcagacact acgtatcac ttccctgct cagctccac ttgcagcgg  
 ggtccccc tgggattcat cagatccaaa ctccatggac tagttaggc tgaagaagc  
 cttagaggta ggaagttctt acagcttagc aaacttct tgaatagct ctatatttg  
 aggtgggaga ctataaaca agtaagttac actgcagttg gaaatgaca gtatagatga  
 taagctgaa gcttaagcga tgcagaca tagactctg tagctctag gctttttc  
 tgccttaact gacgacttt gacaactctt ctccagctg gtaggactg gtaggactg  
 atcgaaagg gaaactttt aagactttg aaagaagcta catlggagaa ctacacttc  
 catgactga ggaagcctg ttgtgtgta ttgtgtaca tgggcacttg cacactgtg  
 tgaagaaac tgtacatt tcttttaca ttctctgat gctttgtta gtgtttctg  
 ctccctgct gttcttaaa aaatccacag ttatcttgt agcttacct ttcttgagg  
 catgtctat tcaatttg gataataga aagatttgt caaagctag gggggtagg  
 tcttaagctc attgaagact ggaagcttg cctgtttc tctacatcc cctaacctt  
 ttgtacagtg tgggcaact agaggtgtct tactgtcag actgaattgc gccagtgcc  
 caccaggac ctgacactt cactaggaat gactttggga ttgcagctg tctatctgc  
 tctctcagc atgaacata agcagatgc ctgttttta ctgacttgg gaccatctc  
 ctgttccct ttgtgatgat tcgggggaaa tctctgtct gtgttccgt atgtgtgca  
 ggctgagggt tggcttctc cctcga

&lt;210&gt; 47

&lt;211&gt; 1536

&lt;212&gt; DNA

<213> Homo sapiens

13

<400> 47

ccacgcgtcc ggggcagaaa ggaaccgggt tgcctgggc cgggcagggc gggctgtgac  
tctcaaaag aatatgac atgacagag atgagacaa tggtagtga acaatttat  
tgcattctc ttcgtcttc cctcttaaga acatltatga aggtccctc gscataltcg  
ctgggttggc cagtctgtc tctgacagg cttccaac ctygttcca tcaagaatt  
gtttggact atgagaag atccctgagt aagaaggac tgcagaagg ggaacatata  
atgatttga agtagaat ggaatagtc aactacaat gaaagagct ctaagaaga  
ataattcgc actatcaaa actgcagag tgaataaa ccgcagagat gaagaataa  
gtaattcca ccaaaagat gtccggagt tccacattt cgaattac ataaactgc  
aagacacat atgacacac agagctaaa gtagtltc laaagatga catctagca  
cttccctcc aactctgaa aaggaagaa aaccacatc tgaataaag atacttccac  
attractac atcgtttag aaacacgca ctatgtgtc ttgctcagt tctcaatc  
aggttggca gggtagtca aatggatga gtagaagg aagaagaat atgagacata  
gcccgtttaa cagaagaat gaagaagac gaagaactt aagtagtgc tctgtgtatg  
gtgaaaccaa gatattggag gctagtcata gctacagag gacatccctga gaattatgt  
aaagtggac caaagactga aagcaaatg tgaagtta aagtaactc agattctgac  
tataaagtg aagcatata cttctcttg gagaagaga cccctggaga aaggtcacac  
agtcgagtag accctcaaa tgcacaaaa ctagaagac aagtgaaag atcacaaat  
ataataga aagaattca atcacaaag aagaagtaa gaagaatga tcaaaactc  
atacgaag laaagacca agatccagc aagaagatc aagagatc acttccatc  
tccagaag aataaactt tctcatat tcaagtaat accatcaga aagaagaaga  
ggatggag atgtlaaag agacaagat gtaacagc atagttcca aatggaga  
tgcacatc cttctcaaa cagtagaact cacaacaa ttgacttaa ggaagtat  
gacatgac atgtggaaa taccactta aagcagaaa gacatagaac tgaagtag  
aggaagaag aacaagaag caaaaaaa aaaaaa

60  
120  
180  
240  
300  
360  
420  
480  
540  
600  
660  
720  
780  
840  
900  
960  
1020  
1080  
1140  
1200  
1260  
1320  
1380  
1440  
1500  
1536

<210> 48

<211> 1038

<212> DNA

<213> Homo sapiens

<400> 48

ccacgcgtcc gagacattt aactagatc ccaagctct ccttcaaa ctygtcttc  
gttttcta taaggaaaa agtcaaatl agtccaana actatccca aagtagtat  
gtgctgtag taatgaaag tggatgatg gatatgac aatgttggc ggcattcaa  
gacctttaa ttagtactt tgcgtctc gctattaaa atttggta tttagcaaa  
gaacattgt tgtatgaac tgggtttt tgaatgctc aagcaagc taaccaatt  
ttaaattcc cttgtgttc cttccattg tcaaatag gacttccata ttaataaac  
ctcaaaaat gatccacca gtagtaaca agatcccaa ggggaagaa aacattttt  
actttaaag aaaaatglt aagattatg atagagatc tcttaactt ggaatttca  
ttagagctc ccttaacaa aatgaatag ttcttagac tcttagact agagcttca  
gatgtgtt gatagctaca gtttcaaat gtaaacctg aaatgaag ttaatttgc  
atgtaagag cacatttgc ctatgtaaa agtgcacat tgggtattt tttaaaaa  
gagaagac tttcaata agtagcagc gtaagaat agatttccat atttcttg  
tctgataca gtagaata ttagacatc aatgttgt tgaagcaac attaatat  
aaatgaag accattact ctygtgctc acttctgt aatgcaat tgttaactg  
cacatttca tatgaatat tgttcaaa tgcattcag tgggtcggc tgaagattt  
gtggcctac agatcatt atttatat ttcatatc aatatata tgaagtag  
tgttagtgc atttcttcc aataaagc cttctcatt tgaataaaa aaaaaaaa  
aaaaaaaa aaaaaa

60  
120  
180  
240  
300  
360  
420  
480  
540  
600  
660  
720  
780  
840  
900  
960  
1020  
1038

<210> 49

<211> 1176

<212> DNA

<213> Homo sapiens

14

<400> 49

ccacgcgtcc gagacaaa aacaggcct ttaaatct ttccagacc agaagatgat  
caagaagag aatgtccac tagcagctc tacttgaag ttagagctga cagaagaaga  
accttcaat tactattgc tcaattctc acaagaaa ctgaagaat gggtagtgc  
aataagaag acatgtgtc gtagggccag gcaaccttg gttatctt gtttcaaac  
tgcatacaa aattatagg aggtcattgt ttgtagtgg gctcctgac caggccctc  
cgggaccaa ccaaaatga gtcattcata ctaaactc agtgcagca accaaacta  
agtgttita tctgacctc caagaatat ggaaggagaa aacacaaa tctccaana  
ggtcattt aatcagctg atagaagat cctcttctt ttaacctat aagaagta  
acttttga atgatacaa cacttggat tcccttagt tgccttct agcccttc  
tgcataaa gccccttcc tctgttcaac ttaatgaag agtatccat ttatgaat  
gagatctgc ccaattcgg aatcactaat aagaacca tagatctta cagtgtga  
aatttctc ttgacaacat tactatgat attattctg gtagccttt cccacatg  
aaatgaca tagcatatc cttccatca gattttctc attaatga gtatatac  
caaacactg aaccagctc acacagatga gcaattgtt aatttactc agaagcat  
tatagatc tagcaagagc aatactgtc ctattagg gagaatlc taagagatga  
cctaagat tgaatttga ttaatacat tgccttagt atttcaat acagctctg  
gggggaaa tcaaatag atctggaac agtgcactc actttggag aattatgaa  
aacgtatag aacataaac atgggaaac atggccctc agttgaaa gtagaatc  
caaccttga attttttt ttttttact agtaacttt tggccatg tgttcatla  
accaaagaa gaagaatlc caaaaaaa aaaaaa

60  
120  
180  
240  
300  
360  
420  
480  
540  
600  
660  
720  
780  
840  
900  
960  
1020  
1080  
1140  
1176

<210> 50

<211> 731

<212> DNA

<213> Homo sapiens

<400> 50

ccacgcgtcc gagagccac ctgggcggac agccagagc tctccatg caggtcgt  
gtgtcatgt tccctgtctc gtagccttc gccgcctcc tgcacactc aacgggtccc  
cacacaacag tgccttccag aagcagccc tgcgaagcag aggaagaaa atgggttgg  
ctgggtctc cttccatcc cttctctc tgccttcc tgccttcc tccctccaa  
aacctcatc cccctgtg cagcctctt gcatatgct gatltggg aggaagaa  
ggcatttga gggagaagg gagaagctt atgcttggc ctggtttct ccttccag  
aggtcttcc tgttccagg tggccccagg gcaagcagg gcaacatc gcttgcgc  
tgcataagat gaccttgc atttaccag agccctgca ttttctgcc ccacagaa  
agatgagag gactcccaa aacttccat cccaagga gttcctggt ttgaagaga  
ctgattttt gctgtccc tgcaccttg tcccttct agggagagga gctatgtag  
gactccaac tcaagagac ggttggcctg cgtatgctc ttlttagat gaactttt  
aaggtggag gttggagag gatgtgcta ataactaat tccaagctc aaaaaaaa  
aaaaaaaa a

60  
120  
180  
240  
300  
360  
420  
480  
540  
600  
660  
720  
731

<210> 51

<211> 1437

<212> DNA

<213> Homo sapiens

<400> 51

cggccagac cgaactcag agctctacg gggagccag acgttccag gccggaag  
caccttcat cccagctgc gcccgatgc tggagtctc gtagctctc ggccttga  
ggcccttcc ggcgcggc tgcagctgc acggggagc cggggctca gacttccag  
tgcgcctc ggcgggtcc gaccagga tcaatgaat tctgtagac agacttctg

60  
120  
180  
240

<210> 53  
<211> 1037  
<212> DNA  
<213> Homo sapiens  
  
<400> 53  
ggcagagcgt cgtgcccraat tgggcacag ggtcatatgc cacagaggtt aaagttaaca  
attctgtatgt gcataccaga ggtcttaggg aagaattccc tttttctt  
ttccacttc ttgtgctgc tggcattctt ttgtcttggg tccatcact cctatcttga  
aggccagcat ttcaaatct gtttctctt cacatagctt ttgtgtgctg cagtgccttc  
tacctcttc ttcaaaagt atttgtatt aaatggaggg tttaggataa tctcgcaag  
atccttaact taatcaaac tgcataaac tcttcccaa ataaagtaac attcaggt  
tccagggatt agaacctatt atctttgta agtattatc agctaccac aatagctaaa  
acaattcga aaagaagaa taaagttaga gaatacagtt tatctgatt cgatactat  
tgtatagcta tggtaataa ggtcgtcagg taataaaga aggcataata tgaatgaac  
agaagacaat ttattggagg aaagacagcc ttltcaaaa atgttactat acaaataga  
tatccatagg caaaaaaaa aaagaatc ttgatctagg gtcacacct tatataaat  
aatattaaac tcatggccag gcacagtac tcatgctcat aatcccaata cactggagg  
ctggagcaag agtatcact gaggccagg gttcaagact agcctgggca acacagtga  
actctatct tacaacaaa ttataaacta gctgggcatg gtggcacatg cctgtagtca  
caactactca cggagctgag agatcactt agctgaggtt gttcaaggtt cttaagagct  
acaatcgtgc cactgcact cagctcaggt gacagacaaa gacccatct caaaaaaa  
aaaaaaaaa actcgtat

<210> 54  
<211> 1373  
<212> DNA  
<213> Homo sapiens  
  
<400> 54  
ggcagcagc caaagagaag tatccacag gccgcctga ccaagctgc gcttttaaca  
gtcttggggc tgggcgcgc atggctacga gaagcgcgt gaccacttc cgttttgggt  
tggtttgggt ttgtgtcag ggcgcagggg ttctgtctt cactcaagtt aatttatct  
ccttttctt ggttaattgt aaaaaacaaa ataaacctc ctgtgagcct ttggagactt  
ctggaaaagt ccttgcctg tgacscgtg actctgagaa gactttttag cagggtctga  
acactatct ctgcaacct ttcttctgt ggtatgtct ggttgacac agcttccca  
caaggcaaa gctgtccctg gatggttggc aaaaatgcgc acacagagt ggttttgggt  
tggcagaggc catgaaaaa ccttgcgtat ggcaggggg gacggcgaca ccaagatgg  
aacaataatc tctctctac yttcaattac aaagagaaa agtctactga aaaaaaagt  
ttaaatact ttaataaag agtcatatat aatccaaag taccaaagg caagtgttca  
gggggaagt ttgtgtggtt aacccactt cagggggatt taaagtgtt gttgtgagga  
tttgttcca ggtatgcct ctgcaacct ggttgggtgt tcccttgggt ggaactctt  
gaaaaatgar ggtggtct ggtcagctg ctcatactg taatccacc actttgggag  
gcgcagggc cagatcacc tgaagccagg agtcaaac cagctggcc aactgttga  
aacttcatc ytacaaatat acaaaaaa gctagcagc atggcaggt cctgtatcc  
cagctacttg ggaagctga scagagaat ccttgaacc caggagtagg aggttscgt  
gagctgagat tgtgccact cattccgtc tgggcagcag agcaagact catctcaaaa  
aaaaaaaaa aaaaaagg ggtggctg ggtgcagttg ctcagctctg tatccagca  
tatgtggagg ccaagggagg aggtatgctt gggccagga gttccagatc agcttggga  
atctssaaa accgggag tacaataac ataaaaata gggggcatg gttgtgagc  
ctgtgagtc cagctactg gaggctaa gttggaggt tacttgagct taggaggtg  
aggtcagat tagcctgat tttactctg tacccagc tgggtgacaa agcaagagcc  
tgtctcaaa ccaaaacaa, acaaaaaaac aaaaaaaa aaaaaactc gta

<210> 55

cccgaatgc cttggggagt gttctgtca gtgagctgct ggaactctg gccagctgc 300  
ggagagaccg caagctgct gttctgctc tcaagaagg agtgaaggc gtgtctgtg 360  
caggtgcaga cctgaaggag cgggaacaga tgaatgaagc agaggtgggg gtgttcttc 420  
agcagactcg gggcctgatg aatgacatg cagcttccc tgcaccacc attgcggcta 480  
tgatgggtt tctcttggc ggaagcctag agcttgcct ggcctgtgac ctgcgagtg 540  
cagcttctc ggcagtcag ggaactgatt agaccacg agggctctc cggggggcgc 600  
gagggactca raggtctgcc cgtgtcttg ggttggcct ggcgaaggag ctcatcttca 660  
ggggcagcag actgagtgga actgagccc acgtactgg gctggtgat cagctgttgg 720  
ccgaacaga ggaaggagc gccgctacc agcgggcacg agcactggcc caggagatc 780  
tgcccagcc cccattgccc gtgcgctgg gcaagtagc cattgaacga ggaacggagg 840  
tgacattgc acttgggatg gccattgaag ggaatgtcta tggccagaat atttccaaac 900  
ggacacgggt agagggeat gsegacttca gggagaagcg gactcccaaa ttgttggga 960  
aalgacccc attttaact tgcagctagg agatgcagc cctgaagagc aggtatcaga 1020  
agaaagattt gggccagat tgccttcatc atttcaact tccagactc catttctca 1080  
caaggatgat gatgaaata aatgactgg cgtgatcct ggaacaaagg tgcgtatcct 1140  
accactact gctacttccc ttagtctac cctggctaga aataatcac aggttgggt 1200  
ttgctttgga aatgcctctg ctcttactt gaatgataaa gaattaaatt agatctctct 1260  
gagcttgggt atcattggct ctacgcccct gacctctctc agttatcagg cactcattag 1320  
agatgtcaga agattttag atacccttag ttcttctctg tgaacaaaca gaggtataa 1380  
ataaactctg gacatcggtt gaacacaggt cagggttccag actgcagatc ccagttct 1437

<210> 52  
<211> 1369  
<212> DNA  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (3)  
<223> n equals a, t, g, or c

<400> 52  
agncagcgt agaacgtagt ggaatccccc gggtcagga attggcagc agatttgata 60  
ccaggtgcca tatttctc aagaagggtt gcaaaaattt aacatccac caagagtgtg 120  
ggagagccat ttgcacata gactacccag tattttttt ttaattttt atccatttg 180  
aagttatttg gaaacttggg tgtttttcc caaaagcaaa ggcaatttgc tcaacaccag 240  
ttataaagg atccctacag atctatttc cctgtagatc tgaatgtctg tcttattgt 300  
atcttttct gatgcctcg tacaaaatta caggtgagct ccatctctct ttgacagcca 360  
ctgcactact gacactcta ctgggtgtc tgaatgtgt ctaagtgat ggaatgatat 420  
gacagttaga tctttgatt actgtcccat ggccttgcct cacttctct ttcttgatg 480  
atggtgccat cacttaccga gtacttttga ccaagcaat gggatgcact ctggattct 540  
tkcttytct ccaattctaa gccatcagta tactggcact gtgttaagc catatttcaa 600  
accagaccac ttgtacact tctgtcact tctactctt ttatcccaac atcaactct 660  
gggtgacca ttgcaactg gaggtgcatc tccagaatat ttgtttgtt atagaacct 720  
tctgtacatc agtagctaga cagtttattt ttttttttag actgttaaca gatactgc 780  
tctgtacatc aaagccctt aaagtgttct ccatctcat tagaataaga tcatagttcc 840  
tcaccagcca ctgcaggtt tataatct agcccctgcc tatctctctt gctctctc 900  
tgtatccac accctgcttt ttgttcaatc agtgtgaac tcaattcaac cttaggttcc 960  
tgtcttctgc tcttcttctg cctagaatgc ttctccttg tcttaaaica tctgtgttct 1020  
gctagttttt argtctaac tcatgtcac ccgttgcct tctctctt tctgtctt 1080  
atttctcta aaacacttg cactatgtar atgttctatt tattactta tttaagggt 1140  
agaattctta tctgttttgc ttggtgcca ttatcaaca tggtaagat tgcctggcac 1200  
ctagcagcca ctggagccta ttctggaat ttcatgttc gcaattgcc tctctgtt 1260  
ttctcatta ctatattct tcaagccaa cccatggcc tcatgactt ttcaaaaaa 1320  
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaactcga 1369

<210> 55

<211> 1347  
<212> DNA  
<213> Homo sapiens

17

<400> 55  
ggcagagcgt ggtctatagt gaattactgt gccattccaa aggtatbaga ttcttggaat  
acatgaaaaa ggaatttctt gcaaaagcta gacttgagct atttggaaga caagttggag  
catagagact ctltgacaaa tgaatgagtg ttaattctat ggtctcagag ctacattcat  
ctaagtgct ttgtatgtat aaactcccca gtagctcaag gattccagaa ggaactgtgc  
aaatttttc cagttgccat aaactgtgtt ttggccagct tgcacagat gaagttagtt  
acgtttggg ctltgagctg gttgaatata gcaatcgaga gccagtgaag aggtccagaa  
ggcagagcgg gattgacat gcaagatgga taaggccca acgtgtatg cacaattatc  
cgcagagcgt actcccaag ccaattccag taacaattat gaaagtitta aacaacctg  
aagaagcgt agttcttca cagcccaag tatgtgag agctgttaaa ccaagtatgg  
accatgttg tatatgact aatgaagaa tgcataagtg aagttaatt ttccacagt  
gaaatagaa aaataacat gattgttga aaataattt aattatgat aataattta  
attttctag gactgttaa tgaatttaa caataatcg agttgataa ttltgactat  
tttgcacata taacaactgc ttatgttgta ttlttacta ttaataagc taataatcaa  
acctctgtt taactcttag ttgacatga ttatagacc aagttaaag ttaacacac  
acatgttat aacctaat aacaagaat taatctctc tatgtaat tttagcaga  
attatttct tgaagaagtc caaggttctg ttccctctt gttctccccc ttltgtgt  
aaattgttt cactcttag caaatgagaa aaacattat atttctag tttatgcaa  
attcttaaa tatcagata caltaaatat ctacctaat agtatcttt cctcagtag  
agttactct ctgtgcact tgaagttag aacttttat gtacaaaat gtcgtttaa  
gcattagag gaaatgaag cctataaggt ggtccccc tatctatgtt ctgtgttcc  
acagtttagt taactcagct ctgaaatcat taagtggaaa attccaaaaa taactactt  
atagtttta aaaaaaaaaa aaaaaaa

<210> 56  
<211> 822  
<212> DNA  
<213> Homo sapiens

<400> 56  
ccgggttgac ccacgcgtcc gcgagcgcgt gggcaaatat tgytaatgct gggaaaggg  
agttagagat gccaaaacgt ttctgtttt atttgccttg ggtgaagacc cagaggggtg  
ggaatlgag ggtgagcag catgtctctg tgtgtttt tctgtgttg ggtgaagat  
agatcatca tgaagctctc tgggcatag tggatgaga gctgtcaca ccaatgcat  
tcaaggtct gttgcacac cagtaatga aaatcatctg tgcacactgt ttatgttaac  
tgatacttt ttltctatag caagattct taatgaaga agtaatgat tgaattaat  
tctgactat tgcattatc ttgtcttga tcaatttga gactgagct gttccacact  
ttgaataca ctattttca ttctacttc catgtaccg gattccagc aaacggggag  
tttaagctg ggtgagaaac ggaacttct gctgactct tgaagggct tatctacaa  
ggcagtgtag ctccagact taatccagg tctltggag gctgagtg ggaattgct  
tgaactcag agtttgagac cagctcgggt aacatagga taactgttcc ctacttaaa  
aaaaaaaaa aaatattagc tgggtgtgt tggtagacac tglagtltca gcatlccar  
aggttgagc aggtgagat gttgacagtg ggaatlgag gctgattgt gctctgagtg  
cgccactgta ctccatcttg gttgaataaa aaaaaaaaaa aa

<210> 57  
<211> 536  
<212> DNA  
<213> Homo sapiens

<221> SITE  
<222> (536)  
<223> n equals a, t, g, or c

18

<400> 57  
gacagagtg ggaactgaaa ggaagatgga gtggagaagt aatcttccct tggattcag  
ctgtcccgct accaaacctc tctctgtccc cagctggact cctctagat ctcagatgct  
ccttctctc ttcccttcc tgcacacaa ttcttctgt ccttgagct tctgtctac  
tctlttgga gscawaagtt tgggtttat atgagtaga gatagtgagc atgttgagac  
aaaaggaac attttgttg caaaaacag aatgcctgt ccaattagag taatggctk  
ccaggttga ggttggggtc ttgttaggg aaccacctc ttctaccag taatttccg  
tctctgtct gttcaatag gtacacata twatlaat taatkaatga ctatcatca  
tgaatgggga aatgcagagt ataaaggaga atgtctgtcc ttgaaagaa atttatttg  
tttttttgt gagatggagt ctgtcttaa gctagaagtc agaatgtaat caaggn

<210> 58  
<211> 1262  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (12)  
<223> n equals a, t, g, or c

<400> 58  
atctctcagt tnttctacgc aaataaat ctgtgaagcg agagcagcag ggaatgtgt  
ctgtatagat gcatgtcga gccatcatgt tccctgttt tatctactg gatgccctc  
ctactgtct gctcttgga atgtgaatg gaaagaaggt gcttggagag caatcaaaag  
caaaaataat acatggaat gtagtttt atctaaaga aaattctaga ctgtcttcc  
ttatttcat tccctcccat acaatttga tgaagcagga cacacttct ttaaaatc  
ccaagtgtat atagattcag tgcattatc tcaagctttt ctltctaa gttcacttg  
tcaactagct ttatatttta atactcaat tctgaggtt aggaatact tgtacttca  
aggttttt ttgttttt ttgttttt ttgttttt ttgttttt ttgttttt ttgttttt  
taattgtca ttgataact taactgtcca gattattta aagttgcca agatccag  
aaggtgtctt gcaagggcat ctltgtctc tcaaatltt aaacagctat tgcattcaag  
atcatctcaa acaagaatta atagagaga aaaaatctat aaagcatgtg ttgaatcc  
tccaggtcat gataacttca ggaatacaaa taatagtaa caccgaagtc ttacaattca  
gtggagcag tcaaatgtct ttlttgtag tctatttat acttgagaa accctgagat  
agtaagtat attttgttc tcaatttata gatgaagaa ctacacata ggaatctg  
gtaacttcc ccagataact cagtaacag tggagctgga attcaaat gtaagttcg  
acttcttgg cccatactca ataatcatgc catctgtct ttccatgaa taactgag  
atgtataga atgttaaaa caagcaaat gccaaactct ctgtcttgc tccctacta  
agccagttta actttgalt tbatgttac taagtatca ttlttataa ttatgttag  
ctagagtt ttattttta ctlttggt attaatgca attatttgg tgaatcc  
tagtatcca aggaagtaca tcaactgtaa aaattcaag aaaaatctt aagttccct  
caccctccct ctacacagat tgaatccaa gcttctatg aaactcgtt accactcgtg  
cc

<210> 59  
<211> 1269  
<212> DNA  
<213> Homo sapiens

<400> 59  
gaattcgaca cgagatataa cgagatgcta ctatgtctgg taaccagctgt acgaggaagc

acactgtgtt ttaattttta taaagtccag ctatttaatt attaaaaaa aaaaaaaa 1800  
aaaaaaa aaaaaaaa aaaaaaaa 1829

<210> 61  
<211> 1112  
<212> DNA  
<213> Homo sapiens

<400> 61  
ggatagcagg ggctcagta tatttttgg atgaatgaac aaacctctga gatgctacat  
ctgacccat atcttcatt tatcttttc ttactctta ttactctaa ttctcttc  
ctgacccat tctatttat ttaaccag ttactctct gctgcagat taatttct  
aatgcacagg ctctacata tcatgattt ctactgcta catatgcta attgccaat  
atttgcac atcgaatgt gtacacttt gaggctgtt ctgttttgt ttagtattg  
gaaagtgt ttagatgtc tgaatccg tatggggtc ttgcatagg atttgaagc  
agccacat ctgacaaa atgataaga ttaatttct atgttagac cattgttt  
caccattcc atagactcc aatgttaa agaagacat gatctaac ttgtttaa  
tattagtaa ctgtttatc tggagaaga caaacaata agaatataa  
attacaggga ctgttttca ttactgaat aatgatttt gcaaggagca cgtggatgtt  
gacattatat cttttaact ttattttct gttctttt ttactctta tcatgatt  
tatctattt tatacttta ctcttatt ctcttgac ttctttgt tgaattgtt  
gcaaggact tactgtctg tgaagactt gaatttctt gctctctt cttagagtt  
gacaggata aagataata agatagct tgggtgat gacactgaa gacaggctg  
gtcaggcct gtagtara ctctccct ctattgaat ttaactgaa agtgaatctg  
aaagcagatg gtcagact accagggt tccatgac ccatgaaat tattttaa  
ctcttaaat agattgagat tcaattgag atcatgtct attttttaa cattgtgtt  
taacaagta gatgtcagt cactagta ggaatgtt ctaaggaaat atgtttcta  
tgtaagta aaaaaaaa aaaaaaac ga

<210> 62  
<211> 1674  
<212> DNA  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (734)  
<223> n equals a, t, g, or c

<400> 62  
gagaagctt agtgcctc tgcgtgtct gaggcagaa gggccagaag ctgttgaagt  
tccctgaac ctgtgtgct tggagtcag tccgaagaa ggcagctgc ccagagatg  
gacaggact gctgttgt tctctgac ctaacagg ttatgacct gacccggg  
tggtttcac tgtttatc ttatttct tctctgtt gctcacatg cgttagtgg  
atctgaaat caaaggctga aggaagctt gacattgac gtatctgta atgtggaat  
tgccagac aggccttct tggagctat acatgttaa aaggccaac cttagcccc  
aaaacagac cccaggtgt gtttaccg cagcagaat agctgagat agagagatt  
tgaccagg tctgcaat ccaactcag cctargctg agctgggct ggagaggaa  
gctgtgac caccgttga gcaatgact gaggacctct gctgcccc ctctgccc  
agagctgac tgacctgatt gtctttgg atccaccac actctggcc caacatctg  
cctgccaag tcaagtgct agtcagac atgtagact caccgtgtac ccaagactg  
tggaagct ctggctgtg gactttcca gggccctat ctctgtta ttcactac  
cagattaac tgaatgga ctgataagg ttgtgacct tgggaatgc accactgga  
rararagg aatgtgact cgcagacct cagttgtc cagtttag atgagaaga  
tcaggatgt ctcccaaga cagttgag tccaacaac tctcaggac ttggctgtg  
ccacatctg gtgcagaagg agaagccat gcaaggcacc cagcttgag gaagcaggg

atacagtaa gttagtctg gattaccaat cagtgtggt agtactgaa acagcaggca 120  
aggtttgga cagccctgt tgaatttgg aagtgaat catgtgtac aagccatcc 180  
ttgctctgt tccctggga tctctgtg atgaattact gcttcccta atgatgttc 240  
ttacagaa gtacagaa tgagttcta ccacagat astgaatcaa caactcagga 300  
gctgggcca gaactttatg ttcaacaaa atctccagt gattctgat tagcctaag 360  
tttaagacc acctgtct agagcataa ttattggg ttagtgctca cggattatt 420  
aaactgat tctctgtc cagtgttga cctaaagaa gaattccaga catgtttatg 480  
aaagagtga gagggtcaa gatttctt ttgaacctt ttagtttct tagactct 540  
ttgggtcact taggaagat gattatgaa gctgtcagg tccatatwac aacaaaagt 600  
aaatgccag gaagacctg tgaatgaaa agtcagtga tcaaccttc aagtcacat 660  
ceaagtcata cctgtcttc agactttct aacttaacc ccgktacta tgactctct 720  
gtctgctcc atcttttat attagtaga ccatatcta atgaattat gacatcatt 780  
acccatttt atcccttaa cagctggac acttttga atagtttga tgaagacaa 840  
atcttcttc attataagg atttggcca tactatgtt aatgttgaat taactcagt 900  
ttgaattat tagcaagct attcttaca gacttagtc tgaagacaa ccaggtcttg 960  
gtaatttcc acctacatt atttcaac agatcaggtt acagtcacg agccagttt 1020  
tatgggccc ctctcttc tttaagact attgtttt ctctccctg tctcttga 1080  
cagggaat gtttcaata tcaattatt tgaatctgt ctgaagactg tcatggaga 1140  
tgttagctg taatgaatgc aaaaagtga taagttag ctcttttt ttgatatgt 1200  
ggctttgaa egccaat ctgaagacta agaccttca agagagaat taataaaaa 1260  
aaactcga 1269

<210> 60  
<211> 1829  
<212> DNA  
<213> Homo sapiens

<400> 60  
ggcagcagtg gccctgat ataacgaag tgaggagga tgaactgaa gtgtcagga 60  
ttatgatgc gtgagcctt ggccttctt tctctctta cttaacttg ggtatgaat 120  
tccacttat taactctaa aataaata tacaacttt ctactacc ctgattttt 180  
tctcagagt cctctctc ctgagtgca agtgtctac cagtactgt acctgctga 240  
acatcataa atctgacaa gaattgaag aatctgaaa tctatcga gatatttcat 300  
acagaacg cactgaatg cctctgaga ttgtccctg acacactgt aattcctaa 360  
acaaaagt caaacactg cagtaactt ggtctctgt atttgaatc tatttctgc 420  
agtatgct cacttttat gaaaagctt tgtgggtgt tgcgtgtctt ccaacctgt 480  
tgctctatt tggaaattat gttgggttt gtaaaagt ctggaagat gtttttaa 540  
aaactctgc ctgctgaatg aatgtttct cctgcaacat tgtgttatt ataataa 600  
ttatcataa aataactt cctgtattt taagtata catcaaac actatgata 660  
tataacagt gtatagtga atattcaca catacataa aatacaaaa tgaatgata 720  
accactgt acacatcac ccaactttt aaaaattta catttttc tggagaagt 780  
ttccgttaa attatagat ataactgat tctcttaa aacttctca attcttct 840  
cactctgt tctctcat anaaccttt taaggatgc tgcgtgata tctacattc 900  
atgttgatc ttactaca aattatata tctataaaa ttatatag cagttttca 960  
aatgttgaa agttggtaa tttacactg tagagatcat gtgtattta ttctataa 1020  
tgctgaata aatcttcaa ttatttga atcttgaat ctactatgt aagtaaaat 1080  
tggtcttca tgccttttg tgttctac ttgtggggc taagtaaat tccatgtaa 1140  
gactgtaca cagttgtgtt atcttca cctactgaag gatattctg tttccaagt 1200  
tgggcagct atgaataaa ctgttata caccgggtt gaaaggtttt ggttgaaa 1260  
ttaagcttc acttttttg ggtgaatac caggaacat ggtatcgg gttatatag 1320  
agaagaatg gttagtgt taaaaact ccaactgc tcccaagt gctatacat 1380  
ttgcatct accagcaata ttgagagct cctgcctac cactctgt tcaagcttt 1440  
atgttgcag tatgtgat ttgaccact ttaatagat tgaagtgtc ttattgtta 1500  
aatgtcaat tatctgata tttaattg taaaagatc ttctatgt gtacttgc 1560  
atctatgag tatctgttc attctttg cctgtttga atcagcttt tcaattttt 1620  
ggtgaggt taaaattat ttgataatt tggataacag tctttata gatagtctt 1680  
gcaaatctt tctccagcc cgtgggtttt atttctatc ttgacaagt ctgttgagc 1740

gugygaagcc acagagcagtg cccctcagga cagatctcca gaacatcggg caagagccgtg  
gaggtgccac atcccacat tggctctggg gacatttga accctctggc tggatgttga  
acaagtcaga gctcttgglt cagggcaggg caggtatlt ggaatgact ggtttggcct  
gtccaagct gctgtcaca ctgttggag gcttgaagcc tgggttggga catgggcgt  
gtgcatctcg tggggcgtg ctggcttgc ggtcggagaa agctctctag tggatgtat  
atttgctctg tgaactgaat caggtggaag, atagggagag aaamcaacat atttggagac  
tgaatggcca gaagatgtct tggcagagaa actggagaa ggtcggaaat gctcggcaga  
gcaagaagaa gactctcaaa gtggggatga cgggttaact ggttcacatg tggagatct  
tcttggagcc tgggggagga gcttaccatg tccctagagc agtggggagc ctgaagagcc  
tggctccaga gtactctgagc attagttaca tggcatlga cagatggagat tggccagga  
cagttggctca tggctaaat cccagcact tgggagacca cagtggagag atactttgaa  
gccagagagt ccagaccagc ctgtctctac aaaaaaaaa aaaaaaact cgt

<210> 63  
<211> 1045  
<212> DNA  
<213> Homo sapiens

<400> 63  
tcgaccacag cgtccagat gacagacatg altatcat ttgtcttag gctctgaga  
gtcgttact taacttttg gtttcttgg ctacctaig ttccaagcc tccatttct  
caaccacta ctgagccttc tccattacc ctccagatg ttggcgaggg taacatcaca  
ctggatbaca tcaatgcat gttctgatac cccagctctg ccatatggc ctctcttlt  
gggtatgtat gaccatag aggcagacc tcttaaacac atcaatbaca atbatacat  
tccaactag actctcaagc aagggctgaa atctctccag gccaaagag agttttatc  
acctccagc aagcttccc ggaacatg ggaacatg tagatltcag aagccagaa  
acatcagta agcaatctc agttctctca taatttgaag gaggacaca tgaatgtta  
tgggggctc ggaatgttga atgctccat aaacacctg ccatattlt tggttccagc  
cttatgttga taatcaaga aggtctttaa taagacttca gcytttttg ctggtagt  
ttgttctct taactatcc tccaagatga cggagagcag gaaatctac atttgcacg  
tcttccatt ctatggcaga acacggctg gggagagaa ttctcttag cttctggaga  
tgaatgttg ggtcttgc aaaggttga tccagagtc taattctag ctctcggaga  
tcccactaa gaattttaa gcaatnaat aacggagat ttgtacttc aaatltgag  
ctgtgtggc tttaacagt aatgatggc cttagtgtt gaataatct tggccggaa  
aaagaaatgt tctatcttc taatttggc aatcaagac aagatagagt aatgaaatga  
aaggaacact gttagaagt gagtgttcc aaaaaaaaaa gggcgccgt  
ctagtagat accaagctt tacgt

<210> 64  
<211> 1051  
<212> DNA  
<213> Homo sapiens

<400> 64  
ggtttccccc gggatcacac tgtctttagt caatttgcac tcaacagtc ctgcacaca  
aaatcacaca taagaggaaa actagagctg gaagaatag, ctgtcttcta cccaaccaat  
gggttcttc ctcttcagtg atttcatag tatgttgac cagtgttct tctatccat  
gaaacttcca aatgtatca gataatcgt gaaatgtatg tgggtttlt cttaacacg  
caatccact ctctccacc tctctgtagt gttgcaact gttctgttct tgaacctt  
cttcaacct acttcccca accctttat catctagag aaattgggac tcaacacct  
cgatatacat ttaagtgat gttcagagt tctctgtag acttagctag agatcagtc  
ttgttttat gggatagat cttagagatc aactcttg aactcttgc tgtctgga  
gtctccgtgt ttgtcttgc agcagtgac ctgatggag tgaatcact ggtctcagct  
gaaatctag ctggccacag tgaacagtc tgcactgct ctctatccc tgaacttacc  
agatccaga tccctgtagc gctgaatca gggcagaaga agagtgcagt ttatgtact  
caatctcat tcaacagac, aaagaatgt agtttgaag gaagaaacta taatgtaggg

tcatgaata taacttagaa aagaagagc ataaagaga ctgttttca ccatgttgc  
caggtctggc tgaacttct gggctcagc aatccacct cctcagctc caaagtgtc  
ggatlaagc gcatgaaca caaatccag ccataggtt ctatcttcat atataatga  
aatgatacca cttagagta gacttggata agttaatcc gtaatttct taacttca  
aaacacct aaatlaag aacaaagat tacaatcaa aaaaaaaaa aaaaactac  
gtaggggggg agcgcttacc caatagcc c

<210> 65  
<211> 1182  
<212> DNA  
<213> Homo sapiens

<400> 65  
ggcagagcc cccagacat ggaagccctg ttaacgtccc tctgtatagt ctgtcttgg  
tccaactct tcttaagta agagctggg tctgagtt tgaacttact gaaatlaaa  
cagatagat tgtttcaaa gaactctgc aagaccagag agttgttct tcatgtcta  
cttgatcag ggaagactat ctgtctct agatcagtg aagaatcag gaatgttct  
caatgtaac cggtaacat tcttaccac tgttaaac acccttga gaagtgtgtg  
agttcagca aaaaaaacat ctgcagcca gtgaccgga aaccttcat gaaataaac  
tttaacaca tccaagatc taccattgat taccattgat gaccctaga attccgtac tgaataagg  
gactgtatg ggaagcaaa gtatcactc cagacagcaa ggaatggccc agaatctc  
tgaacttct tgaactatg tgaacatg cactgtatg gaaatggccc cccctcct  
cagaccagta tccaagaa gaatcaca gaatgttctc caatagat ccaatgtta  
altaccacca caagtaagc agaaagcag caaatctcc cactcaact ccccttgg  
tccctgtga tgtctatga acttaatg gttcaagtg tcccgagaa cttaagat  
alttaagact tgaatttga gggatctatg atctatgag gaaataatg cgtttctc  
ttggagatg gttatctcc gaagatatt gctgtctt tccaagac aagtgaag  
gaaataata aagaagctg tccaacagca atggagaga gaaacttgc tgaactccat  
gagtagctg atctgtact acagatcgt gatggctcgg atgtctaac cgtaccat  
gtgttgaaga gttcttgc atttccagc ctggaagaa atatctgt tgaatnaat  
ccagtagtag cccaccggc tggggcttcc aactcttgc tctgttgc tctaaggca  
aaaagatc tbatatct gaagcttct gttgacag aaaccagc ctagaaca  
altataggt tctatctct aaaaaaaaa aaaaaaaaa aa

<210> 66  
<211> 675  
<212> DNA  
<213> Homo sapiens

<400> 66  
ggcagagct gctcttctc tccaacatgc tctctgtgt gatttccatg gtatgttgg  
ctgtgtgtgt ctacgtcgg ctatataagc atgcagttct cctctgct caccgtgtg  
ttctggctgc agctggccc tgggactctg ggttctgt tctccagaa ggtcgggg  
aaagttagtg agatcaca caatgccat gtcactacc gaaatgact gaaatcag  
aaccttcttg attttgca gaaagagta tgggtcagc agtggctgg ggaatgttg  
gtaaaatga atgtatccc aagaatgac tcaacctta tgcctgttgg gcttctat  
acctccagc taatggcttc tggaaagggg ttggcaaaa aaagcagcag tgaagatg  
ctttaaatg acttttaag aacagagaa gtatatag taatcactg tgtataat  
gttctactc aggggttga gaaatggga gatcttga tatctact tcaaaatga  
caatttagc tggttcaag ggaatgtat atctcattg atgttcaaa gtccagaca  
gatccaact ctgttctac tcttccccc ctctcagtg ctgacttga ctagaataa  
aaaaaaaa aaaa-

<210> 67  
<211> 1105

<212> DNA  
<213> Homo sapiens

33

<220>  
<221> SITE  
<222> (797)  
<223> n equals a.t.g. or c

<400> 67  
gggggaaaaa aggaacaggt gaattctgtt gctttaaatg tataattttt tatttgctga  
aaatgcacag aacataaaat ttgcattag taactagag taactacaa tggctgtgca  
accatcacga ctgtctacag ccagaacttt ttcatccac caaaggaaaa ccgcgtatcc  
atgaaggact caatcccat tgcctcttc cagccttgg cagccacag aatgctttct  
gtctccataa attcattttt aataagtga attctgtg actttaaat aataaagat  
gagcaagatg agttgcttat tggaaagata tccatcggg gagcccgcg ttggagtgcc  
gtatccttc ttgggttact gcttgagat cctctttgc aatggcccc aaataatgc  
tcagccccc cgtctgcatc gctctcagc ttcaggacc tccaccataa aacattccaa  
gttccagact cactctctgg aaaaattccaa tggctcact cctctttg agccagcag  
atcccatggc ctgtggcggg ttgcctttga gctctgagca cctgtgagt agggaaagcag  
gacaggacca cccagggaag gggaaagatc gtctgagtc acagtaattg atatcttgg  
atcgtctcaa gagatactta gctgtgctt aaaaattca ttcttttt ttgtgtttt  
tggwagacaa tctctgntct ttgcgccagg ctggagtga gtggctgat ctacgtctac  
cgaacacttc tctctcggg ttcaagcagc tctctgctc cagctctcg adtgcttggg  
atgcaggca cacactacca cgcctgggta gttttttgta twtttagkgg agacgggggt  
tcactatgtt ggcaggctg gtctcaaat ctgacactcg tgactgctt acctgggct  
cccaaatggg tgggattaca ggcattgagc actgacacca gccaaactagt cttaaaaaa  
aaaaaaaaa aaaaaggcg gcgcg

<210> 68

<211> 1279

<212> DNA

<213> Homo sapiens

<400> 68  
ggcacaggtt aaacgttgtta taaaatgttt cagtggggt ggagacagtg gctcttggc  
atcagctga cagggttggg cacagagca ggcgccgga agtgttattc cagacagcc  
cgcctcagct cgcagctgg actccaaag ttactgttc catgtgagt ataattgatt  
tgcttttctt actttctcca actttcggtt taatcacaga attgcttttc agtccagag  
ttcccaagc tcttctctgc cctctgaagg ctctggagg tggttctcat tccatgagc  
cctgggrrat gtttgcctca gtctctcag gcttgaatc aagtactca ttcccagg  
gctctggggc cagtaagatc ctacccctgg ggcctcagg tgaattcagg aggaggagtc  
actgaactgc attcagaaa ataaacacat ctgtctcagc ttgagtgacc ctggaattt  
tctccctggg aagtacatct ccagagacc ttatcacacc cagggttcag ccaggatct  
tggctgggga acgatgctc ccagagacc ttctctgggt tgaactagg ggtttcagat  
ccatctcttc ttgtgttga gaagaagcca ttctctgggt gcatcgagac ctgctagtga  
gaacaattct gtctctcac ccttgctaa tggcccactg gcatcgagac ctgctagtga  
cattccagggt ttccagctc taagggtgagt cctggcagct ctactgggac tggccaaac  
cagctccccc cagggtgaat taragtcccc atkgctgccc ctacccayt ccccatatt  
cacatttca gtacttttg ctgtgaagta ggcaccaca actagggaga ataaacac  
aacatttca tgcagctcat ggtacagtg tgggaagaat ttaaacaggg caaggagag  
atgctcttga ttgtctcaa aatgtctgga gtctcagta ggaagactcm aagctggga  
gtarttggc acttgggggt tgggatactc tggagactcc ttactcttg gttctttctg  
gtccacaggc tggaaaggck tcagaattag gaccgcagc cagactctg agcttggct  
ctccatlgg ctggcatcc tgcagcac acagagcct ctgggtctga ggggggggct  
cggfaccaca tgccttag

34

<210> 69

<211> 1638

<212> DNA

<213> Homo sapiens

<400> 69

ggcacagag aagtgctcta tggtagagt gttcatggg gaggagcaag acaagcagca  
gctctyga acctgtagtg agaaaggagc gcagaaggag gagcgcgcgt gcaaccacca  
caacacaaa gctgtccag acagctcgg cagccagcc cccagccatg cctaccacgg  
ggcgctctc tagctatgc agcgggctg ggcaggcag ccgggcattc tgaccagtg  
ggacccttc ccaggcagg gggcttcgg cctccacag ggcgcgggg gtcctgggtt  
ttctgcaaa atggagacc actttctgat aggaacttt ccttcttct ttctgttct  
ttctcttct ttctgacaa agccattatg cagggaatat tttaattct gtgatttca  
agatgaatca aatgatggc tggtaatag csaataagt agcaaggca ggtgcttcc  
agaaagatg ctggaaact tgaatccc tagaagtaa agtgagcag aggccttag  
aaacctct ctgaatctc ctatctctt aaatagatg caaataggta agccaggca  
tcgcgaaaa gctgggtgga gcttccagg aaatggaaa acccagcga gaataatg  
tgattccgt tccaaaagt gtcactacc tgtttcagaa aagttagact ttccatggc  
tttctctc atcagttgag tggctgagag agaagtcct catcctgag cccactgat  
ggcgtggag catccagtt atccctggaa agctagaagg gacagaggt gtcctgat  
aagcagaaa cagcaccct ggcgtccca agctagaagg cctgtcagc acaacccgt  
ccccatca accaagcga cctcagatt gtcaattc ctatggag caaacccgt  
gaccagaaa tggcagaga gagtgaact cgaagcatt tccacagatg gtgcagggg  
tttcaagaa tcttaggct tccagggtc cctggagag ccttagaat ttatgggtt  
tttttcaa tacaattat atgttagatt gaggatttt ttctgtagc tcaaaagtg  
aggggttca ttagttaac aatatcgt gagggaatt taaataactg ttactacca  
agattttt taataaagg ttatatgtg gtaacactc tctatatct tactcacag  
aatgtcact tggcaaat attttaaag ttataaac caagctcat aagatgatg  
agtgactaa atttgacga atgatactaa acaactctt gaaattctc aagcacag  
agaaacatca tttagcaaa ggcaggagg aaaaatgaa ataaattgt ctgagatc  
tcattgagt gatgtacat tcccttaat ctgcaactg tggccaagt tcataggtg  
cgtacattc cattattgc taaatcatg caatctgat ctctcttct ctcttgaca  
gaagttagt tgaagtgggt ttgtatata aatactgat taaaattag gcaattacca  
aaaaaaaaa aaaaaaa

<210> 70

<211> 887

<212> DNA

<213> Homo sapiens

<400> 70

ttttttttt tttttttat tagaataat gttgttgcca aatgaaaaa tgacactgta  
tataactgt gaggctatt ctcatgttta accttctaa gccacttct ttaagttagt  
ggagatgaa gactatagta atttctctg catgtctgg acctgctgt ataaagaga  
cagcagtaag catgaagact gttttccca tatttgcca aatcactttg atttgcctt  
tgagtcagag agtcttaaa attgggtgat ttccaatt ttctgctata tagtaattt  
aaaaattag atagcttta ggtacatgaa actttaaaa agtaattata atgacagtt  
aaaaattat agtaagtga tctcaaat catttctaa tagtaattg atagtattac  
ccattaaat gacataaaa atattttac tatgggtttt cctccattt gtttcaatc  
atcttttga taatttita taaagctta taatcatag aggaatttaa ttactactt  
aaattttga tatatgaca gtacattttaa aaattaaga gtcagggtac ggtggtcac  
gctgttaac tcagacttt gagagccaa ggtgggtgga tcaaggagtc agaggttaa  
gtacagctta gtcaactg tgaacctctg tcaactata aatacaaaa ataccctgg  
cgtgggtggt catgctgta atccagctc ctcaggagc tggaggagc gaactcagtt  
aaaccaggag cggaggtg cagttagctg agatcacac attgcactcc agcttgggtg

acatagtag agctgtgcc cctctcaaaa aaaaaaaaaa aaaaaa

15

887

&lt;210&gt; 71

&lt;211&gt; 864

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 71

ggcacagag gaccggccc gccgggctgc tgcggggcga tccggccgg ccgctgcgc  
ggcatggact ccgctgtcca gcttgatgcc cagcttact ggttggcac ccccaagtg  
ctgcagaggg aggaagccc cagacatgac gatctatc atgagaccac gccccacac  
ggggcgggcc aagatcacgc tcatctctac tgcctcgcg gccctggggg cctttacc  
tgggtctgc gtgctacccg cggcttcagc gcatcagcca gtcagaagac gaagaaagca  
tcgttggggga tggggagagc aaggaacct tccctgcgt gcaatctgc gccaaagac  
cgtgcctgga gagaagggc aagctgatka mtcccaagc gscgggaat ycaagstga  
vccagatgc aaagccccc tggctccctg ttgcaagcg gccaaagatg gcttgggaag  
ggcaaaamc atacgagtc gctgtgctct gaggagaag gcttgcact gctggcatg  
cccttcgggg ttctgtccat cgtatgact gatgccggg gaattggctg tccctggct  
cccctgggac tccagtgtag gctggccact gaggacatg ggttaggctg accttcgt  
ggcttcagcc ccttagcgcc ttctgtact tgaatgcta gcttaggctg ttlttgatg  
agctactact gtaatgcgtg aactaaaaa cctgtgact gtaaatagc ccttgaagc  
acctgtttaa gccctttgc tgaattttaa aaatcaltc tgcgcnaaa aaaaaaaaaa  
aaaaaaaaa aaaaaaaaaa aaaa

&lt;210&gt; 72

&lt;211&gt; 1217

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 72

tctgaacct ctctctaat tcaatctcc cgtaaatcgc tccatctgt gtytggaac  
tcagtttgc atattggata gatgaataa agcaagctg ttaatttca taatttcaaa  
tgaanaacc aacatcacca ctgtataat tatltttag tcaatctgt ttatlttca  
aatctcttc actatctat acattgcaca tgccttggg ggttaanaac carataaac  
cataagctca ttltatgac catcttgta ttcagcaagt atcccaagta caatgtgcca  
tacctgaaat ttltttcac ttlttaagtg agataaat tacaatcat aacaactag  
tgggtttcag ttatlttcaa tacaagtg tgcctgcga tgttgcacg gctgtctg  
catttatt ttatlttctc tcaagagtg ggtcctgcca tgttgcacg gctgtctg  
aactctggg cccaagtgat cctctgcct cagtctcca aagctctgg altcaagtg  
tgcgcacca caccacacct caaacaatt ttatlttca aaaaagaac ccccatcca  
taaggacatc caatctcgt tctctcatg atccagctc tggcaagac tatagtkgt  
ctyctgttc tctgtatctg tctatctgc acatgacatg taatggat catcataat  
atggcattt gtcgcctgct tcttccact agcataatg tttaagat catlcatgt  
gtagcatat cagcaattg ttctttat ggtataaa cactgactg tgtgacata  
cccacattg tctatcgtt aatcagtg tgaatctg ggtgttgc acctcgggc  
tatatgat gatgtcttc tgaatctg tgtacaagt ttgttgga cattgttt  
taattcact gatgatgac ctgaagatga atactgggt catgtgtaa cgttttaat  
ttctgaagaa ctggcaaat gttccctaaa gtgctacg tatlttaac tcccatcgt  
actgtagac agtccgtt altccacacc actccaac tgtgttat cgtttgat  
tatataatg catattagt ggtatgaag tcatlttca aaaaaaaaaa gaattcata  
tcaagctat cgaatcc

&lt;210&gt; 73

&lt;211&gt; 1717

&lt;212&gt; DNA

WO 99/24836

PCT/US98/23435

&lt;213&gt; Homo sapiens

36

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (712)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (721)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (903)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 73

gtctctaggg ccaggacttg gcaattgctc aggaatglt tgaagatg gcttccgg  
agaatggcc ctttaacct ggaattggg ccaattgga gcatcacac agtlttaga  
tgcataagag caatactgca cacaagacat gacctggag cagaatcgag gaccacatg  
gcaatctc gctccgggac agtggctct gttgtgtgc tcttccgca ccaagcttg  
ttcaggctgt taactatgc cccgatata tccagataga gaactggac atgatcttc  
tgaaggctg gagaacaaa tgttgcata tcaagagct gttgttgga acatagtaa  
aggagcccg acgttgggac agtgggcca ggcagcatg agaatgggt gccatggct  
cagcttggc ctgagctac tggggagccg agtacttg catgttgc aggaatggg  
aggcagggc tcttctca cagaatgctc tctcttgc ttgttagat gttcttgc  
aaaaaagg tcatatgt ggccttgggt cgaagcccat ctgatgata caaagacac  
ctgcacagc taagtctc ggcctacag ggttaggata agccaagcc gccctctc  
ccaactacc catgtgacag cctcccacc catgtgagc cgaagatc angaarca  
ngccttgct taactctg gtytccyt mactccga ccaaggaat arcacttct  
gtytgaacaa aacgtgcta gttagaacc aytgtctaa tgtagccaa ctgtctcac  
tcnfgatgt taggtacga aaggtttgag ggttggatg gttctctt caccacggc  
acaaagagg aggtgaatga gtaagctg ctgagagc gagggaaga ggcgggtgga  
agggaatlc agggagggaa tgaatgaga acttcttc atagtggaa tcaagttgga  
acttctct gaagctct acgaagtag tggcttgg ccaagacct ctgtctctc  
tccagcatg tgcctggc tggctctg ccaagacca agtcttga tgggggaag  
cccagggcca cgggaacat gggggagcct gatcatgg ctgttgcgt ggcagagagc  
atctctct accaattctc ttctcccta gttgttca gaatacaca gaatggact  
agtcaccca ctccatgag ccaagctca ggcagctgg ccttgcacac gccctcaga  
gaggtatgg cagcctgga gccnaaagt cacaagctag agtccaagag cagggctg  
caagctatc ccttctagc tggagaagt alttctaca gcttcatc tctataga  
aaatgggct aagatggcat cctccagat gggggatga gccaagatga acttccagc  
aaaatgcagc ccttgggagc gatcaggggc cttagctg tttaaaaaa aaaaaggga  
altgatatac aagctatag ataccgtcga cctcga

&lt;210&gt; 74

&lt;211&gt; 1276

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 74

ggcacagtga aaacttgta tttaagaa atgttggag aagccacag ataacacat  
tgcctgtt aatgcaata aatgaatc ttctctat gtaatag tcaatcag  
atggatgca ttatltata agtctgggg ataggaatc ttlttgcgt taatttacc

60

120

180

37

attccagagt ttgtcttga cttcatcttg actaagacag atgagaatat ttcttagaat 240  
 ttgtttttag tcttatttg atccgtcac acgcagcat ttattgtcc ttagctgtct 300  
 gtagctctgg aaacatacgt gtgactgaag tcccaaaa cccaattct gaagaactgg 360  
 aaactccat aaaaagacag cactgattc ctacgctca agccccagc attgctttc 420  
 cactgcgaa cccccctgt gtccgcacc ctgagaaaa gattataag atagagaga 480  
 ctatgaaga attcaaaaaa cagtacatat ttcagttatc atctctgaat cctcaagaac 540  
 gtagtgacta ttgtcatcty attgagaac tagttaccag tattttact aaatccaaaa 600  
 tgcctcatat aataaacata ttggaagtc aaatgtagtc aatattaata tcatittgaa 660  
 agtcgaag tagagaaaaa gaactgggt aactgtctca aggtataca ttgactcagg 720  
 attggaactt tgattttaaa agactctaa ctgactagat tagggattt aaaaattcaaa 780  
 ttgaactcag cagttgaggt ttaagaactt tctgtgctgt ttgactatc attcactaat 840  
 gaagttctaa agacttacta taaaataaa accacattt aatgaacttg aaagtttaat 900  
 aatactaga gagagctcc cctgtgttt ttgtttgtt ttgtccagt tagaaacagt 960  
 gggaggacca ggcacgttg cctgtgctt taactcagc actttggag gtgaggtgg 1020  
 ggggataccc tggggtcagg agtttaagc tagctggcc aacatgtga agccctgtct 1080  
 ctactaaaaa taaaaaaa ttgctgagc gtggagccac atgctctgta tcttagttac 1140  
 tcgggagcct gaggcagga gaatgccttg agcctggag gcggaggttg caatgagcca 1200  
 agatagcgc actgtactcc aggtctctg acaagcag actctgtctc aaaaaaaa 1260  
 aaaaaaaa ctgta 1276

&lt;210&gt; 75

&lt;211&gt; 1144

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 75

gcacacac gtatgcatat aaggattatc atataaat ttataaca attttttatgc 60  
 atgagctga ataaatat gtctgtatat gtacacataa tgcataatgt 120  
 aattacata tatctgtgt tatatatgt ttgtgcacag tcaacacac acacacaaat 180  
 atgtatacag atgttctct gttaacata gattttcact ctgataaatt catgttaat 240  
 caaagattt gcaagtigaa aatgcatttc ataccacgt aagttcatca ttgtkcaaa 300  
 agtatgttaa gtacagaatc atttgacatc tggataagtc cattataaag tcaaaacatt 360  
 ttaagcttaa tcaattgaat ttgggtaccg tctatgaga taccgaaatc atacatttaag 420  
 ggtgactagg tcccagttg aatgttatga aaatgaattt caagctcacc aggcacattc 480  
 acccatlaca aatgatgacc acattcactt attacaaata tglacacactg tatgtgttca 540  
 tgttatactt acaatgpcag agttgcataa ttgtgcagca aatacaatgg cttaacataa 600  
 ctaaggcatt tctacatagc cttttaaagt aaaaagtta ttcatgtgtg tctacataaa 660  
 cgtggaggaa ttgtagcgg acaggctatt acagtcagtg aattgaaagg aaggagagaag 720  
 ttgggggaga ctagtagtct tttagaggtt ttattttaga gatttatgaa kttttggaga 780  
 acaagggatg aggaanaagt attgaagaat ttgggagagc aggtatatcaa ttagtttctg 840  
 actttattgg gaatgcagat cagagaaagg ctgggataga aaactgaat aataattata 900  
 gcttcgggtg aataacagca ggaactgagg gactatagg aggttagact aggtataga 960  
 gccatgttg gcagtttcgg taggacataa ttgtgtata cgtatgtatt atttgtgatt 1020  
 ttgtttatct tttttaata agcaaaagg aaagtgtcct gatagtgttt ggtttgtga 1080  
 ccccatccga atccacctt gnaattgaac aaagttttac cagttaaac aggttagtct 1144  
 cgtg

&lt;210&gt; 76

&lt;211&gt; 918

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 76

ctgcaggaat cggcagrgca gttttcatca tctatgact taagtttctt catgctcttt 60  
 ctcattgtta agacaatcc actatttta gcttatgtt acaatgat ttacttttt 120  
 tctacaact ttgtattagt caagatggga tataataca aatgactctt gaaatttca 180

38

tggtgtccat ggaagagttc aagaacaaa cttgaagtg aattgcata ctttgttttg 240  
 tgtttcattg accactactc attcagtag cttgaagtg actgtgata tcaactgttag 300  
 tatactatgc atgcagata ccaagactc aaacttttcc ttctctttag ataccactta 360  
 cttagtcac aaatttgggt caacttact cactaaatag ctttgacttc cattactta 420  
 ccaatttga ttatgtctat agactctat ttactctct tcatatcaat ccccttaaaa 480  
 ctcccaatg ctccatgtg ttcaacaaa agctcaaat cttttaat aaagtgttat 540  
 atgaactgg accctataa tcttatatcc taactctca tctttcattt atttctttaa 600  
 cctctgactc atgtacaaa aatgtattta tctcagcag ttgtactcc cttgtatgc 660  
 ttctcccaat gtcctgtat ttctattga atagcaatt ccaactttta ttitatatgc 720  
 ttgtgtacc atttataat ttctacta cagactctgc ttttagaag catcacctg 780  
 ccaggcagc ttgtctcac ctgtaatccc agcattttgg gaggtcgagg ctggcggaatc 840  
 atgggtctag gagatcgaga ccatctcgg taacacggtg taactccatc tctactaaa 900  
 ataaaaaaaa aactcgag 918

&lt;210&gt; 77

&lt;211&gt; 1065

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 77

ggcacgagag agaggtgggg ttaatgtgat ggaagttgg cattgcttag ttctcggggc 60  
 tgcctttatg atagtttcta aaccctaaag cttctctcca cagtgcctag cgtctactga 120  
 gtactctgt tagcttttac ccttcacga actgcttttt ttgcagtttc tgtatcttc 180  
 accacccgt gtggcttagg aattcaag tgtttccaga ggaagtgtg tgaaggctg 240  
 ctagaggacc agaacttttt tccctgtgt cctgtgtgc ctgtggcctt ggactccatc 300  
 ttittatcac tagccactg ggcccacac ctgttgggtg tcagtgtccc ccaactgac 360  
 aagtgccctg aggaagaaac gtcggatgc aggcgcagt cagttcatit ctttctatg 420  
 tggatctctc accctctatg tcttcttgg tctccaaag ctcacacagc tgttcttgc 480  
 tgttggcatc acttatgtc cagtcctctg gtgttccat caggaagagc aggcaggctt 540  
 tagcttact gcagagaggg aatctctgt ggcctccatg gcctgtgtt ttctctagt 600  
 ctttttcta tgcacagaca catctctcc ttgtttctt ttgtgtatgc tgtttctaaa 660  
 aggatcttta ttctagaag aaacttagg aggaanaaac aggcagccc ctttaacaga 720  
 gtgctctgg tggcaacttt ccttgttaa ttgtctctg agccctact tcccacagc 780  
 ctgtctgttt ttgggggtac aggcacagc agctgaaagg ggtgtgggc atcgccatca 840  
 tgtacccctt tatccattt gctgacaaag atctgaaagg cccaagcata gaaagaagt 900  
 gctatggctg ccatgtgtca gcagcatagc catggccaac tcaaggccctt gactctacc 960  
 tgaccctct ctgaatgaca ctcaagtaa gggtccctt cccactcaca ggtgaggga 1020  
 aacatttca cttgaaaagc ctcttgccc cagctcccc tggta 1065

&lt;210&gt; 78

&lt;211&gt; 1126

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1124)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 78

ggcaggactg catgactggc aagctttggc ttgtgtgcc taggttgggc catgctgcag 60  
 ccgcccac catgcactc tctgactcag aactggaaag taccctgata tctttgcta 120  
 tagcaattga cagatgaag gctggttacc tgcaggag tgaagagcgt ggttaaggt 180  
 cctctatgt aggttgtcac agtcaccag tactagactc ttggctacaa cattctcac 240  
 caagagcagt gctcttggg aaaaataaa cagggtgag aagggggtta ggaataaac 300  
 tctctcttag agccaggct agaatacata atgggtttta cttcgcaata aagtgacaaag 360

gtcacattcga ataaagccacc ctgataccag gaaagaccctg ggcacagaag taacttccc  
 attgataatag gactgtatcc cataacctt accattagcc aagtttcat taatgaatat  
 tttaacacaa ctactccagt ataatitaa gacaaaatt gataaatat ttatctcttg  
 gtaagccata gaggccaattt tcttttaac ctatgtgttc atttaccag ttggacaaaa  
 tcaattattt taagaatttc caatttaaga cccagctatit atagagctct  
 taagtattgc cctcgaaagt gactccaga tgcagttaag gtagtgcctg aaactttgaa  
 cagggacaaat ccaagaccct taactccctg ttccctgtct taacctcat ccattgcaac  
 ttttttaagc atccatagtg attagttgat ctcatltca aactatagct tggattagcat  
 aactctcat ccaagaccct cctttgaatt tgaatctcta taactaagg ccacccctca  
 ttccctctat cagttccac agacacctta aagtaaatgt ctatcttgt tcccttccac  
 gttcccaaac gactcatgt tcaatttcca ctccctatit cagtaactag aactccatcc  
 ctccagaagc acaaaacaga acctggaggt cactcttgat tcttgctat tccctacctc  
 ccaattccaa cctatcccca agtctctagt actttaactg ctgnaa

420  
480  
540  
600  
660  
720  
780  
840  
900  
960  
1020  
1080  
1126

<210> 79  
 <211> 984  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (232)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (332)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (333)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (929)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (943)  
 <223> n equals a,t,g, or c

<400> 79  
 tgcacaccac cgtccgcgcg tccgtcgttc ggtgcgtccg ggcgcgcgcg ttccmctccg  
 ccatggacac ctggtctccg ctgtcttctc tgcgtgggt gttctctggc tccgtctccg  
 ccccgccccc ccgagcagcc gactgtcagc ccggggagcg ggcgtaccgg gactctctg  
 ggcgcgcgcg ctccgcctg gagaattaca accggggcgg ggcagccggg angcgggcga  
 cgtctggggc cgtgcgcgtt cgcgtccgac ggcggggcga ggcgtgcctg taactccctga  
 ggcggaccct ggaaggacct cctctgaacg amnccacgt gtgcacgtc cctgtctcya  
 agagaccctg ctctcagct ttgaagttt ggaagagcta ggaacacaa tgcattctga  
 ggcggaccct ggcgcagctg ataccaggt caccagatgac aaaaacgaa catgtatctc  
 agctcttcca ctgttgacaa aggaacccct gccccaggac ttltcttga aatgtgcttc  
 aacttcaag gactgtgta ccaactatna tccgagctat gactcgaaag aggaaccca  
 gttggcagat tctgtcttlt ccaacacat gatcgagca cagaagacc aggcattgga  
 cgtggacaca gttcagatg tgggtaccaa gttcagtgac cttaagagg aggaattcca

60  
120  
180  
240  
300  
360  
420  
480  
540  
600  
660  
720

taccattctac ctgaattccc tcttaagaga gtaccatgac aagaacatgc gcttaacaa  
 gttcgtccgc gactctgccc cactccatg gacttgag araaagggg scgtacacaa  
 agtcaaaac caggaatgk tggctctcgc tggcttctt cartccag taagttgag  
 ggcagctgt tcttgaaaca gggcgcttnt ctscctcgc gancargac tcttgactg  
 tgaagaagt gacaggtct cctg

780  
840  
900  
960  
984

<210> 80  
 <211> 1247  
 <212> DNA  
 <213> Homo sapiens

<400> 80  
 ggcagttcat ctaactatgt gttccacagag gatactctc ttgaagctg acagtatgt  
 tgcagacaga agtatgccc catggaatc tcaactccag ggtttccct tagactctac  
 accattagc aggggggtg gaaagatgc ccaggtggc acttttaca ctgtcttcc  
 gttccattcc ttccctact ttgaaagct tcaattctg ctccaagat gaattgtcac  
 gttggaagcg gggatgctt ttgccccttc cagaaagcta acttccaat aatttctta  
 wtttataac agacttctt ctgttaatt agacttaca ttgaagttagc aactaagct  
 ttctgttaca agacttcat cccaagata catcaagtc ccaggttgaa gtagatctg  
 gattagacaa ggtgtgacc atggagacag gagaatgca aggaatctg aggaagaca  
 tgtttgttc caatalagtc cccctctgt gccactcaga ttgtctcag cctccaat  
 gtgcttgat ctataagcag atgctcttg tagttgcag ggtctcttg cttaagggc  
 ttgttgctt gattatgt ctgcactgc attttatit ttgaagcag ggaattagc  
 ccaactgaag ggaatagct ctgagtaat tccctaggg ttgtcttct cctctctac  
 ggtcttgat gaaagagca cagaattctg tgaatccac gttgcatgac tctagagct  
 ttgaattct ctgagatcac ttgacacag ggcgcagcag gttggccag acctgtatc  
 tgcattagc atattatag ttcttgatc cacttgaac caggaatct ttcatctat  
 ctgtaccca tctgttttg gcagaagcta gtagttta ctgaacagag atttaaaag  
 gactttatca acacatcaga gcaattatct ctactgtgt atttttgac tccaatcc  
 ctgaagagctc aataaagccg gtgtcttctc tttagtgata ggaagtatct aggaagccat  
 ttactttaa caggaatglt ctgtctgaga ttgtgttca cgcctgaat accgacatc  
 ttggagacaa accgagcgag atcaattgag gccagggagt ttgaagtagc ctggacacaa  
 ttgtgaacac ccaattctac ttaaaaaaa aaaaaaaa ctctgag

60  
120  
180  
240  
300  
360  
420  
480  
540  
600  
660  
720  
780  
840  
900  
960  
1020  
1080  
1140  
1200  
1247

<210> 81  
 <211> 946  
 <212> DNA  
 <213> Homo sapiens

<400> 81  
 ggcagagtg agattgac cagacagagt tttaaagt tcccggttga gtttaagta  
 cagttgaagt ttgagacatg atctctgcat gtaggggaaa ttttgtctt gttatgtaa  
 gaactatgg aaaccaatlc ttgataltt gaacattca cgaagatagt ttgaattctg  
 agcatgctgt tgcctagagt gggcgggagt gactatgag agtgaatgag ctgtctctga  
 ctgtattt ttgaatctga aatagctt ccaagctggg gcagggaggg gaggccaggt  
 gggatcagta ctgcccacaa cgggttagag tgtgttgtag gatcaatct gctgcgcct  
 gttcgcacaa acaatattct cttctcagc ccttgaagag tgaattgaa taatgcagta  
 acaattatga ttgtatgaa gatattag atgttgagaa ttctgctac ctatgtggt  
 ccaagctcc caaatctgt ttgcaaacg actctacata catctctt agtcttgat  
 aaaccaact tcaagatag attaggtc ctattttaa gatgagagag ctggagctca  
 ggaagaagac gtttgaacac acaacact ttggaatgaa acaattacag ccggagcgcg  
 ttggcggtgc ctgtatccc agtcaattgg gaggcttgaag ctgagagac gottgatcc  
 aggaattctg gactgtagtg cgtatgccc atcggtgtc cgaacaaagt ttgagatcaa  
 tatgttgacg tcccgagagt ggaagacac caggttgctt aaggaagggt gaaccggctc  
 aggtcgagat gaaacattca caaaattga catltcctta ttgatatga tttaactagg  
 tctttaaac ccaagtgat ctgtattaa aaaaaaaa aaaaa

60  
120  
180  
240  
300  
360  
420  
480  
540  
600  
660  
720  
780  
840  
900  
946

<210> 82  
<211> 1392  
<212> DNA  
<213> Homo sapiens

<400> 82  
attgggcaga gcagaaacac agactgcaat tgccttataa aacagagcctt tatctttcct  
tcaataaag cagagttgca ggtgtctgg tatgattca ctggcgtgtt ggtatcagga  
cagatgtctc tatgattaat ttitggcttg teactcatgt ttgcataagg ctgtgtgtgc  
tccagcatt ggaagaaga ggaagcaggaa gcaacattga ctgtaccagg aactccaaaa  
cagctctcac atcttaattg ttggacaatt ccaaatggctc actctttct ggaagtgtac  
tggggacaag atagtgttaa ggaattagatt tggccagaaa gttctgcga cagttagctt  
tctgtctcaa atctcttatt taactgttgt cacttaatat tcaactttg gaaggacac  
tactgttgtt tacaattatg aaaccaactt gaactcttt tagtgaaca ttctagtgt  
cttaattatg ttcaaatagg ttacaaatt tactgttttt agtttagtt ccggtccccc  
ccaacccccc acttttgyta gagggtact ctcttaactt ttgttagaaa gtacaaaagt  
tctctactct acatgttcag ggtggtctgt agaatttctt tttttaaaga aacaggaaga  
cagaactaat tatgcaagtc tcaattttag ttttataaaa aacagcttcta ttgagttaga  
attgacatgc agtaaaatggt acataatttaa agcgtataat ttgttagtt ttgacataag  
tatacatgtt gaaacacatca gtacacacaa tcaggatact tatttaaaa acaacttta  
tttaggatta gtatactgat aatgtgtcca ttgtaagtgt acattttcag tttagacaaa  
tgtatagatt ttgttaacta ccaaccacag tcaagtatga aactttcta gcactccaga  
aagtctcttt gtgtcccttc ttgtgtcagt attccacca tgccttcagg caaccacagt  
tctgttcta tcaatatata adtgacagaa ttttttaca gaatttcaea tagatggat  
catacaatat gtactgtctt gctgtgcttc ttgaggttag ccaaatgctt ttttagagtc  
atgcactgtt ttgcatttat tagttagttta tcttttttt ttggttagt agcattcat  
gtatggatat attccagctt gttttattca ttcacttttt ggaacttttg ttgtttaca  
attttgggct cttttgaatt aatccctccc tcttcccttc ctcccccyc tctctcttc  
ctctccctcc tctctctctc cctctctctt tcttctcttc cctctctccc tctctctttt  
ttttgggcac ga

<210> 83  
<211> 1155  
<212> DNA  
<213> Homo sapiens

<400> 83  
ccgggtgcac ccacggctcc ggtgagtcca ctctaggatg ttcaatgat gacaaaatca  
cttaacaatg tagacatctc agaacataa cctttgttta atcgatgat cactgtatat  
atgtgtgtat atacacatc atatgacat atatttaata catttgtga ttgtgtgta  
tatataata tatatactc tctattatta tactctagc ccagagctc ctagtgtgic  
tccaaaattg gactctcat tctcttttag acagccttca aatgatgtt tttaaagtgc  
taattcaact ctctttcaa aatgtttcca tggcccacta atctctacc aatcaaggaa  
ttcagccata ctgtcccacg atactttccc ttggccagt ggagctcat ttcagctgtt  
ctgggtttat cccctgtctc ttttttccca ctcccaagc ttgtctcagc ccaactctc  
ttctggggat gcccacac ccactctgc atatgtcca aactttcat ctcccgtga  
agctcttgac accaaatca gttacttcta gaaatgta tttttccat ttctcaacta  
aacttttct ttgtgtat ctgtttccgc tgcgaaggca catcgttttt aattctctac  
agcaatgtct atacttgc cagtattata gctttacat atgtgtcttg ctctttatt  
ttgagacaaa aaactaagcc actccacttt ctcttaccag tgaatccagc ttaaaaaac  
tgtgagcaac ctatcagat ttgtgtgaca tgaactctat agaaactta gtccttgat  
cttcgactct gctctccctg acattttact gctcccacaa agcagcagg ttgtggaga  
gaagtggctg tttttttag ttcaatttca gcoctgatic atctaatgt ctccacctt  
ttatctcttt ggcacatgtg tycctcagaa ttgtgaattca attccgacc attctctct  
ttcaatgat gccaatatc tcaaggctttt aagactaaat tttaaatatc gagaataatt

gatcttcaaa cttaagtgtg acctagaaag acaaatctca tgaactcaaa aaaaaaaa  
aaaaaaa aaaa

<210> 84  
<211> 1373  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (877)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (897)  
<223> n equals a,t,g, or c

<400> 84  
gatgtgtgc tgcctctgct gtacctctgt gtacctctgt gtccggaagc acatcaacag agcgggtatc  
gggaacacgt ttcaaggagg tgcaactgc atcaatgttc tctctgcac ccgcccgtc  
cgaactggc tctttctct ctgtgtctg tgcgtctct ctcagcttc cacaagagc  
ccggtggca cctccaaagg tcccgccct tccagccag gagaactca ggaatccca  
gggacccca gggaaacttc aagcacttg agctttgtc ctcttagt ctgtggccta  
ggtgtcct tctgggggt agcamttct gtgagtccct gctgagggc agaatgtcat  
gtcgtgcga ccaagaagcc cgcattatga tgcctcggc tccattggga gacagctgc  
caactcagt tcttctact cctagatcct caggcagcaa ttccamegg taccagctc  
ctggccagc ggtggcgtt catctcata aggttagcag ttgagttcgg gaagccgtg  
gccacagct gtggccacag tgcctccac cagtggacct ttgagttctg aggcacac  
agactgtt acaactag ggacacacat ctgtgacct atctctgt tgattaaata  
agctgtcagg ggcctcaga gatgtccc catcacaca tcatggaga gatccggc  
tggtaaggt gtaagattc ttgggaac ccggttttc ttggagact ttgtcaacag  
aggaacact tgcattcac caggttgaag gtycctgar ttgcattgt gaccacagg  
ggcaagcaca gccggcga ctgctcagg acagantct ccccggsct cgtgcnctt  
ccytccatg gctgtaac ctggcgtg ctgggtttg agtgcaga caggccaga  
tccactec tgtccctact gtcatcact cagacacagg ttctctctt ccaattccaa  
agctggaaca agggcagaa gaggcgtctc aggaacccc cgaagacccc actgtctc  
cagctcttt cttagaacc tctcttctt gggagagaca aagggatga gtaggaggg  
gtctggctt attactct tagtttagtt ttgttagt aaagtggcg gagagatag  
taatccaaat acgattctc agccgggca cagtggctca cactgtaac cctagactt  
tggagggcca aggcaggcag atcacttag gtcaggagt ttgagaccag ctggccaca  
tggggaacc ctgtttctac taaatatac aaaaaaaa aaaaaactc gta

<210> 85  
<211> 1258  
<212> DNA  
<213> Homo sapiens

<400> 85  
tgcactgtg gtgtccacc acacttctg ttctctatg cctaccccag cctttctct  
cactggct ccaacttcc ctggagacag agggtagca tgcgtcatt tctctgagg  
ttgtggctga ccaattctc tgggatttc caggccact ctctttccc ttctctcac  
tcaaccaga ctgtctcag tggcctatt gctctgat ttggctttac ttgtaggagg  
tttagtggct gctctggct gccatggaat ttggctgca attttggcag ttgtggaga  
actggatca ggaagggaa cccaggatag ttatgaat gatgtgggg atggggacag  
aggaacatg gactgtccc tcttgaact tgcctttggg cacatgggag atggggacag

43  
 gaaagatgat aacagtgagaa cccctgtgaag aatagagaa tgggaattct aaataccag  
 tcccaaa aaccattct ccaattgaa agagctgt gcaaccgt ttaattaa  
 ctctgtat aagcaatgt atgttataa gcttgaagt aacagaa atgttcaag  
 gccgaagaa aaatatcgt tccctgtct ctgccttac ctgtctgtg cctctgtgct  
 taagacagat tgaatgttga atgtgttg ttaattctc taagtctga ctctgaag  
 gggccagaa ttgccttct ggaatgtgaa gggacagt tcaagctaa cctctgaa  
 tgaatgat gctgaattt aacccttct ttacagat ggccttcaa aagggaattg  
 gaagctccg cgaatlaag agtgggtgag tcttgagag aaccaagac taagtgaagt  
 tgaatctgt ctgtgtctt gggagccag aatgagaa atccgtgtg gtagagagt  
 gtaagaag gggacagtgt tgggtgaaca gtgcatgga agtcaatgat gcaagctg  
 gccctgac tcccatcgt caaagtgggt ggccttctc atctctaa agtttcaa  
 ctgaagagt gatgggtgaa agatccag agtgggggt aggggtggc cctgaagat  
 ttgtgtat agctgtga tatgtgat ataaccgt ctctgtgac aaccgaagt  
 gaataactt gggcagaaa ttaaaaaa aaaaaaaa ctcgtgag 1258

&lt;210&gt; 86

&lt;211&gt; 1318

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 86

cccacgtgc cgaacagtc ttaatgttg ctctgaatt ttaatgact tccgtatgt  
 aagagtgta gagagcagt gttaacttaa taccgggt cctttcaat gtttgcctt  
 gtgtgtgt cttttacc agctctgaa gggagatgt tgtgtgac aggtttgt  
 taatcctct ccccttctt agtatagt gcatctgc aataagaa taacttca  
 aagagctgt tcaaatgaa ataacta cctcactt ggcattatg taattacaa  
 taagaatgt aacagctgt gttttcag aaaaaaat ccaaaacac cttcttaa  
 caaggaagt ttatttca gttccaat agatlaaa agcatlttg gctttctc  
 tttttctg tgttagat gtaatact gttctata gaagtgtgt agttactt  
 tgaatgag agatttctt gggatgag aacagatgt gagtgaagt tctgtact  
 tctttccc accgtctgt ttgttttc ctacgtct caccgtgtg ccatgtccc  
 ctctctgct cctgtgtct agatgag gacataga gtcaatgtt ccaaggtaa  
 caataccga gttctgtga ctgaagat tccagtct taltaaag ggaattgaa  
 cagtaattt ttaagctca ccaattca cagcagaga ctgtcattt acccttact  
 tgaatcag agatgtgag catcagatc ccaatttg ccaatttca gttcttga  
 aatgacccc atgttgaga tttagtta ttagattcc tcaatgaa aagaagaa  
 caatatatt tgaatgat aatccacac tgttgtct aatatgggt aagaagaa  
 ggaagcaag attttgag aaactgaac actcttaaga ataactct agcgggtg  
 ggtgtgtgc gctgtaat ccaagactt gggagccga agtgggtga tcaagagtc  
 aggtatcga gacatctgt gtaattgt tgaacccc tcttactaa aatacaaa  
 aataagcga gctgtgtgc gggcgtct agtccagat actcggag ctgagtgag  
 agatgtgt gaaacggga gggcagact gagtgaat gagtatgct cactgtact  
 cagctgtgt gacagagca gactcgtct caaaaaa aaaaaaaa aaaaaa 1318

&lt;210&gt; 87

&lt;211&gt; 978

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (977)

&lt;223&gt; n equals a, t, g, or c

&lt;400&gt; 87

ggcacagagc ggcgcaagc' gtcagtgag gattcaagc agcaatgaat cgtgtctgt  
 60

44  
 gtgcccgc ggcgggggc gtccgggct tgaagctat aggtctgggt tccggaagc  
 ttaccgtt gcccgttcc cggatctgg cccacttgc cgcgagaa gagagagc  
 ctgacggccc catgtgatt tccctcaga aagcaacc tcaagctg tccgtgggc  
 ataacatga aagagatcat cagcgacct gttggaagt gctgtccct agctgtcc  
 tctgtgctt gattcatctg tctatmtga ggaaggaag cgaagcgagc cagtgtga  
 gacaggtgt gggagagt tgaagccca gtgactgtc tgaagagct gaaatccag  
 ctgcctaac agcgaaat tgaaggtgt cccgttgggt ctgacagaa ggaagcag  
 agcgcctt cggattgat gtaagttt cccgttact tccgtgat gctgtgtc  
 tcaagctga agaatgtgc tgaatgag ggcacttgc tatgtgat cgggtgag  
 cggagcaga tccagcaga tggaaact cttctgctt gttcttga tccaagat  
 tccatcaga agactctca gacttggg gaagtttca gttcagat atgtgtgt  
 atttccag tcttttata acaaatcat gtttcaag caatttgt gaaattgtc  
 accaggtt agtttcaa taatttgt tctgagag aatatctgt agaatgtga  
 aactgtat catgtcggc ctgtgcaag acatgttc acatgttc ttaacacac  
 aacaatga aataaattt aattttaa tatggaaa aaaaaaaa aggcggcgc  
 gtaaccat ggcgcena 978

&lt;210&gt; 88

&lt;211&gt; 1863

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (82)

&lt;223&gt; n equals a, t, g, or c

&lt;400&gt; 88

tggtgtgt gatgagag catgacccc ttcttccc tgcctctc tgacatgaa  
 tgcctatga taggtgagc ttgggtgtgt agtgaagc aatgtgtt ttggggag  
 aagtgtgt gtcacatgt gtttctct ctcttcaa tagtgttc agcgaagat  
 cctgcttc catccctga gtagaggtt acgtgtgt cttcagct gacgcccc  
 agatctgt gattgagat gttcattt cccggcagc tgtgactt gaggaaaca  
 agcgtctc ttgttctt gatttcaa tcaactgct catttccac caagtgaag  
 ccaaaaaga tgaatgtg caggacac tgaagacac agcatgtg gatgaatg  
 tgaacact gattgtgtt gaatttctc tggtaggga tgaatgat cccgaaggt  
 aaagctgt cctgacaca accctctgc agcaggggt gttgagatc accaaact  
 ctctactt caatttgt ggtgtgaga gcatcact gtagaagat atctgaagc  
 agctctga tctgtcga caggaagct cctctaac caggaagtc cgttctct  
 gctggaat gattgagct tactcaga atgaattca ctgtgagtc aatgtctc  
 acagatgaa cgggtgtgc caccacac agtgttca gttcagagc ttctgtcac  
 gtgtacaa ccccgctt gaaatgtgt gacacagct agcagctcc caagaact  
 ccaatgata agcctgtgt gctgtgag gtagggagc gtagaggt agtgtgtg  
 gaaagtat cttcccttc acccttga gaaagagag tagtgtgagc aatgtgtc  
 gtccctgt gtaactgt tagttgagc ctgtgtcat tgaaggtgt ctatgtctg  
 catcacat ccttgtga gaacatgag cttgtgtat cctgtatg ctatgtctg  
 caatcaaa gtagtgtgt gtttagcgt acctagatc tctgtgtt aaactcaa  
 gaccccaag caatacaa ttagcttgc acctagatc tctgtgtt aaactcaa  
 gatttact agcactat atgtactac actgtctaa gtagtgtt atgattta  
 gtagatga gttccatc ccaagagag aattgtact ataatgta aatgtgtg  
 ctatgtat agtcaaga atatttcaa aaatatat caaatgta aagcttcaa  
 ttagatgta gttgtctct tcaagctgc ctttcaagc aacgtgctg tgttccaaa 1440

ggtccccggg catggtccct tacgaatagg gcaattttat ttccaacttt tgagtgcgt 1500  
aattgaga aaaccagaaa atacaata ttcttttaa agaaagaaa tcaggccagg 1560  
cacagtgct catgctgtga atccaacaa actagctga' gtcaggagg tcacttgagt 1620  
ccaggagttt gagaccagc tgggaacac agtgagact' tgccttaca aaaaataaaa 1680  
aaaaatagct gggcatggg gcaggtgctt gtagtccag ctacttggga ggtgaggtg 1740  
ggagagctc ttgggctgt gagccagg ctagtgag ccatgacac accactgac 1800  
tccagtcgg gagacagagc aaggctctgt ctcaaaggaa aaaaaaaaa aaaaaaac 1860  
gag 1863

<210> 89

<211> 2086

<212> DNA

<213> Homo sapiens

<400> 89  
cgaggaatgg agccggtagc tctgaggc agtccggc ctctccgta gaccgcgga 60  
gcaacttctg gtcgagtaac ctggcgaggc tggcgagcg tgcctacc ttctgccc 120  
ccaagcgtt gctgagggtg gctgaatgt tgcatactta ccacatacag ttctttat 180  
ggctatca gaaacttca ttacttggga agagtgtc ggcataaga gagcaaggaa 240  
aagaactagt atgaaacag cacttgcct tgagaagcta ttcccacac aatgccagt 300  
cttgggatt gtagcccgag gaattgagt gaytccaatg ggtcaggta gcaatcgacc 360  
tcagaaata gaaattggag aatcgggtt tgccttata ttccctcaa ttgaaggat 420  
aaaaatacaa ccttctcat ttataaaga tccaaagaat ttaacattag aaagacatca 480  
actcactgaa glagttctt tagtaacc tgaactctg tggctcttg tcttgggta 540  
taattctgt aagtgaggag ccagtaata tctgcagcaa gtagtcagca ctttcagta 600  
tatgaatc atcttgggtg gggccagggt ggacaacctg tcaactcga ctctgaaaa 660  
gaaaccttg gatattgat cctgggtgt ggttgagctg tcaattagtg gacacggat 720  
ccagagtc actgtctcc tcaagctga cgtcagtgat gagaagctg ctgaggtcgc 780  
gagcagcgc ctcaagcgc caacatctc agagcatac accattggct tcatgtttgc 840  
atgcgttggc aggggcttcc agtattacag agccaagggt aatgttagg ctgactgatt 900  
tagaaagt ttctctagt ttcccttatt cggcttcttt ggaatggag aatgtggatg 960  
tgatcggtata gtcactggga acttattat gaggaaatg aatgaggtaa aagatgata 1020  
tctgtttcat agctatacaa caataatgc actacatct ctgggtctat ccaataata 1080  
attaaagtg ctctcataat atgtaactt tgggttctgc ctltttcaga aatggtgaaac 1140  
tggggccatg tgaatttcaa acaaaaataa cttagatat atctttttg tagcyyttgat 1200  
tgatgctcta agtaccatg aggttagtat ttaatatat agatgaagga caactttgga 1260  
cataacactg actaggagt gtagcttctt gcatcaggca gaagcaact gattatgtt 1320  
ggttgcacc agatcatgta gctgctgtgt aacatgacct taaatagctt tcttgcatag 1380  
gaagagcaaa aggtatctca tcaatagat atagatttaa gacattccct gactacccct 1440  
tgctgttgta ggtgatgct tttagcagaa tcatgaagc ctlttttctc cttaataaa 1500  
ggagaaaaa atactgatg ctggggaat ttctctgc ctctcagtt tatgaatttt 1560  
ttcagaagta acaatattat tatgacttt ttactattt gataaaatt aaagaactat 1620  
tttcttttt cttaaaaat ttactgctt caactaggtc ttaattataa gtaaaagatt 1680  
agaccagagt attacatcat ctatttttg ttatatca ataaacata ggtggaact 1800  
ctaccaggta agttttgca ttctattgt ttggatgaa caaaggaggt aaactaatcc 1860  
ttataaatg aaagaccaga atagtttgta tgcagctag tcaattctgt catattccca 1920  
tgaataatg ttcaagttt wcaattctg aataatct aataaaga tggcagaga 1980  
gcaacaattt tcttcaata tcaattctt acttttca taaatgata accatttgatt 2040  
tttcaagtg gtagctcc tagaataag actacattc ccgagt 2086

<210> 90

<211> 891

<212> DNA

<213> Homo sapiens

<400> 90  
gaaattcgc atgagctgtg attgcaagta attttaaac gctgcagatg ggacaaagta 60  
aatacataa aatgaaaaat gctgtgaag agataggat gaacataat aattgttttc 120  
cccactgttg tgaattatga tgtatcttt taacttaca tggatgggtt ggtttctct 180  
agttcttcaa agtcaaaagag caaagttagc cctccattcc ctccattctc atcaagaggt 240  
caggtctaga atgtcacgga gagagtcgac tggcaggcct ctctgttttg ggttgaagg 300  
gaacatgggt gcgaagacc agtgcacac cgtgactat cctttccct acaggaactt 360  
gccagaaatg gctgcgccc caccacagaa gacagctgc camagactgc accgtccca 420  
ctggtggag ccaaggacc caagctcca gaagccgc gccaatcac agtccacttt 480  
ggacagctgc gccacctcg tccacatgt gtaagagac caaagagcaa catcgcatgt 540  
gaaggccga ggaactgtg gccgagcct gagcaaaa ccaatgcaac accagctaca 600  
ctccacatc tacagaaaag cattaccat ttgaggcca agttcccgag gagaggctgg 660  
acctttcat cacattgact tagcgggtg ctttccaga ttcccgag gggctgactt 720  
cgeagtggt gccaaagac cgtgtctga taatccatt ttccctgta tcactgaac 780  
tgrtcagta tcaatttag ttgtgtgtt ggtgtgtt gttgttgt taatgccc 840  
tgtttctac ttctgttga aatatttgg ggttgaata aaccagtgg a 891

<210> 91

<211> 1974

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (654)

<223> n equals a.t.g. or c

<400> 91

aaaattgcta attaatatta gtaattgggt gcttatctt aaaaacaac ctacctctgt 60  
taataggaaa attagaatt atactatgt ttcttaaga tacaattgt ttcttaact 120  
ccaagggaag tgaagaata ttctcagac tactctgtg tgtgtattt tgtttttgt 180  
aagtggtttt ttcttttgc ttcaattga gagcatcaa acaaaattcc actgtataag 240  
cagtcataat ttgtataat aacatgtgc tagagcactc agattaact attacata 300  
ctaataaat taltcacagt agtactcctt ggtaatgttg gtaattaggga acagggatag 360  
aaccactct caagtcacac cctattactt caagcctttg caggtcctgc tgttcccaag 420  
gatacaatcc aatgcttaat ttacaggat ccgaatacat ttgtgtgtt aaaaactga 480  
gattagcctt tctgcccc ttccagggtg gcccttggaa gcaaaaggct tttaagctta 540  
agttaactgg agaatatttc tgaatagca ggtccagggt ggagggtaca ctcaagata 600  
cttcaacttg ccaaaaacac actccttgc aggttatcag cgaagaggga glanaagag 660  
ccctctctg gccagaaggt ctgttttgc aaggtcttc agctgcctg cagccattgg 720  
gtgaggagag gaaagacac ctcaactgag agagcagcac aaaggctcagg catgtttccc 780  
tctcagctgc gaagtggtgt cctgctcctt cacatgaact gtccagggt tggctcataa 840  
cccaggtccc ctacgtctg cccagatga ctccactggt tccccagaa aacaccaaca 900  
gcagatara atgaattgt tctgtttct gtttcatat tgcactcct ttgtctctc 960  
ytaggacaga aataacatct gmatgccc aramctgtga agtaataac aaccttccc 1020  
ccagctgtt caaacatca cctgtcttg aggtgcaat gtttgcaga agttatagg 1080  
tttgtctgt tcaacccatg ggtcttgg ggttgggga gtttaatgc ccttctcag 1140  
ttcacctca ctggaagaa agagctagaa gtcagtaag atgtgtatg actgtcag 1200  
cttcaggtag ttcaagact gcaactgtga gttcagata caggagaaga actcagaga 1260  
taaatgttgt tccaaagag gccaaataga aaaaaaaag gttcttcaga caaatagtg 1320  
agtgcctga aatttaaat caaaaaatgc attaaacc' acaaaaccac ttcttttaa 1380  
attcttgata caaacatgt tacagcata agtgaacctt aaactaagca aaattcagag 1440  
aagagcatt acactttga tagagacc agccagcag ggtgctgggg ctacgtctt 1500  
gagaaaaatg ttgatgtaa agccttggt gccgtttca gccctcagc ctcctgtta 1560  
agcacatggc aggtcagaa catcataac tgaatgctt gcccctgtga aaaaagcgt 1620  
tacaatggga aatcaactt taagtatgt atgggtatgt gtgataaat ttgatttct 1680  
ctacctctg ttgacttt ggttactta gaaagagtc cataatgtg tgcctcaga 1740

gtgcacatcc atggtcgtgaa cagaatagag tccctttctc tctggtccctt gccctttgg 1800  
 ggatattcca accctgtgga aggtatcatc ttgcatatc gatcatatc ttatatttga 1860  
 ctgcataaga aaactccaga gtccattcca aaaaaaaga gatgacata aggaatctg 1920  
 ctatagatga ggggacaaat aactagagac aaaaaaaga aaaaaaact ccta 1974

&lt;210&gt; 92

&lt;211&gt; 1423

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 92

ggcacagagat acccttcatt ggaatttga tggtttcgtt tttaacatt aaacttctt 60  
 ccccggtgtg tgtgtgtgtg aatctgtgtt tgtgtgagga ggggcatgtt gcttcagaa 120  
 cccactctct gtggccagag agccctgtcc tgtgaggtgt gtgtcacag tggccaggtt 180  
 caattcagaa gaacttgaag gcaagctgat gtttctgaa tgggcccgt gtgtgtctt 240  
 gtccctgaat cctcaattcc ccatctgaat ggaattggac cttaataggc acttggagctg 300  
 gtctgaatcc tgaatgact acttggcaac ttatgtctg gggagcaagt acttaactc 360  
 cccaagccctg tgtctgtgaa atgcgggtgaa atgaatgtag atgtttggca gacagtactc 420  
 ctgtgttgag tctcacagtg aactctctg cctctgctt ccttcccgc ctcctctgt 480  
 gcttgagctc aggtctagcc acttctctct gggccctct cctttctctg tggctggctg 540  
 cctgcgccgc tggcgctgga cctttcaagt aagggaatc agcatgtata tctgtgtctg 600  
 gtctgttctt accttcaat ttgtttccag taatattcc ctgfacccgg agagtctaca 660  
 aacacatttg aagagcttt tcttcagat tcttaacct cccaagaa gttccatgaa 720  
 tgggtttcta gaagctata aaatgctctg aaattgatt ttctcttgg aaagataac 780  
 ttctatctgc ttgttcgtgc tcaaaaagaa tcatgata atgtttctg aattttatgc 840  
 catgtgtctt atactcaagg atatatagcc catctctga gctgxtaac tgttttgc 900  
 acttcaatcc gtccagctgt gggactctct gtaatttag tgaacatgc tatccctgg 960  
 agtggcatct cctcgagagt gggactatc gttttataa cttctctac agactcaat 1020  
 gactccagaa agctacact cctgtgtgta gtatatgata tccattccc taccatggca 1080  
 cttaacatag gtttttcaa ttatttatt tcttgtcac tttaagaa ttgtgtgt 1140  
 aaatcacat aatagaagt gactatctga atcatltta agtatacatc cagtgtgtt 1200  
 aagtatctg ccaattgtgt acaacaatc tccagaact ttctatctg caaacaac 1260  
 tctgtaacca ttaatatca ttaacaatc catctctc agcttcagga acccaattct 1320  
 actttctgt tccgtgagtt tgaattccc aagcatlca tatcagttaa atcatgaagt 1380  
 attgtctgt ctgtgactgt ctatttctc tgaagacagt gtc 1423

&lt;210&gt; 93

&lt;211&gt; 1365

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 93

ggcagaagta acccgagatga agccacttcc gggattcccg ggtgccttcc gcaagtctct 60  
 tccgggtgat gggggccggg tggcccgagat gtatgccttg cgaagaatct ctctctttt 120  
 ccaacttgc ttccgggat tcccgagat agaaacact ctcttcccgc tcaatgccaa 180  
 ggggaagatg accttccag gcttgagaga tgaagagat gaggatgaa tcttggccc 240  
 caagaagag ctgtgtgacc ctgtgtcttg gtacaggggt cctgggggc gttttaag 300  
 caaacactc ttgatalag atgagagaga ggaatgat gatgggggt ccagcaata 360  
 tgaactctg gcttcagag atgtatgaag tcaaggagca gccaactc ccaagagagg 420  
 ggggtttcgt atcacacct ttaacttga gaggagatg gaggaagcc acttggatcc 480  
 cgaatggcaac taacttctga accggagatg tcaatctga gacagctggc tggacaatat 540  
 taaactgggtg aagatccggg agcggtccac tggcgagcgc cagggctcag acttcagaga 600  
 ggaagacagc ttgggccaag cctcaatgag tggccaagc ctcttgagag gactttgaa 660  
 gtctcatct cctagagaa cagtgtcttg ggtcatgag cgtctggagg ccggagagg 720  
 aagcaaaagg agaaagggc ctgggcaaac cagtctccct cagcgctcgg accgctctc 780  
 cgggttgcgc gaccagatg tggccgggg caacttgt gtgtaccag aaacaagga 840

acgttgggt atggtctga aggttttg gtctcagacc ctagaaccc acaatccac 900  
 aaccacacc tcccttgaca ttctctga ggaattgggg gagggagac tgaagaccc 960  
 aacccttacc cagagagag agcagagatc ggggagagat gttctgttg atgtatgtg 1020  
 ggaattaa tggagagaca cggggatgc ggaactgtat gggcccttca ccaagccca 1080  
 gatcagacc tgggtgagtg aagctactc cccgagcgt gttatggc ggaagtgtga 1140  
 ccccttgggt ggtacatct acaattcca acgcatgac tttagccctt acacttgaac 1200  
 ctgtggggg ccaagtttg tgggtcttc ttccctgag tttagagag aggcacaaag 1260  
 tgtctaggc agcgaggaat ttgagagcca ttctcagtc aatttccct tcccatataa 1320  
 agctttagt ttgttaaaa aaaaaaaga aaaaaggcg gtcgc 1365

&lt;210&gt; 94

&lt;211&gt; 756

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 94

agcagaggg tgggaatgt aagagggcag cccagccct gtgttcggg gttgtctc 60  
 tcccgagag cccgtttctg ggaatgtctt tcttctacc ttcaaggcct gcccgcctg 120  
 cgtgtgagcc gcaatctccc cgggtgtcat ttcttcagag tcttcttc atgacctt 180  
 tctctccac gtcccccct gtgtttacc cacactgtc cgttgttctg gatccagttc 240  
 tcccggtgtc tatggatcac cagtttttg gtcttgacca tcaatccag aagttgtctc 300  
 ctccgtgag acaaggtctc gtctcagag ctgtgtgct ccttcaatg ctgcctctc 360  
 cttttgggg ctgtgtgat gcaatgtctg acacaaga ggaagcagc aggcctcgag 420  
 ccaaggtgt cctcagagc cctctgatat cagggagac ggaaccttg ggaactgca 480  
 cagttctgc ctgtctgtgc tctcagagaa ctgaaggat tatgtgtgt gaaagatt 540  
 atgttgat aaaaactgca cctcagagc gggcatgtgt tctatgct gtaatccag 600  
 caacttggaa gggcaggtgt ggaagatcac ttgaagccgt gatttggag ctcccgaa 660  
 gctatgatc caccctgtc ctccagctg ggtcaacaga gtggcaccct gtcttaaaa 720  
 acaaacacac aacacacaa aaaaaaaga aaaaaa 756

&lt;210&gt; 95

&lt;211&gt; 938

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (479)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 95

ggcacaggtg gaggttcag gtcaagggtc agggggcag gtgacgctg gaagaaggca 60  
 gatgacaagg gtcaagttca gatctgtgt ctgtatctc tgtgtgttg ctcttggcca 120  
 agaacttgc cttctgtgac ctatgggtct catatagaa aatggatagc cagcatlgc 180  
 ctatgtgtgt tgttttggc caactgagag ctcaaggagt agctgtcatg atgtttct 240  
 accttgaagg gagaataagg ggaagagag -ccaacacac ccaaggttg gtcccaagt 300  
 ccttcccggg gatgggacgc akctgtgtc ctccccag caaccttgg ctggcccat 360  
 tgggtgtgtt ggaattccc camcagttc ttgtgtat gaaagagaa ctgattggc 420  
 tagaagaggt ctccgaatgc cggcggggg tggggggcgg ggggggttc ctctccant 480  
 gcaagagagg ccacttacc ttcttcttg gggcccata cccctttt ctatctccc 540  
 ctctgaattg aggaagagc tgtggcccc gccacatgtt tggctcttg aaccattgg 600  
 tgaagatgta catcgggcg ataaagggc acctgtgctc tgaactccc tctgttggc 660  
 tgcgtcttg gacccccac ccatgtctg atcogaacc caactcagc tctacacaa 720  
 ggggcacac tatagagaga gagaanaac tctctttag gaaccactg gaagggggc 780  
 ctggcctgt tctatcttg taccatgt aactagaa actgtctta acttggag 840  
 ggtctcatg tctgattcc taatgtttt tatltgtct ttcaattaa taagctcat 900



51  
 tataagctta taactaaca gagaagaca aagatagaaa gcttaattc agtgaatag  
 tgcataata gaagcagagag tgggttcgaa aggaagagaa tcaaatccag atgaatgga  
 caaagagct tccgtagagc attcattag agccagagaa cctccacagg  
 atccagagct gctatagtc attccatgc tgcataaa gacaaccca agactgggt  
 wactataaa ggaagagat ttaagtact cacagtcar caaggttggg aggtccagg  
 cagcttaaca tcatgagaa agggagagaa aacgtctct cctccacatg aagcagagaa  
 agaaagagc ccaagcaaaa ggggggaaaa gtccctata aacacatcag atccatgag  
 aacagcatga agttaaccac ctccatgat aattaccc ccaacaggct cctccacta  
 cacttgagaa tlataggaac lacatitcaa gatagatgg gtgtgggaca cagtcaaac  
 ataccatag ccaagcagc aggtgtgtgt gtgtgtgtgt gtgtgtgtgt  
 gtgtgtgtgt gtgtatccag tatcttgagc tagaccatg ctcttgagaa tctcttgagc  
 atgtagagc cagatataca cattaagct gaagcaatt gtgaagctgg gaattatagc  
 atgtagagct atgttgagca caaatctat tlatgttcag gtaacagaca gggcatlttg  
 ggtcccttc tttagagat gctaatctt acttcatgt ttatcttga ttaatttgt  
 taccagctcg tgcagatc gatataagc tlatcatag c

<210> 100  
 <211> 881  
 <212> DNA  
 <213> Homo sapiens

<400> 100  
 ggcagagacc agctgttctc tacacagtag calcccaagt gccctgggt tggagctcc  
 tggcagagaa gaagagagat aaccaccca ttctgagaag tcaagcatlg tlatggcct  
 ggaagctgggt ggtgaagaca aaaccaatgt tgtgtgtc taltgagctc tggatctctg  
 accgagagca gcatlgccca tcaattcag gtcaaaagaa ggaagggct ggtccctag  
 gtccagagc ccttgccgyl cttctctct tgtgaagat accctcagag ttccatcagc  
 tgaatagcag caaccagat gccctatgt aaagctagt ttaagatcag ttccagat  
 ttctgggtgt ttltatct tgcagtagag ccaataaagc cctcatgaca gcttggagc  
 ctgcacaaat gatgtctcg agtgcctat tagagttaa tgcagatctc ggaagtagat  
 gtgtctgcaa gcaagagaca ggaagctat gggcagagc cctgatgat actccgctc  
 aagggggctc tggtagatg gtgcagagca ggcagagct acatccatg ggggtgtgt  
 ggtgtcgaaa ggggtcgaca gtgcgtctc ccggcagag ggttggggca ggtgatgca  
 catgcagat gaagagtaga ggggtctag tgggtgtat gggagttaga caacgacat  
 gttcagagag tggtttaaa ctttctct aattaaat gggtagtaaa ttctgacct  
 aacatagata ttgatctga tggatctag ttggggaaaa aattcagctc tgaagctcag  
 caaatccag ttccgtctc aaccttgg tcatctcgta g

<210> 101  
 <211> 947  
 <212> DNA  
 <213> Homo sapiens

<400> 101  
 ggcagagaca gatgttctc ggttagtag catcataaa tggcgagcag gggcactgca  
 gcccttgagc gcaattcctc ggcagtagtg gtacagctct ttltcttg taltgagtag  
 ggaatcagag ctgagcagat gcccaagag tgcctgcac gctgataga ggaatgtag  
 gttctatgc aaaaagctat gttggatata cttagcgggt tgcattgaaa gtatccagc  
 agagtttgc tagtagagaa tgtgcctcc gctagatcag tagatgca gcccagatcc  
 tggccttgg gtgaggtgc cgcctatga acgacatca gactgctca ttgtcagag  
 actcccttc gttccctact acttcatc aggccttga ggaatctac caagcagag  
 caagccaca aataatagc ttgtgtcca ccaatgcat agtggcgtc aataactgt  
 ggaagagaa ccaatccc tcccttgg ccttccagc gctctgtgt tccacgtct  
 tctgtgacct gaagaactc tgaatgttg tgaagatct ccagctgaca ttccagaca  
 tctgtgtaac tcaatgtct aacattaaa tatgtctgaa aggggtcagc tgggtggctg  
 gatgtgagca gaagtagag gtttccctt ggtatcttt acagggcaga gatgactct

52  
 tacaatggc accagatc ccttcgctc ctgataacca tctaacagaa aagtacacc  
 tgcataata aaaaaccag gccacatgt ttctatgta cccgtgctc tggctcagc  
 tgcattgaa caaatcaga caatagat ttctctct gaaactgct gtgagacaca  
 gagaacagc ggaatgag acaatctcg gatgtgaag atgtgc

<210> 102  
 <211> 1369  
 <212> DNA  
 <213> Homo sapiens

<400> 102  
 ccaacggcgc cggccacgc tccggctgc aagatggcg gagggtgct gccctgmng  
 ggtcccgag ccttggtgtc ggtgtgtctc ttccctcgc agtctgcac tctgtgggc  
 ggtgaagag ctgaatccc accatagtg atgaagtgca cgaagatgg ttgtgtatg  
 aggtccctcg cagactat agactcaga acaattctc cctgtaccia tgggaagcct  
 gcaacttgg actgtcagt gaacacatc gttaacctg ttgacaaaga ctcaaaccc  
 caaagaact tcatcataa catgacttgc agatlttgc gcaagcttc tgaacagat  
 taagagtga ccaatcac cagctgcag acgtgtcct gttctggca ggcctacct  
 gcaactgca cgttgcgga ccaagctcac tgccttgga accgacttt tcccaatag  
 ctatattgca attgactga aggtcataag tggctcagc ctctgctct aagcatcac  
 ctctgtgggt ttgagagca ccgttctac ctggcgcaat gggggagag cctcgcaag  
 ctctcagct tccgtgctc ggaatagag acgttagag acgtccgct catgtagtt  
 ggtcatgttg gaccacagca tggctcttg taactttag cgtgtgtgtgt agtataat  
 ttcatgttt ttaagtaca gcatcttgac ttgttgcg ttgataaag taagataaat  
 gaacgctga actatgcaa tctgaattt gttttatct gccitgaata tatlttttc  
 ttgtaaaaa ttaaacgta cttaagcag gagaatgat tatacagta ttgaatcc  
 alttaaaatc tatgacttt gttttgtat gcccaagctc aactacatga ctgtatcc  
 cagcccaat gtatctgccc ttgaagatc ttccagctg gactgagaa agtggagtg  
 ttattatgt tagcaatly ctgtactgc aggaagtgag agtgtcttg ttgttgca  
 atgagatga ttagctcac cttcagcat gttgaagtt tgcagtga taatagta  
 gtccgctgc tatataaa aatttgaat aaactcaga atgtttatgt ctgattatg  
 tttaatttt cttagtagta tataaaggt aagatctg aaaaattat aaatttgca  
 gtaaaaaa aaaaaaaa aaaaaaaa agggggggc

<210> 103  
 <211> 1231  
 <212> DNA  
 <213> Homo sapiens

<400> 103  
 ggaagagaa agcaattca aaaaacaat ttcaagcta ttlttaact aactatct  
 ttcttaatg tgcattcat atagttagt tatcttcc tcccttagc tcaagataa  
 gcaattcc tggtagcaa tggctgta ttltttgt tatlaaat gtttagcaa  
 agtgaatga gcaattact alttaatgt ttgagagac tggtagcga aatacaaat  
 ttgtataac ttatlaact aaaaatltc ataatatcc tcaataatga ttcaatgaa  
 gatgatitga gtaatttat accatctt atgtttaag agtctgata gtaacatga  
 aaaaaata gccatctc actctttac tgaatcaaa tagatgcat gtgatgta  
 acaataaaa gaacacatc acaatatat ntggtagag tggcagctca atgaaaaat  
 agcaactat tatctact tatitctg ttattatg aataagatg tacaanaatg  
 aaaaatttt ctaagagat ttltcttca acaccagca ttaagctega tgtgtctga  
 atgtgttaa ttgagacaa taatatgta taatatat aatagatg tggcttagag  
 gaattttt gatccataa ttaagacaa ttacagaca tatctgag  
 actacataa tggagcaag ttatcttgc acccttgaaa aatacagtg gacaaaaat  
 tgcacaaat catgaaaaa cttaatttt gccagttcat acatgagat ctcaattca  
 cgaatttaa atgtttaat aattatct ttgtgcttg aaaaatat ttgattcaat

54  
 aaagaaaga ggttaggcg agtggctcag gctgttaatt caagcacttt ggggggctga  
 ggcaggcga tcaattgaag tctggagttc gggaccggcc tggccaacat ggtgaagccc  
 cccatctct attaaata caaaatcat acttaccgg caggggagat accatgacg  
 cgaagtggt ttcccgagg caaggttag caattgcat cggatgtgc tgaagctgcg  
 ttccccc aaagtggaaa ctgagtcgt aatttgggt agtggaggga ctgtgtcac  
 actgtcccc ccgcacaaa aaaaataaa tacaataat gtcgggggt ggtggtcac  
 gctgtcatc ccagcacttt ggaagccga ggtgggtgga tcaactgagg tcaagagttt  
 gagaccagc tggccaacat ggtgaaatt gggaggcga ggcggcga tcccaaggtc  
 aggagatcga tacatctcgg ctaacacagt gaaaccccg cttactataa aaaaaaaa  
 aaaaactcgt a

&lt;210&gt; 106

&lt;211&gt; 1628

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 106

gagaaatat cctctccatg aggcatacac caagtaaatg actttgtaac ttactttcat  
 cctctcatc tacacaggc ataatgaag taaccaatgg aatcctctag ggggtattta  
 aactccaaa aattctgtaa cggggccctt gaggccctat gcttgggtcc atccccaac  
 tggggaggt acttccatt tcaataaatt tctgtttttg ttgttcatt cttctctgc  
 ttgtttgag cgtttgtcc aattattgt tcaagacgc aagaacctgc sacacctcc  
 accggtaaa cttctacaat tagcagttg tgcagtgct agccctgac actatattg  
 gcatgtgc ccaactaga atgagagcg catatttcc tgcattatca ccaaaaat  
 gttatctct ttatttatt attatttt ttggtcagg ccttgccctg tcaaccaggc  
 tggagtcag tgcagcagtc tgcagcactc gcaacctctg cctgtcaggc tgaagtgga  
 tgatacatt agtcaggag ttgagacca gcttgggcaa cctggcaaaa cccatctct  
 acagaaata attagctgga tgtgtgtatg catgctgta gtccagcta ytcaggagac  
 tgaatggga agatcacttg agccaggat tttagargctg cagttagcta tgatcatgc  
 accgaatcc cgtttggga acagaatgaa aytctgtaa aaaaaaaa gaagagaga  
 aagaaaaag aagtaaaaa ttgtaaaa cytccaagt ctatgtagg aatatgtaa  
 tgggtgcca ttccaagt gaagtctc aagtaggctt ggtctgcca gtcagagag  
 gacgaatat cytaggacct tggtaaaa gctggagcct gcttgtgg gtcgcttag  
 tgtctctat cgaacctaa ggtttagtc tagaagaa attactagc ctgcaaaa  
 gctcaatta tctattctt tatcagctt cctgactacc tagtctatag gcaaatat  
 taagaacc ttgagcagc tataattgca atgcattatg ggtgcaaca aatgacag  
 agacaacct caacttcgga ggcgaagcg ggtgagcac ttgtcaggag ttgagacg  
 gcaatccca cgtgtgtct cataactac agcctatgag gaaccaggag agggccctg  
 gcttgccaa ataatgct tgttgaact gtgcgggga tgcctgcca ccagacact  
 acactagag ataatgct tgttgaact gtgcgggga tgcctgcca ccagacact  
 gacttgcaa gacttatta aagctctac ttccgtatt ctcgtgtct ctgagctcat  
 tcttgggt ttgacggggt agttgttc tcaactgta gacttagat gtagaagact  
 ttgacatat caccagga gatgtgtgga tgaatttta tagtaaaa tacactagc  
 tcaatttt ttacaaggga aactgattt gcatctttt aattaaaa aaaaaaaa  
 actctag

&lt;210&gt; 107

&lt;211&gt; 1465

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 107

ggcagagcg agccaagttt gcacctgc actcagcct gggcgacaga gcaagactca  
 gctcgaaaa aaaaaagt ggaagcagaa gtaaaaaa tggtaagaa tgagactaa  
 ataatataa taattgagc gctgcatta gatgtggcag ggaagacaag caaaagga  
 ttacagaga gatcactgga attggcagc gcttgaagg gcagagctta gcatacaga

ttcaagtaaa tatcatcagg ggaattggat ggggaagagc aagaggggaa gaagagagag  
 aggaattta gctcagact attccagct gatccacc cagcatggct agactacagg  
 acaccaattc aatagatga atctctttt aagtaattgc tgaataaaat  
 aaaaagagg gagaaaaatc aagtactcta aatgataaa gcgtatgaat aagtgaaaa  
 tgttgcaaa attgagaagg aaggagaatc ggaagtggt tatttatggt gttcaatat  
 gtaaggttaa aaaaaaaaa aaaaaactcg a

&lt;210&gt; 104

&lt;211&gt; 1242

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (288)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 104

ttcgtatcca ctaggatggc tctaataat aacaaagtat tgtcaaggt gtgaaaaaat  
 tggagccctc ctgcttggt gggagtgtaa tatgtgcca gataaacct ccactctgaa  
 gctcatctgt atgcttctgt ttgtgtttt taaactttta ctatatcttt atgtctctat  
 aagaatatgt actatactt ggtgttttaa agtgtacata aatgctgca tctgaacaa  
 tctctctgc taactgac ttttaactta tactatat tcaagatntg tccattgtga  
 tccactgagc tccctagttc cctttaactg ctataagata ttctgttgcg tcaatatatg  
 acaattgtg cagcttgtg tgcagggtaa ttggatttt agttgttgc ctttaaaaa  
 atcaactgat cttttgaca gtctacttg tgcataatga ctgaggtaaa attgtgggc  
 ctactctkaa atattgtt ttacttact ttgctgtct gtaacagaat accatagat  
 ggtgtcttat aagaagaa gaattatttc tcatgtctt ggagaatcgg aattcaga  
 tcaattaca ggttcgtgt tctgggaar actttctta cacatctca ctggcagaa  
 cgaagggcc cgtgtgtatg ctgtgtgaam cctctttat aagggcctta gttcatctc  
 caagtaggag cctctatga ctaataact cttaacggc cccactcaa tactatgca  
 tgaagataa acatctgaat tttagagggg acactgcaa cctgcatat gctttatct  
 ttactatac taatgtctc aaagtgtatg caacagtat ttatactc aaccacaga  
 gtataagaat ttctcttct tagctggca cgttggctca cgcagtagt cccagctac  
 tgggagggcg agatggggcg atcacttag gccagaggt caagaccag ctggcaca  
 cagtgaacc ccatctgc taaataatga aaagttagc tagctatggt ggcgcacac  
 tgaatctta gctatttggg ggcgtgagc aagagaattg ctggacctg gaggctgag  
 ttagcagtag actgagatcg taccattgca ctccagctg ggtgacagag cgagactctg  
 tctcagaaa aaaaaaaaa aaaaaactcg ta

&lt;210&gt; 105

&lt;211&gt; 1151

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 105

gcagggacag cccacagcat gggaggtggt ggcagccat caccacagg tgaattctc  
 taagagcagt cctaggccag ggggtgagt tggaaagtc agggcgttt ccatcagtta  
 acgtttcaga ggggttccc gctgaagtg ctgaaatac ccagatgca tcttagcat  
 ttatgaact cactgtctg tctttagct tctgtctt ggtctgtca  
 gtggaagcat cctgtcagtc cactgtacag tgggttggag ccgacgacg ggtgggtgtg  
 ccgtttgatt ggtcagtaa tgaacaggc aaggtcact aagtatgt tgaagttg gatactgaa  
 tgttggatt atataacca gataaagtc tgcctggca cagtcagc agtgcctgt  
 ggtccagct gcttgaagt ggagagagc ttacgtcag gatttcagg ctataggag  
 cctgtgtccc acctgtcac cccagcctgg gtgacagagt gagccccat ctcaaaaa

gatgtaaac cacatctctg gaagtaagt agatgctt accctcttg cactgactg  
 ggcattatg gggtaaat gattactt tccgtatg cttagcaag agtttgcct  
 atagacaga ccgactctg gcttgtag tactgacta ctgttgta cagatcaaa  
 agacttga atgactagt taagtcttg atgacttg aagatcaaa gattatgagc  
 accctggag tgatccacag aagacagat tatltaga tgtataaac taagacac  
 atgatttga aatgtatga aaaaattga tagnaataa accattgat ctgctgctg  
 agtccaaga gaattat ctctactc aacttga ctgaagtggg tgcagaat  
 ccaatggat agtaatgca ttgaanaa aacttga ctgaagtggg tgcagaat  
 ttgttctat cttaattga tgacttca ttaagaay latltatga agtttctta  
 ttctggcat ttlttaata agaaaagt taattcagt cacatttga aattcaag  
 accaatata atggcaag tatatgaag cataatcat agaaagat atctgcaaa  
 tgcattca taactatt tttaataa aattagctg tgrtaagt tgaatgag  
 aagaataag aagttacga gttactac agcttgat atgaacat agatgtaga  
 ctcttctca tagttagg aacttctca aatgcttca atlgaccca ttatttct  
 accatttag aatgtagg aacttctca atgcttca atlgaccca ttatttct  
 tccaatgag aaaaagtga aacttctg aggtataga gagaaga gacatttca  
 gaatttga aacttgaag tactaagat tgacttga ctgaatgtgt tagataag  
 atagattga gttatgaag agtttctt ttctactg tgtgactg tcaataaac  
 aagattat agaaataaa catgagatg cactgagat tatltcaag ttltgaat  
 gacttga agtacttca aaaaataat tctagcgag gttgagct atgcttga  
 ttaaaaaaa aaaaaaac tctga

300  
360  
420  
480  
540  
600  
660  
720  
780  
840  
900  
960  
1020  
1080  
1140  
1200  
1260  
1320  
1380  
1440  
1465

<210> 109  
 <211> 1006  
 <212> DNA  
 <213> Homo sapiens  
 <400> 109  
 ccagcttc ggcataatg accatttg gttttaat tatcactga aaagattag  
 gtttcttc aggtatttc agatgagc cttaataat ggggacata cgaattcaa  
 ctatagat aggtcttat aacttccc tttagacat ttcttllga accgtgtc  
 ttctgtcga aggtcttct ctatctta ttttctcaa atcttllga aaaaatag  
 caaatatt taagaatt tatatttc caaatatg attttagat ttaggatc  
 tgatcttgg gatttcaac attcgagat atgtgttca gttgtatt tggggggat  
 atatccaga tcccataag tgaatata ttgtgcata aaaaagat aaatattg  
 tcaatcaga acatttga ccttaaaa atatttctca tgaagaag ccaactaa  
 aagctcag tacttggg tttaattga aatgttga attatcaca accaaaaca  
 ataactct acagaaaaa ataaagctg ttccatata atgagata  
 aagagatg acaataat gcaattat atgttgat acattctga tcaagtga  
 atagctata aagaaatla ttgagacat ttgttaaat ttgaatag aggtattg  
 gctgtcga gttgttca tctgtatc cagaactg ggaagcag gttgtgat  
 tacttggg cagagttca agacagctt ggcacatg gcaaaccc tctactaa  
 aatataaaa attagatgg cgtgtgtg tgatctga atctagcta ctggagga  
 tgagcttga accggagg cagagttg agttagctg gattcagcta ctgattca  
 gctgggtga cagagcaga ctccatctca aaaaaaaa aaaaaa

60  
120  
180  
240  
300  
360  
420  
480  
540  
600  
660  
720  
780  
840  
900  
960  
1006

<210> 108  
 <211> 1265  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (766)  
 <223> n equals a,t,g, or c

<400> 108  
 ggggcagatg gaattctc ggaatttga atgaagaag agaacagat agtctctcc  
 aagttgat agaatgaac ccgtccagat gtgagccac caatgctt gcaatccaa  
 atggcagat aggtatga acgttctac cacttctg cagataaaa tctgcaaat  
 cgcctgaag tcttgatg gctgactg tgtgtgtg tttctcag ccaaaaaa  
 cagttctc ccttgatca tcaagctg cctgcttg ttcaagcag caacggag  
 gccccttg cagttatg agcttcaag tttaagta cctggagag aagtgtgtg  
 acttcttg cagcgttg tgaagaatg tcttccaa gttgttgg tccatgta  
 cccagccc cactgctg aggtctgac cagttatc gcaacagtg gcttcaat  
 tgcatttg tcttcaag ggcctgggc cctcttga ggaattgac ctgagtgag  
 gtgactga taaattgct gatgcttct tgatttact cagtltcaa cacccttga  
 aattcaaga ggtctcag aggtcttc tccattgat gaagttag ccagactca  
 ccgttctc ctggaacag cttaactg ccgtcagt cacactcc caccacagc  
 tcaactct gcaattgag ggggcagc ggcagcaga cccctnac gacacagtg  
 ctcaactg tcaagagat gcaatgac tgttccca ccaagagc cactgctc  
 tccctcag ccagccaga gctggctga cccacccg gcaatagg gtggcaggg  
 ctcaagaga gttgattag ttgagcag gattataa ttgactgac acacagtc  
 taagaatg attgaaga agtaactg tatattat atttcaac ttgttctc  
 aagtactt gctgtgtg tctaaggt taacctta gcttccat tctatggc  
 cagttctc acagccaca cacaacaa cagaagat cagttctc ccatcgat  
 acactcct gtttcaat aatgagatg aactaat tttaactaa cctgactt  
 gggaaacaaa cgaataaa gacattct gattgaag taaaaaaa aaaaaaac  
 tctga

60  
120  
180  
240  
300  
360  
420  
480  
540  
600  
660  
720  
780  
840  
900  
960  
1020  
1080  
1140  
1200  
1260  
1265

<400> 110  
 aacctcact aaggaaga aagcttag ctccacgg gtcggcgct ctgctgac  
 ggcataaac taaattga ttattcct agtataaac atcagctga ttatgta  
 tatacttg cctctatc tatatagt tgcattggt ttcttaaaa taagtgtt  
 acctatg tgaagagc aaaaagca taagtata aggtatg ctatctag  
 gttctaac aagaagag atattatc aacttga attacagc aggttgtg  
 ccagaccca agatcatg ggtttttt ttaaaac tatagaag aggtgact  
 ctctcttg tctaagat ctaagaag gtagcact gttlaatt ttgttacc  
 ctgcttct cctgttca tcttctgt atagaag aaaaactc ttacttct  
 ttccaagc cctctgct gattacca gactgagc accagatc aggtattg  
 tgtgagat attttcac tttaactc aagcaatg taagaatc ttgatgta  
 tttctatt atctatga ctgaagat tttaagt ttatttat attagcaa  
 ctctgcaa aagttccct aagcaact atttact cttaagcc tcttgcga  
 ttaacaa atgagatt aagttat ttcatagaa ctgatttt gttcaagat  
 tttaactga aagcaaat tatgtgct ctgaatc atcttcaga tcttllca  
 gaatgaat atgactgct actgtatg tccaagaa tatatga cacaatga  
 tgcctagat tggttttg agaaagat ctctctct aaaaactt atgtgctc  
 ttcaatga aactcact gtttaact gtagagc taagtatga aaggtatc  
 gttctatc tgtatag attgaaga cataatga atctacttg aacttga  
 aatgatg ttgagctat tctgttct ccaatcag tctgtgtg gcaatgtg  
 gaaatgac atgtgtgt gtaatacac atgttaaga acagaaat cttaaaaa  
 taacagaa tggagctg aaaaaaaa aaaaaaaa aaaaaaaa aaaaaa

60  
120  
180  
240  
300  
360  
420  
480  
540  
600  
660  
720  
780  
840  
900  
960  
1020  
1080  
1140  
1200  
1260  
1265

<210> 111  
 <211> 1453  
 <212> DNA  
 <213> Homo sapiens

57

<220>  
 <221> SITE  
 <222> (946)  
 <223> n equals a,t,g, or c

<400> 111  
 gggtacattt ctctgtctg tacagagagg agacacctt agaaatggag atttctacta 60  
 cagatgaaaa ttcttttat aaagggttaa .cttctgtga ttatctgtg ttgtctattt 120  
 ctgagaaata taagctgaaa atattctctt ttggctlaag gattatttgg ttggcagtg 180  
 ttggaacctt cactgttggc attcttctt ttgtagcaga aactatggaa catgtgtga 240  
 ataatgacta aattattgtc actgcacat .ttgttagtaa ctttttttaa tataatggc 300  
 ataaatgta aaagcagca tctagacat tcaaatgta attktgatac tcttttaaa 360  
 aataagatgc taatatlaata gataaggtgg gtttctcag tatatttca tcttaacca 420  
 tccactaaag tagggctaaa gaggaattta gtttaggaag acttaggttt tgtattctgc 480  
 ctgtgtcag tatcagtggt actttggcca agttacctga ctctgaact gcatttggct 540  
 ttctctaaa taagtggggg taactacctat attagaggat tatgataaaa agatgtgaac 600  
 atattataaa attattttat aaactagaag .acatttcaa gaagttaaagc tggcaactgt 660  
 agtttcaag acttgggtgt attagatgaa cagcttttca gttattgtct ctatgttgt 720  
 cctctggcc ttctctggat tatcagtttc tgcctgtcta cctagtcatt cccactcagt 780  
 taaaacattt atagtgttat ttcttcaag ttcagaaaa accctcty ty gaytcccccc 840  
 atcccatccc agcacttttg gagggcaagg cgggcagatc atgaggtcag gagatcgagm 900  
 ccatyctggc taacatgggt accccatctt ctactaaaa tacaanaaaa attagccggg 960  
 ctgtgtgtg gggcctgtga atcccgatga cggggagc tngagcagga gaaagggcat 1020  
 aaccagagg gcagagcttg cagtgagcca agattggcc atgcaactc agcctggggc 1080  
 acagagtgg acccatctt aaaaaaanga aaaaaaaa caacttattt taaattattt 1140  
 tcttagaat tatgatgtca gcagaggtgag ctagggtgga ttatgggtga cttttgttat 1200  
 tttaagaata ctctcgtat ttcttagag ttgtctgaa gaacatggta tggggagaac 1260  
 atataattt gtcatacat ttcttagatg ttcttagatc ctgtacaaga atatttggtta 1320  
 acagagaaa acaaaagttt aagacatgta taccatcat atacatggga gatactggg 1380  
 ggaagtgtt aatcttctca gagggtggctt aaataaccatc atgtctctga aaaaaaaa 1440  
 aaagggcgc cgc 1453

<210> 112

<211> 1552

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1035)

<223> n equals a,t,g, or c

<400> 112  
 ttgtctagg cccactgtgc caaattagat aatacaagaa gttcatttac actgtagacc 60  
 agtgacgtca atgactgttt gctgtgtgat accgtttcaa aaatccaaaa tgcagacttt 120  
 tctctgtgcc atgcagatg cagctgtgtg tgatagttt tagatlaata ttctttctc 180  
 aaagtacgac gcttgttaag gaaaagataa gcaacacatc tggggaaaaa ggcaggtggc 240  
 cagaactcga tgtggtagct atttgcctct ctggacagc aggaattagc ttcccagtc 300  
 attttctgta tgtgagttgt atttgggtat gtacaaatat catctgttcc ttgggtttc 360  
 caggccagta gctctctatt ttgggttcaa acatgggttc tcaggccggg cgcgtgtgct 420  
 caccggtgta atccccgca tttggggagg caagcggggc ggatcacgag gtccggagat 480  
 ggagaccatc ctggctcaaca tgggtgaacc ccaactctac taaaataca aaaaattag 540  
 caggcatggt ggcgggtgcs tgtgtctccc gctactcagg aggtcagggc agggagaatgg 600  
 tgtggaccgc ggaaggttga ggttgcagta agccagatatt gcaccactgc mctcagcct 660  
 gggaacagca gcgagactcc atttcaaaaa acaacaac aaacaacaa aaacatgggt 720  
 tctcaaaagg catgcccact gtctcccatg gagcttgaca gccactgcca ttactctca 780

58

ctgttagtt tctgggaag gttcttctac ttgattggaa aatttccaaa taactcttcc 840  
 cagaagatc tatgcacaa gtaagtggc ctgtctgtgg agtaaccttt ttgtaaacaa 900  
 acagaacct aaagcttgat gtttgggg gctcgtgtc actataggt tcattaggt 960  
 gtatttaga agagatcca tgaacctt gtttctgt tacataataa tcaataata 1020  
 tgatttaaa tgnacatt gatttttr aattccraaa tacaagcga tatgtatwat 1080  
 taagtcaaat ggtatgtca gtgagcaga tgggcttgg gcaaaacaa tcttcttct 1140  
 ccaagagga tacaacttc agggagatc ttcatcttg ctttlaaggt catctaact 1200  
 aattcacata atttcaagaa aactaattca catcatcat tcatgtgtaa aatcaaaagg 1260  
 aagactgttt ttctgtctc tegtgtcca actggccatt taactacta gtttgattaa 1320  
 gggattggc tttttctgt gatatggca caaaagtct taagatctt taagggcaat 1380  
 ggaataatc gccacatgg gaaaattga tattgtcacc atgaggtgc tcttttctt 1440  
 ggtgaagagt gaactaatc tgatttctt ctcatcaga tatgctctt taacaacaa 1500  
 aaaaaaaa aagggaattcg atatcaagt tategatacc gtgagactcg ta 1552

<210> 113

<211> 1489

<212> DNA

<213> Homo sapiens

<400> 113

gaattcgga cgaagtgcga gctctctgtg taattagtc cagctgtacc ccttctatc 60  
 cctctctcc accagaccat cctgaccca ggaactttcc gcagactgc cgcactctg 120  
 gagtgaaga acatggatgc agtcagcca gtcccattg agtctgtct tcccaagca 180  
 atcttgata tctgtgttat tgcctcatc atcttgcca ccaattgcat catgactctg 240  
 ttgttgtgt gccagccac tgcagtaac atctatgca tgcgactca tccgactctt 300  
 agtgggctg tttagagcc tcccaagagg gccgggtgag ggaatgaggac aggcactcta 360  
 tcccagctt ctctctgtct tcgaaaaagg agcggggagg actttggggc atgagactga 420  
 gttctgttt tgattctgcc acgagccagc tgttgaatt tggtaaggg acctactct 480  
 ctgagtcca gttctctat ctttcaaat gggatgggtga tccctgacct ttctactca 540  
 tagggatgt agaacacct gacttagtg atgtgaagc tgtttrgat cagttaaagt 600  
 accacagata taagggtgtt atgtgaatc ctgagaagct ttcaagaacc agagaactg 660  
 attgtgatg atggcttaa agtgtgtgag ggagatactg gggggagagc agacttgcg 720  
 agtccccct aggtcaaac aagcaagag caccctgtcc ccattccaa gggccagcag 780  
 cactttggc caagtattt tcttaaggt gccattctt catgtttct cagtgttag 840  
 ggtatgggt agactttcc agaacttct ccattccaga atcttggcc ctgtgtatc 900  
 tgaaggaagg ctgtgcatc ttgggcaact gccaggggag tgggggtgat gggcttttt 960  
 ctgcactgga gtctacatc ttttagcttt gacactcaag caatgttga aatgcaggg 1020  
 tgactgatt ccttggcag ctttcgggt ctctggccc catccccctg ttgtgtccc 1080  
 tctgccagc tctgtgta attagctca cgtgtacccc ctctacccc tcccaagc 1140  
 tctgcagca gctatgga attatattt aagagggttt cccagactt ttgggaacta 1200  
 ctaaaacat gatgttatt tttagtgtga tgattatat ttatgtagag atattctgg 1260  
 accactcaag ctctcagta ccaaatcag gacactctt ggaattatta aattatgaa 1320  
 gaagtagca cagatctcg gataatctg ttgaaaaat ctgcttttac ttgtgtga 1380  
 tctcatgat gtacacaa accagttccat aagtgctag aatgtgaaaa aaaaaaaa 1440  
 aaaactgca gggggggacc cgtaacctta atcgactta atgagtga 1489

<210> 114

<211> 607

<212> DNA

<213> Homo sapiens

<400> 114

ggcacagatt tcaacttgag atttggagg gacagacatc caaacctgat cattaaattt 60  
 aatagtttta tgcagttttt ttggctctag atctgtttag actctcgag tcaagtctct 120  
 gtaactagcc ttgtgtcctt tttagagatt cacagtttgg tgcacacct ttgattgat 180  
 tatttgggaa atgggatat ctggcagcct gtgtccctgc tttaacttat ctttttgt 240

gctctgccca gctctctcat tagcatccct gccaaagcca gtgagagagg atggagatgc 300  
 ggtgcacatc agctgacagt tgcacagagt tgataatagc taacagaccaca tctctccccc 360  
 ggtctctccc ctatgtcacc aattagccca gctctatctg caactggagc tcaatgtgcc 420  
 taacaatatt tcaattccca tagcagagaa tgcacatcat ctatagctgag actgaataaa 480  
 caaacaatcc agaatgttgg accttccatg ctctgcacac agaggtccac aatgtcttaag 540  
 ggcgtctcct cccagcacc aggttatggt ttctaagctc cagaataata tcaataataac 600  
 cctgcgcc 607

&lt;210&gt; 115

&lt;211&gt; 1498

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (791)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (895)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (915)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (916)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1017)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 115

gcattcccat tctctgtcct ggaacctctt ctgtcacccc atcgacnagt aaagaataca 60  
 agaatcccaa actgaltcga agccagctct ttaataatca agctttcat gcaaatatg 120  
 gcaacttaga gaaatgtgt agtaaaagt ctacaacag atatacaact tctgtccag 180  
 ggttagagaa gactctctgt ctctccatg ctgatgatc atccggact cgtatccca 240  
 gtacgttcc actctctctt tctctata ctcccttacc gacttactcc cgtggagag 300  
 gtaactcagt tgaacccaag agcagtgaaa gtaagatcac acaaccaag aagcttact 360  
 taataatcag aaatcccat ccttaaatca actgcttcat gaagagagca aaaaagagc 420  
 agcagagagt aatgtatgt gtacacaaa gctaaagcag tggctggggc ttgttttta 480  
 aatttgggt ttttttttg ttgtgtttaa tgaagagaaa gagaagacata atgcacgtg 540  
 atgttaact ttcatattt caaatatgat tccctagag gtataatata tatctttga 600  
 gtaataatgt ggttaagaaa ttccaatgt atagtgaagt gtaatgaaa acactcttag 660  
 gaatgtcct taacacatgc tgcaaaagat acaagtctgc atttatltgt gcaggaacc 720  
 accatttaac ttgtctagat tttaagact taanaatcgt atgaagctt acatccgtc 780  
 aatgttccca ncttgtatag caacttgagg gggacttggg aggttgagaa gatactgat 840  
 ttcttcacga gtctccagc ccacttgaaa agtcacatg aagtagagca aatancgctc 900  
 tgcatttttg ggcgmcctc cgaatttggg tgaacatag ttgtaacggg acattcccaa 960  
 atttaaatct ggcagtgaaa atccacaaa gatcttctgt aacttlyagc tataatnct 1020  
 taataatat mgatgtatga ttcttttat ttccagagaa ttatattat aatatttgg 1080

tttaacttt agatgttact tgtctttat taaatgatga atccatgtc aatcagctgt 1140  
 tatcccaact atcatgtcta agcatatga acagacttta ttgttactaa tgcataatt 1200  
 tccatcaaaa ttgtctctg gaatatcac agtctttat tttaactgt cagtcttga 1260  
 gataacccgt gtagatcat tgcagcttc tcatlttcaa atgcacata gcatatcat 1320  
 aatttgatat taagaatat ttgttttta aaatatatg atgatatac aagatgatc 1380  
 aatttgtaa tgcataatga tgtgtgtta ctltttataa tfgtaataaa tgaataatga 1440  
 atttactcaa aataaacaat aggttaatga gaaaataaaa aaaaaaaa aactcgaa 1498

&lt;210&gt; 116

&lt;211&gt; 1797

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 116

ggaacacaaa aaaaacacgt ggaanaagaa atgaaatct agcagaagt ggaactttt 60  
 atactatata aatagatag tcttatgtt tctctttag catttatgt ttcaattaaa 120  
 aatgtttta aatcaagggt tctcttctt tatgttcaag taagaacgt ttgtcatgat 180  
 ctggaatgt ttaaacat gtttgttagc atctgttag cagcaaacat tatagtata 240  
 aaatcagat gtgttataa tgaatcttac cagtgcaca tagtaatga aaggaacata 300  
 aaagccagc aggtctgtac caagtccca gcagtatagc tatgtactgc agagctgat 360  
 gaagtgcct ttgtgcacac tttaatttc atggagatgc atctttagct ttaaaattc 420  
 tagatgaaa ttgacagcc aggttatcat attgagact tttaagtgt ctttccaaag 480  
 agatttcat aacgtttag atgaatat ctgtccaat tgttcaagt aatatatgc 540  
 tgaatatct aacaactgaa gtaatgcca calgtgttat ttlttcaat tgtgtttga 600  
 attttttat tgtgttat ttaaaatit acataltgca ctggagaac tccactctg 660  
 tgcacataga ttatatat aattttaga aaatatltc ttatatatt tccattccat 720  
 acaagtgctc ttgttgtat ggaanaact tgttttgtat ttgacagaa aaggaacct 780  
 caagttctt tttaagtal agttgacaa tgtataatg ttacactac ttccagagt 840  
 ctlttttagt cttaagaagt cagttcaaaa atgaaatga atgagact tgaataatct 900  
 aattcgtta agttagtag tatlatgat agcatctgt tttaacctc tccattctta 960  
 tcccttagtg atcagttgat cactataaga aagcttaag atgagact tgaataatct 1020  
 gctcttata aatgataga ttlttgaag gatattgaa tcatgtcgt gtgatctat 1080  
 ctgtgattgt aaaaatcat ttatatct tgggtcttc ccccccacca atgcacaaat 1140  
 aatttgaac agcttgaat gacttaact gtaatccaaa tggagacatc tgaataat 1200  
 tcaatgact gttatgtaaa taacttaat tgcataagt ttagcttga atttatgtt 1260  
 agaaaacata ttgatctcc atggtatga tataactat gtaactctc aatgtgact 1320  
 ctctcaact taatatgta tatattaat aacttatag aatataagat actatgtt 1380  
 agctgttta aaagtacca gatgtagag tcaataat atgcattaa agaatgtcat 1440  
 agattccaca tgaatgaaa tgtgtatat gtagacatg ctgttaaca gttaatgta 1500  
 tgtatgttt ctgttttga aatgttagt aatgtacca ctgttaggt cataaggaag 1560  
 ctacttttt tttaagtg agcttaata aaatatttc agaatcaag agacttaat 1620  
 gtaataatt tttaatttc ttatctctta ctltttagt ttcaagtat aaaaatcag 1680  
 gaatttttt attaactgt acttaatat taaataat ttatatttg cttaaaaaa 1740  
 aaaaaaaa aaaaaaaa aaaaaaaa aactagttc agatgcgg cgcgcg 1797

&lt;210&gt; 117

&lt;211&gt; 952

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 117

ggcagagcc tggcacatag aaggtgcca ttaattgat gaacgatag gggatgata 60  
 gtacgtacta gaaaagat gggattatc tttaagag ccaaatgaa attgggaaa 120  
 tagcatttt cgaagatt aaaaagacc atttttaaa tgcataat aatttatgg 180  
 ttatatatt ttaagcatt atcatgggt ctattatag gaattgaaa agacttcat 240  
 ccacattatt taactcag aactctag ttgttgaga tcaatcgagt ttacagag 300

gaaagccgc cacctaagag aaggttgcag aagaaacccc cagccaagtc cccaggggag 720  
gcccactctg tgaagcagag aggttccaaa cctgcacctt aagtctcagc tggccagcgg 780  
gggaaagctg ggcctctgac taagaagca cctctaagg ccaaaagccc tggcaagag 840  
accagacctt cctcacagct catcaagaaa cctagtgttg gctctcaaa gaagcctgca 900  
accagctgaa gaaagaaagt aaatgtccg ggaaggggca aatccacctt gaaagagctt 960  
ttcagagatg aaaaataaat ttataggaa aaaggggtat catgatgaaa ttcaaaatctt 1020  
tatattctaa gacttttga tatcaagca gtggcttctt ttgttagata ttaaaaaaaa 1080  
aaaaaaagg gggggcgc 1098

<210> 120

<211> 805

<212> DNA

<213> Homo sapiens

<400> 120

ggcagaggt cctaatgtt cttgtacctt gccctaggt gaccagggca ggggaatcat 60  
ggcagaggt gtaaggctt gatgaagag gtgtgtggg tgtgggtctt agccacttg 120  
gtttgtgtg agaggtggt gacagaggt tgttctgt atgtagggt tatccagccc 180  
tgaagggca gtcctccag tgttgcaca gccgaagat gtctgcatc aaatcacaga 240  
ataaagat aggttacta caagtacta ggaagactga taatctgtca tcatcatctt 300  
catgacctt aagcagagct aactgatgt taatatgc ttctatgta acagtcttgg 360  
actttattaa tgggtgggtg aagttaact aatgtatga tgcaaaactaa aaagtggcat 420  
cttttcat aatgaccaa ccatattca agagtatgt ctagttaggg acttcagact 480  
tttgaagaa atgaagaaat aatgcagat acatgggctc gcacttggaa tcccagctac 540  
ttgggggacc ggggtggag gacgcttga gcccgaggt tcagagccag cctgggcaac 600  
atagcgaaac cctgcctcag tttaaaaaa gaaaaaaga agtagtgaag aaattggaaa 660  
ggattctgag agaaataatg caaggtggaa agagccttag aagaagaagt gacagatgt 720  
ggagattgt cgtcagaaga gatactagg aatatcagg gcagccctca agtactagct 780  
ccacttaaaa aaaaaaaaaa aaaa 805

<210> 121

<211> 1598

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1067)

<223> n equals a.t.g, or c

<220>

<221> SITE

<222> (1069)

<223> n equals a.t.g, or c

<220>

<221> SITE

<222> (1577)

<223> n equals a.t.g, or c

<400> 121

aggaagaac aaaggttatt tcttgagaa aagacaattt attcaacac aacragggac 60  
tatcatatg ggcacactc tgggtctctt ctatggagaa aacctcaagt aaagtcttat 120  
tctgctttr gaaatgctt caaaagaga cctgtcccc acacagttca agactacaga 180  
gaaggcttgg tagaattgtg tcaactatgt acaccctgta cttacacatt tctcttttg 240  
gaaaatgag atacttgaag taacargaaa attaagacat actggcctgg tgcagcaga 300

aaaaaacagg gcagagagaa cggtaatttc ctcaagttct cactctgttc acttaataga 360  
tgaatattc caaccagat ctgatgtga agtcagatata agcttcttgg agaaaggagt 420  
agagttaagg tgggggatgg ggcctgaaga cttgatagga ttaggggttgg gagtgtaaac 480  
tcgggatccc acagtcaggc ggaaggaaac cacaaggca ggaatgcaca cagcatgctc 540  
agaggagatg gaaactgaaa atagagagaa tttagcaagta gtgccatttg gatggagtta 600  
agagccatc ctgaagggtt atcacttggg aacctatgta agagtcttgg cctgtgtctg 660  
tggctcagc ctgtaatccc agcacttgg gaggccaagg cagagagatc acctgaggtc 720  
agaggttga gaccagcttg gccaaatga tgaaccacca tctgtactaa aactacgaaa 780  
attatctggg tgtggcgga ggcacctgta atccaccata ctgggaggtg acgcaagggg 840  
aatgtctga accggggagg cagaggtggc agtgagccac gatgggtgcca ctgcactta 900  
gctggggcga cagagcgaga tccgtctcaa aaaaaaaaaa aaaaaactcg ag 952

<210> 118

<211> 1185

<212> DNA

<213> Homo sapiens

<400> 118

ggcagagct tatgtctatg ttttgagata gaatccttct attttatgc agggatgggc 60  
aaacacaaag caagggggcca aatccagctt gctgctgtt tttgtaaaa aagttttatt 120  
ggaacacagc catggccatt cacttccata tcatcaatg gctgcttttg tgtacaatt 180  
gccacacatg ccagtggggc ctgtggcaca caactgcaga agtgagtggt ttgtgcagaa 240  
atactttagc cttcaagcc taaagcaact actatctgac cctttcaga aaaaatttgc 300  
tgaccttctg tttagagata caaactaaca tacttacaga taagtatct gaatatgaag 360  
caaatattca acatactct gtttgatggg gaacctgtt acataaac aaatccagag 420  
ctaactatg ccaggtgagg gctgtgcaga cgatccagc actattctt ttgtcatatg 480  
ttttccataa taanaagctt tttagaaaa tcaatgattt aggggtttta atactctgta 540  
gtcaatttgg aaaaagttt ttaagttctt caaagttag acatagaat acctatgac 600  
ccagagcttc ctttctaga tatacccca agagaattaa aacacacat tcacacaaaa 660  
acctgcacac aaatgtttac agggacattg ccttaatag aaaaacagcg aaacaaccca 720  
aatgccatc aggtgacggg tggacaaca cagtcggctc tgcctatca tggaaatgtga 780  
ctcagccaca ggcakgaatg aagcctgac acacgcagca acacggatga accgtgaggt 840  
cacggagtgg agtgaagat accgtctgac agtcacaca cgtatgatg ccattgacat 900  
gaagtgttca gagcaagtaa atccttacag atggaaggca gagcgttgac tggccaggagc 960  
taggaagtgg gggccagggg gtagctgata atgggtatgg gatctattt cggggctggt 1020  
ggaaacgttc cggagccaga gtagttagat agctgacaaa ctctatgat atgctatgaa 1080  
tcaccaccga atggatatt tttaagagc gaatttatgg tatgtaaatt gtgtctcaat 1140  
aaagtgtcta tcttaaaatt caaaaaaaa aaaaaaact cgtag 1185

<210> 119

<211> 1098

<212> DNA

<213> Homo sapiens

<400> 119

tcgacccagc cgtccgcaga actctagatc tgggaataac cctgtatcta tttcttaca 60  
tttttttc attaatgat ttatcactat tttttttt tttttttt caggcctcag 120  
cgtgtgaaga acgctctgca gagagcagca gagaggggccc agttagaaca gataactgac 180  
aaagggtctt cggggacatt cagggaactc gacccacctt ggtcagagg agtctgtct 240  
tgacctgctt tgggagagtg ttgtcttgat gctttctct tctctcttg aaaaacagctg 300  
agaaatacag gggggaaccc cctgcttggg ggaagcctga tggaaatgc aatcttgtct 360  
gcatctgctc ccatgaatga gccgaagacc tgccttacc ctgctctgaa gagtatgct 420  
ctagagaatc accaggaac caatttcaac tatcaatga atttctgaa aaaaacctg 480  
cagaagaatgc aaagaatgg gtgagtggaa cagatctctg ggaaggggtt cagtgccac 540  
ttccagctct gtttcccta ttatccagc ccaggagttc tgtttccgaa gaaagagcca 600  
gatgattcta gagatgagga tgaagatgaa gatgagtcat cagaagaaga ctctggagat 660

tggccttctc atagacaaac taggttagtg tgaagagat aggtlaaat aaactatgc 360  
 gtttatttla tctcccaac ctgatttgga gctagactt tttaggtct caattatgc 420  
 cccgtttt tccattatla taattatga tagggcaga tttaggtct aacttatgc 480  
 ttctcaggt gctctgcaga gaagtgcga taattatc gtctgtaca tgaacaag 540  
 cccattgact cctcgcagtc ttgtttgt aatttctta atattttat caagggcag 600  
 tgggaaggtc tgggttttla gcccagcty tttaagact tctgtatcc tgccttcag 660  
 gaattagtg gaaagctatg aattttaca ctatagtaatt ttgtatccc acataagtt 720  
 gagtgtacg aaaaactccc tttaagggg tctgtgtac acaaatag ccaagactc 780  
 acagaaacag cactgtctag aaatgtatc ccaatgata gatcttgaaa caagctcca 840  
 taacacactc tctctctgt agactagct cactgtata tttaactgt tctgtgact 900  
 tgaanaacc taatttcat caggtatca tgtctctgt actgtatcac ctcttgatc 960  
 ctcttcaac agttttccc caagggggg aatttact aaccttagt attgaaaca 1020  
 ctaataatt gaattgtgc cccattgct tttaactga ctgtatnct gttatcaaa 1080  
 aatggctct aaccacagct actttgact ccaagattt ccaatccct caatccacc 1140  
 taattttca tctgtcttag ttactgtct ttcttcatg tcttattct ctgtcttg 1200  
 gaacttaaa gattttaca gacctaat ttgttctct ccttgagcc atagtacc 1260  
 tgcgaagaag agtlaaaaaa ggtttactc cctgttctgc tccacaaaca cctgtgag 1320  
 tccatcatc agctagagca tgaatcttca caggtttgac agcactggaa ctctcaga 1380  
 gtaaggtct tctgtcagag gtctctctg gctatctt ccaatgact aattatgac 1440  
 taagctaac agagcccaag tacaactat ttgcagaatg gctgttacc tagattact 1500  
 atggcacata tgaagatata gtgttactc ctatagata ggaactgacc ccaactata 1560  
 actttgataa taagaanaa aaaaaaaaaa actcttag 1598

&lt;210&gt; 122

&lt;211&gt; 1020

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3)

&lt;223&gt; n equals a, t, g, or c

&lt;400&gt; 122

cgncaagagg tgaagtcaa cccaatgcaa ctctcctca gtccttcgt gaagagcct 60  
 gtaaaaaat aggtatatt tcccttctc agtcggccc ctccgtttt gctctccgt 120  
 ttcttctt gtctcacag atgtttact atgttttct ttgttttg ctgttgaag 180  
 acactaagt gatccttct ccaattctt ttcatctat aaatgtccg atgtttaga 240  
 aaaggaagt cctcttgca cttagcttg taactgttg ttaagtgtt aacaaaagg 300  
 aaagctctt cgaagtgtg taccattca gatacaaga ccgtttatc tcccagcty 360  
 acaatttg cgaagtgaat gattatctt ccttgctt gtaattatc taattaat 420  
 cctgtttgt ttctcttc agtaaccag ggttatat ttcaatag acatgtact 480  
 ttgtttcag gctagttag agtcgaaa atgaagctg taagtattc ggcagtatc 540  
 taattgtat tcaattact gatgttagg caagaagt ggaactact aagacaaag 600  
 ggccttcag cgaagcagc aaaggggct tacaagacc agccatagc cagatagta 660  
 ttgtactgc tgaatgttg aaatagcaa tctccagag tccgtatcc tgttcaagt 720  
 aatttttct ttgaacaat cccctttta ataatcaaa atgtttaaa tctgaatga 780  
 tgaacttaa aactacttg ttgaacatc aactgtgga gaaaaaaaa aaaaaagac 840  
 atctaaat ttgttatcc cagtctgat atgaanaat aggtcatcac aagaaaaaa 900  
 aataacttg attaactagt gttaacaaa aatagtgt actaatcc gtgcgaat 960  
 cgatataag ctatcgata ccgtcgact cgtaggggg gcccgtacc aatgcctgt 1020

&lt;210&gt; 123

&lt;211&gt; 1378

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

atcttagaa tctctctgac ccaaaactc aaccatctt gpaagggag ggaagagaa 60  
 tgtctgac tatcttgat gaggaggtt ggttggacc tgaagctct cctgtttgg 120  
 ctatagatg gggagaggg ctgttactca cgaactctc caacagata ccagaacag 180  
 gaaagcact cagtgtatg taagatgct aggcnaaga accagcttc accaatgac 240  
 cccgttaat cctgtctc ccaagactc ctactttag tcaagatgt altatgta 300  
 ggttaagt ttgtttat gtgaatgac tgaactgac caagcccaa gagaacctc 360  
 aagaacagt agactcccg tagaaggtc ctgatggac ttcaacat gctgtccaa 420  
 ctcttgatg caacaaatc acctgtgat gttaaatgc agactgtac ttacagatc 480  
 tggggagc caagtcttg calttccaa agctccag atgatggca cactgtgat 540  
 ctgaggaaca catlttgac agcaatctt aaaaacaa agctgttg accgactcc 600  
 tgaagagga cctcaactt ggaagagt yaaagagt gcatlcaac catccagag 660  
 aagtttaca attgttag gaaactgata ctaaaatla ccaatcaaa actctgtag 720  
 gaaggtctac ttgttgtt tcaatgaca ttcatlga tgcctcat aacctgtag 780  
 ggaattcaga gatggagat atgatggag ttcaaatla aactgttaa aactggcca 840  
 ggaatcaca actatgaaga ggtctgag ggaattct taattttat ttltgaaac 900  
 aggtctac tatgtgccc agactgtct cgaactct agctttaga atccctcgc 960  
 cctgcacct gagtgttg gactagat gtvagacag atpcagacc tgtgtatg 1020  
 ggaattgac ccaagtttg ctgtctgta agctccag ttgtgaaga ctatgctac 1080  
 ccaatgac cagcgaac agcaagtt ttgtcagc aatgagact aatgaagag 1140  
 ccaatgtc aaccagatc gcaagagcc aatgtatc ctgaagaca cccctacc 1200  
 gctgaagat tcttctgac cctgaggt ctctctgaa tccaccnaa tgttctca 1260  
 ctaagcgaa atctgtctc tccgttttg gctgtggag aacactaac ctacgctct 1320  
 gtaacacgc cctgtgccc aattgatat caagttatc gatacctgc accctga 1378

&lt;210&gt; 124

&lt;211&gt; 1146

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 124

tctttctgt aacttactt agcaactaaa acaatatac taattatgt taactttga 60  
 ctacaactt atcttctc ttacaagct tttaatgt tttaatatc ttgttatct 120  
 ctgtgaaac tagttaatg ttactttgaa attctctt ttctaatc acctatgta 180  
 ctccagtgga cagtatgt tacttactgt ggtcctctgt taggtttt aattcttca 240  
 aatgcctt gaattatag aaatactac atgaatat actgtgtgc ataatltt 300  
 tgaatagt taactctat acttactt agctatgt gtccagagt gatctccaa 360  
 tgaanaaa taagtactc tatcttgg gaacatgt agcaatgaa ggtctgct 420  
 ttcttgaga gatccctag attcaagg aacactctt gatltatat caatctat 480  
 acagagact gagaatgga tgaagagc tgtgtctt tgaatgaa tttaattc 540  
 tcttgagct ttctatctc caaccacac tcttctca gtccttctt tatgttat 600  
 tcaagtact cccaagctc tatatagt ccttggctc ctgtcaagg gaaactgtc 660  
 aacacacccc taactctca tcaatgtct ctgtcttg gacttact gttgccttc 720  
 ttctgtct gtttagcaa caatatac catagttt ctgaatcca tcatagacc 780  
 tggctttgt gtggtctc ttctatcc tgcctatc ggtatattt aatatctt 840  
 accgttgata cagtgaat ttgtggaag agatagaaa calagcaaa tctccctc 900  
 tgaatggac atctatct aattacact catcaataa atgttctta ttgttatc 960  
 ttatgttagt aaagatgaa agataagac aaaaactgc tcttaata cgaattatg 1020  
 taacataat attatgat tatgtgggg ggcctgacc caatgcctc aatgatgc 1080  
 tataca 1140

&lt;210&gt; 125

&lt;211&gt; 1675

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 125

cttaagacg ccaggtagag acacacagaa cgtatgtatt aagaataacc tctctgggct 60  
 cgaataattt aggaagtatt ctatccact ccaagtgtga agtattgtga gaattttgtg 120  
 caaacaaaca aaactactca aatgaagaga aatgtactc aacctactt atagttagca 180  
 gctgaattca tcaactcttc cctgcacaga tataccaca gtggtgaaga aatagttagca 240  
 atgcttgttt tctgtctctt ctttccaact gttactgtgc ttgtttgaa agtagtttcc 300  
 tctctcaaaag ccgtgtgcta taccgtttaag aatgaaggtt tgtgttaaaa attattgtca 360  
 ttgcacaaag tagtttcaact gaagctatgc accattaaat aagatgaat attgtatttt 420  
 atgttccctac tctctaaagc ttaactctgt ttctctgtg aatttgactt gactcaactca 480  
 tgtcacacta catcgcttta gttatttgaga tggcatttat gttctcttc gtttataatg 540  
 aaatggggtc agattctcat agattctcacc tctgtcaggt ggaactttgt ctgctcttcca 600  
 tgaatagatt tttttctctc ttccctcttc ttttaagagag gctgaacagat ctagggttca 660  
 atcaaatgtga aaccagcttc tgaatttttt tcatatgtta ttctctatca ttagttttcc 720  
 tgtgtaaat agataataac tgcactttct taaaaaaaaa tacaatctcc tattactctc 780  
 ttgaagatt tacttctga ggcctttttc aataggtcca tgaactgaga caaggaaaaa 840  
 aaagtataaa acaaaaacag tatgtgctg aatagacaa aaaaaaatt tglacattt 900  
 aaaaaaaga cctgaatagc ctttaattct ttaataatc acttaaat ttatgtaaat 960  
 ggtttctgcc acgtgtgttt gttcacattc taaatgaact aatgggattc tcaaggctctg 1020  
 tgcctttgtg taccgtctgc tgcctgggagt gggctgttga accgtcttc ggttcaactgg 1080  
 gtctctcttg ggtatattgg agagatgggg ggggctgtgg gcaaatcttc acacattgtt 1200  
 tcttaactca tttgcagaaa ctttcaaaag gcaatttgatt aaactcttg gcagtacagt 1260  
 atcttctgat ttgttaactg cgtgttttag gtaactgtac ctttttgtt taaatgttct 1320  
 taagtgtgtt cttcaaaagt aatttacttt tagtatgata gttatatgaa aattatgtga 1380  
 ttgtgtgca gagaattttt ttataaagt ctttgraaaa aaaaaaaat gtaactagc 1440  
 ttgtgcgga cataatgttg atcaattttaa taacctagc agttaagtgc aattatttca 1500  
 tcaacttaaa aatgtctatt ttgtgtcagt tctgcaggt gttttcatt ctttcaaat 1560  
 tgaacatttt tgaactcttc ttgataaagt gttgacatt ttgtatgtt ctgaaaaatt 1620  
 tgtattcata cgttatcaat gaaaaataaa gaaatgaaa gtgtgggtca aaact 1675

&lt;210&gt; 126

&lt;211&gt; 1064

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 126

ggcggagggt ttctgtgacg gacggaggtc tcagagagga gacggatgtg ggggggggag 60  
 gccggccacg cgttgagacag agcggagggt ccagggtgac ccgaagaccg taccaccccg 120  
 acagcaacgc aagtgccttt gacctgatt tggactttc tccctttgc atttggctgt 180  
 acagacttga gacacagca gaatttgtt tcagcccgcc cccgtctgc cgtctccggc 240  
 cgtgggtggc gccactgtga ttgtgtcca ccttgccttc ttgcagcca agcattttt 300  
 gtggatggga cttaacttga cgcgccagg gcttttcagg attcaggatc acttttctt 360  
 tacaatgggt tctctcggc agagcccggg ttgtggggga tctgtgtggg ttctcaagc 420  
 agatccatcc tgggggtccc cgggcagga tggctgacct cgaactccct ccttcccca 480  
 gaactgtctc tgtcccgagg gcaetcaaca agggctgagc cccagggtaca ggttgcctc 540  
 tccacggcag gaattttac caaataaca agcaaaac accagaccc accagacca 600  
 acacaaaaa tgggggggtar ggttttgtaa agtttctgtt aggtttcat ttattatca 660  
 ttgttgcctt aatgcgga gtttgcctgg gaatttgag acaattgac tatgttttta 720  
 tggtttttca gggaagtgt tctgggggcc ggtctctct cagctgtggg aggcctgtct 780  
 cctctggggg gaccccttgg gggccttggg aggccttggg aggccttctc tgcacaatgc 840  
 agacaggggg tgaacttgc agcgttttgc acgtccccc agcacaggt catatttct 900  
 gaggatccgg catagcatag gacgttga ctttgcata aatgtgtaga tgaacttct 960  
 ctacagcttt tatttgtgaa ttaaatgac attatggtt aaaaaaaaaa aaaaaaaa 1020  
 aaaaaaaa aaaaaaaa aaaaaaaa aaaaaggcgg ccgc 1064

&lt;210&gt; 127

&lt;211&gt; 1607

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 127

ggcagcagga aaacttatt tatcgataga cctcatttat gcaaatgttt gtaaatatc 60  
 atgttatat gtaattatt ttattttta tctatcac atcagacaag ctatgtgaaa 120  
 taatatat taaatcata gatagatta tctaacaga gagaactag taataaaaaa 180  
 agactgaaa aacatcccat taagaaaaaa gctttatat gggacattat tcaatttct 240  
 gaaatgaaa ttcttgatt aactgccata tattatatta ttgaaatac tttagraag 300  
 rtaatttcc aagctgtgtc cctggtagta tttttctcg gctgaaattg ggccttaaaa 360  
 caaaactga gcaatgcaag ctgacgtatc cagttacagg ttcaagaact tcaagtgcag 420  
 gcaattaaa gtgatttaag aaaggcaaaa tcaattcttc acaaatgtgt atgttaaac 480  
 tgtaaatga tatacaaaa ccaaacccg aatagacaa ttgtctctc ttgcttctc 540  
 ggggtgtct ccgcagctgc ctgccagata atatactgt tgtaaacttc cttaattaca 600  
 gagctttta gtttaactc ctgggccagc cttaagggt tcttaccctc ttgaaatgac 660  
 agaataattg aaattgtctt cagcagacag tcaggcaata atgaatttt tctctgtga 720  
 ttgcacgca aggttgaca tagcaactga acagaaatg atcccaacc gggycctcca 780  
 gggaggggca cgcgtaac tttggcatga ggcacaatc cgacgggttc ccttccacg 840  
 ggtctctgaa rtcaagcag cccaccagc ttctgacaa caggtgtcac cacagltgc 900  
 gcgtgaacaa tgaatccatt ggttctctg actctccaga ggcagcttaa aggttgggaa 960  
 aggttgggt taggtatt ctgatgggg cagcgggga gatgacaga gtaggtctgt 1020  
 atgagaggac gctgctgtt tctgaactca ggaacttc ccaactctt gaatgtttt 1080  
 ttggaagcc ggggttctt tctgaactca ggaacttc ccaactctt gaatgtttt 1140  
 atgagaggac gctgctgtt tctgaactca ggaacttc ccaactctt gaatgtttt 1200  
 gctgtgtga ttgaaata agcttctgt agcctctgga acacactaa atcttcaaaa 1260  
 aacttaaga ctgatttca cttactcac ggaaggttg aagaatttt gaataattaa 1320  
 tataagcaac taacttga ttatggctac ttccatgata tgcgttagag gtggaattg 1380  
 gggatgaga aggaactac ctaagacaa tatgtattta agccacatga gaagtgtga 1440  
 gattaaacag cggggctgg tgaatcact ctgtaatcc agccacgcta ctcatgagc 1500  
 tgaggcagga gaatcgttg aacctggag ccggaggtt cagtaagccg agattgac 1560  
 actgactcc agctcaaaa aaaaaaaa aactcga 1607

&lt;210&gt; 128

&lt;211&gt; 1037

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 128

agctactcc tctggcccg cctttctct gctctctga accttaggc ttgtctcggc 60  
 ccaattgaag accaggaggt tgatcaacc cgaggctgt gagagacggt ggcgcgctg 120  
 ggacagctgc cagggtatgc tgagcgtgaa gatgcagcg gtgtccggc tgcctctcg 180  
 gacgtgagc agagctctgt ggtctccgg cctctctgag ccggagagct cccggcagc 240  
 ccggaactag gaagagaa gctagagagt ttatgatttg attagaacta tccggagacc 300  
 agaaaagccc aactattag aagaactgga agtggctctg gaaagtgtg ttgaaattca 360  
 ccttttggcg actttattg ggtctgtctt aagatgaaa cttcagcag tttaacctg 420  
 ggagataaat gaagaagaat acttggttat tatcagttc agccaacag tactctatg 480  
 taaactaag ttgaaatct acatttctga agaaacccac tcaacagag agacatcaa 540  
 taagcagata gaataaaa agctgcaatg gaaacccca acttcagg 600  
 aatgtggaa cagtgttcc ttgaacttga ctatagctg tttaagagc cactggcctg 660  
 taattgttg atatttgt ttaactttt tgaactttt tgaatgt cagagactca ttttaatc 720  
 atagggtatt tgaactcag acatttttt aaaggattct tccaagcga gatttaata 780  
 taaggtagta ctaattgt tcaatgata acattctcg gatttgaac acttaaatga 840  
 tcagacagaa taatttct tagttattat gtgaagatg agttgctatt ttctgtatg 900  
 tcaattctat acaactattt tctgtgtcaa atatctactg tgcacaaatg tactcaattt 960

aaatcattac tctgtaaat aataagcag atgattctta aaaaaaaaaa ataaaaaaaaa  
 aaaaaaggg cggccgc

1020  
1037

<210> 129

<211> 1146

<212> DNA

<213> Homo sapiens

<400> 129

ggcacagagat ttctgtcag gttttatgt tgttttcag tttaagag tctgtatata  
 ttcttctac tgcattttg ttatagatg gcttcagtg tgcagtatga tctcagatg  
 taatgtatag tgtatgtga gtagatatt gctttcaaa atccagctt tgcattctaa  
 tttaagaat agtatcttt tgtgtatag gttatttta tcttttgta tttaaaat  
 caagtccat tgtatata tagtactaa gttctcagt tgaattctaa aatgtgtat  
 acctatata tccacacac tgtatccca tcatctatc aacacctg aaatctcc  
 tgcctctt cctatcaac cccacctg cctcaagtaa gtactctt gattctgt  
 cctatagat agttctact gcttcagac atcatatgt gggctgtggc gcgatggctc  
 acgcagatga tcccagact tggagggctg aggtggcag atccattgag gtcagagat  
 tgaagaccag ctggcaaca tggltgaac ctgtctctac taataatga aaaaataac  
 tgggtgtgtg gcatgctct tgaatcccc agctactca ggaagccag gcccagat  
 cactgaacc tggagagac aggttgcact agctgtcag actccagct gggcaacaga  
 gtgagactgt ctgaagaaaa agagtctat atgattgat tatcacatga ataatctga  
 tcatattca tttagcatt tatctatga atcatgcat gttttacta ttaatatct  
 ttctggcccg gctcgtggc tcaagctgt aatccagca cttttgaggg ctgagcag  
 tggatcacta ggtcagagat tcaagccag cctagcgaaa gatgttga cccatctc  
 actaaaaa caaaatag ctgggcctg tggcagggcg ctgtaatccc agctactcag  
 gggctgaggg cagagaaat ctggaacct ggaagcagag gtgcagcaa gctgagatg  
 tgcacctga ctccagctg gggagcagag cgaactcca tctcaaaaa aaaaaaaaaa  
 aaaaaa

1146

<210> 130

<211> 1172

<212> DNA

<213> Homo sapiens

<400> 130

ccaagcgtc gaacacctg cagcttacc tgtatgtc aagcttga agatcttat  
 ttctgtgac atattggct gcttgacc agtgcaca ctatgtcag ttatgcaga  
 gaagtctct ttaccacac caattgtgc aaaaatgaa gcaatcttg caaatcgc  
 ttvggcacag gggatctcag acccgtcga atccatgaat gcatctag gatgtatga  
 agacagacaa gaagggaggt atcgctctga atcacatca tgcggagga acttctaa  
 tgaacatca ctgttaacc tagagatgt aagcagag ttatgaagt tggtaaggg  
 agcagatct tcatctcca caactctac cagctggaa ggaacagag cctcacagac  
 cctctatc caaagaatg cctctctga agtctgac gtggctggac tgaatgaaa  
 tgtgtgggaag ataatctata caagctcag gtagtctaa gaaaatctg ctgtcat  
 ggaagcggcc caagcagaag caaaatgaa cccatccca gtaaatcag atttgaac  
 tcatgtatg ctctatacc aggaagaat aaggtatgc agagtcat tagaagaac  
 taacctata accccttc cagtttact ttgtgtgt gatataag ttcagacag  
 agaagctct ctctcattg atgctggat ctatttcag gccctgtaa agatggctgt  
 catttcaag cagctgagag tctctatga ttcaattta agaaaaagc tgaataacc  
 aagatgtcc ctgtaaatga caagatttg cagatcata cgaatagat aaaaacagag  
 aaaaactga actgaatc atgttcaact gcttataaa ttaagatga gatcacgca  
 tgaatctac tgaatggg tcatctact aagatctca ttactataa tgttgtact  
 agcatcaac ttaaggtgg tgggaaaaa gcaatctct caaatctga taattctta  
 gtctcttct aatgtatgt atctgaatg taattgcac taacttaca ataatctct  
 tggatctatg aaaaaaaaaa aaaaaaaaaa aa

1172

<210> 131

<211> 663

<212> DNA

<213> Homo sapiens

<400> 131

ggcacagaa accatgaag tcttctctg gatccactt atctctatg gtctgcatt  
 tactgttca ctgatatcc cctctaggg cctgtggag ttcatatg ctcttcga  
 tctcagaca aaggtgtgg aaggggaat ggaagaatgc cctctgtct tgtctctc  
 cgtgtccca gctacagatg caaagatt ctctgtag cacacctg atgtaatc  
 atgaataat ggaatttg aaacttacc ctgaagctg atttgggtg taattctact  
 tctgacagc ctaaatata agggcggaga ctttgaat tgaatatac gtcggttc  
 atgttaagaa gccctgtgtc tagagtgct attcagat tcttctctc ataacact  
 tgaatatt ttgtgtgt tgttctctc ttctgaagc gttctctct ttaaatlt  
 ttaacacat tgaataaac tatcttacc cactctgt tctactatag ttatltta  
 tttaaatgt ttaattgat ttgattaac acttaactg atttggat attaaatc  
 tcttccact tggctttta aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa  
 aaaa

663

<210> 132

<211> 776

<212> DNA

<213> Homo sapiens

<400> 132

ggcacagact gattctat tttagagct acttgattt gtagtatt ttctacgtg  
 aaaaatgt tactttcac ttltgttca gtactataat tgcataatga ctcttccc  
 cctttgaga caticagatga atcacatca ttgccaag ttgccaag gagaatc  
 gcatgagtg gaaaatgaga tgcctgtac cagaacaga aaggttacc atgatacag  
 cacagaagt aggggtgtg acttgttgg ccataatgt tatctctt ttgaaatga  
 caggacacag cagcagttt ctcaagtaa atgtctacc ccaactctc atgaacagt  
 tgcggagagc ttaattcca ttctatlt tatcacatc tctacaaga caattctaa  
 tgaagttag tgaatttgt aaaaatcga gaggaaatga tgaatggg tgtttggg  
 ttcttctg tatcatlt ttaatgaga aagttttaa tgaatgtag gttagacca  
 actactact tactatata ggaagattct atgttctgt taaatctc aagtaactt  
 cctctgggga aaaatgaca ctggacact taaaggaat ggaattttg tctacttg  
 ataaagcagt tgaattctta agtaagaca atagtgtaa atgtcatlt gtttgatg  
 ttaagttagc aataaaaaa catgttgaaa ttgtaaaaa aaaaaaaaaa aaaaaa

776

<210> 133

<211> 1543

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1055)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1143)

<223> n equals a,t,g, or c

&lt;400&gt; 133

cttcgacgtc atccgcttcg aaagcactat ccacgagctc gaccgctggt ttaactatag  
 atcaacacat catcttgcac ctacaggggt ctatgaattt ttaatttgggt tgaagaaag  
 agcatgggtat ccatcaggaa gaatagtagg tggactgtgt taccaggggt tgaatgaac  
 cgtcgccctt attcatcga ttttaaatc acatgaacata ctatgcaca taagagacgt  
 agtggcttc attcagcaa ccttttaggg ccttaacatc atactactt tctctgtac  
 aagagaactt tggaaacaa ggcgaggaact tttagctgct tgttttttg cttatgtacc  
 agctacata tctcgttcag tagctggatc ctttgataat gaagccttg cttttttgc  
 acttcagtc acatactat tatgggttaa atctgtaaaa actgggtcag tttttggac  
 aatggcttc tgccttact attctatat ggtctctgct tgggtgtggt atgtatttat  
 catcaactt attccactgc atgtatttgt gtgttactg atgcagat acagcaaaa  
 agtctaca gcatcaga cttctacat tgtgggttta atattaca tgaagatacc  
 ttttgggga ttcagcga tcagaaacag tgaacacag gcagctcag ggtctttgc  
 attgtcgga gcttatgctt tcttgagta tctgagagac gatacaaa acaagagtt  
 ccagacacct tctttttg gtgtacact agctgcaggt gctgtgtcc ttatgtctat  
 ctattgact taccaggtt acattgcacc atggagctgg aggttttcat cttgtggga  
 tactgggtat gcaaaaatac acattccaat tattgcata gttctgagc atcaacctac  
 gtgtgtctg tctttctct tcaactgata tattcttga tgtacttcc cagcagcct  
 tgggttctg atcaaaaata tcaacagata aagantattt gtaagrag gtttttaag  
 actacttga tatgaatag tatttttct ttttgagatt attacttta aattttgtt  
 tttctatgt tgcctcata tatcaaat aattttctc ttltatttt catagtgct  
 taacaagaa aaattcact agagctggc catggtggca cagcctkta atccagcac  
 tttgggagc cagggcggc gatacactg agtccaggag ttcagacca gcttgccaa  
 catggtgaa cctgtctct actaaata caaaaattag ccgaactgg tggctatgc  
 ctgtaacc agtactcag gaggctggg caggataatt gcttgaacct gggagcgga  
 ggttcagtg agtcaagatc aagccactgc actccacct ggaatcaga ggggactct  
 gttcaaaa aaaaaaaa aaaaaaaa aaagggcggc cgc

&lt;210&gt; 134

&lt;211&gt; 2157

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (309)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 134

caaaaaggac cggccattga agatgccatt gctctctccg atgtcttga gactgtctt  
 aaatctgcta atccaccga cagattcaaa gctacagaag agcagagttc aaccacaga  
 ccggtgaaa agtctggcaa gctgagcgag caaatagatg tgaaggcga actggagaag  
 cggcaaggag ggaagcagct actcaacta gtggctatg tgcatttga tcttgggaaa  
 agtactctga tgggctcat gtttctctt ctggtaata taacaaaag aactatgat  
 agtatganc aggaattaa aaagcctggc aaagcttctg ttgcatagc atgggtcttg  
 gatgaactg gcgaagaaag ggaaggggga gtaacctagg atgttgat gcaagattt  
 gaaaccacaa ccaagttat tacattaatg gatgtctccag gccataagg cttactcca  
 aatgatcca cagagcagc caggcggtat gtagctgtt tagtttga tgcagcagg  
 ggaggtttg agctggatt tgaactgga ggacaacac gagagcatgg actctgtc  
 cgtctcttgg gagtgcga cgttcaggtt gcagtaata aaagggata ggttaattg  
 caacaagaa gtttcaaga gattactga aaactgggc acttctttaa gcaagcaggt  
 ttaagaga gtgatgtag ttttactct acaagtggc tagtggta aatctaata  
 acaagatctc agtcaagta gctcaaaa tggataaag gactatgtt attagaaca  
 atgatctct tgaagctcc cagcgatct attgacaac ctttagatt atgtgtcc  
 gatgtttca agatcaagg atctgatt tgcataactg gtaaataga agctgttat  
 atcaactg gtgacagact actggcaatg cctcctaag aaattgtac cgtgaagga  
 atcaactgc atgatgaac tgcagactg gcggcagcag gcatcatgt tagtctact

70

ttggttggga tggatatcat caaatcaat gttggctgca tattttggg ccccaagta  
 cccattaaag ctgcactcg ttcagagcc cgaactcca tcttaatat tgaattctt  
 atactaaag gattctctgt gctgttacac taccaaactg tcaaggaacc cgccttatt  
 aaagatgta ttagtctctt aaacaaaagc aggggtgaag tcacaaaga aaagcctag  
 ttttgata aagccagaa tgcattgga gactcacaga cacaagacc aagctctct  
 gagctata aagcctttaa aggtctggg aggttcatgc taccgtacgg tggttctca  
 atagctgctg gtgtgtcac tgaataaaa gaatgatgg tcmgaattc taccacgtt  
 ctggatagag tgaatagctt aactctgt tcaagaatgc agttattag tcaaggaac  
 atgtgtcaat tgaatgttt ttatagaga ggaataaatt aaagctaaa tagctgaa  
 agagatata aatcaactc ctgcaaaa tctaaagttc caactgcaa agraagtta  
 agttaaaaa caactttgct ttgaamcgt taataaaagg atttacttg ctaagatta  
 tgggaagt ctcaaatagt atcgaagt actgaatcat cagaaatga actcacttc  
 tggcaagac acaatgatt tgcagtttct tcttttgat caattact gcactgtt  
 taagaaag taacttaatt ggtttttca ggcagttgat attgactca agctttttt  
 tttttttt ttccagttaa tgcataaaa agatttggg aaggttataa taaaagtatt  
 ttgtgtgac caaagaatg tccctccca acaagtaaa cttggaag ttaatttgg  
 aattagtag agctgttct ttgaagcca agatattatt taagtgtaa agccagctaa  
 taaatgct tagtttggc ataaaaaa aaaaaaaa actcgg

&lt;210&gt; 135

&lt;211&gt; 420

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 135

ggcagagag agagcagagc tacaatagc tatccaggtc taacttcac aagaataga  
 tggtttctt tcaatttcaa tgcatacat acttttgcag actttttt cagttgcag  
 tcttcttgg actggtgata gttatgctt tattaatct cacttctc actttact  
 tccacaaca ttgtagaag gccacaaagc tctaggaga ggaataatggt ttataaat  
 agtcttctt gggataaagg aaattataa tctgtactac ttaatagtag ccaatagcca  
 catgtgttt tcaacaaga ttccacac cttccacac acttctctt cattgtcag  
 actagaacc cgaaagactg tctcttcat tgtttctcc gcttctaca aactagata

&lt;210&gt; 136

&lt;211&gt; 334

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 136

Met Phe Gln Cys Gly Leu Leu Gln Leu Cys Thr Ile Leu Met Ala  
 1 5 10 15

Thr Gly Val Pro Ala Asp Ile Leu Thr Glu Thr Ile Asn Thr Val Ser  
 20 25 30

Glu Val Ile Arg Gly Cys Gln Val Asn Gln Asp Tyr Phe Ala Ser Val  
 35 40 45

Asn Ala Pro Ser Asn Pro Pro Arg Pro Ala Ile Val Val Leu Leu Met  
 50 55 60

Ser Met Val Asn Glu Arg Gln Pro Phe Val Leu Arg Cys Ala Val Leu  
 65 70 75 80

Tyr Cys Phe Gln Cys Phe Leu Tyr Lys Asn Gln Lys Gly Gln Gly Glu  
 85 90 95

Ile Val Ser Thr Leu Leu Pro Ser Thr Ile Asp Ala Thr Gly Asn Ser  
 100 105 110  
 Val Ser Ala Gly Gln Leu Leu Cys Gly Gly Leu Phe Ser Thr Asp Ser  
 115 120 125  
 Leu Ser Asn Trp Cys Ala Ala Val Ala Leu Ala His Ala Leu Gln Gln  
 130 135 140  
 Asn Ala Thr Gln Lys Gln Gln Leu Leu Arg Val Gln Leu Ala Thr Ser  
 145 150 155 160  
 Ile Gly Asn Pro Pro Val Ser Leu Leu Gln Gln Cys Thr Asn Ile Leu  
 165 170 175  
 Ser Gln Gly Ser Lys Ile Gln Thr Arg Val Gly Leu Leu Met Leu Leu  
 180 185 190  
 Cys Thr Trp Leu Ser Asn Cys Pro Ile Ala Val Thr His Phe Leu His  
 195 200 205  
 Asn Ser Ala Asn Val Pro Phe Leu Thr Gly Gln Ile Ala Gln Asn Leu  
 210 215 220  
 Gly Gln Gln Gln Leu Val Gln Gly Leu Cys Ala Leu Leu Leu Gly  
 225 230 235 240  
 Ile Ser Ile Tyr Phe Asn Asp Asn Ser Leu Gln Ser Tyr Met Lys Gln  
 245 250 255  
 Lys Leu Lys Gln Leu Ile Gln Lys Arg Ile Gly Lys Gln Asn Phe Ile  
 260 265 270  
 Gln Lys Leu Gly Phe Ile Ser Lys His Gln Leu Tyr Ser Arg Ala Ser  
 275 280 285  
 Gln Lys Pro Gln Pro Asn Phe Pro Ser Pro Gln Tyr Met Ile Phe Asp  
 290 295 300  
 His Gln Phe Thr Lys Leu Val Lys Gln Leu Gln Gly Val Ile Thr Lys  
 305 310 315 320  
 Ala Ile Tyr Lys Ser Ser Gln Gln Asp Lys Lys Lys Lys  
 325 330  
 <210> 137  
 <211> 43  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (43)  
 <223> Xaa equals stop translation  
 <400> 137

Met Thr Val Ala Ser Ile Arg His Ile Leu Val Gln Ile Trp Leu Pro  
 1 5 10 15  
 Ile Ala Leu Ala Met Gly Thr Arg Gly Leu Thr Gln Ile Val Ala Val  
 20 25 30  
 Ile Gln Ser Arg Ser Gln Trp Ala Leu Ser Xaa  
 35 40  
 <210> 138  
 <211> 87  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (87)  
 <223> Xaa equals stop translation  
 <400> 138  
 Met Leu Phe Ile Phe Leu Leu Leu Ile Leu Ser Ile Thr Ala Ser Tyr  
 1 5 10 15  
 Ser Leu Thr Cys Ile Leu Ser Gly Ala Gly Gln Pro Ser Ser Val Ser  
 20 25 30  
 Ala Ser Val Val Ser Gly Pro Gly Phe Cys Leu Ala Ala Leu Leu  
 35 40 45  
 Met Arg Thr Gly Gly Phe Ala Ala Thr Leu Leu Pro Val Ala Pro Thr  
 50 55 60  
 Gln Arg Phe Phe Ser Cys Cys Thr Val Leu Ser Ala Gln Arg Asn Val  
 65 70 75 80  
 Ser Arg Thr Arg Ser Pro Xaa  
 85  
 <210> 139  
 <211> 122  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (122)  
 <223> Xaa equals stop translation  
 <400> 139  
 Met Leu Ser Thr Arg Trp Met Gly Leu His Leu Val Gln Ile Leu Trp  
 1 5 10 15  
 Arg Cys Trp Thr Ser Ser Ala Thr Ile Thr Ser Arg Lys Leu Ser Thr  
 20 25 30  
 Ala Leu Arg Ser Pro Val Leu Ser Gly Thr Gln Thr Ser Arg Ser Ser

WO 99/24836

PCT/US98/23435

WO 99/24836

PCT/US98/23435

35 40 73 45  
Gly Asp Ser Gly Trp Ser Met Lys Thr Ser Val Lys Ala Thr Pro His 60  
50 55  
Gln Met Ser Leu Arg Ser Gly Lys Glu Thr Pro Ser Ala Asp Ile Pro 80  
65 70 75  
Arg Ile His His Gln Leu Val Arg Leu Arg His Gln Ala His Gly Gly 95  
85 90  
Trp Ser Pro His Gly Val Pro Glu Gln Gly Thr Met Pro Leu Val Leu 110  
100 105  
Pro Pro Val Ser Cys Asp Ile Gln Pro Xaa 120  
115  
<210> 140  
<211> 276  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (131)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (276)  
<223> Xaa equals stop translation  
<400> 140  
Met Ala Asn Thr Gly Val Phe Gly Phe Ser Phe Leu Leu Thr Val 15  
1 5 10  
Ala Leu Leu Ala Ser Tyr Ser Val His Leu Leu Ser Met Cys Ile 30  
20 25  
Gln Thr Ala Val Thr Ser Tyr Glu Asp Leu Gly Leu Phe Ala Phe Gly 45  
35 40  
Leu Pro Gly Lys Leu Val Ala Gly Thr Ile Ile Ile Gln Asn Ile 60  
50 55  
Gly Ala Met Ser Ser Tyr Leu Leu Ile Ile Lys Thr Glu Leu Pro Ala 80  
65 70 75  
Ala Ile Ala Glu Phe Leu Thr Gly Asp Tyr Ser Arg Tyr Trp Tyr Leu 95  
85 90  
Asp Gly Gln Thr Leu Leu Ile Ile Ile Cys Val Gly Ile Val Phe Pro 110  
100 105  
Leu Ala Leu Leu Pro Lys Ile Gly Phe Leu Gly Tyr Thr Ser Ser Leu 125  
115 120

74  
Ser Phe Xaa Phe Met Met Phe Phe Ala Leu Val Val Ile Ile Lys Lys 140  
130 135  
Trp Ser Ile Pro Cys Pro Leu Thr Leu Asn Tyr Val Glu Lys Gly Phe 160  
145 150 155  
Gln Ile Ser Asn Val Thr Asp Asp Cys Lys Pro Lys Leu Phe His Phe 175  
165 170  
Ser Lys Glu Ser Ala Tyr Ala Leu Pro Thr Met Ala Phe Ser Phe Leu 190  
180 185  
Cys His Thr Ser Ile Leu Pro Ile Tyr Cys Glu Leu Gln Ser Pro Ser 205  
195 200  
Lys Lys Arg Met Gln Asn Val Thr Asn Thr Ala Ile Ala Leu Ser Phe 220  
210 215  
Leu Ile Tyr Phe Ile Ser Ala Leu Phe Gly Tyr Leu Thr Phe Tyr Gly 240  
225 230 235  
Ser His Ser Val Ala Gln Val Gly Val Gln Trp Cys Asp Leu Ser Ser 255  
245 250  
Leu Gln Pro Leu Pro Gly Leu Lys Lys Gln Ser Ser His Leu Ser Leu 270  
260 265  
Gln Ser Ser Xaa 275  
<210> 141  
<211> 195  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (138)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (195)  
<223> Xaa equals stop translation  
<400> 141  
Met Lys Leu Ala Ser Gly Phe Leu Val Leu Trp Leu Ser Leu Gly Gly 15  
1 5 10  
Gly Leu Ala Gln Ser Asp Thr Ser Pro Asp Thr Glu Glu Ser Tyr Ser 30  
20 25  
Asp Trp Gly Leu Arg His Leu Arg Gly Ser Phe Glu Ser Val Asn Ser 45  
35 40  
Tyr Phe Asp Ser Phe Leu Glu Leu Leu Gly Gly Lys Asn Gly Val Cys 60  
50 55

Gln Tyr Arg Cys Arg Tyr Gly Lys Ala Pro Met Pro Arg Pro Gly Tyr  
 65 70 75 80  
 Lys Pro Gln Glu Pro Asn Gly Cys Gly Ser Tyr Phe Leu Gly Leu Lys  
 85 90 95  
 Val Pro Glu Ser Met Asp Leu Gly Ile Pro Ala Met Thr Lys Cys Cys  
 100 105 110  
 Asn Gln Leu Asp Val Cys Tyr Asp Thr Cys Gly Ala Asn Lys Tyr Arg  
 115 120 125  
 Cys Asp Ala Lys Phe Arg Trp Cys Leu Xaa Ser Ile Cys Ser Asp Leu  
 130 135 140  
 Lys Arg Ser Leu Gly Phe Val Ser Lys Val Glu Ala Cys Asp Ser Leu  
 145 150 155 160  
 Val Asp Thr Val Phe Asn Thr Val Trp Thr Leu Gly Cys Arg Pro Phe  
 165 170 175  
 Met Asn Ser Gln Arg Ala Ala Cys Ile Cys Ala Glu Glu Lys Glu  
 180 185 190  
 Glu Leu Xaa  
 195  
 <210> 142  
 <211> 183  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (183)  
 <223> Xaa equals stop translation  
 <400> 142  
 Met Leu Leu Leu Cys His Ala Leu Ala Ile Ala Val Val Gln Ile Val  
 1 5 10 15  
 Ile Phe Ser Glu Ser Trp Ala Phe Ala Lys Asn Ile Asn Phe Tyr Asn  
 20 25 30  
 Val Arg Pro Pro Leu Asp Pro Thr Thr Phe Pro Asn Ser Phe Lys Cys  
 35 40 45  
 Phe Thr Cys Glu Asn Ala Gly Asp Asn Tyr Asn Cys Asn Arg Trp Ala  
 50 55 60  
 Glu Asp Lys Trp Cys Pro Gln Asn Thr Gln Tyr Cys Leu Thr Val His  
 65 70 75 80  
 His Phe Thr Ser His Gly Arg Ser Thr Ser Ile Thr Lys Lys Cys Ala  
 85 90 95

Ser Arg Ser Glu Cys His Phe Val Gly Cys His His Ser Arg Asp Ser  
 100 105 110  
 Glu His Thr Glu Cys Arg Ser Cys Cys Glu Gly Met Ile Cys Asn Val  
 115 120 125  
 Glu Leu Pro Thr Asn His Thr Asn Ala Val Phe Ala Val Met His Ala  
 130 135 140  
 Gln Arg Thr Ser Gly Ser Ser Ala Pro Thr Leu Tyr Leu Thr Ser Ala  
 145 150 155 160  
 Cys Leu Gly Leu Cys Ala Ser Ile Ala Val Met Pro Pro Phe Leu Gly  
 165 170 175  
 Glu Ala Glu Thr Ser Leu Xaa  
 180  
 <210> 143  
 <211> 122  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (122)  
 <223> Xaa equals stop translation  
 <400> 143  
 Met Leu Arg Gly Thr Met Thr Ala Trp Arg Gly Met Arg Pro Glu Val  
 1 5 10 15  
 Thr Leu Ala Cys Leu Leu Leu Ala Thr Ala Gly Cys Phe Ala Asp Leu  
 20 25 30  
 Asn Glu Val Pro Gln Val Thr Val Gln Pro Ala Ser Thr Val Gln Lys  
 35 40 45  
 Pro Gly Gly Thr Val Ile Leu Gly Cys Val Val Glu Pro Pro Arg Met  
 50 55 60  
 Asn Val Thr Trp Arg Leu Asn Gly Lys Glu Leu Asn Gly Ser Asp Asp  
 65 70 75 80  
 Ala Leu Gly Val Leu Ile Thr His Gly Thr Leu Val Ile Thr Ala Leu  
 85 90 95  
 Asn Asn His Thr Val Gly Arg Tyr Gln Cys Val Ala Arg Met Pro Ala  
 100 105 110  
 Gly Ala Val Ala Thr Cys Gln Pro Leu Xaa  
 115 120  
 <210> 144  
 <211> 267  
 <212> PRT

&lt;213&gt; Homo sapiens

77

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (267)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 144

Met Trp Trp Phe Gln Gln Gly Leu Ser Phe Leu Pro Ser Ala Leu Val  
1 5 10 15Ile Trp Thr Ser Ala Ala Phe Ile Phe Ser Tyr Ile Thr Ala Val Thr  
20 25 30Leu His His Ile Asp Pro Ala Leu Pro Tyr Ile Ser Asp Thr Gly Thr  
35 40 45Val Ala Pro Glu Lys Cys Leu Phe Gly Ala Met Leu Asn Ile Ala Ala  
50 55 60Val Leu Cys Ile Ala Thr Ile Tyr Val Arg Tyr Lys Gln Val His Ala  
65 70 75 80Leu Ser Pro Glu Glu Asn Val Ile Ile Lys Leu Asn Lys Ala Gly Leu  
85 90 95Val Leu Gly Ile Leu Ser Cys Leu Gly Leu Ser Ile Val Ala Asn Phe  
100 105 110Gln Lys Thr Thr Leu Phe Ala His Val Ser Gly Ala Val Leu Thr  
115 120 125Phe Gly Met Gly Ser Leu Tyr Met Phe Val Gln Thr Ile Leu Ser Tyr  
130 135 140Gln Met Gln Pro Lys Ile His Gly Lys Gln Val Phe Thr Ile Arg Leu  
145 150 155 160Leu Leu Val Ile Trp Cys Gly Val Ser Ala Leu Ser Met Leu Thr Cys  
165 170 175Ser Ser Val Leu His Ser Gly Asn Phe Gly Thr Asp Leu Glu Lys  
180 185 190Leu His Trp Asn Pro Glu Asp Lys Gly Tyr Val Leu His Met Ile Thr  
195 200 205Thr Ala Ala Glu Trp Ser Met Ser Phe Ser Phe Gly Phe Phe Leu  
210 215 220Thr Tyr Ile Arg Asp Phe Gln Lys Ile Ser Leu Arg Val Glu Ala Asn  
225 230 235 240Leu His Gly Leu Thr Leu Tyr Asp Thr Ala Pro Cys Pro Ile Asn Asn  
245 250 255Glu Arg Thr Arg Leu Leu Ser Arg Asp Ile Xaa  
260 265

78

&lt;210&gt; 145

&lt;211&gt; 92

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (92)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 145

Met Leu Cys His Pro His Val His His His Leu Val Cys Leu Leu Ala  
1 5 10 15Thr Leu Thr Phe Ser Leu Asn Ala Ser Cys Ala Glu Gln Thr Phe His  
20 25 30Ser Gln Gln Ser Asn Gly Glu Phe Met Ala Thr Leu Pro Ser Ile Ser  
35 40 45Lys Gln Phe Gly Val Ile Val Trp Lys Pro Gln Arg Lys Asp Val Ile  
50 55 60Arg Leu Pro Val Ala Leu Ser Phe Ser Met Gly Leu Gly Leu Ser  
65 70 75 80Pro Ala Leu Gly Arg Phe Leu Ala Ser Glu Leu Xaa  
85 90

&lt;210&gt; 146

&lt;211&gt; 109

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (109)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 146

Met Ala Ile Leu Leu Ala Cys Phe Thr Ala Val Leu Ala Phe Ile Cys  
1 5 10 15Leu Gln Phe Trp Cys Val Arg Cys His Glu Pro Arg Trp Ser Tyr Arg  
20 25 30Ala Gly His Met Glu Glu Ala Asn Gly Leu Val Arg Trp Pro Glu Glu  
35 40 45Ala Pro Asp Leu Gly Gln Arg Glu Glu Asp Leu Gln Gly Leu Pro Leu  
50 55 60Val Glu Met Pro Arg Lys Asn Ser Arg Asp Gly Ala Glu Leu Asp Pro  
65 70 75 80

71  
Glu Ala Asn Gln Asp Ala Pro Asp Ala Gly Ala Leu Gln Arg Gly Gly  
85 90 95  
Gly Asp Pro Pro Ala Ile Leu Pro His Cys Gly Glu Xaa  
100 105

<210> 147  
<211> 88  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (88)  
<223> Xaa equals stop translation

<400> 147  
Met Leu Leu Arg Val Phe His Phe Leu His Ile Leu His Lys Lys  
1 5 10 15  
Gln Thr Gly Val Ser Leu Leu Tyr Leu Leu Leu Thr Leu Phe Leu Leu  
20 25 30  
Gln Gln Gln Val Ile Pro Gln Pro Ser Leu Pro Leu Leu His Leu Val  
35 40 45  
Ser Phe Gln Ile Cys His Tyr Pro Phe Pro Gln Trp Met Leu Gln Tyr  
50 55 60  
Arg Gln Ala Lys Met Val Leu Gly Thr Arg Cys Gln Met Ser Leu Met  
65 70 75 80  
His Phe Gln Asn Ser Gln Asn Xaa  
85

<210> 148  
<211> 74  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (74)  
<223> Xaa equals stop translation

<400> 148  
Met Ser Arg Val Val Ser Leu Phe Phe Phe Ile Leu Phe Ser Phe Phe  
1 5 10 15  
Phe Phe Ala Phe Ser Leu Ser Ser Ser Leu Ser Phe Val His Tyr Glu  
20 25 30  
Lys Leu Val Gln Val Lys Glu Cys Leu Asp Ser Phe Leu Lys Lys Ile  
35 40 45  
Lys Ile Lys Glu Tyr Lys Thr Arg Gln Cys Tyr His Leu Ile Arg Trp

50 55 60 65  
Glu Asn Asn Gly Ala Lys Leu Gln Ser Xaa  
65 70

<210> 149  
<211> 72  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (72)  
<223> Xaa equals stop translation

<400> 149  
Met Ser Ala Ser Leu Lys Asn His Leu Thr His Cys Phe Leu Leu Leu  
1 5 10 15  
Leu Leu Lys Glu Leu Val Ser Pro Thr Met Ile Ser Phe Val Pro Thr  
20 25 30  
Leu Arg His Ser Tyr Arg Phe Phe Asn Leu Phe Ser Cys Asp Ala Glu  
35 40 45  
Ser Thr Lys Glu Ser Pro Gly Arg Thr Val Gln Phe Ser Lys Thr Pro  
50 55 60  
Arg Gly Val Thr Met Phe Ile Xaa  
65 70

<210> 150  
<211> 152  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (152)  
<223> Xaa equals stop translation

<400> 150  
Met Lys Tyr Gly Leu Thr Gly Pro Trp Ile Lys Arg Leu Leu Pro Val  
1 5 10 15  
Ile Phe Leu Val Gln Ala Ser Gly Met Asn Val Tyr Met Ser Arg Ser  
20 25 30  
Leu Glu Ser Ile Lys Gly Ile Ala Val Met Asp Lys Glu Gly Asn Val  
35 40 45  
Leu Gly His Ser Arg Ile Ala Gly Thr Lys Ala Val Arg Glu Thr Leu  
50 55 60  
Ala Ser Arg Ile Val Leu Phe Gly Thr Ser Ala Leu Ile Pro Glu Val  
65 70 75 80

Phe Thr Tyr Phe Phe Lys Arg Thr Gln Tyr Phe Arg Lys Asn Pro Gly 91  
85 90 95  
Ser Leu Trp Ile Leu Lys Leu Ser Cys Thr Val Leu Ala Met Gly Leu 105  
100 110  
Met Val Pro Phe Ser Phe Ser Ile Phe Pro Gln Ile Gly Gln Ile Gln 125  
115 120  
Tyr Cys Ser Leu Glu Glu Lys Ile Gln Ser Pro Thr Glu Glu Thr Glu 140  
130 135  
Ile Phe Tyr His Arg Gly Val Xaa 150  
145  
<210> 151  
<211> 61  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (61)  
<223> Xaa equals stop translation  
<400> 151  
Met Leu Arg Val Ala Gly Val Leu Gln Phe Leu Pro Leu Ser Tyr Gly 15  
1 10  
Thr Lys Val Ala Ser Leu Trp Asn Thr Tyr Glu Asn Val Val Met Pro 20  
25  
Pro Ser Phe Thr Thr Leu Val Leu Pro Leu Ser His Glu Phe 35  
40 45  
Tyr Asn Tyr Ser Tyr Pro Phe Ala Cys Asp Gln Lys Xaa 50  
55 60  
<210> 152  
<211> 123  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (89)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (91)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (91)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (97)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (98)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (123)  
<223> Xaa equals stop translation  
<400> 152  
Met His Arg Ser Glu Pro Phe Leu Lys Met Ser Leu Leu Ile Leu Leu 15  
1 10  
Phe Leu Gly Leu Ala Glu Ala Cys Thr Pro Arg Glu Val Asn Leu Leu 20  
25 30  
Lys Gly Ile Ile Gly Leu Met Ser Arg Leu Ser Pro Asp Glu Ile Leu 35  
40 45  
Gly Leu Leu Ser Leu Gln Val Leu His Glu Glu Thr Ser Gly Cys Lys 50  
55 60  
Glu Glu Val Lys Pro Phe Ser Gly Thr Thr Pro Ser Arg Lys Pro Leu 65  
70 75 80  
Pro Lys Arg Glu Glu His Val Glu Xaa Pro Xaa Asn Ala Xaa Thr Trp 85  
90 95  
Xaa Xaa Thr Tyr Leu Phe Val Ser Tyr Asn Lys Gly Asp Trp Phe Thr 100  
105 110  
Phe Ser Ser Gln Val Leu Leu Pro Leu Leu Xaa 115  
120  
<210> 153  
<211> 55  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (55)  
<223> Xaa equals stop translation  
<400> 153  
Met Ser Pro Cys Ala His Ile Cys Leu Tyr Val Leu Val Phe Leu Cys 15  
1 10

Asn Val Thr Arg Cys Lys Cys Val Arg Ala Phe Thr Thr Trp Asp Thr  
20 25 30

Glu Lys Val Lys Tyr Phe Met Ala His Trp Ser Lys Leu Lys Arg Val  
35 40 45

Arg Gly Thr Arg Val Glu Xaa  
50 55

<210> 154

<211> 111

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (93)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (111)

<223> Xaa equals stop translation

<400> 154

Met Phe Leu Ala Ser Trp Leu Leu Phe Cys Ile Val Ala Pro Lys Asp  
1 5 10 15

Asp Ala His Leu Ser Phe Ile Gln Cys Lys Asp Ile Trp Lys Asp Asn  
20 25 30

Arg Lys Tyr Ser Cys Phe His Phe Lys Ser Asp Gln Leu Leu Glu Leu  
35 40 45

Ala Ser Lys Ala Cys Thr Ser Phe Gln Ala Gln Ser Arg Ser Phe Thr  
50 55 60

Ala Gly Ala Val Pro Ser Glu His Pro Glu Leu Pro Cys Gly Ser Gln  
65 70 75 80

Gln Leu Cys Cys Gly Cys Thr Ala Arg Leu Gly Gly Xaa Trp Ile Gly  
85 90 95

Ala Ser Arg Cys Gly Ser Gly Ser Ala Phe Leu Ala Ser Pro Xaa  
100 105 110

<210> 155

<211> 48

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (48)

<223> Xaa equals stop translation

<400> 155  
Met Ser Leu Gln Ala Ile Asp Leu Leu Trp Ser Leu Cys Thr Gln Thr  
1 5 10 15

Ser Leu Leu Thr Leu Ile Cys Ile Cys Ser His Ser Gln Ala Leu Ser  
20 25 30

Ser Ser Pro Gln Leu His Leu Arg Ser Ser Ile Arg Phe Ser Xaa  
35 40 45

<210> 156

<211> 82

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (82)

<223> Xaa equals stop translation

<400> 156

Met Phe His Phe Gly Leu Trp Asp Leu His Phe Phe Leu Ile Val Met  
1 5 10 15

Ala His Arg Asp Asp Cys Ser Phe Lys Gly Gly Cys Gly Leu Leu Glu  
20 25 30

Arg Phe Gln Cys Pro His Thr Ser Phe Ser Ser Ala Ser Gln Lys Arg  
35 40 45

Leu Ala Asp Gly Met Glu Cys Lys Leu Cys Glu Ile Glu Arg Thr Gln Thr  
50 55 60

Arg Ile Arg Lys Ile Cys Leu Pro Thr Leu His Gly His Leu Leu Ala  
65 70 75 80

Val Xaa

<210> 157

<211> 156

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (108)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (113)

<223> Xaa equals any of the naturally occurring L-amino acids

WO 99/24836

PCT/US98/23435 -

<220>

<221> SITE

<222> (156)

<223> Xaa equals stop translation

<400> 157

Met Met Ala Arg Gln Thr Gly Val Phe Tyr Leu Thr Leu Val Leu Ile  
1 5 10 15

Leu Val Thr Ser Gly Leu Phe Phe Ala Phe Asp Cys Pro Tyr Leu Ala  
20 25 30

Val Lys Ile Thr Pro Ala Ile Pro Ala Val Ala Gly Ile Leu Phe Phe  
35 40 45

Phe Val Met Gly Thr Leu Leu Arg Thr Ser Phe Ser Asp Pro Gly Val  
50 55 60

Leu Pro Arg Ala Thr Pro Asp Glu Ala Ala Asp Leu Glu Arg Gln Ile  
65 70 75 80

Gly Asn Thr Glu Ser Leu Pro Met Ala Ser Gly His Phe Pro Pro Gly  
85 90 95

Pro Ser Tyr Ser Gly Glu Gly Arg Pro Arg Ala-Xaa Gln Glu Glu Leu  
100 105 110

Xaa Ala Gly Lys Glu Gly Gln Lys Ser Ala Phe Leu Ser Ser Leu  
115 120 125

Gly Gly Gln Asp Glu Leu Lys Arg Cys Asp Ile Arg Leu Glu Gly  
130 135 140

Gln Val Ser Trp Arg Gln Asp Cys Arg Pro Thr Xaa  
145 150 155

<210> 158

<211> 295

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (295)

<223> Xaa equals stop translation

<400> 158

Met Arg Leu Asp Lys Pro Ile Gly Thr Trp Leu Leu Tyr Leu Pro Cys  
1 5 10 15

Thr Trp Ser Ile Gly Leu Ala Ala Glu Pro Gly Cys Phe Pro Asp Trp  
20 25 30

Tyr Met Leu Ser Leu Phe Gly Thr Gly Ala Ile Leu Met Arg Gly Ala  
35 40 45

WO 99/24836

PCT/US98/23435 -

Gly Cys Thr Ile Asn Asp Met Trp Asp Gln Asp Tyr Asp Lys Lys Val  
50 55 60

Thr Arg Thr Ala Asn Arg Pro Ile Ala Ala Gly Asp Ile Ser Thr Phe  
65 70 75 80

Gln Ser Phe Val Phe Leu Gly Gln Leu Thr Leu Ala Leu Gly Val  
85 90 95

Leu Leu Cys Leu Asn Tyr Tyr Ser Ile Ala Leu Gly Ala Gly Ser Leu  
100 105 110

Leu Leu Val Ile Thr Tyr Pro Leu Met Lys Arg Ile Ser Tyr Trp Pro  
115 120 125

Gln Leu Ala Leu Gly Leu Thr Phe Asn Trp Gly Ala Leu Leu Gly Trp  
130 135 140

Ser Ala Ile Lys Gly Ser Cys Asp Pro Ser Val Cys Leu Pro Leu Tyr  
145 150 155 160

Phe Ser Gly Val Met Trp Thr Leu Ile Tyr Asp Thr Ile Tyr Ala His  
165 170 175

Gln Asp Lys Arg Asp Asp Val Leu Ile Gly Leu Lys Ser Thr Ala Leu  
180 185 190

Arg Phe Gly Glu Asn Thr Lys Pro Trp Leu Ser Gly Phe Ser Val Ala  
195 200 205

Met Leu Gly Ala Leu Ser Leu Val Gly Val Asn Ser Gly Gln Thr Ala  
210 215 220

Pro Tyr Tyr Ala Ala Leu Gly Ala Val Gly Ala His Leu Thr His Gln  
225 230 235 240

Ile Tyr Thr Leu Asp Ile His Arg Pro Glu Asp Cys Trp Asn Lys Phe  
245 250 255

Ile Ser Asn Arg Thr Leu Gly Leu Ile Val Phe Leu Gly Ile Val Leu  
260 265 270

Gly Asn Leu Trp Lys Glu Lys Lys Thr Asp Lys Thr Lys Lys Gly Ile  
275 280 285

Glu Asn Lys Ile Glu Asn Xaa  
290 295

<210> 159

<211> 60

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (60)

<223> Xaa equals stop translation

<400> 159  
 Met Gly Pro Phe Leu Leu Val Phe Leu Phe Pro Ile Leu Arg Val Cys  
 1 5 10 15  
 Gly Ile Ile Arg Glu Pro Thr Gln Asp Trp Ser Val Leu Leu Glu Arg  
 20 25 30  
 Ala Arg Leu Thr Ala Pro Gly Gln Pro Pro Ala Leu Phe Pro Leu Glu  
 35 40 45  
 Ser Gly Pro Met Ala Thr Ala Gln Asn Thr Ser Xaa  
 50 55 60  
 <210> 160  
 <211> 122  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (30)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
 <220>  
 <221> SITE  
 <222> (32)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
 <220>  
 <221> SITE  
 <222> (87)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
 <220>  
 <221> SITE  
 <222> (101)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
 <220>  
 <221> SITE  
 <222> (115)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
 <220>  
 <221> SITE  
 <222> (122)  
 <223> Xaa equals stop translation  
 <400> 160  
 Met Cys Ser His Ser Thr Leu Ile His Leu Tyr Leu Val Leu Pro Phe  
 1 5 10 15  
 Phe Phe Leu Phe Leu Pro Ser Ser Phe Pro Phe Pro Ser Xaa Ser Xaa  
 20 25 30  
 Ser Ser Ile Leu Pro Ser Leu Arg Leu Pro Pro Phe Phe Pro Pro Ser

35 40 45  
 Leu Phe Leu His Ser Ser Leu Pro Pro Ser Leu Ser His Pro Leu Gly  
 50 55 60  
 Leu Ser Ile Thr Ser Ser Arg Gln Ser Phe Leu Asp Tyr His His Leu  
 65 70 75 80  
 Cys Thr Lys His Leu Ser Xaa Thr Leu Cys Gly Leu Ile Tyr His Cys  
 85 90 95  
 Leu Asn Ile Phe Xaa Thr Arg Ala Val Met Trp His Met Gln Val Ser  
 100 105 110  
 Phe Leu Xaa Ile His Trp Leu Leu Pro Xaa  
 115 120  
 <210> 161  
 <211> 73  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (73)  
 <223> Xaa equals stop translation  
 <400> 161  
 Met Ser Ile Tyr His Val Cys Leu Ile Leu Leu Leu Tyr Ile Thr Ser  
 1 5 10 15  
 His Ser His Gln Asn Met Ser Ser Cys Leu Gln Val Pro Leu Ser Leu  
 20 25 30  
 Leu Ser Cys Pro Leu Lys Gly Glu His Leu Ser Gln Phe Ala Gly Asp  
 35 40 45  
 His Ser Leu Pro Glu Val Arg Asp Arg Asn His His Cys Ile Leu Phe  
 50 55 60  
 Lys Glu Ser His Gln Lys Arg Lys Xaa  
 65 70  
 <210> 162  
 <211> 123  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (123)  
 <223> Xaa equals stop translation  
 <400> 162  
 Met Leu Ala Asn Phe Thr Leu Phe Ile Leu Thr Leu Ile Ser Phe Leu  
 1 5 10 15

Leu Leu Val Cys Ser Pro Cys Lys His Leu Lys Met Met Gln Leu His	20	25	30
Gly Lys Gly Ser Gln Asp Leu Ser Thr Lys Val His Ile Lys Pro Leu	35	40	45
Gln Thr Val Ile Ser Phe Leu Met Leu Phe Ala Ile Tyr Phe Leu Cys	50	55	60
Ile Ile Thr Ser Thr Trp Asn Pro Arg Thr Gln Gln Ser Asn Leu Val	65	70	75
Phe Leu Leu Tyr Gln Thr Leu Ala Ile Met Tyr Pro Ser Phe His Ser	85	90	95
Phe Ile Leu Ile Met Arg Ser Arg Lys Leu Lys Gln Thr Ser Leu Ser	100	105	110
Val Leu Cys Gln Val Thr Cys Trp Val Lys Xaa	115	120	
<210> 163			
<211> 143			
<212> PRT			
<213> Homo sapiens			
<220>			
<221> SITE			
<222> (143)			
<223> Xaa equals stop translation			
<400> 163			
Met Pro Gly Pro Cys Leu Ser Gln Gln His Pro Phe Leu Ser Leu Ser	1	5	10
Leu Phe Pro Phe Cys Leu Trp Ile Cys Leu Ala Arg Val Pro Gly Val	20	25	30
Arg Asn Ile Cys Lys Thr Gln Pro Ala Pro Ser Gln Pro Ser Leu Leu	35	40	45
Gly Leu Gly Leu Ser His Pro Ala Ala Gly Thr Thr Asp Ala Gly Thr	50	55	60
Gln Ser Leu Pro Arg Ser Gln His Lys Cys Thr Ser Ala Leu Trp Gly	65	70	75
Leu Cys Pro Ala Gln Arg Pro Leu Leu Leu Pro Ala His Ile His Ser	85	90	95
Ser Gly His Gly Ala Pro Gln Glu Leu Gln Ser His Leu Ser His Arg	100	105	110
Leu Pro Ala Ser Ala Ser Leu Ser Met Met Ser Pro Phe Ser Glu Ala	115	120	
Trp Thr His Pro Ser Leu Ser Leu Gly Pro Ala Pro Ser His Xaa	130	135	140
<210> 164			
<211> 117			
<212> PRT			
<213> Homo sapiens			
<220>			
<221> SITE			
<222> (46)			
<223> Xaa equals any of the naturally occurring L-amino acids			
<220>			
<221> SITE			
<222> (117)			
<223> Xaa equals stop translation			
<400> 164			
Met Pro Gly Gly Thr Arg Cys Arg Val Leu Leu Ser Leu Thr Phe	1	5	10
Gly Thr Ser Met Ala Cys Gly Asn Val Gly Leu Arg Leu Cys Pro Trp	20	25	30
Thr Trp His Asn Trp Leu Leu Pro Pro His Leu Cys Ser Xaa Trp Pro	35	40	45
Cys Arg Arg Cys Cys Trp Ala Ala Ala Thr Thr His Phe Ser Trp Pro	50	55	60
Pro Trp Val Arg Ser Ala Trp Gly Pro Pro Ala Ala Trp Leu Glu Ser	65	70	75
Ser Gly His Pro Leu Pro Ala Val Ala Ser Cys Ser Gln Pro Pro Ala	85	90	95
Ser Ala Asp Ser Ser Arg Phe Ser Lys Val Pro Cys Cys Arg Arg Arg	100	105	110
Gly Trp Thr Arg Xaa	115		
<210> 165			
<211> 59			
<212> PRT			
<213> Homo sapiens			
<220>			
<221> SITE			
<222> (59)			
<223> Xaa equals stop translation			
<400> 165			
Met Ser Val Cys Leu Pro Leu His Leu Pro Phe Leu Met Leu Ala Lys	1	5	10

Val Ala Thr Ser Phe Cys Arg Trp Gln Leu Thr Leu Phe Val Ser Thr  
20 25 30  
Phe Tyr Lys Asp Ala Leu Val His Thr Val Asn Asp Arg Asn Gln Glu  
35 40 45  
Ala Glu Leu Glu Ala Leu Lys Lys Ser Cys Xaa  
50 55

<210> 166  
<211> 126  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (126)  
<223> Xaa equals stop translation

<400> 166  
Met Lys Ala Leu Met Leu Leu Thr Leu Ser Val Leu Leu Cys Trp Val  
1 5 10 15

Ser Ala Asp Ile Arg Cys His Ser Cys Tyr Lys Val Pro Val Leu Gly  
20 25 30

Cys Val Asp Arg Gln Ser Cys Arg Leu Glu Pro Gly Gln Cys Leu  
35 40 45

Thr Thr His Ala Tyr Leu Gly Lys Met Trp Val Phe Ser Asn Leu Arg  
50 55 60

Cys Gly Thr Pro Glu Glu Pro Cys Gln Glu Ala Phe Asn Gln Thr Asn  
65 70 75 80

Arg Lys Leu Gly Leu Thr Tyr Asn Thr Thr Cys Cys Asn Lys Asp Asn  
85 90 95

Cys Asn Ser Ala Gly Pro Arg Pro Thr Pro Ala Leu Gly Leu Val Phe  
100 105 110

Leu Thr Ser Leu Ala Gly Leu Gly Leu Trp Leu Leu His Xaa  
115 120 125

<210> 167  
<211> 87  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (87)  
<223> Xaa equals stop translation

<400> 167

Met Phe Leu Val Ala Val Trp Trp Arg Phe Gly Ile Leu Ser Ile Cys  
1 5 10 15

Met Leu Cys Val Gly Leu Val Leu Gly Phe Leu Ile Ser Ser Val Thr  
20 25 30

Phe Phe Thr Pro Leu Gly Asn Leu Lys Ile Phe His Asp Asp Gly Val  
35 40 45

Phe Trp Val Thr Phe Ser Cys Ile Ala Ile Leu Ile Pro Val Val Phe  
50 55 60

Met Gly Cys Leu Arg Ile Leu Asn Ile Leu Thr Cys Gly Ser His Trp  
65 70 75 80

Ala Pro Ile Arg Trp Phe Xaa  
85

<210> 168  
<211> 63  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (16)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (54)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (63)  
<223> Xaa equals stop translation

<400> 168  
Met Val Thr Gly Phe Phe Phe Ile Leu Met Thr Val Leu Trp Phe Xaa  
1 5 10 15

Arg Glu Pro Gly Phe Val Pro Gly Trp Asp Ser Phe Phe Glu Lys Lys  
20 25 30

Gly Tyr Arg Thr Asp Ala Thr Val Ser Val Phe Leu Gly Phe Leu Leu  
35 40 45

Phe Leu Ile Pro Ala Xaa Glu Ala Leu Leu Trp Glu Lys Glu Xaa  
50 55 60

<210> 169  
<211> 48  
<212> PRT  
<213> Homo sapiens

WO 99/24836

44

Met Ile Arg Ala Cys Arg Val Asn Xaa  
130 135

<210> 171  
<211> 89  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (40)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (89)  
<223> Xaa equals stop translation

<400> 171  
Met Glu Leu Ser Phe Val Arg Arg Leu Leu Phe Thr Phe Phe  
1 5 10 15

Ser Thr Phe Ser Pro Pro Thr Pro Cys Leu Glu Gly Leu Met  
20 25 30

Ser Cys Leu Pro Ser Pro Leu Xaa Lys Asn Thr Ala Gly Ser Gln Thr  
35 40 45

Lys Ser Leu Arg Glu Ile Gly Thr Gly Ile Ser Asp Thr His Val Ser  
50 55 60

Pro Ser Pro Ala Gln Ala Pro Leu Cys Ser Arg Ser Pro Thr Trp Asp  
65 70 75 80

Ser Ser Asp Pro Asn Ser Met Asp Xaa  
85

<210> 172  
<211> 58  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (58)  
<223> Xaa equals stop translation

<400> 172  
Met Thr Met Val Met Glu Gln Val Tyr Leu Met Ser Phe Leu Leu  
1 5 10 15

Leu Leu Arg Thr Met Met Lys Ala His Trp Thr Tyr Thr Leu Gly Trp  
20 25 30

Thr Val Leu Phe Leu Thr Ala Leu Pro Asn Pro Val Tyr His Gln Glu

PCT/US98/23435 -

WO 99/24836

43

<220>  
<221> SITE  
<222> (48)  
<223> Xaa equals stop translation

<400> 169  
Met Ser Gln Leu Cys Phe Ser Leu Leu Ser Thr Cys His Gly  
1 10 15

Gly Val Ala Ser Leu Thr Ser Asp Leu Ser Ser Gln Ser His Arg  
20 25 30

Phe Ser Ile Cys Thr Asn Val Asn His Ser Lys Tyr Ser Ser Leu Xaa  
35 40 45

<210> 170  
<211> 137  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (84)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (137)  
<223> Xaa equals stop translation

<400> 170  
Met Leu Phe Ser Leu Arg Glu Leu Val Gln Trp Leu Gly Phe Ala Thr  
1 5 10 15

Phe Glu Ile Phe Val His Leu Leu Ala Leu Leu Val Phe Ser Val Leu  
20 25 30

Leu Ala Leu Arg Val Asp Gly Leu Val Pro Gly Leu Ser Trp Trp Asn  
35 40 45

Val Phe Val Pro Phe Phe Ala Ala Asp Gly Leu Ser Thr Tyr Phe Thr  
50 55 60

Thr Ile Val Ser Val Arg Leu Phe Gln Asp Gly Glu Lys Arg Leu Ala  
65 70 75 80

Val Leu Arg Xaa Phe Trp Val Leu Thr Val Ser Leu Lys Phe Val  
85 90 95

Phe Glu Met Leu Leu Cys Gln Lys Leu Ala Glu Gln Thr Arg Glu Leu  
100 105 110

Trp Phe Gly Leu Ile Thr Ser Pro Leu Phe Ile Leu Leu Gln Leu Leu  
115 120 125

35 40 45  
Ile Val Trp Thr Tyr Met Lys Arg Ser Xaa  
50 55

<210> 173  
<211> 64  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (64)  
<223> Xaa equals stop translation

<400> 173  
Met Asp Thr Asp Asn Gly Gly Arg His Phe Lys Pro Phe Lys Leu Val  
1 5 10 15  
Leu Phe Val Val Leu Leu Ile Lys Ile Leu Leu Ile Leu Ala Lys Thr  
20 25 30  
Asn Cys Cys Asp Lys Leu Val Phe Phe Gly Cys Phe Lys His Thr Leu  
35 40 45  
Thr Asn Phe Leu Ile Pro Leu Leu Val Pro Pro Ile Val Leu Lys Xaa  
50 55 60

<210> 174  
<211> 61  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (61)  
<223> Xaa equals stop translation

<400> 174  
Met Cys Leu Trp Gly Gln Ala Asn Leu Gly Leu Ile Leu Phe Gln His  
1 5 10 15  
Cys Leu Thr Lys Phe Met Gly Gly Tyr Cys Phe Gly Leu Gly Ser Cys  
20 25 30  
Thr Arg Pro Leu Arg Asp Gln Thr Lys Met Glu Ser Leu Ile Leu Lys  
35 40 45  
Leu Gln Val Thr Glu Pro Lys Leu Ser Cys Phe Ile Xaa  
50 55 60

<210> 175

<211> 104  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (104)  
<223> Xaa equals stop translation

<400> 175  
Met Gly Met Ala Gly Ala Leu Ser Ile Leu Leu Phe Ser Leu Pro Ser  
1 5 10 15  
His Gly Trp Pro Ser Pro Pro Lys Pro Pro Phe Pro Cys Gln Pro  
20 25 30  
Leu Cys His Ser Leu Ile Leu Gly Arg Lys Gly Arg Phe Glu Gly  
35 40 45  
Glu Gly Glu Lys Ala Tyr Gly Trp Val Trp Phe Leu Pro Phe Pro Glu  
50 55 60  
Gly Leu Thr Val Pro Gly Trp Pro Gln Gly Arg Gln Gly Pro His Tyr  
65 70 75 80  
Ala Cys Ala Leu Val Lys Val Thr Pro Ala Ile Tyr Gln Gln Pro Trp  
85 90 95  
His Val Pro Ala Pro Gln Glu Xaa  
100

<210> 176  
<211> 293  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (293)  
<223> Xaa equals stop translation

<400> 176  
Met Leu Arg Val Leu Cys Leu Leu Arg Pro Trp Arg Pro Leu Arg Ala  
1 5 10 15  
Arg Gly Cys Ala Ser Asp Gly Ala Ala Gly Gly Ser Glu Ile Gln Val  
20 25 30  
Arg Ala Leu Ala Gly Pro Asp Gln Gly Ile Thr Glu Ile Leu Met Asn  
35 40 45  
Arg Pro Ser Ala Arg Asn Ala Leu Gly Asn Val Phe Val Ser Glu Leu  
50 55 60  
Leu Glu Thr Leu Ala Gln Leu Arg Glu Asp Arg Gln Val Arg Val Leu  
65 70 75 80

WO 99/24836

PCT/US98/23435 -

Leu Phe Arg Ser Gly Val Lys Gly Val Phe Cys Ala Gly Ala Asp Leu 95  
 85  
 Lys Glu Arg Glu Gln Met Ser Glu Ala Glu Val Gly Val Phe Val Gln 110  
 100 105  
 Arg Leu Arg Gly Leu Met Asn Asp Ile Ala Ala Phe Pro Ala Pro Thr 125  
 115 120  
 Ile Ala Ala Met Asp Gly Phe Ala Leu Gly Gly Leu Glu Leu Ala 140  
 130 135  
 Leu Ala Cys Asp Leu Arg Val Ala Ala Ser Ser Ala Val Met Gly Leu 160  
 145 150 155  
 Ile Glu Thr Thr Arg Gly Leu Leu Pro Gly Ala Gly Gly Thr Gln Arg 175  
 165 170  
 Leu Pro Arg Cys Leu Gly Val Ala Leu Ala Lys Glu Leu Ile Phe Thr 190  
 180 185  
 Gly Arg Arg Leu Ser Gly Thr Glu Ala His Val Leu Gly Leu Val Asn 205  
 195 200  
 His Ala Val Ala Gln Asn Glu Glu Gly Asp Ala Ala Tyr Gln Arg Ala 220  
 210 215  
 Arg Ala Leu Ala Gln Glu Ile Leu Pro Gln Ala Pro Ile Ala Val Arg 240  
 225 230 235  
 Leu Gly Lys Val Ala Ile Asp Arg Gly Thr Glu Val Asp Ile Ala Ser 255  
 245 250  
 Gly Met Ala Ile Glu Gly Met Cys Tyr Ala Gln Asn Ile Pro Thr Arg 270  
 260 265  
 Asp Arg Leu Glu Gly Met Ala Ala Phe Arg Glu Lys Arg Thr Pro Lys 285  
 275 280  
 Phe Val Gly Lys Xaa 290  
 290  
 <210> 177  
 <211> 46  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (46)  
 <223> Xaa equals stop translation  
 <400> 177  
 Met Leu Ser Ser Leu Tyr Leu Leu Met Pro Pro Tyr Lys Phe Thr 15  
 1 5 10  
 Gly Glu Leu His Pro Pro Val Ala Ala Thr Cys Leu Leu Thr Val Leu

WO 99/24836

PCT/US98/23435 -

Leu Gly Cys Leu Ile Gly Val Ser Ser Asp Gly Trp Ile Xaa 45  
 35 40  
 <210> 178  
 <211> 47  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (47)  
 <223> Xaa equals stop translation  
 <400> 178  
 Met Cys Ile Pro Glu Ala Leu Gly Lys Asn Ser Leu Phe Leu Ser Ser 15  
 1 5 10  
 Thr Phe Leu Trp Leu Leu Ala Phe Phe Gly Leu Trp Ser His His Ser 30  
 20 25  
 Tyr Leu Glu Gly Gln His Leu Gln Ile Cys Phe Phe Thr Xaa 45  
 35 40  
 <210> 179  
 <211> 55  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (55)  
 <223> Xaa equals stop translation  
 <400> 179  
 Met Thr Thr Ser Leu Phe Gly Leu Val Cys Val Val Cys Gln Gly Ala 15  
 1 5 10  
 Gly Val Ser Ala Phe Thr Gln Val Asn Leu Phe Ser Phe Ser Leu Val 30  
 20 25  
 Ile Val Lys Lys Gln Asn Lys Thr Ser Cys Glu Pro Phe Gly Thr Ser 45  
 35 40  
 Gly Lys Val Pro Leu Leu Xaa 55  
 50  
 <210> 180  
 <211> 67  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE

49

100

<222> (67)  
<223> Xaa equals stop translation

<400> 180  
Met Leu Ile Tyr Trp Leu Gln Ser Ser Phe Ile Leu Ser Ala Phe Val  
1 5 10 15

Leu Ile Asn Ser Pro Val Thr Thr Gly Ile Gln Lys Ser Cys Cys Lys  
20 25 30

Phe Phe Pro Val Ser Ile Asn Leu Cys Phe Ala Ser Leu His Arg Met  
35 40 45

Lys Val Val Thr Leu Val Ala Leu Gln Trp Leu Asn Ile Ala Leu Arg  
50 55 60

Ser Ser Xaa  
65

<210> 181  
<211> 51

<212> PRT  
<213> Homo sapiens

<220>

<221> SITE  
<222> (51)

<223> Xaa equals stop translation

<400> 181  
Met Val Cys Cys Gly Phe Phe Leu Leu Trp Ser Arg Val Arg Ser Tyr  
1 5 10 15

Met Lys Leu Ser Gly His Arg Trp Ser Ser Ser Cys Pro His His Cys  
20 25 30

Tyr Ser Lys Cys Gly Leu His Thr Ser Asn Gly Lys Ser Ser Val His  
35 40 45

Thr Val Xaa  
50

<210> 182  
<211> 91

<212> PRT  
<213> Homo sapiens

<220>

<221> SITE  
<222> (29)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE  
<222> (30)

<223> Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

<221> SITE  
<222> (65)

<223> Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

<221> SITE  
<222> (91)

<223> Xaa equals stop translation

<400> 182  
Met Leu Arg Cys Ser Phe Ser Ser Phe Leu Leu Cys His Thr Ile Leu  
1 5 10 15

Leu Phe Leu Gly Ser Ser Ala His Leu Leu Val Glu Xaa Xaa Val Trp  
20 25 30

Gly Leu Tyr Glu Tyr Arg Ile Gly Asp Met Val Asp Gln Lys Ala Thr  
35 40 45

Phe Cys Val Gln Lys Gln Glu Cys Leu Phe Pro Leu Gly Ser Trp Val  
50 55 60

Xaa Arg Val Glu Gly Ala Phe Ala Arg Glu Pro Pro Ser Ser Thr  
65 70 75 80

Gln Tyr Phe Pro Val Ser Cys Leu Tyr Gln Xaa  
85 90

<210> 183  
<211> 55

<212> PRT  
<213> Homo sapiens

&lt;220&gt;

<221> SITE  
<222> (55)

<223> Xaa equals stop translation

<400> 183  
Met Ser Ala Leu Leu Ser His His Val Pro Leu Phe Tyr Leu Thr Gly  
1 5 10 15

Cys Leu Phe Ser Leu Leu Ala Ser Trp Asp Cys Asn Gly Lys Glu Gly  
20 25 30

Ala Gly Arg Ala Ile Lys Gly Lys Asn Asn Thr Trp Asn Cys Met Ile  
35 40 45

Leu Ser Lys Val Lys Phe Xaa  
50 55

<210> 184  
<211> 64

<212> PRT

65 70 107 75 80

Pro Glu Arg Thr Ala Met Pro Arg Ser Ile Val Arg Ala His Thr Val  
85 90 95

Asn Ser Leu Asn Lys Lys Val Gln Thr Arg His Val Thr Trp Ala Leu  
100 105 110

Xaa

<210> 186

<211> 60

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (60)

<223> Xaa equals stop translation

<400> 186

Met Leu His Leu Thr Leu Tyr Leu His Phe Ile Leu Phe Val Phe Pro  
1 5 10 15

Ile Thr Ser Asn Phe Ser Ser Leu His Pro Phe Leu Phe Ile Ser Ser  
20 25 30

Gln Phe Thr Ser Cys Cys Gln Ile Asn Phe Pro Asn Ala Gln Ala Leu  
35 40 45

Ser Tyr His Glu Phe Leu Ile Ala Thr Tyr Asp Xaa  
50 55 60

<210> 187

<211> 64

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (64)

<223> Xaa equals stop translation

<400> 187

Met Pro Cys Ile Arg Gly Val Phe His Cys Phe Ile Leu Ile Ile Leu  
1 5 10 15

Ile Leu Leu Ala Ser His Ala Phe Ser Gly Ser Gly Asn Gln Arg Leu  
20 25 30

Lys Glu Ala Leu Thr Leu Ile Val Ser Val Asn Val Asp Ile Ala Arg  
35 40 45

His Arg Pro Phe Leu Glu Arg Ile His Val Lys Lys Gly Asn Thr Xaa  
50 55 60

<213> Homo sapiens 101

<220>

<221> SITE

<222> (26)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (41)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (64)

<223> Xaa equals stop translation

<400> 184

Met Val His Lys Ala Ile Leu Ala Leu Leu Pro Trp Gly Phe Ser Ala  
1 5 10 15

Asp Glu Leu Leu Ala Ser Leu Met Met Xaa Leu Thr Glu Lys Tyr Gln  
20 25 30

Asn Cys Ser Ser Thr Thr Asp Ile Xaa Asn Gln Gln Leu Arg Ser Leu  
35 40 45

Gly Gln Asn Phe Met Phe Gln Gln Asn Leu Gln Leu Ile Leu Met Xaa  
50 55 60

<210> 185

<211> 113

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (113)

<223> Xaa equals stop translation

<400> 185

Met Met Thr Ser Ser Leu Gly Leu Ser Phe Leu Leu Asn Leu Ile Leu  
1 5 10 15

Gly Met Lys Phe Thr Tyr Leu Ile Pro Gln Asn Lys Tyr Ile Gln Leu  
20 25 30

Phe Thr Thr Ile Leu Ser Phe Ser Gly Val Leu Ser Leu Leu Glu  
35 40 45

Cys Lys Leu Ser Thr Ser Cys Thr Cys Leu Asn Ile His Lys Ser  
50 55 60

Asp Asn Glu Cys Lys Glu Ser Glu Asn Ser Ile Glu Asp Ile Ser Leu

103

<210> 188  
 <211> 71  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (71)  
 <223> Xaa equals stop translation

<400> 188  
 Met Phe Ser Arg Leu His Phe Leu Thr His Ser Leu Ser Leu His  
 1 5 10 15

Leu Pro Ser Gln Val Phe Gly Glu Val His Ser Ser Cys Val Ser Ser  
 20 25 30

Leu Pro Cys Pro Asp Thr Pro Ala Leu Pro Tyr Cys Pro Ser Phe Leu  
 35 40 45

Arg Tyr Asp Asp His Ile Glu Ala Gln Pro Leu Lys His Ile Asn Thr  
 50 55 60

Asn Asp His Ile Ser Ile Xaa  
 65 70

<210> 189  
 <211> 63  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (63)  
 <223> Xaa equals stop translation

<400> 189  
 Met Cys Val Phe Ser Ser Asp Ser Ile Pro Ser Leu Leu Ile Leu Leu  
 1 5 10 15

Val Leu Cys His Ser Val Cys Cys Leu Lys Leu Phe Phe Lys Leu Ile  
 20 25 30

Phe Pro Asn Ser Phe Ile Ile Tyr Glu Lys Leu Gly Leu Asn His Phe  
 35 40 45

Ala Tyr His Leu Ser Gly Trp Phe Glu Leu Ser Leu Asp Thr Xaa  
 50 55 60

<210> 190  
 <211> 193

<212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (193)  
 <223> Xaa equals stop translation

<400> 190  
 Met Glu Ala Leu Leu Gln Ser Ser Leu Val Ile Val Leu Leu Gly Phe Lys  
 1 5 10 15

Ser Phe Leu Ser Glu Glu Leu Gly Ser Glu Val Leu Asn Leu Thr  
 20 25 30

Asn Lys Gln Tyr Glu Leu Leu Ser Lys Asn Leu Arg Lys Thr Arg Glu  
 35 40 45

Leu Phe Val His Gly Leu Pro Gly Ser Gly Lys Thr Ile Leu Ala Leu  
 50 55 60

Arg Ile Met Glu Lys Ile Arg Asn Val Phe His Cys Glu Pro Ala Asn  
 65 70 75 80

Ile Leu Tyr Ile Cys Glu Asn Gln Pro Leu Lys Lys Leu Val Ser Phe  
 85 90 95

Ser Lys Lys Asn Ile Cys Gln Pro Val Thr Arg Lys Thr Phe Met Lys  
 100 105 110

Asn Asn Phe Glu His Ile Gln His Ile Ile Ile Asp Asp Ala Gln Asn  
 115 120 125

Phe Arg Thr Glu Asp Gly Asp Trp Tyr Gly Lys Ala Lys Phe Ile Thr  
 130 135 140

Gln Thr Ala Arg Asp Gly Pro Gly Val Leu Trp Ile Phe Leu Asp Tyr  
 145 150 155 160

Phe Gln Thr Tyr His Leu Ser Cys Ser Ala Ser Pro Leu Pro Gln Thr  
 165 170 175

Ser Ile Gln Glu Lys Arg Ser Thr Glu Trp Ser Ala Met Gln Val Gln  
 180 185 190

Xaa

<210> 191  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (112)  
 <223> Xaa equals stop translation

WO 9974836

PCT/US98/23435 -

<400> 191  
Met Gln Phe Ser Leu Cys Leu Thr Ala Val Phe Leu Leu Gln Leu Ala  
1 5 10 15  
Ala Gly Ile Leu Gly Phe Val Phe Ser Asp Lys Ala Arg Gly Lys Val  
20 25 30  
Ser Glu Ile Ile Asn Asn Ala Ile Val His Tyr Arg Asp Asp Leu Asp  
35 40 45  
Leu Gln Asn Leu Ile Asp Phe Gly Gln Lys Lys Val Trp Val Ser Gln  
50 55 60  
Trp Ser Gly Gly Leu Trp Val Lys Val Asn Val Ile Pro Arg Asp Ala  
65 70 75 80  
Ser Pro Ser Met Pro Val Gly Leu Phe Ile Thr Cys Gln Val Met Ala  
85 90 95  
Ser Gly Lys Gly Phe Gly Lys Lys Ser Thr Arg Ser Arg Val Leu Xaa  
100 105 110  
<210> 192  
<211> 80  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (80)  
<223> Xaa equals stop translation  
<400> 192  
Met Cys Arg Pro Leu Leu Pro Leu Leu Phe Pro Trp Gly His Cys Leu  
1 5 10 15  
Ser Ile Pro Leu Cys Lys Trp Pro Gln Ile Met Ser Gln Pro Pro Arg  
20 25 30  
Leu His Arg Leu Leu Ala Ser Gly Pro Ser Thr Lys Lys His Ser Lys  
35 40 45  
Leu Gln Thr His Ser Trp Glu Asn Ser Asn Gly Leu Thr Leu Pro Phe  
50 55 60  
Glu Pro Ala Arg Ser His Gly Leu Trp Arg Ala Ala Phe Glu Ser Xaa  
65 70 75 80

WO 9974836

PCT/US98/23435 -

<211> 88  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (88)  
<223> Xaa equals stop translation  
<400> 193  
Met Leu Ser Ile Ile Asp Leu Leu Phe Leu Leu Ser Pro Thr Phe Gly  
1 5 10 15  
Leu Ile Thr Glu Leu Leu Phe Ser Pro Glu Val Pro Lys Ala Leu Ser  
20 25 30  
Cys Pro Leu Lys Ala Leu Gly Gly Ser His Ser His Glu Pro Leu  
35 40 45  
Gly Met Phe Ala Pro Val Pro Pro Gly Cys Glu Ser Ser Thr Pro Phe  
50 55 60  
Pro Lys Gly Leu Gly Ala Ser Lys Ile Leu Thr Leu Gly Ala Gln Ala  
65 70 75 80  
Glu Phe Arg Arg Arg Ser His Xaa  
85  
<210> 194  
<211> 42  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (42)  
<223> Xaa equals stop translation  
<400> 194  
Met Glu Asp His Phe Leu Ile Gly His Phe Pro Phe Phe Leu Phe  
1 5 10 15  
Ser Phe Pro Cys Phe Cys Thr Lys Pro Leu Cys Arg Glu Tyr Phe Leu  
20 25 30  
Ile Cys Ser Ile Gln Asp Glu Ser Lys Xaa  
35 40  
<210> 195  
<211> 69  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (69)

<223> Xaa equals stop translation 107  
<400> 195  
Met Phe Asn Leu Pro Lys Pro Val Phe Leu Ser Trp Trp Arg Trp Lys  
1 5 10 15  
Thr Ile Val Ile Phe Leu Ala Cys Leu Ala Ser Ala Ala Ile Lys Glu  
20 25 30  
Thr Ala Val Ser Met Lys Thr Val Phe Pro Ile Phe Val Gln Ile Thr  
35 40 45  
Leu Ile Leu Leu Leu Glu Ser Arg Val Leu Lys Ile Gly Asp Phe Ser  
50 55 60  
Asn Phe Phe Cys Xaa  
65  
<210> 196  
<211> 153  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (66)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (77)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (81)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (84)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<230>  
<221> SITE  
<222> (86)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (87)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (93)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (103)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (110)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (153)  
<223> Xaa equals stop translation  
<400> 196  
Met Asp His Ser Pro Thr Thr Gly Val Val Thr Val Ile Val Ile Leu  
1 5 10 15  
Ile Ala Ile Ala Ala Leu Gly Ala Phe Asp Pro Gly Leu Leu Val Leu  
20 25 30  
Pro Ala Ala Ala Ala His Gln Pro Val Arg Gly Arg Gly Glu His Arg  
35 40 45  
Gly Gly Trp Gly Asp Gln Gly Thr Leu Pro Ala Gly Ala Val Phe Gly  
50 55 60  
Gln Xaa Thr Val Arg Gly Glu Lys Gly Gln Ala Asp Xaa Ser Gln Thr  
65 70 75 80  
Xaa Arg Lys Xaa Thr Xaa Xaa Pro Gly Cys Lys Gly Xaa Leu Val Pro  
85 90 95  
Val Cys Lys Pro Ala Lys Xaa Gly Leu Gly Gly Ala Lys Xaa Ile Arg  
100 105 110  
Met Arg Cys Cys Leu Arg Gly Arg Ala Asp Thr Cys Trp His Gly Leu  
115 120 125  
Cys Gly Phe Arg Pro Ser His Ala Leu Met Pro Gly Asp Leu Ala Val  
130 135 140  
Leu Gly Phe Pro Ser Ala Ser Arg Xaa  
145 150  
<210> 197  
<211> 63  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (63)  
<223> Xaa equals stop translation

WO 99/24836

PCT/US98/23435

WO 99/24836

PCT/US98/23435

<400> 197  
Met Lys Asn Ser Thr Ser Leu Leu Tyr Lys Leu Phe Ser Ser Leu Ser 15  
1 10  
Val Phe Ile Phe Lys Phe Leu Leu Phe Tyr Thr Leu His Ile Ala 30  
20 25  
Leu Gly Val Lys Ile Gln Tyr Lys Pro Leu Ala His Phe Ile Asp His 45  
35 40  
Ser Cys Ile Gln Gln Val Ser Gln Val Gln Trp Ser Ile Pro Xaa 60  
50 55  
<210> 198  
<211> 64  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (64)  
<223> Xaa equals stop translation  
<400> 198  
Met Gln Glu Pro His Gly Lys Phe Leu Ser Trp Gly Arg Trp Leu Trp 15  
1 5 10  
Trp Trp Ser Leu Ala Ala Pro Ala Leu Val Gln Ala Val Asn Met Pro 30  
20 25  
Pro Ala Tyr Ile Gln Ile Glu Asn Trp Tyr Met Met Leu Leu Met Gly 45  
35 40  
Trp Glu Thr Lys Cys Cys His Val Arg Ser Leu Trp Val Gly Thr Xaa 60  
50 55  
<210> 199  
<211> 43  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (43)  
<223> Xaa equals stop translation  
<400> 199  
Met Leu Ile Asn Cys Ile Phe Ser Leu Leu Leu Leu Ser His Ala 15  
1 5 10  
Asp Gly Met His Leu Phe Ile Ser Ser Gly Asp Arg Ile Leu Phe Cys 30  
20 25

Leu Tyr Phe Leu His Ser Arg Val Cys Ala Xaa 40  
35  
<210> 200  
<211> 41  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (41)  
<223> Xaa equals stop translation  
<400> 200  
Met Ser Val Tyr Val Asn Ile Met His Ile Val Ile Tyr Ile Tyr Leu 15  
1 5 10  
Cys Val Tyr Met Cys Val Ala Gln Ser His Thr His Thr Gln Ile Cys 30  
20 25  
Ile Gln Met Leu Pro Gly Leu Gln Xaa 40  
35  
<210> 201  
<211> 44  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (44)  
<223> Xaa equals stop translation  
<400> 201  
Met Ile Leu Ser Phe Leu Met Leu Phe Leu Ile Val Lys Thr Ile Pro 15  
1 5 10  
Leu Ile Leu Ala Tyr Cys Tyr Asn Ser Ile Ser Phe Phe Ser Asn Asn 30  
20 25  
Leu Val Leu Val Lys Met Gly Tyr Asn Asn Lys Xaa 40  
35  
<210> 202  
<211> 42  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (42)  
<223> Xaa equals stop translation  
<400> 202  
Met Arg Leu Leu Ser Thr Leu Leu Ser Phe Tyr Pro Phe Ser Asn Cys

1 5 10 11 15  
Phe Leu Leu Ser Phe Cys Asp Ser His Pro Pro Val Trp Leu Arg Asn  
20 25 30  
Ser Gln Val Phe Pro Glu Glu Val Val Xaa  
35 40

<210> 203  
<211> 42  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (42)  
<223> Xaa equals stop translation

<400> 203  
Met Thr Gly Lys Leu Trp Leu Leu Leu Pro Arg Leu Gly His Ala Ala  
1 5 10 15  
Ala Ala Pro Thr Thr Ala Leu Ser Gly Ser Glu Leu Glu Gly Thr Ser  
20 25 30  
Ile Ser Leu Leu Ile Ala Leu Asp Arg Xaa  
35 40

<210> 204  
<211> 113  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (117)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (57)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (90)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (91)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (113)

<223> Xaa equals stop translation 112

<400> 204  
Met Ala Pro Trp Leu Pro Leu Leu Ser Leu Leu Gly Leu Leu Gly  
1 5 10 15

Xaa Ala Pro Ala Pro Pro Arg Arg Ala Ala Asp Ala Gln Ala Arg Glu  
20 25 30

Ala Ala Tyr Pro Glu Leu Leu Leu Gly Pro Ala Arg Phe Ala Leu Glu Met  
35 40 45

Tyr Asn Arg Gly Arg Ala Ala Gly Xaa Arg Ala Thr Leu Gly Ala Val  
50 55 60

Arg Gly Arg Val Arg Arg Ala Gly Glu Gly Ser Leu Tyr Ser Leu Arg  
65 70 75 80

Ala Thr Leu Glu Glu Pro Pro Cys Asn Xaa Xaa Thr Val Cys Gln Leu  
85 90 95

Pro Val Ser Lys Arg Pro Cys Ser Ala Ala Leu Lys Ser Trp Thr Ser  
100 105 110

Xaa

<210> 205  
<211> 45  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (45)  
<223> Xaa equals stop translation

<400> 205  
Met Pro Thr Trp Pro Leu Leu Gln Leu Leu Ser Cys Ser Phe Pro Ser  
1 5 10 15

Leu Leu Cys Glu Thr Phe Thr Phe Cys Ser Lys Asp Glu Val Ser Arg  
20 25 30

Trp Lys Ala Gly Cys Phe Val Pro Leu Pro Ala Ser Xaa  
35 40 45

<210> 206  
<211> 71  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (71)  
<223> Xaa equals stop translation

<400> 206  
 Met Thr His Trp Ser Gly Cys Ala Ala Leu Tyr Leu Ile Phe Leu Ser  
 1 5 10 15  
 113  
 Leu Lys Leu Ala Phe Gln Ala Gly Ala Gly Arg Gly Ala Gln Val Gly  
 20 25 30  
 Ser Val Leu Pro Ser Gly Ala Val Val Val Asp Gln Tyr Cys  
 35 40 45  
 Cys Arg Leu Ser Ala Gln Thr Tyr Phe Ser Leu Pro Ala Leu Gln Lys  
 50 55 60  
 Cys Ile Gly Ile Cys Arg Xaa  
 65 70  
 <210> 207  
 <211> 42  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (42)  
 <223> Xaa equals stop translation  
 <400> 207  
 Met Ile Asn Phe Trp Pro Val Thr His Val Cys Ile Trp Leu Leu Trp  
 1 5 10 15  
 Leu Gln Ala Leu Glu Ala Arg Gly Gln Gly Ser Asn Ile Asp Cys Thr  
 20 25 30  
 Arg Asn Ser Lys Thr Val Phe Thr Ser Xaa  
 35 40  
 <210> 208  
 <211> 51  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (51)  
 <223> Xaa equals stop translation  
 <400> 208  
 Met Tyr Ile Tyr Leu Ile His Leu Cys Met Cys Val Tyr Ile Tyr Ile  
 1 5 10 15  
 Tyr Ile Leu Leu Ile Ile Tyr Thr Leu Asp Pro Glu Pro Pro Ser Trp  
 20 25 30  
 Ser Pro Lys Leu Asp Ser His Leu Ser Leu Arg Gln Pro Ser Asn Asp  
 35 40 45

Arg Phe Xaa  
 50 114  
 <210> 209  
 <211> 65  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (65)  
 <223> Xaa equals stop translation  
 <400> 209  
 Met Phe Val Leu Cys Thr Arg Ala Val Arg Thr Arg Leu Phe Ser Leu  
 1 5 10 15  
 Cys Cys Cys Cys Ser Ser Gln Pro Pro Thr Lys Ser Pro Ala Gly  
 20 25 30  
 Thr Pro Lys Ala Pro Ala Pro Ser Lys Pro Gly Glu Ser Gln Glu Ser  
 35 40 45  
 Gln Gly Thr Pro Gly Glu Leu Pro Ser Thr Trp Ser Phe Cys Pro Phe  
 50 55 60  
 Xaa  
 65  
 <210> 210  
 <211> 77  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (77)  
 <223> Xaa equals stop translation  
 <400> 210  
 Met Leu Ala Leu Leu Val Gly Leu Val Ala Ala Leu Ala Cys His  
 1 5 10 15  
 Gly Ile Leu Ala Ala Ile Leu Ala Val Cys Gly Glu Leu Val Ser Gly  
 20 25 30  
 Lys Gly Thr Arg Ser Ser Asp Glu Asp Asp Gly Gly Asp Gly Asp Arg  
 35 40 45  
 Gly His Arg Gly Leu Ser Leu Leu Asn Ser Ala Phe Gly His Met Gly  
 50 55 60  
 Asp Gly Asp Arg Lys Asp Asp Asn Ser Gly Thr Leu Xaa  
 65 70 75

<210> 211  
 <211> 45  
 <212> PRT  
 <213> Homo sapiens

115

<220>  
 <221> SITE  
 <222> (45)  
 <223> Xaa equals stop translation

<400> 211  
 Met Phe Val Gly Thr Arg Val Leu Leu Val Pro Leu Pro Phe Phe Ser  
 1 5 10 15  
 Ile Ser Gly Met Leu Ala Ile Asp Lys Tyr Leu His Lys Leu Leu  
 20 25 30

Leu Asn Glu Ile Ile Thr Thr Ser Thr Tyr Ala Leu Xaa  
 35 40 45

<210> 212  
 <211> 66  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (27)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (66)  
 <223> Xaa equals stop translation

<400> 212  
 Met Gly Lys Gly His Gln Arg Pro Tyr Tyr Lys Val Leu Pro Leu Ser  
 1 5 10 15  
 Cys Phe Leu Val Ala Leu Ile Ile Tyr Cys Xaa Leu Arg Glu Glu Ser  
 20 25 30  
 Glu Ala Asp Gln Trp Leu Arg Gln Val Trp Gly Glu Val Pro Glu Pro  
 35 40 45  
 Ser Asp Arg Ser Glu Glu Pro Glu Thr Pro Ala Ala Tyr Arg Ala Arg  
 50 55 60

Thr Xaa  
 65

<210> 213  
 <211> 62  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (62)  
 <223> Xaa equals stop translation

116

<400> 213  
 Met Arg Leu Cys Thr Thr Trp Met Ala Val Lys Phe Leu Trp Tyr Gly  
 1 5 10 15

Met Thr Trp Ile Pro Ser Gly Lys Ala Cys Ser Tyr Thr Gln Pro Leu  
 20 25 30

Cys Ser Ser Gly Gly Trp Ser Ser Pro Thr His Leu Pro Thr Ser Leu  
 35 40 45

Leu Leu Gly Trp Arg Ala Ser Leu Cys Met Lys Arg Ser Xaa  
 50 55 60

<210> 214  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (56)  
 <223> Xaa equals stop translation

<400> 214  
 Met Phe Ala Ser Tyr His Ile Gln Phe Phe Thr Trp Leu Ile Gln Lys  
 1 5 10 15

Leu Ser Leu Val Trp Lys Ser Val Val Ala Ile Arg Glu Gln Gly Lys  
 20 25 30

Glu Leu Val Trp Lys Gln His Leu Pro Leu Arg Ser Tyr Ser Pro Asn  
 35 40 45

Asn Ala Lys Ser Leu Gly Leu Xaa  
 50 55

<210> 215  
 <211> 213  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (88)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (213)  
 <223> Xaa equals stop translation

WO 9924836

PCT/US98/21435

<400> 215  
Met Leu Ser Phe Asn Phe Thr Trp Met Val Trp Val Ser Leu Val Leu 15  
1 10  
Lys Ser Gln Arg Ala Lys Leu Ala Leu His Ser Leu His Leu His Gln 30  
20 25  
Glu Val Arg Leu Arg Met Ser Arg Arg Glu Ser Pro Gly Arg Pro Leu 45  
35 40  
Arg Cys Gly Val Arg Gly Asn Met Gly Ala Arg Thr Pro Val Pro Thr 60  
50 55  
Ala Asp Tyr Pro Ser Pro Tyr Arg Thr Leu Pro Arg Met Ala Ala Pro 80  
65 70 75  
Pro Pro Gln Lys Ser Ser Cys Xaa Arg Leu His Arg Pro His Trp Trp 95  
85 90  
Arg Pro Arg Thr Pro Ser Ser Glu Lys Thr Gly Gln Ser Gln Ser 110  
100 105  
Thr Leu Asp Arg Cys Ala His Leu Val His Met Leu Leu Arg Asp Gln 125  
115 120  
Arg Ala Thr Ser Gln Trp Lys Ala Gly Gly Arg Leu Cys Arg Ala Leu 140  
130 135  
Ser Lys Thr Pro Leu Gln His Gln Leu His Ser Thr Ser Tyr Arg Lys 160  
145 150 155  
Ala Leu Pro Ile Leu Arg Pro Ser Ser Arg Arg Glu Ala Gly Pro Leu 175  
165 170  
His His Ile Asp Leu Arg Arg Cys Phe Ser Arg Leu Gly Arg Gly Ala 190  
180 185  
Asp Phe Ala Val Cys Ala Lys Glu Pro Val Ser Asp Asn Pro Ile Phe 205  
195 200  
Leu Leu Ile Thr Xaa 210  
215  
<210> 216  
<211> 41  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (41)  
<223> Xaa equals stop translation  
<400> 216  
Met Asn Met Phe Gln Thr Ile Leu Val Cys Val Leu Phe Val 15  
1 5 10

WO 9924836

PCT/US98/21435

Arg Trp Phe Phe Leu Leu Leu Gln Ile Glu Ser Ile Gln Thr Lys Phe 30  
20 25  
His Cys Ile Ser Ser Gln Phe Trp Xaa 40  
35  
<210> 217  
<211> 60  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (60)  
<223> Xaa equals stop translation  
<400> 217  
Met Glu Leu Val Trp Phe Arg Phe Leu His Leu Asn Leu Leu Pro Arg 15  
1 5 10  
Gly Val Cys Cys Gly Ile Cys Val Cys Val Arg Arg Gly Met Val Leu 30  
20 25  
Ser Glu Pro Thr Ser Cys Gly Gln Arg Ala Leu Ser Cys Glu Gly Gly 45  
35 40  
Cys His Ser Gly Arg Val Gln Phe Arg Arg Pro Xaa 60  
50 55  
<210> 218  
<211> 59  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (59)  
<223> Xaa equals stop translation  
<400> 218  
Met Arg Arg Met Arg Met Lys Ser Leu Ser Pro Arg Arg Ser Trp Trp 15  
1 5 10  
Thr Leu Trp Leu Gly Gln Gly Val Leu Gly Ala Ala Leu Lys Ala Asn 30  
20 25  
Thr Leu Trp Ile Ala Met Arg Arg Arg Met Met Met Gly Gly Pro 45  
35 40  
Ala Asn Met Thr Ser Trp Pro Gln Arg Met Xaa 55  
50  
<210> 219  
<211> 46

<212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (46)  
 <223> Xaa equals stop translation

119

<400> 219  
 Met Pro Phe Leu Leu Thr Phe Pro Leu Val Leu Tyr Pro His Leu  
 1 5 10 15  
 Ser Arg Gly Ser Asp Pro Val Leu Pro Cys Val Met Gly Ile His Val  
 20 25 30  
 Phe Gly Leu Ser His His Ser Arg Lys Val Ala Pro Pro Xaa  
 35 40 45

<210> 220  
 <211> 62  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (62)  
 <223> Xaa equals stop translation

<400> 220  
 Met Asp Arg Val Arg Phe Arg Ser Trp Leu Leu Tyr Pro Cys Cys Val  
 1 5 10 15  
 Ala Leu Gly Gln Glu Leu Gly Leu Ser Ala Pro Gln Trp Leu Ile Thr  
 20 25 30  
 Glu Asn Gly Met Pro Ala Leu Ala Leu Val Gly Cys Phe Glu Pro Thr  
 35 40 45  
 Ala Gly Ser Gly Ser Ser Trp His Asp Val Phe Leu Pro Xaa  
 50 55 60

<210> 221  
 <211> 52  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (52)  
 <223> Xaa equals stop translation

<400> 221  
 Met Lys Leu Asn Val His Phe Leu Trp Cys Thr Phe Ile Phe Gln Thr  
 1 5 10 15  
 Ser Gly Ser His Ile Glu Leu Leu Ile Ser Gly Gln Val Ser Ser Tyr

<210> 220  
 <211> 25  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (51)  
 <223> Xaa equals stop translation

<400> 222  
 Met Ala Ser Pro Val Phe Lys Thr Phe Trp Arg Leu Glu Ser Val  
 1 5 10 15  
 Pro Leu Ser Leu Leu Phe Ile Leu Gln Ile Val Thr Ser Leu Ser Ser  
 20 25 30  
 Asp Glu Ile Cys Tyr Ser Thr Arg Lys Val Phe Ile Ile Arg Arg Gln  
 35 40 45  
 Leu Tyr Xaa  
 50

<210> 223  
 <211> 47  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (47)  
 <223> Xaa equals stop translation

<400> 223  
 Met Cys Met Cys Val Gly Val Cys Leu Ile Thr Leu Leu Asp Arg Phe  
 1 5 10 15  
 Leu Trp Phe Gly Thr Ala Gly Ala Lys Phe Ile Gln Lys Ser Thr Phe  
 20 25 30  
 Leu Ser Lys Leu Pro Met Thr Leu Val Ser Phe His Ser Ile Xaa  
 35 40 45

<210> 224  
 <211> 52  
 <212> PRT  
 <213> Homo sapiens

121

122

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (52)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 224

Met Cys Pro Phe His Lys Ala Tyr Leu Asp Cys Phe Phe Gln Ile Ser  
1 5 10 15Leu Leu Leu Ile Phe Leu Thr Tyr Leu Asp Ile Gly Lys Cys Gly  
20 25 30Leu Trp Ser His Glu Trp Arg Ile Arg Glu Leu Gly Lys His Glu Arg  
35 40 45Trp Trp Asn Xaa  
50

&lt;210&gt; 225

&lt;211&gt; 66

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (61)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (66)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 225

Met Asn Gln Pro Ile Leu Arg Ser Gln Ala Leu Leu Trp Pro Trp Arg  
1 5 10 15Trp Val Val Lys Ala Lys Pro Cys Val Cys Val Ser Met Asp Ala Trp  
20 25 30Ile Pro Asp Arg Ser Gln His Cys Pro Ser Ile Pro Gly Gln Lys Lys  
35 40 45Glu Arg Ala Gly Ser His Gly His Gln Ala Leu Ala Xaa Leu Leu Phe  
50 55 60Leu Xaa  
65

&lt;210&gt; 226

&lt;211&gt; 47

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (47)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 226

Met Ala Ser Arg Gly Thr Ala Ala Pro Gly Arg Thr Phe Leu Ala Met  
1 5 10 15Met Val Thr Ser Phe Phe Cys Met Arg Trp Gly Ser Trp Ala Glu  
20 25 30Gln Met Pro Gln Arg Cys Leu Pro Cys Cys Met Gln Glu Cys Xaa  
35 40 45

&lt;210&gt; 227

&lt;211&gt; 222

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (184)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (222)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 227

Met Ala Gly Gly Val Arg Pro Leu Arg Gly Leu Arg Ala Leu Cys Arg  
1 5 10 15Val Leu Leu Phe Leu Ser Gln Phe Cys Ile Leu Ser Gly Gly Glu Ser  
20 25 30Thr Glu Ile Pro Pro Tyr Val Met Lys Cys Pro Ser Asn Gly Leu Cys  
35 40 45Ser Arg Leu Pro Ala Asp Cys Ile Asp Cys Thr Thr Asn Phe Ser Cys  
50 55 60Thr Tyr Gly Lys Pro Val Thr Phe Asp Cys Ala Val Lys Pro Ser Val  
65 70 75 80Thr Cys Val Asp Gln Asp Phe Lys Ser Gln Lys Asn Phe Ile Ile Asn  
85 90 95Met Thr Cys Arg Phe Cys Trp Gln Leu Pro Glu Thr Asp Tyr Glu Cys  
100 105 110Thr Asn Ser Thr Ser Cys Met Thr Val Ser Cys Pro Arg Gln Arg Tyr  
115 120 125Pro Ala Asn Cys Thr Val Arg Asp His Val His Cys Leu Gly Asn Arg  
130 135 140

13  
Thr Phe Pro Lys Met Leu Tyr Cys Asn Trp Thr Gly Gly Tyr Lys Trp  
145 150 155 160  
Ser Thr Ala Leu Ala Leu Ser Ile Thr Leu Gly Gly Phe Gly Ala Asp  
165 170 175  
Arg Phe Tyr Leu Gly Gln Trp Xaa Glu Gly Leu Gly Lys Leu Phe Ser  
180 185 190  
Phe Gly Gly Leu Gly Ile Trp Thr Leu Ile Asp Val Leu Leu Ile Gly  
195 200 205  
Val Gly Tyr Val Gly Pro Ala Asp Gly Ser Leu Tyr Ile Xaa  
210 215 220  
<210> 228  
<211> 49  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (49)  
<223> Xaa equals stop translation  
<400> 228  
Met Cys Ile His Tyr Ser Arg Val Ile Phe Ser Phe Leu Lys Leu Arg  
1 5 10 15  
Ile Lys Ser Ile Ser Trp Tyr Ala Met Trp Leu Tyr Phe Cys Tyr  
20 25 30  
Leu Asn Cys Leu Ala Lys Val Arg Ser Ala Thr Thr Tyr Leu Tyr Val  
35 40 45  
Xaa  
<210> 229  
<211> 41  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (41)  
<223> Xaa equals stop translation  
<400> 229  
Met Leu Pro Val Cys Val Phe Lys Leu Leu Leu Tyr Leu Tyr Val Leu  
1 5 10 15  
Ile Arg Ile Cys Thr Ile Ile Trp Cys Phe Lys Val Tyr Ile Asn Ala  
20 25 30  
Val Ile Leu Asn Lys Ser Ser Arg Xaa

35 40 124  
<210> 230  
<211> 53  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (53)  
<223> Xaa equals stop translation  
<400> 230  
Met Asn Cys Gly Gly Ser Thr Leu Cys Val Leu Ser Phe Cys Ser Val  
1 5 10 15  
Val Cys Ser Val Glu Ala Ser Cys Gln Ser Thr Val Gln Trp Gly Gly  
20 25 30  
Ala Ala Ala Arg Val Gly Val Pro Phe Asp Trp Ser Arg Asn Glu Gln  
35 40 45  
Gly Lys Gly His Xaa  
50  
<210> 231  
<211> 50  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (45)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (50)  
<223> Xaa equals stop translation  
<400> 231  
Met Leu Gly Ser Ile Pro Lys Leu Trp Ser Val Leu Ser Phe Ser Ile  
1 5 10 15  
Asn Phe Cys Phe Cys Cys Phe Ile Leu Ser Leu Leu Cys Leu Ser Val  
20 25 30  
Leu Ser Asn Tyr Leu Phe Lys Thr Pro Arg Thr Trp Xaa Thr Leu His  
35 40 45  
Arg Xaa  
50  
<210> 232  
<211> 45

WO 9974836

PCT/US98/23435

<212> PRT  
<213> Homo sapiens

13

<220>  
<221> SITE  
<222> (16)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (45)

<223> Xaa equals stop translation

<400> 232

Met Cys Leu Pro Leu Leu His Cys Thr Gly Ala Leu Trp Gly Lys Xaa  
1 5 10 15

Val Leu Leu Phe Leu Tyr Cys Leu Ala Gln Ser Phe Ala Tyr Ser Arg  
20 25 30

His Gln Thr Val Gly Leu Val Val His Asp Tyr Trp Xaa  
35 40 45

<210> 233  
<211> 55  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (55)  
<223> Xaa equals stop translation

<400> 233

Met Cys Trp Ile Cys Val Trp Leu Phe Phe Ser Pro Thr Lys Thr Ser  
1 5 10 15

Cys Phe Pro Trp Leu Ile Arg Pro Gly Pro Arg Ser Phe Thr Asp Ser  
20 25 30

His Gly Thr Pro Pro Trp Gln Cys Leu Glu Pro Ser Ser Phe Thr Tyr  
35 40 45

Pro Gly Lys Gln Val Trp Xaa  
50 55

<210> 214  
<211> 69  
<212> PRT  
<213> Homo sapiens

<220>

<221> SITE  
<222> (69)  
<223> Xaa equals stop translation

WO 9974836

PCT/US98/23435

<400> 234  
Met Lys Arg Leu Arg Phe Val Leu Arg Val Phe Gln Met Thr Ala Phe  
1 5 10 15

12

Ile Thr Gly Ala His Thr Ile Thr Asn Tyr Ser Asp Arg Arg Leu Tyr  
20 25 30

Ile Ser Pro Leu Ser His Phe Phe Met Asn Ser Gly Ser Ser Ala Gln  
35 40 45

Ser Val Leu Ser His Ser Tyr Val Ser Gln Ile Phe Phe Lys Asn Val  
50 55 60

Ser Lys Tyr Phe Xaa  
65

<210> 235  
<211> 41  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (41)  
<223> Xaa equals stop translation

<400> 235  
Met Val Ala Met Val Phe Leu Lys Ile Ser Val Leu Pro Leu Met Cys  
1 5 10 15

Arg Gly Gln Thr Lys His Lys Val Leu Arg Asp His Ala Tyr Pro Arg  
20 25 30

Val Ser Gln Lys Arg Gly His Ile Xaa  
35 40

<210> 236  
<211> 45  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (34)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (45)  
<223> Xaa equals stop translation

<400> 236  
Met Thr Lys Leu Leu Ser Leu Ser His Leu Leu Val Thr Phe Asn  
1 5 10 15

Ile Ile Ala Ile Lys Cys Lys Lys Gln His Leu Arg His Ser Lys Cys

20 25 30  
 171  
 Asn Xaa Asp Thr Thr Phe Lys Asn Lys Met Leu Asn Xaa  
 35 40 45

<210> 237  
 <211> 78  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (78)  
 <223> Xaa equals stop translation

<400> 237  
 Met Gln Leu Cys Val Ile Trp Phe Thr Val Ile Phe Leu Ser Gln Ser  
 1 5 10 15

Ser Arg Leu Val Lys Glu Lys Ile Ser Asn Thr Ser Gly Glu Lys Gly  
 20 25 30

Arg Trp Pro Ala Ile Asp Val Val Ala Leu Cys Pro Ser Arg Thr Ala  
 35 40 45

Gly Ile Ser Phe Pro Arg His Phe Leu Tyr Val Ser Cys Ile Val Gly  
 50 55 60

Cys Thr Asn Ile Ile Cys Ser Phe Gly Phe Pro Gly Gln Xaa  
 65 70 75

<210> 238  
 <211> 53  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (53)  
 <223> Xaa equals stop translation

<400> 238  
 Met Glu Val Val Leu Pro Lys His Ile Leu Asp Ile Trp Val Ile Val  
 1 5 10 15

Leu Ile Ile Leu Ala Thr Ile Val Ile Met Thr Ser Leu Leu Cys  
 20 25 30

Pro Ala Thr Ala Val Ile Ile Tyr Arg Met Arg Thr His Pro Ile Leu  
 35 40 45

Ser Gly Ala Val Xaa  
 50

<210> 239

<211> 53  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (53)  
 <223> Xaa equals stop translation

<400> 239  
 Met Tyr Tyr Leu Gly Lys Trp Asp Ile Trp Gln Pro Val Ser Leu Leu  
 1 5 10 15

Tyr Ile Ile Leu Phe Ala Ala Cys Pro Ser Leu Leu Ile Ser Ile Pro  
 20 25 30

Ala Lys Ala Ser Gly Glu Gly Trp Arg Cys Gly Asp Ile Gln Leu Thr  
 35 40 45

Val Val Thr Asp Xaa  
 50

<210> 240  
 <211> 43  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (43)  
 <223> Xaa equals stop translation

<400> 240  
 Met Pro Val Ala Phe His Leu Pro Phe Leu Leu Ile Leu Pro Tyr Arg  
 1 5 10 15

Val Leu Pro Val Gly Gln Val Thr Gln Leu Thr Pro Arg Ala Val Glu  
 20 25 30

Val Lys Ile His Asn His Gly Arg Leu Pro Xaa  
 35 40

<210> 241  
 <211> 49  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (49)  
 <223> Xaa equals stop translation

<400> 241  
 Met Ser Tyr Pro Leu Cys Thr Leu Leu Phe Ser Tyr Asp Cys Ile Leu  
 1 5 10 15

WO 99/24836

144

Ala Val Lys Thr Ser Arg Leu Lys Phe Asp Ser Gln Gly Tyr Ile Leu  
20 25 30

Gly Thr Phe Lys Val Ser Phe Gln Arg Asp Phe Ile Asn Arg Leu Asp  
35 40 45

Xaa

<210> 242

<211> 75

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (75)

<223> Xaa equals stop translation

<400> 242

Met Ser Ile Ile Ile Tyr Trp Leu Leu Phe Phe Lys His Leu Leu Trp  
1 5 10 15

Val Leu Ile Ile Gly Met Val Lys Ala Leu His Pro His Tyr Leu Asn  
20 25 30

Leu Arg Ile Tyr Glu Phe Gly Glu Ile Thr Ala Val Leu Gln Arg Lys  
35 40 45

Lys Gln Gly Arg Glu Asn Gly Asn Phe Leu Lys Phe Ser Leu Leu Ser  
50 55 60

Leu Asn Arg Ser Arg Ile Pro Thr Gln Ile Xaa  
65 70 75

<210> 243

<211> 44

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (44)

<223> Xaa equals stop translation

<400> 243

Met Ala Ile His Phe His Ile Ile Gln Trp Leu Leu Cys Tyr Asn  
1 5 10 15

Cys His His Ala Gln Trp Gly Leu Trp His Thr Thr Ala Glu Val Ser  
20 25 30

Gly Cys Gly Arg Asn His Leu Ala Phe Lys Ala Xaa  
35 40

WO 99/24836

130

<210> 244

<211> 65

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (65)

<223> Xaa equals stop translation

<400> 244

Met Tyr Leu Ser Leu Phe Phe Phe Cys Phe Ser Leu Gln Ala Ser Ala  
1 5 10 15

Val Glu Glu Arg Ser Ala Glu Ser Ser Arg Glu Gly Pro Val Arg Thr  
20 25 30

Asp Asn Trp Gln Arg Cys Phe Gly Asp Ile Pro Gly Thr Pro Thr His  
35 40 45

Leu Val Gln Arg Ser Leu Val Leu Thr Cys Phe Gly Arg Val Leu Ser  
50 55 60

Xaa

65

<210> 245

<211> 84

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (84)

<223> Xaa equals stop translation

<400> 245

Met Lys Lys Val Cys Trp Val Trp Ala Leu Ala His Leu Val Leu Cys  
1 5 10 15

Glu Arg Trp Leu Thr Ala Gly Cys Leu Leu Tyr Val Gly Val Ile Gln  
20 25 30

Pro Cys Lys Gly Ser Pro Ser Val Cys Lys Ala Arg Arg Cys Leu  
35 40 45

His Pro Lys Tyr Arg Ile Lys Arg Tyr Tyr Tyr Lys Tyr Ser Val  
50 55 60

Arg Leu Ile Ile Cys His His His Pro His Ala Leu Lys Ala Glu Leu  
65 70 75 80

Thr Asp Asp Xaa

<210> 246

<211> 72  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (72)  
 <223> Xaa equals stop translation

131

<400> 246  
 Met Val Gln Gly Pro Leu Thr His Leu Met Leu Val Leu Ile Ser  
 1 5 10 15  
 Leu Ile Phe Leu Ser Arg Gly Ser Gly Arg Ala Trp Ala Phe Ser His  
 20 25 30  
 Ser Cys Phe Lys Thr Ser Asp Leu Leu Pro Cys Arg Asn Arg Trp Glu  
 35 40 45  
 Val Ile Glu Phe Leu His Tyr Ser Asn Leu His Ser His Ile Ser Leu  
 50 55 60  
 Ser Val Thr Lys Thr Phe Leu Xaa  
 65 70

<210> 247  
 <211> 57  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (57)  
 <223> Xaa equals stop translation

<400> 247  
 Met Arg Ser Tyr Phe Pro Phe Ser Val Cys Pro Phe Pro Phe Cys Ser  
 1 5 10 15  
 Pro Val Phe Phe Phe Val Phe Thr Asp Val Tyr Leu Cys Phe Phe  
 20 25 30  
 Val Phe Ala Val Gly Arg His Leu Ser Asp Pro Phe Pro Ile Leu Phe  
 35 40 45  
 Phe Thr His Lys Cys Pro Asp Val Xaa  
 50 55

<210> 248  
 <211> 67  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (67)

<223> Xaa equals stop translation

132

<400> 248  
 Met Arg Ala Cys Gly Trp Asp Leu Ser Ile Leu Leu Val Gly Leu Val  
 1 5 10 15  
 Met Gly Arg Glu Gly Cys Tyr Ser Arg Leu Pro Pro Thr Glu Tyr Gln  
 20 25 30  
 Lys Gln Ala Gly Ser Ser Gly Val Cys Lys Asp Val Arg Pro Arg Asn  
 35 40 45  
 Gln Pro Ser Pro Ser Tyr Pro Cys Lys Ser Leu Ser Pro His Ala Pro  
 50 55 60  
 Leu Leu Xaa  
 65

<210> 249  
 <211> 46  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (46)  
 <223> Xaa equals stop translation

<400> 249  
 Met Tyr Leu Ile Leu Ser Trp Leu Phe Leu Cys Lys Leu Val Lys Cys  
 1 5 10 15  
 Tyr Phe Glu Ile Leu Leu Phe Ser Thr Ser Pro Gln Leu Gln Trp  
 20 25 30  
 Thr Val Ile Val Thr Tyr Cys Gly Pro Leu Leu Arg Phe Xaa  
 35 40 45

<210> 250  
 <211> 54  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (54)  
 <223> Xaa equals stop translation

<400> 250  
 Met Leu Val Phe Leu Leu Leu Phe Ser Thr Val Thr Val Leu Cys Leu  
 1 5 10 15  
 Lys Val Val Phe Ser Leu Lys Ala Val Ala Tyr Ile Val Lys Asn Glu  
 20 25 30  
 Gly Leu Cys Leu Lys Phe Ile Ala Leu Gln Arg Val Val Ser Leu Lys

WO 99/24836

PCT/US98/23435

WO 99/24836

PCT/US98/23435

35 40 13 45

134

Ser Cys Thr Ile Lys Xaa  
50

<222> (161)  
<223> Xaa equals stop translation

<210> 251

<211> 57

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (57)

<223> Xaa equals stop translation

<400> 251

Met Thr Phe Leu Leu Gln Trp Phe Pro Leu Gly Arg Ala Arg Val Val  
1 5 10 15

Gly Asp Leu Cys Gly Phe Ser Thr Gln Ile His Pro Gly Val Ser Arg  
20 25 30

Ala Gly Met Ala Asp Leu Glu Ser Pro Pro Phe Pro Arg Thr Cys Ser  
35 40 45

Val Pro Arg Ala Ala Asn Lys Gly Xaa  
50 55

<210> 252

<211> 42

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (42)

<223> Xaa equals stop translation

<400> 252

Met Phe Val Lys Tyr His Val Ile Met Val Ile Ile Phe Ile Phe Ile  
1 5 10 15

Leu Ile Thr Ser Asp Lys His Gly Glu Ile Ile Tyr Ile Lys Tyr Ile  
20 25 30

Asp Arg Val Ile Ile Thr Glu Arg Ile Xaa  
35 40

<210> 253

<211> 161

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<400> 254  
Met Leu Phe Phe Ser Leu Lys Glu Ser Leu Tyr Ile Phe His Thr Ala  
1 5 10 15

Ile Leu Leu Val Val Cys Phe Ala Cys Ala Val Val Cys Gln Tyr Val  
20 25 30

Ile Val Arg Val Cys Ala Val Val Phe Cys Phe Ser Lys Ser Gln Ser  
35 40 45

Leu Ile Xaa  
50

135

&lt;210&gt; 255

&lt;211&gt; 279

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (279)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 255

Met Leu Ile Phe Gly Ala Ile Phe Gly Cys Leu Asp Pro Val Ala Thr  
1 5 10 15

Leu Ala Ala Val Met Thr Glu Lys Ser Pro Phe Thr Thr Pro Ile Gly  
20 25 30

Arg Lys Asp Glu Ala Asp Leu Ala Lys Ser Ala Leu Ala Met Ala Asp  
35 40 45

Ser Asp His Leu Thr Ile Tyr Asn Ala Tyr Leu Gly Trp Lys Lys Ala  
50 55 60

Arg Glu Glu Gly Tyr Arg Ser Glu Ile Thr Tyr Cys Arg Arg Asn  
65 70 75 80

Phe Leu Asn Arg Thr Ser Leu Leu Thr Leu Glu Asp Val Lys Glu Glu  
85 90 95

Leu Ile Lys Leu Val Lys Ala Ala Gly Phe Ser Ser Thr Thr Ser  
100 105 110

Thr Ser Trp Glu Gly Asn Arg Ala Ser Glu Thr Leu Ser Phe Glu Glu  
115 120 125

Ile Ala Leu Leu Lys Ala Val Leu Val Ala Gly Leu Tyr Asp Asn Val  
130 135 140

Gly Lys Ile Ile Tyr Thr Lys Ser Val Asp Val Thr Glu Lys Leu Ala  
145 150 155 160

Cys Ile Val Glu Thr Ala Glu Gly Lys Ala Glu Val His Pro Ser Ser  
165 170 175

Val Asn Arg Asp Leu Glu Thr His Gly Trp Leu Leu Tyr Glu Glu Lys  
180 185 190

Ile Arg Tyr Ala Arg Val Tyr Leu Arg Glu Thr Thr Leu Ile Thr Pro  
195 200 205

Phe Pro Val Leu Leu Phe Gly Gly Asp Ile Glu Val Glu His Arg Glu  
210 215 220

Arg Leu Leu Ser Ile Asp Gly Trp Ile Tyr Phe Glu Ala Pro Val Lys

225

230

136 235

240

Ile Ala Val Ile Phe Lys Glu Leu Arg Val Leu Ile Asp Ser Val Leu  
245 250 255

Arg Lys Lys Leu Glu Asn Pro Lys Met Ser Leu Glu Met Thr Arg Phe  
260 265 270

Cys Arg Ser Leu Arg Asn Xaa  
275

&lt;210&gt; 256

&lt;211&gt; 69

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (69)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 256

Met Lys Val Leu Ser Trp Ile His Phe Ile Leu Ile Ser Leu His Phe  
1 5 10 15

Thr Ser Ser Leu Asp Pro Ser Ser Arg Gly Leu Gly Thr Phe Thr Asp  
20 25 30

Ala Leu Pro Asp Ser Arg Ala Lys Val Trp Glu Gly Glu Met Glu Glu  
35 40 45

Cys Pro Pro Val Cys Val Val Leu Cys Ala Thr Ala Thr Asp Ala Glu  
50 55 60

Gly Phe Ser Gly Xaa  
65

&lt;210&gt; 257

&lt;211&gt; 122

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (122)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 257

Met Ile Met Ala Glu Lys Ile Gly Gly Leu Thr Trp Trp Ala Ile Met  
1 5 10 15

Phe Ile Ile Leu Phe Glu Ile Thr Gly Thr Ser Ser Phe Leu Arg  
20 25 30

Ile Asn Ala Leu Pro His Phe Ser Met Asn Arg Cys Gly Glu Ala Tyr  
35 40 45

WO 99/24836

PCT/US98/23435

137  
Phe Pro Phe Ser Tyr Leu Tyr Thr Ser Leu Gln Lys Gln Phe Leu Met  
50 55 60  
Lys Val Ser Gly Ile Val Lys Asn Leu Arg Gly Asn Asp Asp Trp Arg  
65 70 75 80  
Cys Phe Gly Val Phe Phe Cys Ile His Phe Leu Met Arg Lys Val Leu  
85 90 95  
Asn Val Val Gln Val Arg Pro Asn Tyr Tyr Leu Thr Ile Ile Gly Arg  
100 105 110  
Phe Tyr Val Ser Val Lys Val Phe Lys Xaa  
115 120  
<210> 258  
<211> 59  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (59)  
<223> Xaa equals stop translation  
<400> 258  
Met Gly Lys Ile Cys Lys Asn Trp Val Ser Phe Leu Asp Asn Val Leu  
1 5 10 15  
Leu Leu Ile Leu Phe Leu Tyr Gly Leu Cys Leu Gly Trp Leu Cys Ile  
20 25 30  
Tyr His Gln Ser Tyr Ser Thr Ala Cys Ile Cys Val Val Thr Asp Ala  
35 40 45  
Glu Ile Gln Gln Lys Ser Leu His Ser Ile Xaa  
50 55  
<210> 259  
<211> 68  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (68)  
<223> Xaa equals stop translation  
<400> 259  
Met Leu Val Leu Leu Trp Leu Gly Trp Ile Ser Ser Lys Ser Met Leu  
1 5 10 15  
Ala Ala Tyr Phe Val Ala Pro Lys Tyr Pro Leu Lys Leu Ala Leu Val  
20 25 30

WO 99/24836

PCT/US98/23435

138

Ser Glu Pro Glu Ser Ser Ser Leu Ile Leu Lys Phe Leu Ser Leu Lys  
35 40 45  
Asp Phe Leu Cys Cys Tyr Thr Thr Lys Leu Ser Val Asn Pro Pro Leu  
50 55 60  
Leu Asn Asp Xaa  
65  
<210> 260  
<211> 46  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (46)  
<223> Xaa equals stop translation  
<400> 260  
Met Val Ser Phe His Phe Gln Cys Thr Ser Tyr Phe Val Arg Leu Phe  
1 5 10 15  
Phe Gln Leu Gln Leu Phe Val Gly Leu Val Ile Val Leu Ala Leu Leu  
20 25 30  
Ile Ser His Ser Leu Thr Tyr Ser Phe His Lys His Leu Xaa  
35 40 45  
<210> 261  
<211> 110  
<212> PRT  
<213> Homo sapiens  
<400> 261  
Phe Tyr Ile Ala Asp His Ser Phe Thr Ala Arg Pro Thr Leu Arg Met  
1 5 10 15  
Phe Arg Ile Ser Ala Val Val Ala Thr Asp Lys Met Thr Phe Thr Ser  
20 25 30  
Gly Gly Thr Leu Phe Gly Asp Gly Cys Ala Ser Ser Val Ala Gly Glu  
35 40 45  
Val Met Asn Cys Gln Thr Val Leu Cys Ile Leu Trp Thr Pro Phe Val  
50 55 60  
Phe Cys Pro Ser Ile Ala Val Ile Ile Pro Cys Val Phe Thr Ser  
65 70 75 80  
Lys Ala Leu Glu Ala Ile Trp Lys Trp Cys Arg Val Glu Arg Arg Pro  
85 90 95  
His Ile Ile Glu Val Asp Val Leu Gly Lys Cys Pro Ala Phe  
100 105 110

<210> 262  
<211> 25  
<212> PRT  
<213> Homo sapiens

139

<400> 262  
Arg Pro Thr Leu Arg Met Phe Arg Ile Ser Ala Val Val Ala Thr Asp  
1 5 10 15  
Lys Met Thr Phe Thr Ser Gly Gly Thr  
20 25

<210> 263  
<211> 28  
<212> PRT  
<213> Homo sapiens

<400> 263  
Pro Ser Ile Ala Val Ile Ile Ile Pro Cys Val Phe Thr Ser Lys Ala  
1 5 10 15  
Leu Glu Ala Ile Thr Lys Trp Cys Arg Val Glu Arg  
20 25

<210> 264  
<211> 20  
<212> PRT  
<213> Homo sapiens

<400> 264  
Thr Ser Val Ser Phe His His Arg Tyr Lys Ser Ser Asp Arg Pro Ala  
1 5 10 15  
His Lys Val Ser  
20

<210> 265  
<211> 115  
<212> PRT  
<213> Homo sapiens

<400> 265  
Arg His Asn Asp Phe Asn Lys Leu Ser Tyr Thr Glu Cys Asn Asn Met  
1 5 10 15  
Asn Lys Arg Met Ala Lys Pro Glu Lys Lys Lys Gly Ser Val Lys Ser  
20 25 30

Ser Leu Gly Ile Phe Leu Gly Pro Asn Cys His Leu Ile Ser Ser Leu  
35 40 45  
Phe Leu Phe Ser Val Ser Leu Tyr Pro Phe Ala Thr Gln Phe Pro Phe  
50 55 60

His Tyr Val Leu Ile Phe Ile Ile Gln Ala Phe Gly Leu Cys Leu Pro  
65 70 75 80  
Leu Thr Glu Arg Gln Glu Ala Lys Ser Gly Leu Gly Gly Leu Cys Pro  
85 90 95

Asp Tyr Thr Trp Pro Cys Pro Cys Leu Leu Val Ser Cys Leu Ser Leu  
100 105 110  
Leu Arg Leu  
115

<210> 266  
<211> 114  
<212> PRT  
<213> Homo sapiens

<400> 266  
Cys Glu Val Phe Ser Trp His Phe Pro Trp Ser Lys Leu Ser Pro His  
1 5 10 15  
Leu Phe Leu Val Ser Phe Leu Cys Ile Pro Leu Ser Leu Cys His Thr  
20 25 30  
Val Ser Phe Ser Leu Cys Ser Asn Ile Tyr Asn Pro Gly Leu Arg Thr  
35 40 45

Met Leu Ala Pro His Arg Glu Thr Gly Gly Gln Val Trp Ala Gly Trp  
50 55 60  
Ala Leu Ser Arg Leu His Val Ala Leu Pro Met Ser Leu Gly Val Leu  
65 70 75 80  
Ser Leu Pro Ala Pro Thr Val Thr Val Val Arg Met Glu Gly Gly Asp  
85 90 95

Trp Lys Val Cys Glu Gln Leu Glu Gln Cys Thr Tyr Ser His Arg Met  
100 105 110  
Thr Lys  
20

<210> 267  
<211> 23  
<212> PRT  
<213> Homo sapiens

<400> 267  
Lys Arg Met Ala Lys Pro Glu Lys Lys Lys Gly Ser Val Lys Ser Ser  
1 5 10 15  
Leu Gly Ile Phe Leu Gly Pro  
20

<210> 268

WO 99/24836

PCT/US98/23435

WO 99/24836

PCT/US98/23435

141

<211> 31

<212> PRT

<213> Homo sapiens

<400> 268

Tyr Asn Pro Gly Leu Arg Thr Met Leu Ala Pro His Arg Glu Thr Gly  
1 5 10 15

Gly Gln Val Trp Ala Gly Trp Ala Leu Ser Arg Leu His Val Ala  
20 25 30

<210> 269

<211> 251

<212> PRT

<213> Homo sapiens

<400> 269

Met Ser Pro Tyr Ala Ser Gln Gly Phe Pro Phe Leu Pro Pro Tyr Pro  
1 5 10 15

Pro Gln Glu Ala Asn Arg Ser Ile Thr Ser Leu Ser Val Ala Asp Thr  
20 25 30

Val Ser Ser Thr Thr Ser His Thr Thr Ala Lys Pro Ala Ala Pro  
35 40 45

Ser Phe Gly Val Leu Ser Asn Leu Pro Leu Pro Ile Pro Thr Val Asp  
50 55 60

Ala Ser Ile Pro Thr Ser Gln Asn Gly Phe Gly Tyr Lys Met Pro Asp  
65 70 75 80

Val Pro Asp Ala Phe Pro Glu Leu Ser Glu Leu Ser Val Ser Gln Leu  
85 90 95

Thr Asp Met Asn Glu Gln Glu Val Leu Leu Glu Gln Phe Leu Thr  
100 105 110

Leu Pro Gln Leu Lys Gln Ile Ile Thr Asp Lys Asp Asp Leu Val Lys  
115 120 125

Ser Ile Glu Glu Leu Ala Arg Lys Asn Leu Leu Glu Pro Ser Leu  
130 135 140

Glu Ala Lys Arg Gln Thr Val Leu Asp Lys Tyr Glu Leu Thr Gln  
145 150 155 160

Met Lys Ser Thr Phe Glu Lys Lys Met Gln Arg Gln His Glu Leu Ser  
165 170 175

Glu Ser Cys Ser Ala Ser Ala Leu Gln Ala Arg Leu Lys Val Ala Ala  
180 185 190

His Glu Ala Glu Glu Ser Asp Asn Ile Ala Glu Asp Phe Leu Glu  
195 200 205

Gly Lys Met Glu Ile Asp Asp Phe Leu Ser Ser Phe Met Glu Lys Arg

210

215

142

220

Thr Ile Cys His Cys Arg Arg Ala Lys Glu Lys Leu Gln Ala  
225 230 235 240

Ile Ala Met His Ser Gln Phe His Ala Pro Leu  
245 250

<210> 270

<211> 23

<212> PRT

<213> Homo sapiens

<400> 270

Leu Pro Pro Tyr Pro Pro Gln Glu Ala Asn Arg Ser Ile Thr Ser Leu  
1 5 10 15

Ser Val Ala Asp Thr Val Ser  
20

<210> 271

<211> 27

<212> PRT

<213> Homo sapiens

<400> 271

Thr Ala Lys Pro Ala Ala Pro Ser Phe Gly Val Leu Ser Asn Leu Pro  
1 5 10 15

Leu Pro Ile Pro Thr Val Asp Ala Ser Ile Pro  
20 25

<210> 272

<211> 25

<212> PRT

<213> Homo sapiens

<400> 272

Pro Asp Val Pro Asp Ala Phe Pro Glu Leu Ser Glu Leu Ser Val Ser  
1 5 10 15

Gln Leu Thr Asp Met Asn Glu Gln Glu  
20 25

<210> 273

<211> 29

<212> PRT

<213> Homo sapiens

<400> 273

Gln Phe Leu Thr Leu Pro Gln Leu Lys Gln Ile Ile Thr Asp Lys Asp  
1 5 10 15

Asp Leu Val Lys Ser Ile Glu Leu Ala Arg Lys Asn

20

25

143

&lt;210&gt; 274

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 274

Arg Gln Thr Val Leu Asp Lys Tyr Glu Leu Leu Thr Gln Met Lys Ser  
1 5 10 15Thr Phe Glu Lys Lys Met Gln Arg Gln  
20 25

&lt;210&gt; 275

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 275

Ala Ser Ala Leu Gln Ala Arg Leu Lys Val Ala Ala His Glu Ala Glu  
1 5 10 15Glu Glu Ser Asp Asn Ile Ala Glu Asp Phe Leu Glu  
20 25

&lt;210&gt; 276

&lt;211&gt; 27

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 276

Met Glu Lys Arg Thr Ile Cys His Cys Arg Arg Ala Lys Glu Glu Lys  
1 5 10 15Leu Gln Gln Ala Ile Ala Met His Ser Gln Phe  
20 25

&lt;210&gt; 277

&lt;211&gt; 69

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 277

Thr Arg Pro Val Phe Leu Ser Ser Met Thr Pro Leu Lys Gly Ile Lys Ser  
1 5 10 15Val Ile Leu Pro Gln Val Phe Leu Cys Ala Tyr Met Ala Ala Phe Asn  
20 25 30Ser Ile Asn Gly Asn Arg Ser Tyr Thr Cys Lys Pro Leu Glu Arg Ser  
35 40 45

Leu Leu Met Ala Gly Ala Val Ala Ser Ser Thr Phe Leu Gly Val Ile

50

55

144

60

Pro Gln Phe Val Gln  
65

&lt;210&gt; 278

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 278

Pro Leu Lys Gly Ile Lys Ser Val Ile Leu Pro Gln Val Phe Leu Cys  
1 5 10 15Ala Tyr Met Ala Ala  
20

&lt;210&gt; 279

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 279

Ala Phe Asn Ser Ile Asn Gly Asn Arg Ser Tyr Thr Cys Lys Pro Leu  
1 5 10 15Glu Arg Ser Leu Leu  
20

&lt;210&gt; 280

&lt;211&gt; 129

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 280

Met Ser Asp Phe Glu Lys Val Asp Ile Ser Val His Gln His Ile His  
1 5 10 15Val Gly Pro Leu Leu Leu Met Thr Thr Glu Ser Trp Gly Pro Ser Cys  
20 25 30Ala Pro Ser Pro Ala Leu Leu Ser Gly His Thr Ala Ala Ser Phe Thr  
35 40 45His Thr Leu Gly Gly Val Leu Gly Cys Pro Pro Tyr His Lys Phe Tyr  
50 55 60Ser Ser Ala His Thr Ser Asp His Arg Lys Glu Thr Asn Lys Val Glu  
65 70 75 80Glu Gly Arg Trp Val Asp Val Thr Arg Ser Leu Gly Asn Phe Asn Phe  
85 90 95Arg Arg Lys Phe Phe Cys Val Ser Glu Leu Leu Ile Cys Gly Ile Phe  
100 105 110

WO 99/24836

PCT/US98/23435 -

Leu Asp Ser Ser Trp Lys Leu Gln Ile Asn Ser Asn Asp Cys Lys Val  
115 120 125

Leu

<210> 281

<211> 30

<212> PRT

<213> Homo sapiens

<400> 281

Val Gly Pro Leu Leu Leu Met Thr Thr Glu Ser Trp Gly Pro Ser Cys  
1 5 10 15

Ala Pro Ser Pro Ala Leu Ser Gly His Thr Ala Ala Ser  
20 25 30

<210> 282

<211> 27

<212> PRT

<213> Homo sapiens

<400> 282

Glu Thr Asn Lys Val Glu Glu Gly Arg Trp Val Asp Val Thr Arg Ser  
1 5 10 15

Leu Gly Asn Phe Asn Phe Arg Arg Lys Phe  
20 25

<210> 283

<211> 140

<212> PRT

<213> Homo sapiens

<400> 283

Gly Arg Gly Asp Lys Pro Arg Gln Asp Arg Pro Ala Ser Leu Arg Leu  
1 5 10 15

Lys Gly Pro Pro Ser Cys Gln Ala Pro Ala Ser His Ser Ser Thr Leu  
20 25 30

Ser Ser His Cys Pro Cys Ser Leu Phe Ala Cys Gly Ser Val Trp Pro  
35 40 45

Gly Ser Leu Gly Ser Gly Ile Phe Ala Arg Leu Ser Gln Leu Leu Pro  
50 55 60

Ser Pro Ala Ser Trp Gly Trp Asp Phe Leu Thr Leu Arg Gln Ala Gln  
65 70 75 80

Gln Met Leu Gly Pro Ser Leu Cys Pro Gly His Ser Thr Ser Ala His  
85 90 95

WO 99/24836

PCT/US98/23435 -

Gln His Tyr Gly Ala Tyr Val Leu Pro Arg Asp Leu Cys Ser Phe Leu  
100 105 110

Leu Thr Ser Thr Val Gln Gly Thr Ala Pro Leu Lys Asn Ser Arg Val  
115 120 125

Thr Cys Leu Ile Gly Ser Gln Gln Val Pro Leu Cys  
130 135 140

<210> 284

<211> 146

<212> PRT

<213> Homo sapiens

<400> 284

Ala Glu Val Thr Ser Pro Ala Lys Thr Asp Leu Gln Val Phe Val Ser  
1 5 10 15

Arg Asp Leu Pro His Ala Arg Pro Leu Pro Leu Thr Ala Ala Pro Phe  
20 25 30

Pro Leu Ile Val Pro Val Pro Phe Leu Pro Val Asp Leu Phe Gly Gln  
35 40 45

Gly Pro Trp Gly Gln Glu Tyr Leu Gln Asp Ser Ala Ser Ser Phe Pro  
50 55 60

Ala Gln Pro Leu Gly Ala Gly Thr Phe Ser Pro Cys Gly Arg His Asn  
65 70 75 80

Arg Cys Trp Asp Pro Val Ser Ala Gln Val Thr Ala Gln Val His Ile  
85 90 95

Ser Thr Met Gly Pro Met Ser Cys Pro Glu Thr Ser Ala Pro Ser Cys  
100 105 110

Ser His Pro Gln Phe Arg Ala Arg Pro Ser Arg Thr Pro Glu Ser  
115 120 125

Pro Val Ser Ser Ala Pro Ser Lys Cys Leu Phe Val Tyr Asp Val Pro  
130 135 140

Leu Leu  
145

<210> 285

<211> 30

<212> PRT

<213> Homo sapiens

<400> 285

Ser Leu Arg Leu Lys Gly Pro Pro Ser Cys Gln Ala Pro Ala Ser His  
1 5 10 15

Ser Ser Thr Leu Ser Ser His Cys Pro Cys Ser Leu Phe Ala  
20 25 30

147

<210> 286  
 <211> 30  
 <212> PRT  
 <213> Homo sapiens

<400> 286  
 Gln Gln Met Leu Gly Pro Ser Leu Cys Pro Gly His Ser Thr Ser Ala  
 1 5 10 15

His Gln His Tyr Gly Ala Tyr Val Leu Pro Arg Asp Leu Cys  
 20 25 30

<210> 287  
 <211> 31  
 <212> PRT  
 <213> Homo sapiens

<400> 287  
 Asp Leu Gln Val Phe Val Ser Arg Asp Leu Pro His Ala Arg Pro Leu  
 1 5 10 15

Pro Leu Thr Ala Ala Pro Phe Pro Leu Ile Val Pro Val Pro Phe  
 20 25 30

<210> 288  
 <211> 39  
 <212> PRT  
 <213> Homo sapiens

<400> 288  
 Ala Gln Val His Ile Ser Thr Met Gly Pro Met Ser Cys Pro Glu Thr  
 1 5 10 15

Ser Ala Pro Ser Cys Ser His Pro Gln Phe Arg Ala Arg Arg Pro Ser  
 20 25 30

Arg Thr Pro Glu Ser Pro Val  
 35

<210> 289  
 <211> 17  
 <212> PRT  
 <213> Homo sapiens

<400> 289  
 Gln Ala Pro Pro Arg Gln Thr Cys Lys Ser Ser Ser Gln Gly Thr Ser  
 1 5 10 15

Leu

<210> 290

148

<211> 314  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (27)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (111)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 290  
 Ala Ala Leu Arg Pro Ser Gly Ser Leu Ala Gly Pro Glu Trp Pro Trp  
 1 5 10 15

Gln His Trp Cys Gly Cys Trp Arg Glu His Xaa Val Lys Pro Gln Gln  
 20 25 30

Val Asp Leu His Ser Ala Arg Leu Trp Ala Ala Pro Ala Ala Val Gly  
 35 40 45

Pro Ala His Ala Gly Gly Ser Pro Gly Met Pro Pro Gly Gly Thr Ala  
 50 55 60

Pro His Ala Arg Arg His Ser Leu Pro Ser Pro Thr Ala Gln Ser His  
 65 70 75 80

Leu Trp His Val His Gly Leu Arg Gln Arg Gly Pro Lys Ala Val Pro  
 85 90 95

Leu Asp Leu Ala Gln Leu Val Thr Thr Thr Pro Leu Phe Xaa Leu  
 100 105 110

Ala Leu Ser Ala Leu Leu Leu Gly Arg Arg His His Pro Leu Gln Leu  
 115 120 125

Ala Ala Met Gly Pro Leu Cys Leu Gly Ala Ala Cys Ser Leu Ala Gly  
 130 135 140

Glu Phe Arg Thr Pro Thr Thr Gly Cys Gly Phe Leu Leu Ala Ala Thr  
 145 150 155 160

Cys Leu Arg Gly Leu Lys Ser Val Gln Gln Ser Ala Leu Leu Gln Glu  
 165 170 175

Glu Arg Leu Asp Ala Val Thr Leu Leu Tyr Ala Thr Ser Leu Pro Ser  
 180 185 190

Phe Cys Leu Leu Ala Gly Ala Ala Leu Val Leu Glu Ala Gly Val Ala  
 195 200 205

Pro Pro Pro Thr Ala Gly Asp Ser Arg Leu Trp Ala Cys Ile Leu Leu  
 210 215 220

Ser Cys Leu Leu Ser Val Leu Tyr Asn Leu Ala Ser Phe Ser Leu Leu

130

Ser Thr Xaa Ser Ser  
20

<210> 293  
<211> 26  
<212> PRT  
<213> Homo sapiens

<220>

<221> SITE

<222> (15)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 293

Glu Trp Pro Trp Gln His Trp Cys Gly Cys Trp Arg Glu His Xaa Val  
1 5 10 15

Lys Pro Gln Gln Val Asp Leu His Ser Ala  
20 25

<210> 294

<211> 28

<212> PRT

<213> Homo sapiens

<400> 294

Gln Gln Ser Ala Leu Leu Gln Glu Glu Arg Leu Asp Ala Val Thr Leu  
1 5 10 15

Leu Tyr Ala Thr Ser Leu Pro Ser Phe Cys Leu Leu  
20 25

<210> 295

<211> 27

<212> PRT

<213> Homo sapiens

<400> 295

Ala Cys Ile Leu Leu Ser Cys Leu Leu Ser Val Leu Tyr Asn Leu Ala  
1 5 10 15

Ser Phe Ser Leu Leu Ala Leu Thr Ser Ala Leu  
20 25

<210> 296

<211> 21

<212> PRT

<213> Homo sapiens

<400> 296

Ser Leu Asn Lys Trp Ile Phe Thr Val His Gly Phe Gly Arg Pro Leu  
1 5 10 15

240

149 235

230

225

Ala Leu Thr Ser Ala Leu Thr Val His Val Leu Gly Asn Leu Thr Val  
245 250 255

Val Gly Asn Leu Ile Leu Ser Arg Leu Leu Phe Gly Ser Arg Leu Ser  
260 265 270

Ala Leu Ser Tyr Val Gly Ile Ala Leu Thr Leu Ser Gly Met Phe Leu  
275 280 285

Tyr His Asn Cys Glu Phe Val Ala Ser Trp Ala Ala Arg Arg Gly Leu  
290 295 300

Trp Arg Arg Asp Gln Pro Ser Lys Gly Leu  
305 310

<210> 291

<211> 66

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (28)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 291

Gly Gln Pro Ser Gly Pro Pro Ala Ala Trp Pro Gly Pro Ser Gly His  
1 5 10 15

Gly Ser Thr Gly Val Ala Ala Gly Gly Ser Thr Xaa Ser Ser Leu Asn  
20 25 30

Lys Trp Ile Phe Thr Val His Gly Phe Gly Arg Pro Leu Leu Ser  
35 40 45

Ala Leu His Met Leu Val Ala Ala Leu Ala Cys His Arg Gly Ala Arg  
50 55 60

Arg Pro

65

<210> 292

<211> 21

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (19)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 292

Trp Pro Gly Pro Ser Gly His Gly Ser Thr Gly Val Ala Ala Gly Gly  
1 5 10 15

Leu Leu Ser Ala Leu  
20

/51

<210> 297  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 297  
Lys Ser Thr Leu Ser Ala Ala Val Val Ala Thr Ile Leu Arg Thr Leu  
1 5 10 15

Ala

<210> 298  
<211> 100  
<212> PRT  
<213> Homo sapiens

<400> 298  
Gly Asp His Ser Glu Gln Cys Leu Ile Lys Glu Met Gly Ala Arg Glu  
1 5 10 15

Arg Arg Phe Cys Lys Ala Arg Gly Tyr Arg Asp Thr Gly Arg Glu Ala  
20 25 30

Gln Ala Lys Ala Gly Gly Arg Arg Gly Ser Gln Trp Asn Glu Ser Gln  
35 40 45

Cys Ser Ser Gln Arg Pro Arg Pro Ala Lys Glu Val Arg Lys Thr Arg  
50 55 60

Pro Arg Ala Gly Val Gly Arg Gly Pro Ala Leu Leu Gln Leu Ser Leu  
65 70 75 80

Leu Gln Gln Val Val Leu Tyr Val Arg Pro Ser Leu Arg Leu Val Trp  
85 90 95

Leu Lys Ala Ser  
100

<210> 299  
<211> 84  
<212> PRT  
<213> Homo sapiens

<400> 299  
Met Glu Arg Gly Glu Tyr Gly Gly Trp Gly Thr Tyr Gly Ser Leu Asp  
1 5 10 15

Leu Gly Ser Gln Leu Cys Thr Val Arg Ser Ser Gly Pro Cys Gly Ser  
20 25 30

Leu His Trp Gly Gln His Arg Ser Pro Ile Ser Gly Pro Asp Pro Asn

35

40

/52

45

Pro Ser Ser Ser Arg Gly Gln Gln Ser Ile Gly Ser Lys Val Gly Ser  
50 55 60

Pro Ser Arg Ser Gln Trp Arg Ser Tyr Lys Glu Val Gly Arg Asp Pro  
65 70 75 80

Glu Lys Gly Glu

<210> 300  
<211> 23  
<212> PRT  
<213> Homo sapiens

<400> 300  
Gln Ala Lys Ala Gly Gly Arg Arg Gly Ser Gln Trp Asn Glu Ser Gln  
1 5 10 15

Cys Ser Ser Gln Arg Pro Arg  
20

<210> 301  
<211> 26  
<212> PRT  
<213> Homo sapiens

<400> 301  
Val Gly Arg Gly Pro Ala Leu Leu Gln Leu Ser Leu Leu Gln Val  
1 5 10 15

Val Leu Tyr Val Arg Pro Ser Leu Arg Leu  
20 25

<210> 302  
<211> 22  
<212> PRT  
<213> Homo sapiens

<400> 302  
Tyr Gly Ser Leu Asp Leu Gly Ser Gln Leu Cys Thr Val Arg Ser Ser  
1 5 10 15

Gly Pro Cys Gly Ser Leu  
20

<210> 303  
<211> 20  
<212> PRT  
<213> Homo sapiens

<400> 303  
Lys Val Gly Ser Pro Ser Arg Ser Gln Trp Arg Ser Trp Lys Glu Val

1	5	153 10	15
Gly Arg Asp Pro 20			
<210> 304			
<211> 214			
<212> PRT			
<213> Homo sapiens			
<220>			
<221> SITE			
<222> (18)			
<223> Xaa equals any of the naturally occurring L-amino acids			
<400> 304			
Met Pro Gln Ser Leu Ser Ser Leu Ala Ser Ser Ser Ser Phe Gln			
1	5	10	15
Arg Xaa Lys Pro Cys Phe Gly Lys Lys Asn Asp Gly Glu Asn Gln Glu			
20	25	30	
His Ser Leu Gly Thr Glu Pro Ile Ile Thr Trp Lys Asp Phe Gln Lys			
35	40	45	
Thr Met Pro Trp Glu Ile Val Ile Leu Val Gly Gly Tyr Ala Leu			
50	55	60	
Ala Ser Gly Ser Lys Ser Ser Gly Leu Ser Thr Trp Ile Gly Asn Gln			
65	70	75	80
Met Leu Ser Leu Ser Ser Leu Pro Pro Trp Ala Val Thr Leu Leu Ala			
85	90	95	
Cys Ile Leu Val Ser Ile Val Thr Glu Phe Val Ser Asn Pro Ala Thr			
100	105	110	
Ile Thr Ile Phe Leu Pro Ile Leu Cys Ser Leu Ser Glu Thr Leu His			
115	120	125	
Ile Asn Pro Leu Tyr Thr Leu Ile Pro Val Thr Met Cys Ile Ser Phe			
130	135	140	
Ala Val Met Leu Pro Val Gly Asn Pro Pro Asn Ala Ile Val Phe Ser			
145	150	155	160
Tyr Gly His Cys Gln Ile Lys Asp Met Val Lys Ala Gly Leu Gly Val			
165	170	175	
Asn Val Ile Gly Leu Val Ile Val Met Val Ala Ile Asn Thr Trp Gly			
180	185	190	
Val Ser Leu Phe His Leu Asp Thr Tyr Pro Ala Trp Ala Arg Val Ser			
195	200	205	
Asn Ile Thr Asp Gln Ala			
210			

154	1
<210> 305	
<211> 23	
<212> PRT	
<213> Homo sapiens	
<400> 305	
Asn Asp Gly Glu Asn Gln Glu His Ser Leu Gly Thr Glu Pro Ile Ile	
1	5
Thr Trp Lys Asp Phe Gln Lys	
20	
<210> 306	
<211> 24	
<212> PRT	
<213> Homo sapiens	
<400> 306	
Ile Gly Asn Gln Met Leu Ser Leu Ser Ser Leu Pro Pro Trp Ala Val	
1	5
Thr Leu Leu Ala Cys Ile Leu Val	
20	
<210> 307	
<211> 27	
<212> PRT	
<213> Homo sapiens	
<400> 307	
Ala Thr Ile Thr Ile Phe Leu Pro Ile Leu Cys Ser Leu Ser Glu Thr	
1	5
Leu His Ile Asn Pro Leu Tyr Thr Leu Ile Pro	
20	25
<210> 308	
<211> 26	
<212> PRT	
<213> Homo sapiens	
<400> 308	
Leu Pro Val Gly Asn Pro Pro Asn Ala Ile Val Phe Ser Tyr Gly His	
1	5
Cys Gln Ile Lys Asp Met Val Lys Ala Gly	
20	25
<210> 309	
<211> 29	
<212> PRT	
<213> Homo sapiens	

155  
 <400> 309  
 Leu Val Ile Val Met Val Ala Ile Asn Thr Trp Gly Val Ser Leu Phe  
 1 5 10 15  
 His Leu Asp Thr Tyr Pro Ala Trp Ala Arg Val Ser Asn  
 20 25

<210> 310  
 <211> 133  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (44)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (46)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 310  
 Glu Thr Cys Pro Ser Asn Gly Ile Glu Leu Arg Gln Ala Pro Thr Ser  
 1 5 10 15

Leu Tyr Ile Leu Leu Leu His Ile Gln Pro Thr Pro Thr His Pro Met  
 20 25 30

Leu Gly Arg Ser Tyr Val Leu Pro Ala Phe Ser Xaa Asn Xaa Glu His  
 35 40 45

Gly Gly Leu Pro Asn Gln Ile Pro Lys Gly Asp Arg Asn Gly Ile  
 50 55 60

Arg His Ser Arg Ile Thr Phe Pro Cys Ser Ser Thr Leu Gln Pro  
 65 70 75 80

Glu Ser His Leu Gly Phe Ile Arg Ser Lys Leu His Gly Leu Val Arg  
 85 90 95

Pro Gly Lys Asp Leu Arg Gly Arg Arg Ser Leu Gln Leu Ser Lys His  
 100 105 110

Ser Leu Ser Thr Cys Tyr Met Leu Arg Trp Glu Thr Tyr Lys Gln Val  
 115 120 125

Ser Tyr Thr Ala Val  
 130

<210> 311  
 <211> 106  
 <212> PRT  
 <213> Homo sapiens

156  
 <400> 311  
 Gln Arg His Gln Glu Asn Asp Lys Arg Asn Val His Arg Phe Leu His  
 1 5 10 15  
 Thr Cys Val His Met Pro Met Cys Thr His Thr His Thr Gln Ala Val  
 20 25 30

Leu Ser Thr Trp Glu Gly Gln Phe Ser Asn Val Ala Ser Phe Thr Ser  
 35 40 45

Leu Lys Arg Ile Pro Leu Ser Ile Ile Tyr Ile His Ser Ser His Ser  
 50 55 60

Pro Arg Arg Phe Val Lys Val Cys Gln Leu Arg Gln Glu Lys Ala Leu  
 65 70 75 80

Glu Leu Thr Glu Val Tyr Val Ser Ala Ser Leu Lys Leu Gln Leu Tyr  
 85 90 95

His Leu His Cys His Phe His Thr Ala Val  
 100 105

<210> 312  
 <211> 24  
 <212> PRT  
 <213> Homo sapiens

<400> 312  
 Arg Gln Ala Pro Thr Ser Leu Tyr Ile Leu Leu Leu His Ile Gln Pro  
 1 5 10 15

Thr Pro Thr His Pro Met Leu Gly  
 20

<210> 313

<211> 25

<212> PRT

<213> Homo sapiens

<400> 313  
 Ser His Leu Gly Phe Ile Arg Ser Lys Leu His Gly Leu Val Arg Pro  
 1 5 10 15

Gly Lys Asp Leu Arg Gly Arg Arg Ser  
 20 25

<210> 314  
 <211> 22  
 <212> PRT  
 <213> Homo sapiens

<400> 314  
 Arg Asn Val His Arg Phe Leu His Thr Cys Val His Met Pro Met Cys  
 1 5 10 15

158 125

<213> Homo sapiens

Gln Leu Arg Gln Glu Lys Ala Leu Glu Thr Glu Val Tyr Val Ser  
1 5 10 15

20 25

<213> Homo sapiens

Pro Arg Val Arg Gly Arg Lys Glu Pro Gly Cys Leu Gly Pro Gly Arg  
1           5           10           15

Ala Gly Gly Asp Ser Gln Lys Glu Ile Gly Ser Trp Gln Gln Met  
20 25 30

<213> Homo sapiens

Leu Ser Lys Gly Asn Arg Ile Met Ala Ala Asp Asp Asn Gly Asp  
1 1 5 10 15

Gly Thr Ser Leu Phe Asp Val Phe Ser Ala Ser Pro Leu Lys Asn Asn  
20 25 30

Asp Glu Gly Ser Leu Asp Ile Tyr Ala Gly Leu Asp Ser Ala Val Ser  
35 40 45

Asp Ser Ala Ser Lys Ser Cys Val Pro Ser Arg Asn Cys Leu Asp Leu  
50 55 60

Tyr Glu Glu Ile Leu Thr Glu Glu Gly Thr Ala Lys Glu Ala Thr Tyr  
65                 70                 75                 80

Asn Asp Leu Gln Val Glu Tyr Gly Lys Cys Gln Leu Gln Met Lys Glu  
85 90 95

Leu Met Lys Lys Phe Lys Glu Ile Gln Thr Gln Asn Phe Ser Leu Ile  
100 105 110

Asn Glu Asn Asn Gln Ser Leu Lys Lys Asn Ile Ser Ala Leu Ile Lys Thr

Glu Ala Thr Tyr Asn Asp Leu  
20

159

&lt;210&gt; 320

&lt;211&gt; 26

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 320

Asp Glu Glu Ile Ser Asn Leu His Gln Lys Ile Val Leu Ser Phe His  
1 5 10 15

Ile Phe Glu Ile Ile Lys Leu Gln Gly  
20 25

&lt;210&gt; 321

&lt;211&gt; 22

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 321

Glu Lys Glu Gly Lys Pro His Ser Asp Lys Arg Ser Thr Ser His Leu  
1 5 10 15

Pro Thr Ser Val Glu Lys  
20

&lt;210&gt; 322

&lt;211&gt; 26

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 322

Thr Glu Arg Val Arg Lys Asp Leu Ser Thr Gly Cys Gly Asp Gly Glu  
1 5 10 15

Pro Arg Ile Leu Glu Ala Ser Gln Arg Leu  
20 25

&lt;210&gt; 323

&lt;211&gt; 115

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 323

Lys Ser Tyr Phe Arg Thr Met Gly Gly Thr Lys Arg Gly Ile Lys Lys  
1 5 10 15

Leu Val Asn Val Cys Leu Lys His Pro Lys Asn Thr Ser Leu Ser Gln  
20 25 30

Gln Leu Val Phe Ala Lys Ile Asn Lys Ile Leu Ile Ser Lys Thr Thr  
35 40 45

Lys Ser Thr Asn Leu Lys Lys Gly Leu Lys Cys Leu Pro Pro Leu Ser Val  
50 55 60

Ser Ile His Pro Thr Phe Ile Tyr Tyr Lys His Asn Thr Thr Leu Arg  
65 70 75 80

Ile Val Phe Gly Thr Tyr Phe Asp Phe Phe Pro Tyr Arg Lys Asn Lys  
85 90 95

Asp Gln Ala Phe Glu Gly Glu Asp Trp Glu Ser Ser Leu Asn Val Ser  
100 105 110

Asp Ala Trp  
115

&lt;210&gt; 324

&lt;211&gt; 22

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 324

Thr Lys Arg Gly Ile Lys Lys Leu Val Asn Val Cys Leu Lys His Pro  
1 5 10 15

Lys Asn Thr Ser Leu Ser  
20

&lt;210&gt; 325

&lt;211&gt; 26

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 325

Ser Ile His Pro Thr Phe Ile Tyr Tyr Lys His Asn Thr Thr Leu Arg  
1 5 10 15

Ile Val Phe Gly Thr Tyr Phe Asp Phe Phe  
20 25

&lt;210&gt; 326

&lt;211&gt; 70

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (9)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (44)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

WO 99/24836

PCT/US98/23435

WO 99/24836

PCT/US98/23435

<221> SITE

<222> (45)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 326

Gln Arg Pro His Pro Gln Pro Trp Xaa Pro Met Thr Leu Met Gly Thr  
1 5 10 15

Gly Ile Pro Val Phe Ala His Lys Met Leu Pro Phe Asp Pro Pro Cys  
20 25 30

His Leu Ser Cys Thr His Ile Asn Pro Lys Pro Xaa Xaa Pro Gln Gly  
35 40 45

Asp Glu Gln Lys Ser Gln Gly Thr Glu Trp Cys Asp Arg Glu Gly  
50 55 60

Lys Lys Arg Arg Ser Ile  
65 70

<210> 327

<211> 21

<212> PRT

<213> Homo sapiens

<400> 327

Pro Met Thr Leu Met Gly Thr Gly Ile Pro Val Phe Ala His Lys Met  
1 5 10 15

Leu Pro Phe Asp Pro  
20

<210> 328

<211> 21

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (15)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (16)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 328

Pro Pro Cys His Leu Ser Cys Thr His Ile Asn Pro Lys Pro Xaa Xaa  
1 5 10 15

Pro Gln Gly Asp Glu  
20

<210> 329

161

<211> 21

<212> PRT

<213> Homo sapiens

<400> 329

Glu Gln Lys Ser Gln Gly Thr Glu Glu Trp Cys Asp Arg Glu Gly Lys  
1 5 10 15

Lys Arg Arg Ser Ile  
20

<210> 330

<211> 70

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (64)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (65)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 330

Asp Glu Trp Gly Ala Gly Arg Arg Met Glu Trp Glu Asp Asn Leu Pro  
1 5 10 15

Leu Glu Phe Ser Cys Pro Val Thr Lys Leu Leu Ser Val Pro Ser Trp  
20 25 30

Thr Pro Leu Asp Ala Gln Met Leu Leu Leu Phe Phe Pro Ser Leu Ser  
35 40 45

His His Ser Ser Val Pro Trp Leu Phe Cys Ser Ser Pro Cys Gly Xaa  
50 55 60

Xaa Gly Leu Gly Phe Ile  
65 70

<210> 331

<211> 21

<212> PRT

<213> Homo sapiens

<400> 331

Glu Trp Glu Asp Asn Leu Pro Leu Glu Phe Ser Cys Pro Val Thr Lys  
1 5 10 15

Leu Leu Ser Val Pro  
20

<210> 332

<211> 21  
<212> PRT  
<213> Homo sapiens

163

<400> 332  
Pro Ser Trp Thr Pro Leu Asp Ala Gln Met Leu Leu Leu Phe Pro  
1 5 10 15

Ser Leu Ser His His  
20

<210> 333  
<211> 21  
<212> PRT  
<213> Homo sapiens

&lt;220&gt;

<221> SITE  
<222> (15)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

<221> SITE  
<222> (16)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

<400> 333  
His Ser Ser Val Pro Trp Leu Phe Cys Ser Ser Pro Cys Gly Xaa Xaa  
1 5 10 15

Gly Leu Gly Phe Ile  
20

&lt;210&gt; 334

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 334

Gln Gly Leu Ser His Ile Phe Trp Met Asn Glu Gln Thr Leu Lys  
1 5 10 15

&lt;210&gt; 335

&lt;211&gt; 32

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 335

Thr Leu Val Cys Leu Gly Val Ser Ser Glu Glu Gly Ser Cys Pro Arg  
1 5 10 15

Asp Val Thr Gly Pro Gly Cys Cys Phe Ser Leu Thr Leu Thr Gly Phe  
20 25 30

&lt;210&gt; 336

&lt;211&gt; 233

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

164

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (57)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (62)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (78)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (79)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (80)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (231)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 336

Ala Asp Leu Ile Val Leu Trp His His His Pro Leu Trp Pro Gln His  
1 5 10 15

Leu Ala Leu Pro Ser Ser Gly Ala Ser His Asp His Val Glu Leu Thr  
20 25 30

Val Tyr Pro Lys Thr Val Ala Ala Ser Trp Leu Leu Glu Leu Ser Arg  
35 40 45

Pro Pro Ile Phe Cys Leu Phe Thr Xaa Pro Ala Leu Thr Xaa His Gly  
50 55 60

Leu Asp Arg Val Ala Ala Leu Val Glu Cys Thr Ile Trp Xaa Xaa Xaa  
65 70 75 80

Gly Met Trp Tyr Arg Arg Arg Tyr Ser Cys Cys Gln Phe Arg Asp Arg  
85 90 95

Ser Ile Arg Asp Val Phe Pro Glu Ala Val Met Leu Gln Gln His Leu

Arg His Leu Ala Val Ala Thr Tyr Arg Cys Arg Arg Ser Pro Cys 115 120 125	100 105 110	50 55 60	Lys Ser Pro Asn Met Xaa Xaa Ser Ser Pro Ile Leu His Leu Ile Gln 65 70 75 80
Lys Ala Pro Thr Val Glu Ala Glu Gly Lys Pro Arg Ala Val 130 135 140			Phe Thr Gly Gln Ile Ser Ser Pro Leu Gly Xaa Val Gln Pro Pro 85 90 95
Pro Ser Gly Thr Gly Phe Gln Lys His Gly Gln Glu Pro Gly Gly Ser 145 150 155 160			Gly Gln Thr Ala Ser Pro Ile Cys Thr Gln Pro Met Ser His Pro Arg 100 105 110
Thr Ser Pro His Trp Phe Trp Gly His Leu Gln Leu Val Leu Ser 165 170 175			Arg Gln Ala Ser Gln Gln Cys Glu Gln Gln Leu Trp Thr Gly Gln Thr 115 120 125
Val Asn Asn Arg Arg Gln Leu Phe Val Gln Gly Arg Ala Gly Tyr Leu Glu 180 185 190			Ser His Leu Gln Ile Pro Cys Pro Ala Leu Asn Lys Glu Leu Pro Val 130 135 140
Met Thr Gly Leu Pro Cys Pro Lys Leu Leu Thr Leu Arg Gly 195 200 205			Val Asp Thr Gln Asp Lys Glu Leu Gln Met Ser Pro Glu Pro Met Trp 145 150 155 160
Leu Thr Pro Gly Val Gly His Gly Leu Cys Ala Tyr Arg Arg Gly Cys 210 215 220			Gly Cys Gly Pro Ser Arg Leu Leu Pro Met Leu Leu Glu Ser Cys Ala 165 170 175
Leu Ala Trp Arg Leu Asp Xaa Ala Ser 225 230			
<210> 337		<210> 338	
<211> 176		<211> 34	
<212> PRT		<212> PRT	
<213> Homo sapiens		<213> Homo sapiens	
<220>		<400> 338	
<221> SITE		Met Leu Gln Gln His Leu Arg His Leu Ala Val Ala Thr Tyr Arg Cys 1 5 10 15	
<222> (70)			
<223> Xaa equals any of the naturally occurring L-amino acids		Arg Arg Arg Ser Pro Cys Lys Ala Pro Thr Val Glu Glu Ala Glu Gly 20 25 30	
<220>		Gly Lys	
<221> SITE			
<222> (71)			
<223> Xaa equals any of the naturally occurring L-amino acids			
<220>		<210> 339	
<221> SITE		<211> 29	
<222> (92)		<212> PRT	
<223> Xaa equals any of the naturally occurring L-amino acids		<213> Homo sapiens	
<400> 337		<400> 339	
Ile Leu Trp Arg Gln Ala Pro Glu Ala Pro His Cys Ser Gln Asp Ser 1 5 10 15		Val Thr Gln Val Thr Arg His Pro His Phe Arg Ser Leu Pro Ser Ala 1 5 10 15	
Val Ser Ser Ser Pro Arg Leu Gln Glu Asp Leu Ala His Val Thr Gln 20 25 30		Trp Cys Ser His Ser Ser Leu Leu Pro Val Ser Leu Pro 20 25	
Val Thr Arg His Pro His Phe Arg Ser Leu Pro Ser Ala Trp Cys Ser 35 40 45			
His Ser Ser Leu Leu Pro Val Ser Leu Pro Arg His Ala Leu Ala Thr			
		<210> 340	
		<211> 28	

<212> PRT  
<213> Homo sapiens

167

<400> 340

Gly Gln Thr Ala Ser Pro Ile Cys Thr Gln Pro Met Ser His Pro Arg  
1 5 10 15

Arg Gln Ala Ser Gln Gln Cys Glu Gln Gln Leu Trp  
20 25

<210> 341  
<211> 79  
<212> PRT  
<213> Homo sapiens

<400> 341

Phe Ile Thr Leu Arg Leu Gly Pro Lys Asn Met Ala Gly Val Leu Trp  
1 5 10 15

Arg His Ser Asn Leu Gln Thr Pro His Tyr Ile Ser Trp Cys Pro Leu  
20 25 30

Leu Asn Tyr Arg Glu Thr Gly Asn Cys Leu Leu His Val Ser Gly Phe  
35 40 45

Leu Asn Ser Arg Leu Leu Ala Asn Cys Ser Gly Glu Ala Ser Gly Lys  
50 55 60

Val Ile Gln Thr Leu Leu Trp Pro Gly Glu Ile Ser Ala Val Ala  
65 70 75

<210> 342  
<211> 82  
<212> PRT  
<213> Homo sapiens

<400> 342

Lys Ile Arg Thr Phe Leu Phe Ser Gly His Arg Leu Phe Ser Thr Gln  
1 5 10 15

Gly Gln Ser Leu Thr Val Lys Ala His Thr Ala Phe Met Leu Ile Val  
20 25 30

Lys Asn Leu Arg Tyr Phe Ile Ala Phe Lys Phe Leu Met Gly Ile Ser  
35 40 45

Asp Ser Ser Glu Ile Gly Leu Val Met Gln Pro Leu Gln Lys Pro His  
50 55 60

Thr Val Ile Leu Ile Arg Gly Ile Glu Phe Leu Ser Pro Gly Gly Val  
65 70 75 80

Leu Pro

<210> 343  
<211> 26  
<212> PRT  
<213> Homo sapiens

168

<400> 343

Met Ala Gly Val Leu Trp Arg His Ser Asn Leu Gln Thr Pro His Tyr  
1 5 10 15

Ile Ser Trp Cys Pro Leu Leu Asn Tyr Arg  
20 25

<210> 344  
<211> 29  
<212> PRT  
<213> Homo sapiens

<400> 344

Tyr Phe Ile Ala Phe Lys Phe Leu Met Gly Ile Ser Asp Ser Ser Glu  
1 5 10 15

Ile Gly Leu Val Met Gln Pro Leu Gln Lys Pro His Thr  
20 25

<210> 345  
<211> 31  
<212> PRT  
<213> Homo sapiens

<400> 345

Asp Val Leu Leu Pro Leu Leu Tyr Leu Leu Val Arg Lys His Ile Asn  
1 5 10 15

Arg Ala Gly Ile Gly Asn Thr Phe Gln Gly Gly Ala Asn Cys Ile  
20 25 30

<210> 346  
<211> 99  
<212> PRT  
<213> Homo sapiens

<400> 346

Met Cys Cys Cys Leu Cys Cys Thr Ser Trp Ser Gly Ser Thr Ser Thr  
1 5 10 15

Glu Arg Val Ser Gly Thr Arg Phe Arg Glu Val Pro Thr Ala Ser Cys  
20 25 30

Ser Ser Ser Ala Pro Ala Pro Ser Glu Leu Gly Ser Ser Leu Ser Val  
35 40 45

Ala Ala Ala Ala Leu Leu Ser Leu Pro Pro Arg Ala Arg Leu Ala Leu  
50 55 60

Pro Arg Leu Pro Arg Leu Pro Ser Gln Glu Asn Leu Arg Asn Pro Lys

65	70	169	75	80	
Gly Pro Gln Gly Asn Phe Gln Ala Pro Gly Ala Phe Val Leu Ser Ser	85	90		95	
Ser Val Ala					
<210> 347					
<211> 216					
<212> PRT					
<213> Homo sapiens					
<220>					
<221> SITE					
<222> (108)					
<223> Xaa equals any of the naturally occurring L-amino acids					
<220>					
<221> SITE					
<222> (114)					
<223> Xaa equals any of the naturally occurring L-amino acids					
<220>					
<221> SITE					
<222> (155)					
<223> Xaa equals any of the naturally occurring L-amino acids					
<400> 347					
Cys Ala Ala Ala Ser Ala Val Pro Pro Gly Pro Glu Ala His Gln Gln	5	10	15		
Ser Gly Tyr Arg Glu His Val Ser Gly Arg Cys Gln Leu His His Val	20	25	30		
Arg Pro Leu His Pro Arg Arg Pro Asn Ser Ala Leu Leu Ser Leu Leu	35	40	45		
Leu Leu Leu Leu Phe Ser Ala Ser His Gln Glu Pro Gly Trp His Ser	50	55	60		
Gln Gly Ser Arg Ala Phe Gln Ala Arg Arg Ile Ser Gly Ile Pro Arg	65	70	75	80	
Asp Pro Arg Gly Thr Ser Lys His Leu Glu Leu Leu Ser Phe Leu Val	85	90	95		
Leu Trp His Arg Cys Cys Leu Pro Gly Gly Arg Xaa Phe Cys Glu Ser	100	105	110		
Leu Xaa Gln Gly Arg Ser Ala Cys Leu Leu His Gln Lys Pro Pro Leu	115	120	125		
Leu Met Leu Ser Ala Pro Leu Gly Glu Leu Pro Thr Gln Leu Leu	130	135	140		
Leu Pro Pro Arg Ser Ser Gly Ser Lys Phe Xaa Arg Tyr Gln Arg Pro					
145	150	170	155	160	
Gly Pro Arg Val Gly Val His Leu His Lys Gly Ser Ser Glu Ile Arg	165	170		175	
Glu Ala Gly Gly Pro Gln Leu Trp Pro Gln Cys Pro His Pro Val Asp	180	185		190	
Leu Asp Val Leu Arg Thr Thr Gln His Cys Leu Gln Ser Glu Gly Pro	195	200		205	
Thr Ser Val His Leu Ser Ser Val	210	215			
<210> 348					
<211> 147					
<212> PRT					
<213> Homo sapiens					
<220>					
<221> SITE					
<222> (34)					
<223> Xaa equals any of the naturally occurring L-amino acids					
<220>					
<221> SITE					
<222> (39)					
<223> Xaa equals any of the naturally occurring L-amino acids					
<400> 348					
Glu Val Glu Glu Ala Glu Leu Ala Ala Leu Pro Met Glu Pro Arg	1	5	10	15	
Ala Ser Ile Ala Gly Ala Ser Gly Ala Ala Asp Met His Phe Cys Pro	20	25	30		
Ala Xaa Gly Thr His Arg Xaa Ala Tyr Pro Gln Glu Gly Ser Thr Tyr	35	40	45		
Ala Thr Glu Leu Glu Arg Thr Lys Ala Pro Gly Ala Trp Lys Phe Pro	50	55	60		
Trp Gly Pro Leu Gly Phe Leu Arg Phe Ser Trp Leu Gly Arg Arg Gly	65	70	75	80	
Ser Leu Gly Ser Ala Ser Arg Ala Leu Gly Gly Arg Leu Arg Ala	85	90	95		
Ala Ala Ala Thr Glu Arg Glu Pro Ser Ser Asp Gly Ala Gly Ala	100	105	110		
Glu Asp Glu His Asp Ala Val Gly Thr Ser Leu Lys Arg Val Pro Asp	115	120	125		
Thr Arg Ser Val Asp Val Leu Pro Asp Gln Glu Val Gln Arg Gln	130	135	140		

Gln His Ile  
145

171

<210> 349  
<211> 31  
<212> PRT  
<213> Homo sapiens

<400> 349  
Arg Arg Ile Ser Gly Ile Pro Arg Asp Pro Arg Gly Thr Ser Lys His  
1 5 10 15

Leu Glu Leu Leu Ser Phe Leu Val Leu Trp His Arg Cys Lys Leu  
20 25 30

<210> 350  
<211> 29  
<212> PRT  
<213> Homo sapiens

<400> 350  
Arg Thr Lys Ala Pro Gly Ala Trp Lys Phe Pro Trp Gly Pro Leu Gly  
1 5 10 15

Phe Leu Arg Phe Ser Trp Leu Gly Arg Arg Gly Ser Leu  
20 25

<210> 351  
<211> 11  
<212> PRT  
<213> Homo sapiens

<400> 351  
Pro Arg Leu Ala Gln Leu Arg Leu Leu Ser Leu  
1 5 10

<210> 352  
<211> 178  
<212> PRT  
<213> Homo sapiens

<400> 352  
Gln Ser Asp Phe Arg Glu Met Asn Gln Thr Asn Ser Thr Ser Asn Ala  
1 5 10 15

Ala Lys Ala Arg Glu Ala Gln Gln Gly Arg Gly Arg Asp Arg Glu Ala  
20 25 30

Ile Phe Ser Ser Ala Leu Glu His Leu Val Cys Tyr Leu Leu Ala  
35 40 45

Tyr Lys His Thr Leu Leu Phe Ile Arg Ser Leu Asn Glu His Gly Leu  
50 55 60

Gln Gln Leu Leu Phe Gln Trp Arg Asp Gly Leu Phe Gly Asn Trp Tyr  
65 70 75 80

Phe Arg Ile Pro Ile Leu Leu Phe Phe Thr Gly Phe His Cys Tyr His  
85 90 95

Leu Ser Cys Pro His Leu Pro Cys Ala Gln Arg Gln Ser Ser Arg Gly  
100 105 110

Thr Val Pro Tyr Val Leu Cys Pro His Pro His His His Leu His His  
115 120 125

Tyr Ser Trp Phe Pro Phe Leu Ile Pro Val Leu His Thr Leu Pro Lys  
130 135 140

Leu Gln Pro Lys Phe His Gly Arg Pro Glu Gln Pro Leu Asn Leu Leu  
145 150 155 160

Gln Val Lys Pro Thr Ser Gly Thr Ile Ala Ser Ala Glu Gln Val Trp  
165 170 175

Val Lys

<210> 353  
<211> 29  
<212> PRT  
<213> Homo sapiens

<400> 353  
Val Cys Tyr Leu Gln Ala Tyr Lys His Thr Leu Leu Phe Ile Arg Ser  
1 5 10 15

Leu Asn Glu His Gly Leu Gln Gln Leu Leu Phe Gln Trp  
20 25

<210> 354  
<211> 32  
<212> PRT  
<213> Homo sapiens

<400> 354  
Val Pro Tyr Val Leu Cys Pro His Pro His His His Leu His Tyr  
1 5 10 15

Ser Trp Phe Pro Phe Leu Ile Pro Val Leu His Thr Leu Pro Lys Leu  
20 25 30

<210> 355  
<211> 31  
<212> PRT  
<213> Homo sapiens

173

&lt;400&gt; 355

Glu Ser Glu Arg Ala Val Val Tyr Leu Ile Thr Gly Ala Leu Phe Ile  
1 5 10 15

Val Ser Ser Cys Val Leu Cys Phe Leu Pro Ser Ser Arg Arg Glu  
20 25 30

&lt;210&gt; 356

&lt;211&gt; 249

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (4)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (221)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 356

Met Trp Val Xaa Gly Glu Glu Val Leu Gly Ser His Ala Ala Ser Pro  
1 5 10 15

Ala Phe Leu His Arg Cys Phe Ser Glu Glu Ser Cys Val Ser Ile Pro  
20 25 30

Glu Val Glu Gly Tyr Val Val Leu Gln Pro Asp Ala Pro Gln Ile  
35 40 45

Leu Leu Ser Gly Thr Ala His Phe Ala Arg Pro Ala Val Asp Phe Glu  
50 55 60

Gly Thr Asn Gly Val Pro Leu Phe Pro Asp Leu Gln Ile Thr Cys Ser  
65 70 75 80

Ile Ser His Gln Val Glu Ala Lys Lys Asp Glu Ser Trp Gln Gly Thr  
85 90 95

Val Thr Asp Thr Arg Met Ser Asp Glu Ile Val His Asn Leu Asp Gly  
100 105 110

Cys Glu Ile Ser Leu Val Gly Asp Asp Leu Asp Pro Glu Arg Glu Ser  
115 120 125

Leu Leu Leu Asp Thr Thr Ser Leu Gln Gln Arg Gly Leu Glu Leu Thr  
130 135 140

Asn Thr Ser Ala Tyr Leu Thr Ile Ala Gly Val Glu Ser Ile Thr Val  
145 150 155 160

Tyr Glu Glu Ile Leu Arg Gln Ala Arg Tyr Arg Leu Arg His Gly Ala  
165 170 175

174

Ala Leu Tyr Thr Arg Lys Phe Arg Leu Ser Cys Ser Glu Met Asn Gly  
180 185 190

Arg Tyr Ser Ser Asn Glu Phe Ile Val Glu Val Asn Val Leu His Ser  
195 200 205

Met Asn Arg Val Ala His Pro Ser His Val Leu Ser Xaa Gln Gln Phe  
210 215 220

Leu His Arg Gly His Gln Pro Pro Glu Met Ala Gly His Ser Leu  
225 230 235 240

Ala Ser Ser His Arg Asn Ser Ser Thr  
245

&lt;210&gt; 357

&lt;211&gt; 23

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 357

Leu Gly Ser His Ala Ala Ser Pro Ala Phe Leu His Arg Cys Phe Ser  
1 5 10 15

Glu Glu Ser Cys Val Ser Ile  
20

&lt;210&gt; 358

&lt;211&gt; 29

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 358

Gly Tyr Val Val Val Leu Gln Pro Asp Ala Pro Gln Ile Leu Leu Ser  
1 5 10 15

Gly Thr Ala His Phe Ala Arg Pro Ala Val Asp Phe Glu  
20 25

&lt;210&gt; 359

&lt;211&gt; 26

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 359

Ile Thr Cys Ser Ile Ser His Gln Val Glu Ala Lys Lys Asp Glu Ser  
1 5 10 15

Trp Gln Gly Thr Val Thr Asp Thr Arg Met  
20 25

&lt;210&gt; 360

&lt;211&gt; 29

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

195

<400> 360  
 Asn Leu Asp Gly Cys Glu Ile Ser Leu Val Gly Asp Asp Leu Asp Pro  
 1 5 10 15

Glu Arg Glu Ser Leu Leu Leu Asp Thr Thr Ser Leu Gln  
 20 25

&lt;210&gt; 361

&lt;211&gt; 23

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

<400> 361  
 Ser Ala Tyr Leu Thr Ile Ala Gly Val Glu Ser Ile Thr Val Tyr Glu  
 1 5 10 15

Glu Ile Leu Arg Gln Ala Arg  
 20

&lt;210&gt; 362

&lt;211&gt; 26

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

<400> 362  
 Arg Leu Ser Cys Ser Glu Met Asn Gly Arg Tyr Ser Ser Asn Glu Phe  
 1 5 10 15

Ile Val Glu Val Asn Val Leu His Ser Met  
 20 25

&lt;210&gt; 363

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

<400> 363  
 Gln Gln Phe Leu His Arg Gly His Gln Pro Pro Glu Met Ala Gly  
 1 5 10 15

His Ser Leu Ala Ser Ser His Arg Asn  
 20 25

&lt;210&gt; 364

&lt;211&gt; 299

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (52)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

196

<400> 364  
 Met Ala Asp Ser Glu Thr Phe Ile Ser Leu Glu Glu Cys Arg Gly His  
 1 5 10 15

Lys Arg Ala Arg Lys Arg Thr Ser Met Glu Thr Ala Leu Ala Leu Glu  
 20 25 30

Lys Leu Phe Pro Lys Gln Cys Gln Val Leu Gly Ile Val Thr Pro Gly  
 35 40 45

Ile Val Val Xaa Pro Met Gly Ser Gly Ser Asn Arg Pro Gln Glu Ile  
 50 55 60

Glu Ile Gly Glu Ser Gly Phe Ala Leu Leu Phe Pro Gln Ile Glu Gly  
 65 70 75 80

Ile Lys Ile Gln Pro Phe His Phe Ile Lys Asp Pro Lys Asn Leu Thr  
 85 90 95

Leu Glu Arg His Gln Leu Thr Glu Val Gly Leu Leu Asp Asn Pro Glu  
 100 105 110

Leu Arg Val Val Leu Val Phe Gly Tyr Asn Cys Cys Lys Val Gly Ala  
 115 120 125

Ser Asn Tyr Leu Gln Gln Val Val Ser Thr Phe Ser Asp Met Asn Ile  
 130 135 140

Ile Leu Ala Gly Gly Gln Val Asp Asn Leu Ser Ser Leu Thr Ser Glu  
 145 150 155 160

Lys Asn Pro Leu Asp Ile Asp Ala Ser Gly Val Val Gly Leu Ser Phe  
 165 170 175

Ser Gly His Arg Ile Gln Ser Ala Thr Val Leu Leu Asn Glu Asp Val  
 180 185 190

Ser Asp Glu Lys Thr Ala Glu Ala Ala Met Gln Arg Leu Lys Ala Ala  
 195 200 205

Asn Ile Pro Glu His Asn Thr Ile Gly Phe Met Phe Ala Cys Val Gly  
 210 215 220

Arg Gly Phe Gln Tyr Tyr Arg Ala Lys Gly Asn Val Glu Ala Asp Ala  
 225 230 235 240

Phe Arg Lys Phe Phe Pro Ser Val Pro Leu Phe Gly Phe Phe Gly Asn  
 245 250 255

Gly Glu Ile Gly Cys Asp Arg Ile Val Thr Gly Asn Phe Ile Leu Arg  
 260 265 270

Lys Cys Asn Glu Val Lys Asp Asp Leu Phe His Ser Tyr Thr Thr  
 275 280 285

Ile Met Ala Leu Ile His Leu Gly Ser Ser Lys  
 290 295

-WO 99/24836

PCT/US98/23435

PCT/US98/23435

177

<210> 365  
<211> 21  
<212> PRT  
<213> Homo sapiens

<400> 365  
His Lys Arg Ala Arg Lys Arg Thr Ser Met Glu Thr Ala Leu Ala Leu  
1 5 10 15

Glu Lys Leu Phe Pro  
20

<210> 366  
<211> 24  
<212> PRT  
<213> Homo sapiens

<400> 366  
Met Gly Ser Gly Ser Asn Arg Pro Gln Glu Ile Glu Ile Gly Glu Ser  
1 5 10 15

Gly Phe Ala Leu Leu Phe Pro Gln  
20

<210> 367  
<211> 22  
<212> PRT  
<213> Homo sapiens

<400> 367  
Phe His Phe Ile Lys Asp Pro Lys Asn Leu Thr Leu Glu Arg His Gln  
1 5 10 15

Leu Thr Glu Val Gly Leu  
20

<210> 368  
<211> 23  
<212> PRT  
<213> Homo sapiens

<400> 368  
Phe Gly Tyr Asn Cys Cys Lys Val Gly Ala Ser Asn Tyr Leu Gln Gln  
1 5 10 15

Val Val Ser Thr Phe Ser Asp  
20

<210> 369  
<211> 20  
<212> PRT  
<213> Homo sapiens

-WO 99/24836

178

<400> 369  
Thr Ser Glu Lys Asn Pro Leu Asp Ile Asp Ala Ser Gly Val Val Gly  
1 5 10 15

Leu Ser Phe Ser  
20

<210> 370  
<211> 26  
<212> PRT  
<213> Homo sapiens

<400> 370  
Asn Glu Asp Val Ser Asp Glu Lys Thr Ala Glu Ala Ala Met Gln Arg  
1 5 10 15

Leu Lys Ala Ala Asn Ile Pro Glu His Asn  
20 25

<210> 371  
<211> 25  
<212> PRT  
<213> Homo sapiens

<400> 371  
Tyr Tyr Arg Ala Lys Gly Asn Val Glu Ala Asp Ala Phe Arg Lys Phe  
1 5 10 15

Phe Pro Ser Val Pro Leu Phe Gly Phe  
20 25

<210> 372  
<211> 26  
<212> PRT  
<213> Homo sapiens

<400> 372  
Ile Gly Cys Asp Arg Ile Val Thr Gly Asn Phe Ile Leu Arg Lys Cys  
1 5 10 15

Asn Glu Val Lys Asp Asp Leu Phe His  
20 25

<210> 373  
<211> 341  
<212> PRT  
<213> Homo sapiens

<400> 373  
Met Pro Lys Arg Lys Val Thr Phe Gln Gly Val Gly Asp Glu Glu Asp  
1 5 10 15

Glu Asp Glu Ile Ile Val Pro Lys Lys Lys Leu Val Asp Pro Val Ala

20 25 179 30  
 Gly Ser Gly Gly Pro Gly Ser Arg Phe Lys Gly Lys His Ser Leu Asp  
 35 40 45  
 Ser Asp Glu Glu Glu Asp Asp Asp Gly Gly Ser Ser Lys Tyr Asp  
 50 55 60  
 Ile Leu Ala Ser Glu Asp Val Glu Gly Gln Glu Ala Ala Thr Leu Pro  
 65 70 75 80  
 Ser Glu Gly Gly Val Arg Ile Thr Pro Phe Asn Leu Gln Glu Met  
 85 90 95  
 Glu Glu Gly His Phe Asp Ala Asp Gly Asn Tyr Phe Leu Asn Arg Asp  
 100 105 110  
 Ala Gln Ile Arg Asp Ser Trp Leu Asp Asn Ile Asp Trp Val Lys Ile  
 115 120 125  
 Arg Glu Arg Pro Pro Gly Gln Arg Gln Ala Ser Asp Ser Glu Glu Glu  
 130 135 140  
 Asp Ser Leu Gly Gln Thr Ser Met Ser Ala Gln Ala Leu Leu Glu Gly  
 145 150 155 160  
 Leu Leu Glu Leu Leu Leu Pro Arg Glu Thr Val Ala Gly Ala Leu Arg  
 165 170 175  
 Arg Leu Gly Ala Arg Gly Gly Lys Gly Arg Lys Gly Pro Gly Gln  
 180 185 190  
 Pro Ser Ser Pro Gln Arg Leu Asp Arg Leu Ser Gly Leu Ala Asp Gln  
 195 200 205  
 Met Val Ala Arg Gly Asn Leu Gly Val Tyr Gln Glu Thr Arg Glu Arg  
 210 215 220  
 Leu Ala Met Arg Leu Lys Gly Leu Gly Cys Gln Thr Leu Gly Pro His  
 225 230 235 240  
 Asn Pro Thr Pro Pro Ser Leu Asp Met Phe Ala Glu Glu Leu Ala  
 245 250 255  
 Glu Glu Glu Leu Glu Thr Thr Pro Thr Gln Arg Gly Glu Ala Glu  
 260 265 270  
 Ser Arg Gly Asp Gly Leu Val Asp Val Met Trp Glu Tyr Lys Trp Glu  
 275 280 285  
 Asn Thr Gly Asp Ala Glu Leu Tyr Gly Pro Phe Thr Ser Ala Gln Met  
 290 295 300  
 Gln Thr Trp Val Ser Glu Gly Tyr Phe Pro Asp Gly Val Tyr Cys Arg  
 305 310 315 320  
 Lys Leu Asp Pro Pro Gly Gly Gln Phe Tyr Asn Ser Lys Arg Ile Asp  
 325 330 335

Phe Asp Leu Tyr Thr  
 340  
 <210> 374  
 <211> 24  
 <212> PRT  
 <213> Homo sapiens  
 <400> 374  
 Thr Phe Gln Gly Val Gly Asp Glu Glu Asp Glu Ile Ile Val  
 1 5 10 15  
 Pro Lys Lys Lys Leu Val Asp Pro  
 20  
 <210> 375  
 <211> 27  
 <212> PRT  
 <213> Homo sapiens  
 <400> 375  
 Pro Gly Ser Arg Phe Lys Gly Lys His Ser Leu Asp Ser Asp Glu Glu  
 1 5 10 15  
 Glu Asp Asp Asp Gly Gly Ser Ser Lys Tyr  
 20 25  
 <210> 376  
 <211> 25  
 <212> PRT  
 <213> Homo sapiens  
 <400> 376  
 Glu Ala Ala Thr Leu Pro Ser Glu Gly Gly Val Arg Ile Thr Pro Phe  
 1 5 10 15  
 Asn Leu Gln Glu Glu Met Glu Glu Gly  
 20 25  
 <210> 377  
 <211> 29  
 <212> PRT  
 <213> Homo sapiens  
 <400> 377  
 Phe Leu Asn Arg Asp Ala Gln Ile Arg Asp Ser Trp Leu Asp Asn Ile  
 1 5 10 15  
 Asp Trp Val Lys Ile Arg Glu Arg Pro Pro Gly Gln Arg  
 20 25  
 <210> 378

1 5 10 15

Glu Gly Tyr Phe Pro Asp Gly Val Tyr Cys Arg Lys Leu Asp  
20 25 30

<210> 383

<211> 14

<212> PRT

<213> Homo sapiens

<400> 383

Pro His Ser Ser Arg Val Ser Phe Leu Gln Ser Leu Ser Phe  
1 5 10

<210> 384

<211> 141

<212> PRT

<213> Homo sapiens

<400> 384

Arg Gly Gln Pro Arg Pro Cys Val Ser Gly Val Cys Leu Ser Pro His  
1 5 10 15

Ser Arg Phe Trp Glu Cys Ser Phe Tyr Leu Gln Gly Leu Pro Ala  
20 25 30

Leu Arg Cys Ser Arg Thr Pro Pro Gly Cys His Phe Phe Arg Val Phe  
35 40 45

Pro Ser Cys Pro Phe Ser Ser Arg Ser Pro Ser Cys Phe Thr His  
50 55 60

Ile Cys Pro Val Val Arg Ile Gln Phe Ser Arg Ala Leu Trp Val Ser  
65 70 75 80

Thr Cys Leu Val Leu Ala Ile Thr Pro Gly Lys Trp Leu Leu Pro Glu  
85 90 95

Asp Arg Ala Leu Ser Leu Met Leu Leu Ala Ser Leu Gln Cys Cys Pro  
100 105 110

Pro Pro Phe Gly Ala Trp Trp Met Gln Val Leu Thr His Lys Gly Arg  
115 120 125

Gln Ala Gly Leu Gly Pro Gly Val Ser Ser Arg Pro Leu  
130 135 140

<210> 385

<211> 133

<212> PRT

<213> Homo sapiens

<400> 385

Ser Asn Ile Lys Ser Leu Pro Pro Thr Asn Ser Leu Ser Leu Arg  
1 5 10 15

10/

<211> 26

<212> PRT

<213> Homo sapiens

<400> 378

Ser Leu Gly Gln Thr Ser Met Ser Ala Gln Ala Leu Leu Glu Gly Leu  
1 5 10 15

Leu Glu Leu Leu Leu Pro Arg Glu Thr Val  
20 25

<210> 379

<211> 28

<212> PRT

<213> Homo sapiens

<400> 379

Arg Gly Gly Lys Gly Arg Lys Gly Pro Gly Gln Pro Ser Ser Pro  
1 5 10 15

Gln Arg Leu Asp Arg Leu Ser Gly Leu Ala Asp Gln  
20 25

<210> 380

<211> 24

<212> PRT

<213> Homo sapiens

<400> 380

Gln Glu Thr Arg Glu Arg Leu Ala Met Arg Leu Lys Gly Leu Gly Cys  
1 5 10 15

Gln Thr Leu Gly Pro His Asn Pro  
20

<210> 381

<211> 28

<212> PRT

<213> Homo sapiens

<400> 381

Asp Met Phe Ala Glu Glu Leu Ala Glu Glu Glu Leu Glu Thr Pro Thr  
1 5 10 15

Pro Thr Gln Arg Gly Glu Ala Glu Ser Arg Gly Asp  
20 25

<210> 382

<211> 30

<212> PRT

<213> Homo sapiens

<400> 382

Glu Leu Tyr Gly Pro Phe Thr Ser Ala Gln Met Gln Thr Trp Val Ser  
1 5 10

Ala Gln Thr Gly Thr Asp Cys Ala Val Ser Pro Gly Leu Ala Gly Pro  
20 25 30  
Cys His Gln Arg Gly Leu Glu Asp Thr Pro Gly Pro Arg Pro Ala Cys  
35 40 45  
Leu Pro Leu Cys Val Ser Thr Cys Ile His Gln Ala Pro Lys Gly Gly  
50 55 60  
Gly Gln His Trp Arg Glu Ala Ser Ser Ile Arg Asp Arg Ala Leu Ser  
65 70 75 80  
Ser Gly Arg Ser His Phe Pro Gly Val Met Ala Lys Thr Lys His Val  
85 90 95  
Asp Thr His Asn Ala Arg Glu Asn Trp Ile Arg Thr Thr Gly Gln Met  
100 105 110  
Trp Val Lys His Glu Gly Glu Arg Glu Glu Lys Gly His Glu Gly  
115 120 125  
Lys Thr Leu Lys Lys  
130

<210> 386  
<211> 25  
<212> PRT  
<213> Homo sapiens

<400> 386  
Val Cys Leu Ser Pro His Ser Arg Phe Trp Glu Cys Ser Phe Tyr  
1 5 10 15  
Leu Gln Gly Leu Pro Ala Leu Arg Cys  
20 25

<210> 387  
<211> 27  
<212> PRT  
<213> Homo sapiens

<400> 387  
Gln Phe Ser Arg Ala Leu Trp Val Ser Thr Cys Leu Val Leu Ala Ile  
1 5 10 15  
Thr Pro Gly Lys Trp Leu Leu Pro Glu Asp Arg  
20 25

<210> 388  
<211> 27  
<212> PRT  
<213> Homo sapiens

<400> 388

Ser Leu Ser Leu Leu Arg Ala Gln Thr Gly Thr Asp Cys Ala Val Ser  
1 5 10 15  
Pro Gly Leu Ala Gly Pro Cys His Gln Arg Gly  
20 25

<210> 389  
<211> 28  
<212> PRT  
<213> Homo sapiens

<400> 389  
Ser Gly Arg Ser His Phe Pro Gly Val Met Ala Lys Thr Lys His Val  
1 5 10 15

Asp Thr His Asn Ala Arg Glu Asn Trp Ile Arg Thr  
20 25

<210> 390  
<211> 20  
<212> PRT  
<213> Homo sapiens

<400> 390  
Ala Arg Val Glu Val Gln Gly Gln Gly Pro Gly Ala Lys Val Asp Ala  
1 5 10 15  
Gly Glu Gly Gln  
20

<210> 391  
<211> 121  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (46)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (66)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (98)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (121)  
<223> Xaa equals any of the naturally occurring L-amino acids

WO 99/24836

PCT/US98/23435

<400> 391  
Trp Val Val Leu Ser Gln Leu Gln Ala Gln Gly Val Ala Gly Met Met 15  
1 5 10  
Cys Ser Tyr Pro Glu Gly Gln Lys Lys Gly Lys Lys Glu Ala Thr Arg Ser 25  
20 30  
His Arg Trp Val Pro Arg Ser Leu Pro Gly Met Gly Ser Xaa Leu Ala 45  
35 40  
Ala Pro His Ser Asn Pro Trp Leu Ala Pro Leu Ala Leu Leu Glu Ile 60  
50 55 75  
Pro Xaa Pro Val Leu Cys Glu Trp Lys Arg Lys Leu Ile Ala Leu Glu 80  
65 70  
Glu Val Ser Glu Cys Arg Pro Gly Val Gly Gly Gly Gly Phe Leu 95  
85 90  
Ser Xaa Cys Arg Arg Gly His Leu Ser Phe Leu Ser Gly Ala Pro Tyr 105  
100 110  
Pro Leu Phe Pro Ile Ser Pro Leu Xaa 120  
115  
<210> 392  
<211> 206  
<212> PRT  
<213> Homo sapiens  
<220>  
<221> SITE  
<222> (105)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (127)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (131)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<220>  
<221> SITE  
<222> (180)  
<223> Xaa equals any of the naturally occurring L-amino acids  
<400> 392  
Glu Leu Arg His Gly Gly Pro Arg Gln Val Lys Asp Ser Phe Leu Asp 15  
1 5 10  
Tyr Met Gly Tyr Pro Asp Glu Asp Arg Ala Gly Pro Pro Ser Arg Trp 20  
25 30

WO 99/24836

PCT/US98/23435

186

phe Pro Arg Glu Arg Phe Leu Ser Pro Pro Thr Val Val Pro Leu Cys 45  
35 40  
Val Glu Leu Arg Leu Gly Phe Glu Ser Gly Met Gly Trp Gly Val Pro 60  
50 55  
Gly Ser Ser His Ser Glu Gly Gly Pro Glu Ala Arg Trp Pro Leu Ile 80  
65 70 75  
Ala Pro Met Tyr Thr Val Thr Gln Trp Phe Gln Arg Pro Asn Ser Gly 95  
85 90  
Arg Gly Pro Gln Pro Pro Gln Xaa Arg Gly Glu Ile Gly Lys Arg 110  
100 105  
Gly Tyr Gly Ala Pro Glu Arg Lys Leu Arg Trp Pro Leu Leu Xaa Trp 125  
115 120  
Glu Arg Xaa Pro Pro Pro Pro Thr Pro Gly Arg His Ser Glu Thr 140  
130 135  
Ser Ser Ser Ala Ile Ser Phe Leu Phe His Ser Gln Arg Thr Gly Trp 160  
145 150 155  
Gly Ile Ser Ser Ser Ala Asn Gly Ala Ser Gln Gly Leu Leu Trp Gly 175  
165 170  
Ala Ala Arg Xaa Leu Pro Ile Pro Gly Arg Asp Leu Gly Thr His Leu 180  
185  
Trp Asp Leu Val Ala Ser Phe Pro Phe Phe Cys Pro Ser Gly 205  
195 200  
<210> 393  
<211> 24  
<212> PRT  
<213> Homo sapiens  
<400> 393  
Pro Glu Gly Gln Lys Lys Lys Glu Ala Thr Arg Ser His Arg Trp 15  
1 5 10  
Val Pro Arg Ser Leu Pro Gly Met 20  
25  
<210> 394  
<211> 26  
<212> PRT  
<213> Homo sapiens  
<400> 394  
Leu Arg Leu Gly Phe Glu Ser Gly Met Gly Trp Gly Val Pro Gly Ser 15  
1 5 10  
Ser His Ser Glu Gly Gly Pro Glu Ala Arg 25  
20

157

<210> 395  
<211> 24  
<212> PRT  
<213> Homo sapiens

<400> 395  
His Ser Gln Arg Thr Gly Trp Gly Ile Ser Ser Ser Ala Asn Gly Ala  
1 5 10 15

Ser Gln Gly Leu Leu Trp Gly Ala  
20

<210> 396  
<211> 54  
<212> PRT  
<213> Homo sapiens

<400> 396  
Phe Ile Met Lys Leu Leu Tyr Gln Leu Leu Met Leu Thr Thr Ser Ser  
1 5 10 15

Ser Tyr Ser Leu Ile Thr His Leu Cys Tyr Ser Ile Phe Leu Cys Ser  
20 25 30

Phe Tyr Phe His Phe Pro Cys Asn Val Ser Leu Phe Val Leu Ile Ser  
35 40 45

Glu Glu Phe Ile Tyr Asp  
50

<210> 397  
<211> 21  
<212> PRT  
<213> Homo sapiens

<400> 397  
Leu Met Leu Thr Thr Ser Ser Ser Tyr Ser Ser Leu Ile Thr His Leu Cys  
1 5 10 15

Tyr Ser Ile Phe Leu  
20

<210> 398  
<211> 21  
<212> PRT  
<213> Homo sapiens

<400> 398  
Leu Cys Ser Phe Tyr Phe His Phe Pro Cys Asn Val Ser Leu Phe Val  
1 5 10 15

Leu Ile Ser Glu Glu  
20

168

<210> 399  
<211> 53  
<212> PRT  
<213> Homo sapiens

<400> 399  
Met Arg Lys Asn Ile Phe Ala Ile Leu Asp Lys Met Leu Thr Cys Leu  
1 5 10 15

Ile Ile Asn Glu Leu Phe Arg Asn Gln Tyr Lys Glu Thr Asn Ile Thr  
20 25 30

Arg Glu Val Lys Ile Lys Gly Thr Glu Glu Asn Gly Ile Ala Gln Met  
35 40 45

Ser Tyr Lys Ala Ile  
50

<210> 400  
<211> 21  
<212> PRT  
<213> Homo sapiens

<400> 400  
Asp Lys Met Leu Thr Cys Leu Ile Ile Asn Glu Leu Phe Arg Asn Gln  
1 5 10 15

Tyr Lys Glu Thr Asn  
20

<210> 401  
<211> 21  
<212> PRT  
<213> Homo sapiens

<400> 401  
Asn Ile Thr Arg Glu Val Lys Ile Lys Gly Thr Glu Glu Asn Gly Ile  
1 5 10 15

Ala Gln Met Ser Tyr  
20

<210> 402  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 402  
Gly Ile Ser Glu Arg Lys Pro  
1 5

<210> 403

WO 99724836

PCT/US98/23435

189

<211> 25  
<212> PRT  
<213> Homo sapiens  
<400> 403  
Gln Ser Pro Ala Val Ser Tyr Thr Val Thr Ser Gln Val Pro Trp Gly  
1 5 10 15

Leu Gly Leu Leu Ala Gly Glu Lys Arg  
20 25

<210> 404  
<211> 100  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (96)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 404  
Leu Pro Ser His Pro Leu Arg Pro Leu Thr Phe Ser Ser Ala Met Cys  
1 5 10 15

Met His Leu Pro Pro Leu Cys Arg Arg Ala Ala Leu Ser Ala Pro  
20 25 30

Phe Ala Thr Gln His Arg Pro Trp Ser Val Ala Ala Cys Leu Pro  
35 40 45

Arg Ile His Gln Asn Pro Leu Asp Ala Glu Tyr Pro Ser Gly Cys Cys  
50 55 60

Arg Met Ser Phe Leu Pro Ala Ala Cys Ser Asn Ile Tyr Ser Gln Glu  
65 70 75 80

Cys His Tyr Thr Leu Met Ser His Ser Glu Ala Ser Thr Leu Gln Xaa  
85 90 95

Ala Gln Leu Leu  
100

<210> 405  
<211> 76  
<212> PRT  
<213> Homo sapiens

<400> 405  
Met Leu Leu Gln Ala Ala Gly Arg Lys Leu Met Arg Gln Gln Pro Asp  
1 5 10 15

Gly Tyr Ser Ala Ser Arg Gly Phe Trp Trp Met Arg Gly Arg Gln Ala  
20 25 30

Ala Ala Thr Leu His Gly Arg Cys Trp Val Ala Lys Gly Ala Asp Ser

WO 99724836

PCT/US98/23435

35 40 45

Ala Ala Leu Arg Gln Arg Gly Gly Arg Cys Met His Ile Ala Asp  
50 55 60

Glu Lys Val Arg Gly Leu Ser Gly Cys Asp Gly Ser  
65 70 75

<210> 406  
<211> 25  
<212> PRT  
<213> Homo sapiens

<400> 406  
Leu Cys Arg Arg Ala Ala Leu Ser Ala Pro Phe Ala Thr Gln His Arg  
1 5 10 15

Pro Trp Ser Val Ala Ala Cys Leu  
20 25

<210> 407  
<211> 24  
<212> PRT  
<213> Homo sapiens

<400> 407  
Arg Gly Phe Trp Trp Met Arg Gly Arg Gln Ala Ala Thr Leu His  
1 5 10 15

Gly Arg Cys Trp Val Ala Lys Gly  
20

<210> 408  
<211> 23  
<212> PRT  
<213> Homo sapiens

<400> 408  
Gln Arg Gly Gly Arg Cys Met His Ile Ala Asp Glu Lys Val Arg  
1 5 10 15

Gly Leu Ser Gly Cys Asp Gly  
20

<210> 409  
<211> 106  
<212> PRT  
<213> Homo sapiens

<400> 409  
Thr His Pro Ser His Pro Ser Ile Val Ile Gln Ser Thr Val Ser Leu  
1 5 10 15

Cys Leu Thr Ala Ser Ser Arg Arg Lys Ser Asp Cys Leu Ser Leu

20 25 141 30

Cys Gln Val Ser Cys Ser Gln Arg Pro Gly Ser His Lys Thr Asn Val  
35 40 45

Ala Trp Gly Phe Leu Met Ser Arg Val His Phe Ser Val Arg Trp Val  
50 55 60

Ser Gly Gly Arg Gly Ile Thr Gly Ala Ile Cys Lys Glu Ser Ser Leu  
65 70 75 80

Pro Cys Lys Glu Ile Gln Gly Lys Ala Cys Tyr Phe Cys His His Pro  
85 90 95

Ala Gln Gln Ser Thr Pro Phe Ser His Ile  
100 105

<210> 410  
<211> 27  
<212> PRT  
<213> Homo sapiens

<400> 410  
Val Ile Gln Ser Thr Val Ser Leu Cys Leu Thr Ala Ser Ser Arg Arg  
1 5 10 15

Lys Lys Ser Asp Cys Leu Ser Leu Cys Gln Val  
20 25

<210> 411  
<211> 26  
<212> PRT  
<213> Homo sapiens

<400> 411  
Ile Cys Lys Glu Ser Ser Leu Pro Cys Lys Glu Ile Gln Gly Lys Ala  
1 5 10 15

Cys Tyr Phe Cys His His Pro Ala Gln Gln  
20 25

<210> 412  
<211> 188  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (140)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (149)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 412  
Ser Leu Gln Val Leu Arg Thr Leu Gly Ser Lys Cys Gly Asp Phe Leu  
1 5 10 15

Arg Ser Arg Phe Cys Lys Asp Val Leu Pro Lys Leu Ala Gly Ser Leu  
20 25 30

Val Thr Gln Ala Pro Ile Ser Ala Arg Ala Gly Pro Val Tyr Ser His  
35 40 45

Thr Leu Ala Phe Lys Leu Gln Leu Ala Val Leu Gln Gly Leu Gly Pro  
50 55 60

Leu Cys Glu Arg Leu Asp Leu Gly Glu Gly Asp Leu Asn Lys Val Ala  
65 70 75 80

Asp Ala Cys Leu Ile Tyr Leu Ser Val Lys Gln Pro Val Lys Leu Gln  
85 90 95

Glu Ala Ala Arg Ser Val Phe Leu His Leu Met Lys Val Asp Pro Asp  
100 105 110

Ser Thr Tyr Phe Leu Leu Asn Glu Leu Tyr Cys Pro Val Gln Phe Thr  
115 120 125

Pro Pro His Pro Ser Leu His Pro Val Gln Leu Xaa Gly Ala Ser Gly  
130 135 140

Gln Gln Asn Pro Xaa His Asp Gln Arg Ala Pro Ala Ala Gln Gly Ala  
145 150 155 160

Ala Val Thr Leu Leu Pro His His Arg Gly His Arg Ser Leu Pro Tyr  
165 170 175

Cys Gln Pro Glu Ala Gly Leu Thr Pro Pro Arg Pro  
180 185

<210> 413  
<211> 138  
<212> PRT  
<213> Homo sapiens

<400> 413  
Gly Ala Asp Gly Asn Val Ser Asp Phe Asp Asn Glu Glu Glu Gln  
1 5 10 15

Ser Val Pro Pro Lys Val Asp Glu Asn Asp Thr Arg Pro Asp Val Glu  
20 25 30

Pro Pro Leu Pro Leu Gln Ile Gln Ile Ala Met Asp Val Met Glu Arg  
35 40 45

Cys Ile His Leu Leu Ser Asp Lys Asn Leu Gln Ile Arg Leu Lys Val  
50 55 60

Leu Asp Val Leu Asp Leu Cys Val Val Val Leu Gln Ser His Lys Asn

WO 99/24836

PCT/US98/23435

WO 99/24836

PCT/US98/23435

65 70 75 80

193

194

Gln Leu Leu Pro Leu Ala His Gln Ala Trp Pro Ser Leu Val His Arg 95

Trp Pro Ser Leu Val His Arg Leu Thr Arg Asp Ala Pro Leu Ala Val 15

Leu Thr Arg Asp Ala Pro Leu Ala Val Leu Arg Ala Phe Lys Phe Tyr 110

Leu Arg Ala Phe Lys Phe Tyr Val Pro Trp 25

Val Pro Trp Glu Ala Ser Val Thr Phe Phe Ala Ala Gly Ser Ala 125

<210> 418

<211> 58

<212> PRT

<213> Homo sapiens

Lys Met Ser Cys Gln Ser Trp Leu Ala Pro 135

<210> 414

<211> 26

<212> PRT

<213> Homo sapiens

Ser Leu Gly Ile Ser Thr Phe Gly Ile Met Val Phe Ser Val Tyr Phe 15

Gly Gly Ile Met Ile Ser Ile Pro Tyr Ser Gly Ile Ser Phe Gly Asn 30

<400> 414

Thr Leu Gly Ser Lys Cys Gly Asp Phe Leu Arg Ser Arg Phe Cys Lys 15

Asp Val Leu Pro Lys Leu Ala Gly Ser Leu 25

Asn Ile Met Phe Ser Glu Arg Ser Gln Thr 55

<210> 415

<211> 29

<212> PRT

<213> Homo sapiens

Pro Val Tyr Ser His Thr Leu Ala Phe Lys Leu Gln Leu Ala Val Leu 15

His Ala Ser Gly Asn Asn Asp Pro Leu Trp Phe Leu Thr Tyr Leu 15

Gln Gly Leu Gly Pro Leu Cys Glu Arg Leu Asp Leu Gly 25

<210> 416

<211> 27

<212> PRT

<213> Homo sapiens

Ser Val Pro Pro Lys Val Asp Glu Asn Asp Thr Arg Pro Asp Val Glu 15

Ser Gly Ile Ser Phe 20

Pro Pro Leu Pro Leu Gln Ile Gln Ile Ala Met 25

<210> 421

<211> 20

<212> PRT

<213> Homo sapiens

<210> 417

<211> 26

<212> PRT

<213> Homo sapiens

Phe Gly Asn Lys Lys Glu Leu Asn Ile Asp Ser Cys Tyr Asn Met Val

1 5 10 15  
Asn Leu Lys Asn 20

<210> 422  
<211> 75  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (48)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (49)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (50)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (72)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (74)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 422  
Met Asn Ser Phe Ser Val Ile Ala Ser Ile Val Val Leu Leu Pro Phe  
1 5 10 15

Pro Gly Leu Ser Val Ser Ala Cys Leu Pro Ser His Ser His Gln Cys  
20 25 30

Lys Thr Phe Ile Leu Leu Phe Leu Pro Ser Ser Glu Lys Thr Leu Xaa  
35 40 45

Xaa Xaa Pro Pro Ser His Ser Ser Thr Leu Gly Gly Gln Gly Gln  
50 55 60

Ile Met Arg Ser Gly Asp Arg Xaa His Xaa Gly  
65 70 75

<210> 423  
<211> 81  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (5)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (6)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (60)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (74)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 423  
Val Val Phe Phe Xaa Xaa Phe Phe Glu Met Glu Ser His Ser Val Ala  
1 5 10 15  
Gln Ala Gly Val Gln Trp Arg Asn Leu Gly Ser Leu Gln Ala Leu Pro  
20 25 30

Pro Gly Phe Met Pro Phe Ser Cys Leu Ser Leu Pro Gly Ser Trp Asp  
35 40 45

Tyr Arg Arg Pro Pro Pro Ser Pro Ala Asn Leu Xaa Cys Ile Phe Ser  
50 55 60

Arg Asp Gly Gly His His Val Ser Gln Xaa Gly Leu Asp Leu Thr  
65 70 75 80

Ser

<210> 424  
<211> 28  
<212> PRT  
<213> Homo sapiens

<400> 424

Ile Val Val Leu Leu Pro Phe Pro Gly Leu Ser Val Ser Ala Cys Leu  
1 5 10 15

Pro Ser His Ser His Gln Cys Lys Thr Phe Ile Leu  
20 25

<210> 425  
<211> 26  
<212> PRT  
<213> Homo sapiens

<400> 425  
 Pro Gly Phe Met Pro Phe Ser Cys Leu Ser Leu Pro Gly Ser Trp Asp 15  
 1  
 Tyr Arg Arg Pro Pro Ser Pro Ala Asn 25  
 20  
 <210> 426  
 <211> 16  
 <212> PRT  
 <213> Homo sapiens  
 <400> 426  
 Tyr Arg Phe Lys Asn Pro Lys Cys Arg Leu Phe Ser Val Pro Cys Arg 15  
 1  
 5  
 10  
 <210> 427  
 <211> 128  
 <212> PRT  
 <213> Homo sapiens  
 <400> 427  
 Thr Gln Asn Arg Glu Leu Ala Trp Lys Pro Lys Gly Thr Asp Asp 15  
 1  
 5  
 10  
 Ile Cys Thr Ser His Asn Thr Thr His Ile Gln Lys Met Pro Gly Glu 30  
 20  
 25  
 Ala Asn Ser Cys Cys Pro Arg Gly Ala Lys Ser Tyr His Ile Asp Cys 45  
 35  
 40  
 Trp Pro Pro Ala Leu Phe Pro Arg Cys Val Ala Tyr Leu Phe Leu Asn 60  
 50  
 55  
 Lys Pro Ala Thr Leu Arg Lys Lys Tyr Tyr Cys Lys Pro Tyr His Thr 80  
 65  
 70  
 75  
 Gln Leu His Pro Ala Trp His Arg Glu Lys Ser Ala Phe Trp Ile Phe 95  
 85  
 90  
 Glu Thr Val Ser Gln Ser Lys Gln Ser Leu Thr Ser Leu Val Tyr Ser 110  
 100  
 105  
 Val Asn Glu Leu Leu Val Leu Ser Asn Leu Ala Gln Trp Ala Leu Gly 125  
 115  
 120  
 <210> 428  
 <211> 23  
 <212> PRT  
 <400> 428  
 Ala Trp Lys Pro Lys Gly Thr Asp Asp Ile Cys Thr Ser His Asn Thr 15  
 1  
 5  
 10  
 Thr His Ile Gln Lys Met Pro 20  
 <210> 429  
 <211> 25  
 <212> PRT  
 <213> Homo sapiens  
 <400> 429  
 Cys Pro Arg Gly Ala Lys Ser Tyr His Ile Asp Cys Trp Pro Pro Ala 15  
 1  
 5  
 10  
 Leu Phe Pro Arg Cys Val Ala Tyr Leu 25  
 20  
 <210> 430  
 <211> 26  
 <212> PRT  
 <213> Homo sapiens  
 <400> 430  
 Ser Tyr His Ile Asp Cys Trp Pro Pro Ala Leu Phe Pro Arg Cys Val 15  
 1  
 5  
 10  
 Ala Tyr Leu Phe Leu Asn Lys Pro Ala Thr 25  
 20  
 <210> 431  
 <211> 29  
 <212> PRT  
 <213> Homo sapiens  
 <400> 431  
 Arg Lys Lys Tyr Tyr Cys Lys Pro Tyr His Thr Gln Leu His Pro Ala 15  
 1  
 5  
 10  
 Trp His Arg Glu Lys Ser Ala Phe Trp Ile Phe Glu Thr 25  
 20  
 <210> 432  
 <211> 28  
 <212> PRT  
 <213> Homo sapiens  
 <400> 432  
 Ile Cys Leu Asp Ser Cys Ser Gln Val Ser Val Thr Ser Leu Trp Ser 15  
 1  
 5  
 10

Phe Leu Arg Val His Ser Leu Val Gln Thr Leu Trp  
20 25

&lt;210&gt; 433

&lt;211&gt; 75

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 433

His Tyr Cys Cys Asp Phe Gly Thr Ser Leu Leu Gly Phe Tyr Val Pro  
1 5 10 15

Phe His Tyr Tyr Val His Met Val Asn Ile Ile Leu Thr Thr Ile Asp  
20 25 30

Phe Tyr His Tyr Lys Phe Cys Cys Ser Gln Asn Ala Asn Lys His Cys  
35 40 45

Phe Lys His Phe Gln Ile Met Thr Thr Val Pro Tyr Leu Asn Ile Asn  
50 55 60

Lys Glu Asn Leu Arg Phe Lys Asn Ile Phe Lys  
65 70 75

&lt;210&gt; 434

&lt;211&gt; 27

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 434

Thr Ser Leu Leu Gly Phe Tyr Val Pro Phe His Tyr Tyr Val His Met  
1 5 10 15

Val Asn Ile Ile Leu Thr Thr Ile Asp Phe Tyr  
20 25

&lt;210&gt; 435

&lt;211&gt; 22

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 435

Phe Gln Ile Met Thr Thr Val Pro Tyr Leu Asn Ile Asn Lys Glu Asn  
1 5 10 15

Leu Arg Phe Lys Asn Ile  
20

&lt;210&gt; 436

&lt;211&gt; 106

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 436

Ile Ser Glu Ser Met Ser Leu Val Arg Ser Leu Gln Phe Tyr Arg Gly  
1 5 10 15

Lys Asn Arg Ala Glu Arg Thr Val Ile Ser Ser Ser Ser His Ser Cys  
20 25 30

His Leu Ile Asp Leu Glu Phe Gln Pro Arg Ser Asp Gly Glu Val Ser  
35 40 45

Ile Ser Phe Leu Glu Lys Gly Val Glu Leu Arg Trp Gly Met Gly Leu  
50 55 60

Glu Asp Leu Ile Gly Leu Gly Leu Gly Val Ser Thr Arg Arg Ser Thr  
65 70 75 80

Val Arg Arg Lys Glu Pro Thr Lys Ala Gly Met His Thr Ala Cys Ser  
85 90 95

Glu Glu Met Glu Pro Glu Asn Arg Glu Asn  
100 105

&lt;210&gt; 437

&lt;211&gt; 143

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 437

Asp Gly Ser Arg Ser Val Ala Gln Ala Arg Val Gln Trp His His Arg  
1 5 10 15

Gly Ser Leu Pro Pro Leu Pro Pro Arg Phe Lys Gln Phe Pro Leu Arg  
20 25 30

His Leu Arg Val Gly Gly Ile Thr Gly Ala Cys Arg His Thr Gln Ile  
35 40 45

Ile Phe Val Val Leu Val Gln Met Gly Phe His His Val Gly Gln Ala  
50 55 60

Gly Leu Glu Leu Leu Thr Ser Gly Asp Pro Pro Ala Leu Ala Ser Gln  
65 70 75 80

Ser Ala Gly Ile Thr Gly Val Ser His Ser Thr Arg Pro Lys Leu Leu  
85 90 95

Ser Trp Leu Pro Ser Asp Asn Leu Leu Gly Met Ala Leu Tyr Ser Ile  
100 105 110

Gln Trp Ala Leu Leu Ala Asn Ser Leu Tyr Phe Gln Val Pro Ser Pro  
115 120 125

Leu Ser Met Leu Cys Ala Phe Leu Pro Leu Trp Val Pro Ser Ala  
130 135 140

&lt;210&gt; 438

&lt;211&gt; 27

WO 9974836

PCT/US98/23435

<212> PRT  
<213> Homo sapiens

20

<400> 438

Arg Gly Lys Asn Arg Ala Glu Arg Thr Val Ile Ser Ser Ser His  
1 5 10 15

Ser Cys His Leu Ile Asp Leu Glu Phe Gln Pro  
20 25

<210> 439

<211> 32

<212> PRT

<213> Homo sapiens

<400> 439

Leu Gly Leu Gly Val Ser Thr Arg Arg Ser Thr Val Arg Arg Lys Glu  
1 5 10 15

Pro Thr Lys Ala Gly Met His Thr Ala Cys Ser Glu Glu Met Glu Pro  
20 25 30

<210> 440

<211> 24

<212> PRT

<213> Homo sapiens

<400> 440

Gly Asp Pro Pro Ala Leu Ala Ser Gln Ser Ala Gly Ile Thr Gly Val  
1 5 10 15

Ser His Ser Thr Arg Pro Lys Leu  
20

<210> 441

<211> 25

<212> PRT

<213> Homo sapiens

<400> 441

Ala Leu Tyr Ser Ile Gln Trp Ala Leu Leu Ala Asn Ser Leu Tyr Phe  
1 5 10 15

Gln Val Pro Ser Pro Leu Ser Met Leu  
20 25

<210> 442

<211> 35

<212> PRT

<213> Homo sapiens

WO 9974836

PCT/US98/23435

<400> 442

Asp Arg Ile Leu Leu Phe Tyr Ser Arg Asp Gly Gln Thr Thr Ser Lys  
1 5 10 15

Gly Pro Asn Pro Ala Cys Cys Leu Phe Leu Leu Lys Lys Phe Tyr Trp  
20 25 30

Asn Thr Ala  
35

<210> 443

<211> 21

<212> PRT

<213> Homo sapiens

<400> 443

Asp Gly Gln Thr Thr Ser Lys Gly Pro Asn Pro Ala Cys Cys Leu Phe  
1 5 10 15

Leu Leu Lys Lys Phe  
20

<210> 444

<211> 24

<212> PRT

<213> Homo sapiens

<400> 444

Asp Pro Arg Val Arg Arg Thr Leu Asp Leu Gly Ile Thr Leu Tyr Leu  
1 5 10 15

Phe Leu Tyr Ile Phe Leu Ser Leu  
20

<210> 445

<211> 244

<212> PRT

<213> Homo sapiens

<400> 445

Pro Ala Leu Gly Glu Cys Cys Leu Asp Ala Phe Leu Phe Leu Leu Gly  
1 5 10 15

Lys Gln Leu Lys Lys Ser Gly Glu Lys Pro Leu Leu Gly Gly Ser Leu  
20 25 30

Met Glu Tyr Ala Ile Leu Ser Ala Ile Ala Ala Met Asn Glu Pro Lys  
35 40 45

Thr Cys Ser Thr Thr Ala Leu Lys Lys Tyr Val Leu Glu Asn His Pro  
50 55 60

Gly Thr Asn Ser Asn Tyr Gln Met His Leu Leu Lys Lys Thr Leu Gln  
65 70 75 80

Lys Cys Glu Lys Asn Gly Trp Met Glu Gln Ile Ser Gly Lys Gly Phe 90  
 85  
 Ser Gly Thr Phe Gln Leu Cys Phe Pro Tyr Tyr Pro Ser Pro Gly Val 100  
 105  
 Leu Phe Pro Lys Lys Glu Pro Asp Asp Ser Arg Asp Glu Asp Glu Asp 115  
 120  
 Glu Asp Glu Ser Ser Glu Glu Asp Ser Glu Asp Glu Glu Pro Pro Pro 130  
 135  
 Lys Arg Arg Leu Gln Lys Lys Thr Pro Ala Lys Ser Pro Gly Lys Ala 145  
 150  
 Ala Ser Val Lys Gln Arg Gly Ser Lys Pro Ala Pro Lys Val Ser Ala 165  
 170  
 Ala Gln Arg Gly Lys Ala Arg Pro Leu Pro Lys Lys Ala Pro Pro Lys 180  
 185  
 Ala Lys Thr Pro Ala Lys Lys Thr Arg Pro Ser Ser Thr Val Ile Lys 195  
 200  
 Lys Pro Ser Gly Gly Ser Ser Lys Lys Pro Ala Thr Ser Ala Arg Lys 210  
 215  
 Glu Val Lys Leu Pro Gly Lys Gly Lys Ser Thr Met Lys Lys Ser Phe 225  
 230  
 Arg Val Lys Lys  
  
 <210> 446  
 <211> 152  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 446  
 Asp Phe Glu Phe His His Asp Thr Leu Phe Ser Tyr Lys Ile Tyr Phe 1  
 5  
 Phe Thr Leu Lys Asp Phe Phe Met Val Asp Leu Pro Leu Pro Gly Asn 20  
 25  
 Phe Thr Ser Phe Leu Ala Leu Val Ala Gly Phe Phe Glu Glu Pro Pro 35  
 40  
 Leu Gly Phe Leu Met Thr Val Asp Glu Gly Leu Val Phe Leu Ala Gly 50  
 55  
 Val Leu Ala Leu Gly Gly Ala Phe Leu Gly Lys Gly Leu Ala Phe Pro 65  
 70  
 Arg Trp Ala Ala Glu Thr Leu Gly Ala Gly Leu Asp Pro Leu Cys Phe 85  
 90

Thr Asp Ala Ala Phe Pro Gly Asp Leu Ala Gly Val Phe Phe Cys Asn 100  
 105  
 Leu Leu Leu Gly Gly Gly Ser Ser Ser Ser Glu Ser Ser Ser Asp Asp 115  
 120  
 Ser Ser Ser Ser Ser Ser Ser Ser Leu Glu Ser Ser Gly Ser Phe Phe 130  
 135  
 Gly Asn Arg Thr Pro Gly Leu Gly 145  
 150  
 <210> 447  
 <211> 28  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 447  
 Cys Leu Asp Ala Phe Leu Phe Leu Leu Gly Lys Gln Leu Lys Lys Ser 1  
 5  
 Gly Glu Lys Pro Leu Leu Gly Gly Ser Leu Met Glu 20  
 25  
 <210> 448  
 <211> 30  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 448  
 Tyr Gln Met His Leu Leu Lys Lys Thr Leu Gln Lys Cys Glu Lys Asn 1  
 5  
 Gly Trp Met Glu Gln Ile Ser Gly Lys Gly Phe Ser Gly Thr 20  
 25  
 <210> 449  
 <211> 28  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 449  
 Lys Thr Pro Ala Lys Ser Pro Gly Lys Ala Ala Ser Val Lys Gln Arg 1  
 5  
 Gly Ser Lys Pro Ala Pro Lys Val Ser Ala Ala Gln 20  
 25  
 <210> 450  
 <211> 28  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 450

WO 99/24836

Asp Arg Ala Gly Phe Arg Met Gln Ala Leu Val Ser Gln Ala Ala Cys  
1 5 10 15

Arg Arg Ser Arg Tyr Lys Leu  
20

<210> 455  
<211> 22  
<212> PRT  
<213> Homo sapiens

<400> 455  
Leu Ala Ala Gly Ile Leu Asn Ser Ser Leu Pro Ala Leu Tyr His Ser  
1 5 10 15

Val Glu Glu Ile Ser Gln  
20

<210> 456  
<211> 45  
<212> PRT  
<213> Homo sapiens

<400> 456  
Xaa Tyr Arg Met Asn Thr Lys Phe Leu Glu Ser Tyr Lys Met Ser Thr  
1 5 10 15

Thr Leu Ser Arg Arg His Gln Asn Val Ser Leu Cys Lys Asp Met Lys  
20 25 30

Thr Pro Ala Gly Thr Asp Thr Lys Ile Ala Phe Leu Glu  
35 40 45

<210> 457  
<211> 21  
<212> PRT  
<213> Homo sapiens

<400> 457  
Ser Tyr Lys Met Ser Thr Thr Leu Ser Arg Arg His Gln Asn Val Ser  
1 5 10 15

Leu Cys Lys Asp Met  
20

<210> 458  
<211> 57  
<212> PRT  
<213> Homo sapiens

<400> 458  
Ile Cys Ile Glu Ser Leu Met Leu His Tyr Ile Ala Leu Val Phe Glu  
1 5 10 15

PCT/US98/23435 -

WO 99/24836

Ser Ser Lys Lys Pro Ala Thr Ser Ala Arg Lys Glu Val Lys Leu Pro  
1 5 10 15

Gly Lys Gly Lys Ser Thr Met Lys Lys Ser Phe Arg  
20 25

<210> 451  
<211> 23  
<212> PRT  
<213> Homo sapiens

<400> 451  
Val Asp Glu Gly Leu Val Phe Leu Ala Gly Val Leu Ala Leu Gly Gly  
1 5 10 15

Ala Phe Leu Gly Lys Gly Leu  
20

<210> 452  
<211> 25  
<212> PRT  
<213> Homo sapiens

<400> 452  
Gly Leu Asp Pro Leu Cys Phe Thr Asp Ala Ala Phe Pro Gly Asp Leu  
1 5 10 15

Ala Gly Val Phe Phe Cys Asn Leu Leu  
20 25

<210> 453  
<211> 59  
<212> PRT  
<213> Homo sapiens

<400> 453  
Thr Met Leu Phe Tyr Leu Ser Ser Gln Pro Asp Trp Gln Leu Asp Phe  
1 5 10 15

Phe Arg Val Ser Phe Asn Gly Pro Val Phe Ile Ile Phe Asn  
20 25 30

Asp Arg Ala Gly Phe Arg Met Gln Ala Leu Val Ser Gln Ala Ala Cys  
35 40 45

Arg Arg Ser Arg Tyr Lys Leu Ser Val Val Tyr  
50 55

<210> 454  
<211> 23  
<212> PRT  
<213> Homo sapiens

<400> 454

Met Ala Phe Met Phe Pro Leu Val Tyr His Glu Met Gly Ser Asp Ser  
20 25 30

Ile Arg Phe His Leu Cys Gln Val Asp Ser Cys Leu Pro Ser Met Met  
35 40 45

Arg Phe Phe Ser Ser Phe Pro Phe Leu  
50 55

<210> 459

<211> 21

<212> PRT

<213> Homo sapiens

<400> 459

Tyr Ile Ala Leu Val Phe Glu Met Ala Phe Met Phe Pro Leu Val Tyr  
1 5 10 15

His Glu Met Gly Ser  
20

<210> 460

<211> 21

<212> PRT

<213> Homo sapiens

<400> 460

Ser Asp Ser Ile Arg Phe His Leu Cys Gln Val Asp Ser Cys Leu Pro  
1 5 10 15

Ser Met Met Arg Phe  
20

<210> 461

<211> 115

<212> PRT

<213> Homo sapiens

<400> 461

Gly Gly Val Ser Val Gln Asp Gly Ser Leu Arg Glu Glu Thr Asp Val  
1 5 10 15

Gly Glu Gly Gly Arg Pro Arg Gly Gly Gln Ser Glu Gly Ala Arg Val  
20 25 30

Thr Arg Arg Pro Ser Pro Asp Ser Asn Ala Ser Ala Phe Asp Leu  
35 40 45

Asp Leu Asp Phe Ser Pro Phe Cys Ile Tyr Cys Tyr Arg Leu Glu Thr  
50 55 60

Pro Ala Glu Val Val Phe Ser Pro Ala Pro Leu Arg Leu Ser Gly Pro  
65 70 75 80

Gly Leu Ala Pro Val Val Phe Val Ser Thr Leu Pro Ser Leu Gln Pro

85

90

95

Ser Ser Phe Cys Gly Tyr Asp Leu Pro Ala Arg Pro Arg Gly Leu Ser  
100 105 110

Gly Phe Arg  
115

<210> 462

<211> 111

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (82)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 462

Phe Thr Asn Lys Ser Cys Ser Lys Met Ser Ser Thr His Leu Tyr Lys  
1 5 10 15

Gly Ser Asp Val Leu Cys Tyr Ala Arg Ser Ser Glu Ser Met Ser Leu  
20 25 30

Ser Cys Gly Asp Val Ala Asn Ala Gly Arg Leu Thr Pro Arg Leu His  
35 40 45

Leu Ala Arg Ser Ala Ser Gln Gly Pro Pro Thr Leu Pro Arg Val Pro  
50 55 60

Pro Arg Gly Ser Arg Pro Pro Thr Ala Gly Glu Ser Pro Ala Pro Arg  
65 70 75 80

Thr Xaa Ser Leu Glu Asn His Lys Asn Ile Asp His Leu Ser Ser Asn  
85 90 95

Ser His Gly Lys Phe Arg Ile Tyr Gly Gln Asn Asp Ile Lys Ile  
100 105 110

<210> 463

<211> 80

<212> PRT

<213> Homo sapiens

<400> 463

Gln Asp Val Ile Tyr Thr Phe Val Gln Arg Phe Arg Pro Met Leu  
1 5 10 15

Cys Thr Ile Leu Arg Lys Tyr Glu Pro Val Val Arg Gly Arg Arg Lys  
20 25 30

Arg Tyr Gln Ala His Pro Ser Ser Ala Phe Gly Lys Lys Arg Leu Pro  
35 40 45

Arg Pro Pro His Pro Ala Gln Gly Ala Pro Gln Arg Glu Gln Ala Ser

WO 99/24836

PCT/US98/23435

50 55 60  
His Ser Trp Arg Glu Pro Gly Pro Gln Asn Thr Phe Pro Arg Lys Pro  
65 70 75 80

<210> 464  
<211> 22  
<212> PRT  
<213> Homo sapiens

<400> 464  
Arg Glu Glu Thr Asp Val Gly Glu Gly Arg Pro Arg Gly Gly Gln  
1 5 10 15

Ser Glu Gly Ala Arg Val  
20

<210> 465  
<211> 27  
<212> PRT  
<213> Homo sapiens

<400> 465  
Gly Pro Gly Leu Ala Pro Val Phe Val Ser Thr Leu Pro Ser Leu  
1 5 10 15

Gln Pro Ser Ser Phe Cys Gly Trp Asp Leu Pro  
20 25

<210> 466  
<211> 24  
<212> PRT  
<213> Homo sapiens

<400> 466  
Met Ser Ser Thr His Leu Tyr Lys Gly Ser Asp Val Leu Cys Tyr Ala  
1 5 10 15

Arg Ser Ser Glu Ser Met Ser Leu  
20

<210> 467  
<211> 28  
<212> PRT  
<213> Homo sapiens

<400> 467  
Ser Gln Gly Pro Pro Thr Leu Pro Arg Val Pro Pro Arg Gly Ser Arg  
1 5 10 15

Pro Pro Thr Ala Gly Glu Ser Pro Ala Pro Arg Thr

WO 99/24836

PCT/US98/23435

20 25 30

<210> 468  
<211> 25  
<212> PRT  
<213> Homo sapiens

<400> 468  
Arg Phe Arg Arg Pro Met Leu Cys Thr Ile Leu Arg Lys Tyr Glu Pro  
1 5 10 15

Val Val Arg Gly Arg Arg Lys Arg Trp  
20 25

<210> 469  
<211> 24  
<212> PRT  
<213> Homo sapiens

<400> 469  
Arg Leu Pro Arg Pro Pro His Pro Ala Gln Gly Ala Pro Gln Arg Glu  
1 5 10 15

Gln Ala Ser His Ser Trp Arg Glu  
20

<210> 470  
<211> 81  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (43)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 470  
Arg Gly Met Arg Gly Arg Trp Leu Val Ser Ser Gly Ala Ala Phe Pro  
1 5 10 15

Ile Pro Leu Asn Gly Phe Cys Glu Ser Arg Glu Phe Phe Pro Asp Ser  
20 25 30

Gly Ser Val Leu Leu His Trp Arg Pro Asn Xaa Val Leu Ile Glu Ile  
35 40 45

Lys Val Phe Gly Ser Arg Ser Gln Ser Leu Ile Ser Ser Lys Asn Leu  
50 55 60

Lys Thr Ser Leu Thr Phe Ile Tyr Gly Lys Val Glu Glu Val Leu Asn  
65 70 75 80

Asn

211

<210> 471  
 <211> 81  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (62)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 471  
 Leu Lys Leu Ser Ser Ala Asp Ser Gln Ala Ile Met Asn Ile Phe Ser  
 1 5 10 15

Ala Asp Cys Met Pro Arg Leu His Ile Ala Leu Gln Thr Glu Met Ile  
 20 25 30

Pro Asn Arg Ala Pro Gln Gly Ala Ala Ala Asn Leu Trp His Glu  
 35 40 45

Ala Gln Tyr Arg Arg Leu Pro Phe Ser Arg Ala Pro Glu Xaa Thr Asp  
 50 55 60

Ala His Gln Ala Ser Ala Gln Arg Gly Ala Ala Gln Leu Pro Arg Glu  
 65 70 75 80

Gln

<210> 472  
 <211> 28  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (28)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 472  
 Pro Ile Pro Leu Asn Gly Phe Cys Glu Ser Arg Glu Phe Phe Pro Asp  
 1 5 10 15

Ser Gly Ser Val Leu Leu His Trp Arg Pro Asn Xaa  
 20 25

<210> 473  
 <211> 29  
 <212> PRT  
 <213> Homo sapiens

<400> 473  
 Asn Ile Phe Ser Ala Asp Cys Met Pro Arg Leu His Ile Ala Leu Gln  
 1 5 10 15

212

Thr Glu Met Ile Pro Asn Arg Ala Pro Gln Gly Gly Ala  
 20 25

<210> 474  
 <211> 37  
 <212> PRT  
 <213> Homo sapiens

<400> 474  
 Thr Phe Arg Leu Val Ser Ala His Leu Lys Thr Arg Lys Leu Ile Asn  
 1 5 10 15

Pro Glu Ala Ala Glu Arg Arg Trp Arg Asp Trp Asp Ser Arg Gln Gly  
 20 25 30

Trp Leu Ser Val Lys  
 35

<210> 475  
 <211> 21  
 <212> PRT  
 <213> Homo sapiens

<400> 475  
 Lys Thr Arg Lys Leu Ile Asn Pro Glu Ala Ala Glu Arg Arg Trp Arg  
 1 5 10 15

Asp Trp Asp Ser Arg  
 20

<210> 476  
 <211> 83  
 <212> PRT  
 <213> Homo sapiens

<400> 476  
 Trp Asn Tyr Thr Val Asn Asn Leu Tyr Leu Phe Ser Phe Ser Ile Val  
 1 5 10 15

Ser Met Lys Phe Met His Val Leu Ser Ile Asn Ile Phe Phe Gly Arg  
 20 25 30

Ala Arg Trp Leu Thr Pro Val Ile Pro Ala Leu Leu Glu Ala Glu Ala  
 35 40 45

Gly Gly Ser Leu Gly Gln Glu Phe Lys Thr Ser Leu Gly Lys Asp Gly  
 50 55 60

Glu Thr Pro Ser Leu Leu Lys Ile Gln Lys Leu Ala Gly His Gly Gly  
 65 70 75 80

Arg Arg Leu

214

<210> 481  
 <211> 77  
 <212> PRT  
 <213> Homo sapiens

<400> 481  
 Leu Val Cys Ile Leu Leu Val His Trp Ile Pro Pro Leu Gly Ala Trp  
 1 5 10 15

Gly Leu Ser Leu Met Leu Phe Leu Ile Leu Glu Gln Arg Cys Gly Lys  
 20 25 30

Gly Lys Trp Arg Asn Ala Leu Leu Ser Val Ser Phe Ser Val Pro Gln  
 35 40 45

Leu Gln Met Gln Lys Val Ser Leu Asp Ser Thr Pro Leu Asn Val Asn  
 50 55 60

His Asp Lys Met Asp Ile Trp Lys Leu Thr Pro Lys Leu  
 65 70 75

<210> 482  
 <211> 57  
 <212> PRT  
 <213> Homo sapiens

<400> 482  
 Ile Met Ile Lys Trp Ile Phe Gly Asn Leu Leu Ser Cys Asp Leu  
 1 5 10 15

Gly Cys Ile Ser Thr Ser Gly Leu Pro Gln Tyr Gln Gly Leu Arg Leu  
 20 25 30

Leu Asn Phe Glu Tyr Ser Leu Gly Phe Met Leu Arg Ser Leu Trp Ser  
 35 40 45

Arg Ser Ala Ile Gln Cys Phe Ser  
 50 55

<210> 483  
 <211> 21  
 <212> PRT  
 <213> Homo sapiens

<400> 483  
 Leu Leu Leu Ser Cys Asp Leu Gly Cys Ile Ser Thr Ser Gly Leu Pro  
 1 5 10 15

Gln Tyr Gln Gly Leu  
 20

<210> 484

215

<210> 477  
 <211> 76  
 <212> PRT  
 <213> Homo sapiens

<400> 477  
 Asp Gln Pro Gly Lys His Gly Glu Thr Leu Ser Leu Leu Lys Met Gln  
 1 5 10 15

Lys Leu Thr Trp Cys Gly Gly Met Pro Phe Val Ile Pro Ser Tyr Ser  
 20 25 30

Arg Ser Pro Arg Pro Glu Asn Arg Leu Asn Leu Gly Asp Arg Gly Cys  
 35 40 45

Thr Glu Leu Leu His Ser Ser Leu Gly Asn Arg Val Arg Leu Ser Lys  
 50 55 60

Lys Lys Glu Val Tyr Met Met Glu Leu Tyr Ser Lys  
 65 70 75

<210> 478  
 <211> 28  
 <212> PRT  
 <213> Homo sapiens

<400> 478  
 Val Ile Pro Ala Leu Leu Glu Ala Glu Ala Gly Gly Ser Leu Gly Gln  
 1 5 10 15

Glu Phe Lys Thr Ser Leu Gly Lys Asp Gly Glu Thr  
 20 25

<210> 479  
 <211> 29  
 <212> PRT  
 <213> Homo sapiens

<400> 479  
 Asn Arg Leu Asn Leu Glu Asp Arg Gly Cys Thr Glu Leu His Ser  
 1 5 10 15

Ser Leu Gly Asn Arg Val Arg Leu Ser Lys Lys Lys Glu  
 20 25

<210> 480  
 <211> 17  
 <212> PRT  
 <213> Homo sapiens

<400> 480  
 His Ala Ser Glu His Leu Ala Ala Leu Pro Val Asn Val Lys Ile Gly  
 1 5 10 15

Lys

<211> 21  
 <212> PRT  
 <213> Homo sapiens

415

<400> 484  
 Leu Arg Leu Leu Asn Phe Glu Tyr Ser Leu Gly Phe Met Leu Arg Ser  
 1 5 10 15

Leu Trp Ser Arg Ser  
 20

<210> 485  
 <211> 78  
 <212> PRT  
 <213> Homo sapiens

<400> 485  
 Ala Ser Pro His Leu Phe Ile Glu Lys Trp Gly Arg Ala Phe Ile Leu  
 1 5 10 15

Arg Lys Leu Leu Val Pro Val Ile Ser Lys Arg Ile Ile Asn Ile  
 20 25 30

Met Ala His Gln Val Lys Pro Pro Ile Phe Cys Ala Met Ile Met Cys  
 35 40 45

Asn Leu Phe Cys Ser Gly Tyr Glu His Leu Leu Phe Thr Leu Met Arg  
 50 55 60

Phe Phe Ser Phe Glu Gln Ile Phe Asp Glu Val Val Phe His  
 65 70 75

<210> 486  
 <211> 25  
 <212> PRT  
 <213> Homo sapiens

<400> 486  
 Lys Leu Leu Leu Val Pro Val Ile Ser Lys Arg Ile Ile Asn Ile Met  
 1 5 10 15

Ala His Gln Val Lys Pro Pro Ile Phe  
 20 25

<210> 487  
 <211> 358  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (352)

<223> Xaa equals any of the naturally occurring L-amino acids  
 <220>

<221> SITE  
 <222> (356)  
 <223> Xaa equals any of the naturally occurring L-amino acids

416

<400> 487  
 Phe Ala Val Ile Arg Phe Glu Ser Ile Ile His Glu Phe Asp Pro Trp  
 1 5 10 15

Phe Asn Tyr Arg Ser Thr His His Leu Ala Ser His Gly Phe Tyr Glu  
 20 25 30

Phe Leu Asn Trp Phe Asp Glu Arg Ala Trp Tyr Pro Leu Gly Arg Ile  
 35 40 45

Val Gly Gly Thr Val Tyr Pro Gly Leu Met Ile Thr Ala Gly Leu Ile  
 50 55 60

His Trp Ile Leu Asn Thr Leu Asn Ile Thr Val His Ile Arg Asp Val  
 65 70 75 80

Cys Val Phe Leu Ala Pro Thr Phe Ser Gly Leu Thr Ser Ile Ser Thr  
 85 90 95

Phe Leu Leu Thr Arg Glu Leu Trp Asn Gln Gly Ala Gly Leu Leu Ala  
 100 105 110

Ala Cys Phe Ile Ala Ile Val Pro Gly Tyr Ile Ser Arg Ser Val Ala  
 115 120 125

Gly Ser Phe Asp Asn Glu Gly Ile Ala Ile Phe Ala Leu Gln Phe Thr  
 130 135 140

Tyr Tyr Leu Trp Val Lys Ser Val Lys Thr Gly Ser Val Phe Trp Thr  
 145 150 155 160

Met Cys Cys Lys Leu Ser Tyr Phe Tyr Met Val Ser Ala Trp Gly Gly  
 165 170 175

Tyr Val Phe Ile Ile Asn Leu Ile Pro Leu His Val Phe Val Leu Leu  
 180 185 190

Leu Met Gln Arg Tyr Ser Lys Arg Val Tyr Ile Ala Tyr Ser Thr Phe  
 195 200 205

Tyr Ile Val Gly Leu Ile Leu Ser Met Gln Ile Pro Phe Val Gly Phe  
 210 215 220

Gln Pro Ile Arg Thr Ser Glu His Met Ala Ala Ala Gly Val Phe Ala  
 225 230 235 240

Leu Leu Gln Ala Tyr Ala Phe Leu Gln Tyr Leu Arg Asp Arg Leu Thr  
 245 250 255

Lys Gln Glu Phe Gln Thr Leu Phe Phe Leu Gly Val Ser Leu Ala Ala  
 260 265 270

Gly Ala Val Phe Leu Ser Val Ile Tyr Leu Thr Tyr Thr Gly Tyr Ile  
 275 280 285

WO 99/24836

PCT/US98/23435

WO 99/24836

PCT/US98/23435

Ala Pro Trp Ser Gly Arg Phe Tyr Ser Leu Trp Asp Thr Gly Tyr Ala  
290 295 300

Lys Ile His Ile Pro Ile Ile Ala Ser Val Ser Glu His Gln Pro Thr  
305 310 315 320

Thr Trp Val Ser Phe Phe Asp Leu His Ile Leu Val Cys Thr Phe  
325 330 335

Pro Ala Gly Leu Trp Phe Cys Ile Lys Asn Ile Asn Asp Glu Arg Xaa  
340 345 350

Phe Gly Lys Xaa Gly Phe  
355

<210> 488  
<211> 27  
<212> PRT  
<213> Homo sapiens

<400> 488  
Glu Phe Asp Pro Trp Phe Asn Tyr Arg Ser Thr His His Leu Ala Ser  
1 5 10 15

His Gly Phe Tyr Glu Phe Leu Asn Trp Phe Asp  
20 25

<210> 489  
<211> 23  
<212> PRT  
<213> Homo sapiens

<400> 489  
Thr Arg Glu Leu Trp Asn Gln Gly Ala Gly Leu Leu Ala Ala Cys Phe  
1 5 10 15

Ile Ala Ile Val Pro Gly Tyr  
20

<210> 490  
<211> 22  
<212> PRT  
<213> Homo sapiens

<400> 490  
Thr Tyr Tyr Leu Trp Val Lys Ser Val Lys Thr Gly Ser Val Phe Trp  
1 5 10 15

Thr Met Cys Cys Cys Leu  
20

<210> 491  
<211> 25

<212> PRT  
<213> Homo sapiens

<400> 491  
Gly Val Phe Ala Leu Leu Gln Ala Tyr Ala Phe Leu Gln Tyr Leu Arg  
1 5 10 15

Asp Arg Leu Thr Lys Gln Glu Phe Gln  
20 25

<210> 492  
<211> 27  
<212> PRT  
<213> Homo sapiens

<400> 492  
Tyr Ser Leu Trp Asp Thr Gly Tyr Ala Lys Ile His Ile Pro Ile Ile  
1 5 10 15

Ala Ser Val Ser Glu His Gln Pro Thr Thr Trp  
20 25

<210> 493  
<211> 408  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (20)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 493  
Met Gly His Met Leu Tyr Leu Leu Gly Asn Ile Asn Lys Arg Thr Met  
1 5 10 15

His Lys Tyr Xaa Gln Glu Ser Lys Lys Ala Gly Lys Ala Ser Phe Ala  
20 25 30

Tyr Ala Trp Val Leu Asp Glu Thr Gly Glu Glu Arg Glu Arg Gly Val  
35 40 45

Thr Met Asp Val Gly Met Thr Lys Phe Glu Thr Thr Lys Val Ile  
50 55 60

Thr Leu Met Asp Ala Pro Gly His Lys Asp Phe Ile Pro Asn Met Ile  
65 70 75 80

Thr Gly Ala Ala Gln Ala Asp Val Ala Val Leu Val Val Asp Ala Ser  
85 90 95

Arg Gly Glu Phe Glu Ala Gly Phe Glu Thr Gly Gly Gln Thr Arg Glu  
100 105 110

His Gly Leu Leu Val Arg Ser Leu Gly Val Thr Gln Leu Ala Val Ala  
115 120 125

Val Asn Lys Met Asp Gln Val Asn Trp Gln Gln Glu Arg Phe Gln Glu  
 130 135 140  
 Ile Thr Gly Lys Leu Gly His Phe Leu Lys Gln Ala Gly Phe Lys Glu  
 145 150 155 160  
 Ser Asp Val Gly Phe Ile Pro Thr Ser Gly Leu Ser Gly Glu Asn Leu  
 165 170 175  
 Ile Thr Arg Ser Gln Ser Ser Glu Leu Thr Lys Trp Tyr Lys Gly Leu  
 180 185 190  
 Cys Leu Leu Glu Gln Ile Asp Ser Phe Lys Pro Pro Gln Arg Ser Ile  
 195 200 205  
 Asp Lys Pro Phe Arg Leu Cys Val Ser Asp Val Phe Lys Asp Gln Gly  
 210 215 220  
 Ser Gly Phe Cys Ile Thr Gly Lys Ile Glu Ala Gly Tyr Ile Gln Thr  
 225 230 235 240  
 Gly Asp Arg Leu Leu Ala Met Pro Pro Asn Glu Thr Cys Thr Val Lys  
 245 250 255  
 Gly Ile Thr Leu His Asp Glu Pro Val Asp Trp Ala Ala Gly Asp  
 260 265 270  
 His Val Ser Leu Thr Leu Val Gly Met Asp Ile Ile Lys Ile Asn Val  
 275 280 285  
 Gly Cys Ile Phe Cys Gly Pro Lys Val Pro Ile Lys Ala Cys Thr Arg  
 290 295 300  
 Phe Arg Ala Arg Ile Leu Ile Phe Asn Ile Glu Ile Pro Ile Thr Lys  
 305 310 315 320  
 Gly Phe Pro Val Leu Leu His Tyr Gln Thr Val Ser Glu Pro Ala Val  
 325 330 335  
 Ile Lys Arg Leu Ile Ser Val Leu Asn Lys Ser Thr Gly Glu Val Thr  
 340 345 350  
 Lys Lys Lys Pro Lys Phe Leu Thr Lys Gly Gln Asn Ala Leu Val Glu  
 355 360 365  
 Leu Gln Thr Gln Arg Pro Ile Ala Leu Glu Leu Tyr Lys Asp Phe Lys  
 370 375 380  
 Glu Leu Gly Arg Phe Met Leu Arg Tyr Gly Gly Ser Thr Ile Ala Ala  
 385 390 395 400  
 Gly Val Val Thr Glu Ile Lys Glu  
 405

<210> 494  
 <211> 21

<212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (16)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
 <400> 494  
 Leu Tyr Leu Leu Gly Asn Ile Asn Lys Arg Thr Met His Lys Tyr Xaa  
 1 5 10 15  
 Gln Glu Ser Lys Lys  
 20  
 <210> 495  
 <211> 23  
 <212> PRT  
 <213> Homo sapiens  
 <400> 495  
 Leu Asp Glu Thr Gly Glu Glu Arg Glu Arg Gly Val Thr Met Asp Val  
 1 5 10 15  
 Gly Met Thr Lys Phe Glu Thr  
 20  
 <210> 496  
 <211> 22  
 <212> PRT  
 <213> Homo sapiens  
 <400> 496  
 Gly His Lys Asp Phe Ile Pro Asn Met Ile Thr Gly Ala Ala Gln Ala  
 1 5 10 15  
 Asp Val Ala Val Leu Val  
 20  
 <210> 497  
 <211> 23  
 <212> PRT  
 <213> Homo sapiens  
 <400> 497  
 Gly Phe Glu Thr Gly Gly Gln Thr Arg Glu His Gly Leu Leu Val Arg  
 1 5 10 15  
 Ser Leu Gly Val Thr Gln Leu  
 20  
 <210> 498  
 <211> 23  
 <212> PRT

WO 99/24836

PCT/US98/23435

WO 99/24836

272

&lt;213&gt; Homo sapiens

Arg Phe Met Leu Arg Tyr Gly Ser  
20 25

&lt;400&gt; 498

Trp Gln Gln Glu Arg Phe Gln Glu Ile Thr Gly Lys Leu Gly His Phe  
1 10 15

Leu Lys Gln Ala Gly Phe Lys

20

&lt;210&gt; 499

&lt;211&gt; 22

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 499

Thr Ser Gly Leu Ser Gly Glu Asn Leu Ile Thr Arg Ser Gln Ser Ser  
1 5 10 15

Glu Leu Thr Lys Trp Tyr

20

&lt;210&gt; 500

&lt;211&gt; 23

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 500

Pro Gln Arg Ser Ile Asp Lys Pro Phe Arg Leu Cys Val Ser Asp Val  
1 5 10 15

Phe Lys Asp Gln Gly Ser Gly

20

&lt;210&gt; 501

&lt;211&gt; 22

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 501

Leu Ile Ser Val Leu Asn Lys Ser Thr Gly Glu Val Thr Lys Lys Lys  
1 5 10 15

Pro Lys Phe Leu Thr Lys

20

&lt;210&gt; 502

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 502

Gln Arg Pro Ile Ala Leu Glu Leu Tyr Lys Asp Phe Lys Glu Leu Gly  
1 5 10 15

# INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>183</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection ("ATCC")	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 16 OCTOBER 1997	Accession Number 209368
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer <i>Melvin B. Barbary, Jr.</i>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer

# INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>183</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection ("ATCC")	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 23 OCTOBER 1997	Accession Number 209407
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer <i>Melvin B. Barbary, Jr.</i>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer

# INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 183, line N/A	
B. IDENTIFICATION OF DEPOSIT	
Name of depositary institution American Type Culture Collection ("ATCC")	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 30 OCTOBER 1997	Accession Number 209423
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer <i>Melvin S. Anderson, Jr.</i>	<input type="checkbox"/> For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer
--	--

INTERNATIONAL SEARCH REPORT		International application No. PCT/US98/23435
A. CLASSIFICATION OF SUBJECT MATTER		
IPC(6) : Please See Extra Sheet. US CL : Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) U.S. : 536/23.5, 23.1; 435/320.1, 440, 252.3, 69.1, 7.1; 530/350, 387.1; 514/12		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SAPPERSTEIN, S.K. et al. p115 is a general vesicular transport factor related to the yeast endoplasmic reticulum to Golgi transport factor Usolp. Proceedings of the National Academy of Sciences USA. 17 January 1995, Vol. 92, No. 2, pages 522-526, see entire document.	1, 2, 5, and 7-10
X	BARROSO et al. Transcytosis-associated protein (TAP)/p115 is a general fusion factor required for binding of vesicles to acceptor membranes. Proceedings of the National Academy of Sciences USA. 17 January 1995, Vol. 92, No. 2, pages 527-531, see entire document.	11-13 and 16
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
Special categories of cited documents: *A* documents defining the general state of the art which is not considered to be of particular relevance *B* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *C* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *D* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *E* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *F* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *G* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *H* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *I* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *J* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *K* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *L* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *M* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *N* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *O* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *P* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *Q* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *R* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *S* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *T* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *U* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *V* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *W* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *X* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *Y* documents published on or after the international filing date of the invention which are not considered to be of particular relevance *Z* documents published on or after the international filing date of the invention which are not considered to be of particular relevance		
Date of the actual completion of the international search		Date of mailing of the international search report
29 JANUARY 1999		25 FEB 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20331 Facsimile No. (703) 305-3230		Authorized officer JAMES MARTINELLI Telephone No. (703) 308-0196
Form PCT/ISA/210 (second sheet) (July 1992) *		

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/23435

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/23435

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	SOHADA et al, Phosphorylation of the vesicle docking protein p115 regulates its association with the Golgi membrane. Journal of Biological Chemistry. 27 February 1998, Vol. 273, No. 9, Pages 5385-5388, see entire document.	1, 2, 5-13, and 16
A	ADAMS et al, complementary DNA sequencing: Expressed sequence tags and the human genome project. Science. 21 June 1991, Vol. 252, pages 1651-1656, see entire document.	1-22

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 23  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Claim 23 is directed to a product of the process of claim 20. Claim 20 is not a process for the production of a product, but a process for the detection of a substance. Hence, no meaningful search can be carried out.

3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
- ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
- ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remarks on Prior Art

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/23435

## A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

G01N 33/68, 33/53; C07K 16/00; C12N 15/11, 15/12, 15/00, 15/63; A61K 38/17, 38/16; C12P 21/02

## A. CLASSIFICATION OF SUBJECT MATTER: US CL :

536/23.5, 23.1; 435/320.1, 440, 252.3, 69.1, 7.1; 530/350, 387.1; 514/12

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN, MPRCH (SEQ ID NOs 11 and 136 only). One nucleotide sequence and one amino acid sequence have been searched. It is not clear which sequences are embraced by the claims because the claims refer to sequences X and Y. The table beginning at page 183 contains many sequences X and Y, yet the claims refer to X and Y in the singular. If the claims are to embrace more than one X and more than one Y, it is not clear whether each X always requires the corresponding sequence Y. Additionally, the claims are in improper format in referring to the description (see PCT Rule 6.2(e)). Accordingly, the first X nucleotide sequence disclosed and the first Y amino acid sequence corresponding to the first X sequence disclosed in the table were searched.